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Computerised Physician Order Entry (CPOE) and clinical decision support has been shown to 
have some unintended and unanticipated consequences, such as on communication and 
coordination of care.  I set out to investigate whether CPOE has an impact on 
communication between pharmacists and physicians in the hospital setting. 
 
An analysis of over 34,000 free-text messages assigned by pharmacists to prescription 
orders over a 12-month period showed a sub-optimal exchange of information with the 
physician.  Focus groups and observational research were conducted to provide a more in-
depth understanding of the factors involved.  The use of CPOE did not reduce opportunities 
for personal interaction.  The capability to communicate electronically facilitated a non-
interruptive workflow, beneficial for staff time and for limiting distractions.  It also improved 
clinical documentation, which helped coordinate care of patients between members of the 
pharmacy team.  However, the research identified several barriers to the effectiveness of 
communication via the CPOE system, including: the increased frequency of messages sent; 
poor display characteristics of the message; poor access to information to inform decision-
making; one-way communication; and no assigned responsibility to respond.  These factors 
need to be considered in the design of systems and supported by interprofessional training 
to optimise communication between the professionals.   
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Chapter 1 INTRODUCTION 
 
In this chapter, I provide a background to the themes that underpin the research question 
and the chapters of the thesis.  I introduce the prescribing landscape in the United Kingdom 
(UK) hospital setting and discuss the role of the pharmacist.  I discuss the national and 
international drivers to implement health information technology and the intended and 
unintended consequences of such interventions.  Finally, I describe the aims and objectives 
of the research and outline the structure of the thesis. 
 
1.1 The medication process 
Pharmacological therapy remains the most common therapeutic intervention in the modern 
National Health Service (NHS) and the use of medicines is increasing year-on-year, largely 
due to an ageing population living with multiple morbidities (NHS England, 2014a).  The cost 
of prescribing is also increasing year on year—£16.8 billion was spent on medication in 
2015–16 (45% of which was in the hospital setting), compared to £13.0 billion in 2010–11 
(Health and Social Care Information Centre, 2016).   
 
The medication process comprises the steps of prescribing, the pharmacist’s clinical check 
(validation), dispensing, administration and ongoing monitoring for the beneficial and 
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adverse effects of treatment.  Viewed in its simplest form, the central roles of the three main 
healthcare professionals that interact with the process in the hospital setting may be 
considered as: 1) the physician writing or generating the prescription order for a patient; 2) 
the pharmacist validating and supplying the medicine; and, 3) the nurse administering the 
medicine.  The process is far from simple though; the provision of pharmacological therapy 
to hospitalised patients is a complex and dynamic process that involves many healthcare 
professionals at each of the stages.  The roles of those involved are also evolving, with many 
nurses and pharmacists now qualified as prescribers in the NHS and the role extending to 
allied healthcare professionals such as physiotherapists (Cooper et al., 2008).  This 
transformation of the medication process and change in skills mix means that many more 
professionals interact with the medication process in modern healthcare settings.  Although 
intended to improve service delivery for patients, the articulation of the process may also 
introduce vulnerabilities, with an increased risk for error.   
  
1.1.1 Medication errors 
Medication errors are defined as “a failure in the treatment process that leads to, or has the 
potential to lead to, harm to the patient” (Ferner & Aronson, 2000).  Errors can occur at any 
stage of the medication process, can cause serious harm to patients and are largely 
preventable.  Errors and the associated harms are also a financial burden for healthcare 
organisations, costing an estimated $42 million each year worldwide (World Health 
Organization, 2017).  In the UK, medication-related incidents account for approximately 10% 
of all adverse events reported to the National Reporting and Learning System (NRLS), listed 
in the top four most common incident types (NHS England, 2017).  This figure is likely to 
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underestimate the true scale of the problem, since the statistics reported are completely 
dependent on the voluntary reporting of incidents and therefore an ethos of transparency 
amongst individuals and the organisation.  A comprehensive review of patient safety 
incidents reported to the NRLS between 2005 and 2010 found that errors relating to the 
administration and prescribing of medicines were the most frequently occurring (Cousins et 
al., 2012).  Owing to the scale of the problem worldwide, in March 2017 the World Health 
Organisation (WHO) identified errors in this process as one of their global patient safety 
challenges; “Medication without harm”, which aims to halve mediation-related incidents by 
2022 (World Health Organization, 2017).  
 
1.1.2 Hospital pharmacists 
In the UK, hospital pharmacists work closely and collaboratively with medical and nursing 
staff to ensure patients receive safe and effective treatment(s) that will optimise outcomes.  
Pharmacists work on inpatient wards—and increasingly in outpatient clinics—in close 
proximity to the multidisciplinary teams and the patient and their carer/relative (Royal 
Pharmaceutical Society, 2014).  This is usual practice in the UK and a norm prompted by NHS 
reports that foresaw pharmacists having the skills and knowledge to play an integral role in 
delivering a plan for reform of the NHS (Department of Health., 2000). 
 
One of the main roles of a pharmacist is to perform a clinical check of prescriptions that 
require supply (Royal Pharmaceutical Society, 2016; p 10).  This is conducted to ensure the 
prescription is safe for a patient and takes into account patient demographics, the medical 
history, the history of any presenting complaint and any concomitant treatment(s).  In the 
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hospital setting, pharmacists spend a proportion of their time undertaking medicines 
reconciliation, “the process of identifying an accurate list of a person's current medicines and 
comparing them with the current list in use, recognising any discrepancies and documenting 
any changes” (National Institute for Health and Care Excellence, 2015).  Reconciliation 
involves collecting and verifying patient information to identify intentional and non-
intentional discrepancies—ideally within 24 hours of admission—and documenting and 
communicating this to ensure patients’ regimens reflect those taken prior to admission.  It is 
conducted because evidence suggests that up to 50% of inpatient drug charts contain errors 
and that these are most likely to occur on admission to hospital (Basey et al., 2013).  
Pharmacist involvement early on in the process can reduce the rate of discrepancies and risk 
of patient harm.  Pharmacist-led medicines reconciliation and history taking have also been 
shown to provide a more accurate outcome, compared to when the two are completed by 
nurses and physicians, possibly because of their training, familiarity with medicines and 
information gathering skills (De Winter et al., 2010). The difference in accuracy may also be 
because pharmacists have more time to dedicate to this process.   
 
Hospital pharmacists spend a proportion of their time conducting ‘medication reviews’.  This 
encompasses the clinical check, but also considers the stage of administration.  The review 
takes into account factors such as the timing and duration of regimens, adherence to 
treatment, omitted and delayed medicines and any medicines the patient has on their 
person (prescribed, purchased over-the-counter or even recreational) (Royal Pharmaceutical 
Society, 2012).  The process of clinical check, reconciliation and medication review require a 
great deal of information gathering, both from the patient (or their relative/carer) and other 
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healthcare professionals.  It can also include the use of health information databases and 
pharmaceutical resources, such as the British National Formulary (BNF).   
 
There is a wealth of research that supports the role of the pharmacist, particularly those that 
are ward-based and working in partnership with physicians.  Pharmacists can identify 
prescribing errors and rectify unintended discrepancies before they reach the patient 
(Dornan et al., 2009; Marvin et al., 2016).  In one study by Dornan et al (2009), hospital 
pharmacists in 19 acute NHS hospitals detected 11,000 prescribing errors over just seven 
days.  Their interventions—defined as “any proactive or reactive (in response to a question 
from another healthcare professional) activity undertaken by the pharmacist to suggest 
changes in drug therapy or monitoring, which involved contacting medical or nursing staff” 
(Barber et al., 2006), or perhaps more simply a request for a “change in a patient’s 
management or therapy” (Dooley et al., 2004)—can reduce the risk of patient harm and 
adverse drug events.  Evidence also suggests that the presence of a ward-based pharmacist 
can reduce readmissions to hospital and lower patient morbidity (Creswick and Westbrook, 
2015; Gillespie et al., 2009) and that their interventions can save money for the health 
service (Gallagher et al., 2014).  Their impact on the medication process is probably greatest 
when the pharmacist is part of the multidisciplinary team (Langebrake & Hilgarth, 2010).  
Research conducted in Australia also shows that the pharmacist acts as a “hub” of 





1.2 Health Information Technology 
1.2.1 Computerised Physician Order Entry 
Computerised Physician Order Entry (CPOE)—more commonly referred to as electronic 
prescribing (ePrescribing) or Electronic Prescribing and Medicines Administration (EPMA) in 
the UK—is defined as: “the utilisation of electronic systems to facilitate and enhance the 
communication of a prescription order, aiding the choice, administration and supply of a 
medicine through knowledge and decision support and providing a robust audit trail for the 
entire medicines use process” (NHS Connecting for Health, 2009).  It is part of an electronic 
patient record (EPR), specifically designed to document and facilitate the medication 
process.  In the UK, the term CPOE does not entirely reflect the operation of the system in 
practice since other healthcare professionals (e.g. pharmacists and nurses) can also generate 
orders.  Many systems have integrated Clinical Decision Support (CDS) systems, which are 
designed to facilitate clinical decision-making at the point of care through the connection of 
patient information, a pre-configured knowledge base and occasionally the demographics of 
the user (Beeler et al., 2014; Shortliffe, 1987).   
 
Studies conducted in the United States (US) in the late 1990s found that CPOE could reduce 
medication errors with potential for harm by between 55% and 88% (Bates et al., 1998; 
Bates et al., 1999).  More recent studies show a consistent, albeit slightly smaller reduction, 
with CPOE associated with almost half as many medication errors (Nuckols et al., 2014; 
Radley et al., 2013; Ranji et al., 2014).  Of course, the reduction in error rates observed in 
sites is variable, depending on the complexity of the system(s) in use, the methods adopted 
7 
 
for data collection and the baseline error rate of the site (Barber et al., 2006; Shamliyan et 
al., 2008).  As more patient information is digitised, the more the technology has the 
potential to improve health outcomes for patients.  Electronic patient records enable real-
time sharing of information across the interface of care and importantly with patients, to 
inform decision-making and empower self-management (Lee et al., 2015; Liddell et al., 2008; 
National Information Board, 2014).  It is not surprising then that evidence also suggests that 
CPOE can have a positive impact on reducing the length of stay of patients in hospital and 
reduce patient mortality (Lyons et al., 2017).  Although perhaps not the main driver, CPOE 
also has significant financial benefits for healthcare organisations.  A review commissioned 
by the Department of Health (UK) identified cost savings of £270 million each year if CPOE 
was implemented across NHS hospitals, as well as electronic prescription services in the 
community setting, where NHS prescriptions can be sent electronically to a nominated 
pharmacy for dispensing.  In addition, the capability to integrate Electronic Patient Records 
(EPRs) across settings is reported to save a further £560 million each year 
(PricewaterhouseCoopers LLP, 2013).   
 
Given the proven benefits of CPOE on rates of medication errors and the safety and quality 
of care for patients, financial incentives have been and continue to be offered to healthcare 
organisations to encourage the implementation of health information technology.  In the US 
(2009), the Health Information Technology for Economic and Clinical Health Act (HITECH) 
permitted financial payments for organisations that implemented certified EPR technologies 
for “meaningful use”, to focus on improvements of care (Blumenthal  & Tavenner 2010; 
Slight et al., 2015).  This has accelerated the adoption of technologies—in 2003, only 2.7% of 
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hospitals in the US had CPOE with integrated CDS, compared to approximately 80% in 2015 
(Pedersen et al., 2015).   
 
In the UK, the process of implementation has been somewhat slower, with less than a 
quarter of hospitals in England having CPOE embedded across inpatient wards (McLeod et 
al., 2014), though questionnaire studies have consistently shown that many more are either 
in the process of procurement or planning implementation (Ahmed et al., 2013; Cresswell et 
al., 2013a; Crowe et al., 2010; McLeod et al., 2014).  This rate of implementation has 
particularly increased since 2013, as a result of funding made available to NHS organisations 
to incentivise the adoption of digital technology.  The ‘Integrated Digital Care Fund’ 
(formerly referred to as the ‘Safer Hospitals, Safer Wards Technology Fund’) was established 
by NHS England in 2013 to “facilitate the widespread adoption of modern, safe standards of 
electronic record-keeping” (NHS England, 2014; NHS England, 2013).  A further £4.2 billion 
was allocated in 2016 to support the digitisation of the NHS (National Information Board, 
2014), with the implementation of CPOE one of the main recommendations for hospitals 
(Wachter, 2016). 
 
1.2.2 Unintended consequences of CPOE 
The implementation of new technology into complex systems, such as in healthcare, can 
have some unintended and often unanticipated consequences.  Unintended effects have 
been defined as those that are “neither anticipated nor specific to the goals of the associated 
project” (Campbell et al., 2006).  Some of these may not become immediately apparent, but 
may evolve as systems become more embedded into the culture of an organisation.  
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Medication errors caused by staff interacting with the CPOE system—so called ‘socio-
technical’ incidents—have the potential to introduce new risks to patient safety (Barber et 
al., 2006; Brown et al., 2016; Redwood et al., 2011; Westbrook et al., 2013).  Some of these 
errors are not surprising (and were likely predicted) when you consider the process of 
prescribing with a pen on paper and then the process on a computer.   
 
CPOE systems contain a dictionary of names of medicines.  On starting to generate a 
prescription order in a computer, most drug dictionaries will create a drop down menu of 
the medicines that start with the letters typed.  This display can lead to ‘selection errors’, 
with a potential to generate a prescription for the wrong drug and increase the risk of 
patient harm (Brown et al., 2016; Castro. G. M., 2016).  Many systems have complex CDS, 
which can generate an order in its entirety based on a medicine selected from a drug 
dictionary (i.e. with the common dose, frequency, route and time auto-populated).  In 
theory this can help ensure an accurate prescription and save some time for the physician.  
In practice though this can lead to ‘default errors’, where the proposed order is accepted 
contrary to that required by the patient (Brown et al., 2016; Koppel et al., 2005).  There have 
also been multiple reports of errors occurring in relation to the timing of administration, 
specifically delays as prescription orders are generated unbeknown to the nurse (Amato et 
al., 2017).  Compared to paper, healthcare professionals are now exposed to active alerts 
(e.g. warnings) generated by CDS when interacting with a patient’s clinical record and 
prescription profile (‘drug chart’).  As users are faced with multiple alerts over a period of 
time, their response to these can fall.  The so called “alert fatigue” can render CDS less 
effective than intended, or even ineffective, with the potential to impact on patient safety as 
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staff are not fully informed of the potential implications of their actions (Khalifa & Zabani, 
2016; van der Sijs et al., 2008b; van der Sijs et al., 2010).  Finally, there is evidence to suggest 
that information in CPOE systems can be fragmented, or even hidden, compared to paper 
processes; user displays may not prompt the access or generation of information or data 
(Varpio et al., 2015a), which can have an impact on clinical reasoning.   
 
The use of CPOE has also been found to change communication, coordination of work and 
workflow patterns.  The technology can often facilitate remote working, whereby staff 
depend more on computers to complete their tasks and can access these away from the 
clinical setting (i.e. the ward).  This can have a direct impact on opportunities for personal 
interaction with patients and colleagues, with the potential to impact on the coordination of 
care and interprofessional relationships in the longer-term (Taylor et al., 2014).  The CPOE 
system can also lead to breakdowns in communication, where the system—as a modality for 
medication-related communication—is dependent on the documentation of information by 
users and access to information already within the system (Saleem et al., 2011), both of 
which are highly dependent on user display as well as the appropriate training. 
 
Active (interruptive) alerts generated by CDS can impact on the workflow of professionals.  
Users of the system can be forced to pay attention to the alerts in order to progress through 
an electronic process (e.g. when adding a new prescription) (Murphy et al., 2012).  This can 
be a particular problem when alerts require immediate attention, which are not directly 
relevant to the task at hand.  Such active alerts can be disruptive to workflow and often lead 
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to a need to multi-task, which can increase the risk of procedural errors (Laxmisan et al., 
2007).   
 
Finally, CPOE systems store user interactions, as well as the data generated on a daily basis.  
This can be used to drive quality improvement through the ongoing monitoring of safety 
indicators and using the information to provide feedback to staff.  However, this has also 
been shown to impact on the workflow and workload of staff, since it can encourage users 
to prioritise or conduct tasks that are monitored (Dixon-Woods et al., 2013), rather than 
those that require attention.    
 
Research has shown that the unintended effects of CPOE technology can be minimised by 
ensuring engagement of users during the process of procurement and implementation, 
appropriate planning and training and local control of how systems are configured to reflect 
the working environment (Cresswell et al., 2013b). 
 
1.3 Communication in healthcare 
Communication is the “process of submitting information and common understanding from 
one person to another” (Keyton, 2010, cited in Lunenburg, 2010).  It is a non-technical (social 
and cognitive) skill that complements clinical skills in healthcare.  The process requires a 
sender and recipient, with information transferred and received.   The effectiveness of 
communication has been shown to depend on the modality used (e.g. face-to-face) and any 
“noise” in the process (Figure 1.1, adapted from Lunenburg, 2010).  Noise may include 
factors such as language barriers, or the frequency of communications, such as with 
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receiving hundreds of emails on a daily basis.  Upon receipt of information, the process of 
communication is complete when feedback has been provided and received by the sender. 
 
Figure 1.1 – Process of communication 
 
The delivery of safe, effective and seamless care is highly dependent on effective 
communication between healthcare staff and between staff and patients.  In a complex 
health setting such as a hospital, many people with a range of professional backgrounds will 
interact with the patient and contribute to their care.  In doing so, healthcare professionals 
will clearly document their encounter and any outcomes or recommendations in the 
patient’s clinical (medical) records.  This is a core and essential component of their role and 
ensures that the wider multidisciplinary team are aware of the actions taken and decisions 
made by others, which allows for care to be effectively coordinated during an admission.   
This is never more important than in a health system where patients’ clinical records are not 
integrated across sectors of care, such as in parts of the NHS.   
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In the hospital setting, healthcare staff rely on a combination of modalities of 
communication to perform their tasks and coordinate their care.  There are many 
technologies that can facilitate this, including: alphanumeric pagers, Smartphones, mobile 
phones, hands-free devices and task management systems (Wu et al., 2012).  Electronic 
patient records, such as CPOE, may also provide such a capability, with the ability to send 
electronic messages to or between staff.  All these methods can facilitate ad-hoc 
communication and are especially important for communicating in a setting where staff are 
likely to be distributed, such as in a hospital.  Depending on the modality selected, 
communication can be synchronous—where two (or more) people participate in a 
conversation at the same time—or asynchronous, that does not require participants to be 
present at the same time.  Synchronous communication is interactive, but may be 
interruptive if the exchange is not planned (such as it would be during a handover) (Edwards 
et al., 2009).  In contrast, asynchronous communication provides flexibility for when 
information is sent and received (i.e. at a time considered convenient for each) (Parker & 
Coiera, 2000).  Studies investigating the satisfaction of professionals using the various 
modalities of communication highlight the importance of considering workflow and 
workload during their implementation (Nguyen et al., 2015; Wu et al., 2012).  The ability to 
communicate ad-hoc is beneficial, but can lead to interruptions and distractions for the 
recipient, particularly with mobile devices and Smartphones (Gill et al., 2012). Therefore 
systems introduced to facilitate, improve, enhance, or replace existing channels of 
communication should consider the participants of the communication (sender and receiver) 




Despite the array of methods to facilitate the process, poor or ineffective communication 
remains one of the leading contributing factors of adverse events in healthcare (Ackermann, 
1996; Castro. G. M., 2016; Reason, 2004; The Joint Commission on Accreditation of 
Healthcare Organizations, 2015; Zinn.C, 1995).  It is also repeatedly listed as one of the 
perceived causes of prescribing errors by those directly involved with such incidents (Dean et 
al., 2002a; Dornan et al., 2009; Ross et al., 2013; Ryan et al., 2013; Tully et al., 2009).  As 
healthcare transactions become more digitised, maintaining effectual communication is a 
priority for organisations and system developers.  In view of the risks associated with 
breakdowns in communication amongst staff, guidance has been issued in the US so that 
organisations can assess the safety of their technology in relation to “Clinician 
communication” and take the necessary steps to optimise use (Office of the National 
Coordinator for Health Information Technology, 2016).  Examples of guidance include the 
ability to assign an urgency to a message and for the status of electronic communications to 
be visible (e.g. read, acknowledged). 
 
1.3.1 Communication and the medication process 
The drug chart is considered the focal point for healthcare professionals to communicate 
and coordinate necessary and relevant information about the medication process and the 
patient.  The process, traditionally documented on paper drug charts, is gradually being 
replaced with CPOE (see 1.2.1).  In paper-based prescribing environments, research has 
shown that pharmacists write on or leave notes on drug charts to facilitate nurse 
administration or “subtly influence medical prescribing” to benefit patient care (Liu et al., 
2014).  In response to any medication-related problems identified, the pharmacist would 
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communicate with the physician synchronously (e.g. face-to-face discussion or telephone 
conversation); or asynchronously with written advice in the clinical record or on paper 
intervention notes attached directly to the drug chart.  In the presence of CPOE, the ability 
to write on the prescriptions is removed, but there is often a function for pharmacists to 
communicate information electronically, by assigning a message to an individual prescription 
order or patient profile.  In addition to the formal documentation of the activities of the 
medication process, healthcare professionals interact with one another to seek advice 
regarding medication.  In environments where information seeking networks are limited 
among staff, the rate of medication errors has been reported to increase (Creswick and 
Westbrook, 2015).  This may highlight the importance of multidisciplinary working and direct 
interaction to coordinate the process safely and effectively. 
 
The drive to digitise patient records in the NHS will see an increase in the implementation of 
CPOE systems in the hospital sector.  The technology will change the focal point of 
medication-related communication and coordination, from a paper-based system of drug 
charts to a single computer interface.  This has the potential to change how pharmacists 
communicate with prescribers, particularly physicians, regarding the optimisation of 
pharmacological treatment regimens for patients.  Since the delivery of safe, effective and 
seamless care is dependent on effective communication between healthcare staff, it is 
important that the impact of CPOE on pharmacist-physician communication is investigated.  
Such research will allow for any unintended effects on the medication process to be 
identified, which will enable hospitals to adapt their processes accordingly to minimise any 
potential impact on patient care.  
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1.4 Aims and objectives 
The aim of this research is to understand how the use of CPOE and CDS technologies in the 
hospital setting have an impact on pharmacist-physician communication.  The objectives of 
the research are to: 
1. Determine the effectiveness of uni-directional electronic communications sent via a 
CPOE system in a large acute hospital and identify factors that may influence this; 
2. Ascertain the perceptions of pharmacists and physicians of their interprofessional 
communication in the context of the technology; and 
3. Observe pharmacists’ routine clinical work and their professional interactions in the 
context of the technology. 
 
1.5 Outline of the thesis 
The chapters of this thesis are presented as follows: 
 Chapter 2: presents the findings of a systematic review of the literature of 
pharmacist-physician communication in the context of CPOE in the hospital setting.  
Emerging themes from the review inform the qualitative research described in 
chapter 8 and the final discussion.  
 Chapter 3: presents the findings of a narrative review of studies that examine the 
incidence and prevalence of medication prescribing errors or drug-related problems 
in the hospital setting.  The findings inform the method used to code the themes of 
communications described in chapter 5. 
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 Chapter 4: presents an eDelphi study to identify high-risk prescribing indicators that 
are relevant to the hospital setting and amenable to CDS.  The findings inform the 
method used to identify and code communications relating to high-risk errors 
described in chapter 5. 
 Chapter 5: presents the methods used to capture and code data relating to 
pharmacist-physician communications in the CPOE system at the University Hospital 
Birmingham NHS Foundation Trust. 
 Chapter 6: presents the findings of a descriptive analysis of the database of 
pharmacist-physician communications.  
 Chapter 7: presents the findings from a statistical analysis of temporal, prescription 
and message factors on the sign-off and action of pharmacist-physician 
communications.    
 Chapter 8: presents the findings from qualitative research conducted at University 
Hospital Birmingham NHS Foundation Trust and Guy’s and St Thomas’ NHS 
Foundation Trust. 
 Chapter 9: presents a summary of the findings of the research through a process of 
triangulation and recommendations for system design and workflow that may 














Chapter 2 A SYSTEMATIC REVIEW OF THE LITERATURE 
 
In this chapter, I describe the methods used to identify relevant studies that examine 
pharmacist-physician communication in the context of CPOE and CDS in the hospital setting. 
I categorise the topics that emerged during the review into five key themes and provide a 
narrative of the main findings.  I demonstrate that, at the time of the review in 2012, very 
few published studies focused on pharmacist-physician communication, highlighting a gap in 
the research landscape relating to this topic.  
 
A summary of this chapter has been published in the European Journal of Hospital 
Pharmacy: Thomas, S. K. and Coleman, J. J. (2012). The impact of computerised physician 
order entry with integrated clinical decision support on pharmacist–physician 
communication in the hospital setting: a systematic review of the literature. European 




2.1 Background and research question 
As new technology is embedded into the culture and organisation of a hospital, unintended 
and unanticipated consequences can also emerge.  In light of this, the implementation of 
CPOE has the potential to change communication between healthcare professionals who are 
involved in the medication process.  The objective of this study was to determine whether 
the introduction of CPOE with integrated CDS has an impact on pharmacist-physician 
communication in the hospital setting and to document any themes identified from the 




2.2.1 Methodological approach 
A systematic review of the literature can identify quantitative and qualitative studies specific 
to a defined research question.  The methodology adopted can focus the search to consider 
factors relating to the population (or participants) of interest, any interventions, 
comparisons, outcomes and the study design (referred to as the PICOS elements) (Cochrane, 
2012).  In this case, the PICOS elements to search for articles relating to pharmacist-
physician communication in the context of CPOE in hospital are as follows: 
 Participants: pharmacists and physicians 
 Intervention: CPOE and CDS technology 
 Comparison: paper-based prescribing processes 
 Outcome: communication 
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 Study design: quantitative or qualitative  
 
2.2.2 Study identification 
A search was performed on MEDLINE (1948 to November Week 3 2011, including In-Process 
& Other Non-Indexed Citations and Daily updates), EMBASE (1947 to November 23 2011) 
and PubMed. 
 
2.2.3 Search terms 
Subject headings, for example Medical Subject Headings or MeSH® terms (U.S. National 
Library of Medicine, 2011), were identified for each database relating to the elements of 
PICOS to increase the specificity of the search.  The study design was not specified in the 
search to avoid any restriction.  A ‘$’ was used to identify where a word may contain an ‘s’ or 
‘z’ to include articles with US and British English spelling. 
 EMBASE: [computeri$ed provider order entry (exp); [OR] electronic prescribing (exp); 
[OR] decision support system; [OR] hospital information system (exp)]; [AND] 
[interpersonal communication; [OR] interdisciplinary communication] [AND]; 
[pharmacist; [AND] physician (exp)]. 
 MEDLINE / PubMed: [medical order entry systems (exp) [OR]; electronic prescribing 
(exp) [OR], drug therapy, computer-assisted (exp) [OR[; decision making, computer 
assisted (exp) [OR]; hospital information system (exp)]; [AND] [interprofessional 
relations; [OR] interpersonal relations; [OR] interdisciplinary communication (exp); 
[OR] communication]; [AND] [pharmacist (exp); [OR] physician (exp)].  
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The subject headings were exploded to include narrower related terms where appropriate.  
Where narrower terms were not included under the subject headings, these were added to 
the search as ‘free text’.  An ‘any field’ search was also carried out using the NHS Evidence 
database.   
 
2.2.4 Inclusion/exclusion criteria 
Papers that focused on medication-related communication between pharmacists and 
physicians in hospital were included in the review.  All modalities of communication were 
included (e.g. face-to-face, phone, written or electronic).  The medication process in the 
hospital site of study was required to be supported by a CPOE system and integrated with 
CDS.  Papers were excluded in the review that focused on CPOE systems in the community 
setting or at the care interface.  Studies that focused solely on communication between 
other specified healthcare professionals, such as between the nurse and physician, were also 
excluded.  The language and date of publication were not defined. 
 
When studies appeared to meet the inclusion criteria or when a decision could not be made 
based solely on the title or abstract, full-text copies were obtained.  Articles that cited or 
were cited by the included studies were screened to identify any further relevant studies.  In 
addition, reference lists from important reviews were searched and personal files were 
examined to identify further studies. The selection process was validated by two 




2.2.5 Review and emerging topics 
For each of the studies selected for inclusion, the following data were recorded: the country 
and year of publication; the electronic system defined; and, pharmacist participation in any 
qualitative work was highlighted.  The content of the articles was analysed in full and 
categories applied to specific areas of the text that related to the research question (e.g. 
CDS).  After all articles were analysed, the categories were collated and grouped together to 
allow for a structured narrative review of the studies. 
 
The quality of the studies was also considered during the review, with any discrepancies in 
the reporting or sources of bias identified.  Qualitative studies were assessed for the clarity 
of their aims and objectives, the appropriateness of the research design, the recruitment of 
participants (and who they were), the setting and method for data collection, the 
researchers (who they were and how many), methods for data analysis and finally the 
reporting of the findings (Mays & Pope, 2000; Spina et al., 2011).   
 
2.3 Results 
2.3.1 Summary of the studies 
In November 2011, MEDLINE (1948 to November Week 3 2011, including In-Process & Other 
Non-Indexed Citations and Daily updates), EMBASE (1947 to November 23 2011) and 
PubMed were searched using the terms described (see 2.2.2).  A total of 48 papers were 
identified, of which 24 were excluded based on the title and abstract.  The remaining 24 
papers were reviewed in full-text and seven were selected for inclusion (Figure 2.1).  Table 
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2.1 lists the articles identified, the country where the research was conducted, the year of 
publication and the aims and objectives of each study.  The review identified six journal 
articles and one proceeding paper; of which three were based in the US, three in France and 
one in the Netherlands.  The research methods used were qualitative (n=5), quantitative 
(n=1) and mixed-methodology (n=1).  All studies were conducted in the hospital setting.  The 
focus of the seven publications were: work flow (n=1); communication/ task coordination 
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personal files 
(n=1) 
Records identified from 
database search 
(n=58) 
Articles cited by individual 
studies 
(n=10) 
Studies excluded based on abstract 
(n= 24):  
Pharmacy ordering/automation (n=1) 
Alerts (n=5) 
Physician-nurse communication (n=1) 
Economic factors (n=1) 
Electronic histories (n=2) 
Implementation of CPOE (n=1) 
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Physician-nurse communication (n=1) 
Effect of CPOE on error rates (n=4) 
Error cause/prevention analysis (n=2) 
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Observations/recommendations (n=2) 
Review of communication (n=2) 
Healthcare team communication (n=1) 
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USA To describe the perceived 
effects of CPOE on 
professional collaboration, 




Not defined 16 semi-structured interviews 
17 participatants  
One interviewed 
(Ash et al., 
2004) 
USA To assess the types of 
medication errors 
witnessed in hospitals 
using CPOE and the nature 
of these errors  
Qualitative Various CPOE 
systems with 
integrated CDS 
Summarises literature on Patient 
Care Information Systems (PCIS): 
340 hours of observations (USA) 
59 formal interviews (USA) 





France To analyse pharmacists’ 
interventions in a setting 
where CPOE is in use and a 
pharmacist works on the 
ward and the acceptance 
of these 








France To describe the prescribing 
error rate during a 
patient’s stay and the 
characteristics of the error 
most predictive of their 
reproduction the next day 







Prospective analysis of 96 
pharmacy alerts communicated 


















USA To examine how CPOE 
alters the full range of 
communication within 
institutions and how 
communication influences 






Retrospective re-examination of 
qualitative data  
 
Not directly defined 
(Estellat et 
al., 2007) 
France To describe pharmacists’ 
interventions via CPOE, 
their impact and the 
extent CPOE is responsible 









Prospective analysis of 81 
pharmacy alerts communicated 
via CPOE  
48 semi-structured interviews  
with targeted physicians  
Data collection, 
independent review 







To assess the effects of a 
CPOE system on 
interprofessional work 










2.3.2 Narrative review of included studies 
Several topics emerged during the analysis of the seven studies, which were grouped to 
illustrate the potential impact of CPOE and CDS on pharmacist-physician communication: 
computer entry: a false communication; interpersonal communication; the impact of 
pharmacist messages in an electronic format; physician accessibility to pharmacist alerts; 
and the effect of CDS on communication. 
 
2.3.2.1 Computer entry: “a false communication”  
Communication in the context of CPOE is largely one-way—where the person-computer 
interaction is one that is uni-directional.  This was found to impact on the effectiveness of 
communication, as well as the coordination of work between healthcare professionals (Ash 
et al., 2004; Dykstra, 2002).  Initiating a communication via the computer was found to give 
a “false sense” (Dykstra, 2002) that a communication had been completed, with the 
information transferred effectively and received as intended.  This was compared to 
communications that were written, which were more likely to be followed up with direct 
communication as there was more of a sense that “it hasn’t gone anywhere” (Dykstra, 
2002).  The assumption that a communication had been completed via the computer was 
found to increase the risk of miscommunication regarding management plans (Ash et al., 
2004), particularly because further action may not be taken to ensure the information had 
been received. 
 
Ash et al (2004) describes how communication in healthcare is conducted to generate an 
“effect” and that it is not just about the transfer of information, but also the “testing of 
assumptions regarding the other person’s understanding of the situation and willingness to 
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act on the information”.  Effective two-way communication is vital in healthcare and for the 
medication process to run efficiently.  The authors concluded that two-way communication 
could be beneficial since it can provide flexibility in the system—needed to better fit real 
working practices—and that feedback mechanisms are needed so that professionals can 
better coordinate tasks and maintain an awareness of the steps of the medication process 
(Ash et al., 2004). 
 
2.3.2.2 Interpersonal communication 
The increased interaction with the computer and false sense that a communication has 
taken place, has the potential to reduce interpersonal communications (Ash et al., 2004).  
CPOE systems also facilitate remote working where physicians can generate prescription 
orders from any location and simultaneously review patient records that are being used by 
another healthcare professional.  This capability can reduce the opportunities for direct 
interaction with other healthcare professionals working on the ward; “One of the complaints 
we’ve heard is that there’s not that physical presence; that people aren’t around as much to 
ask questions and to get this interaction with”(Dykstra, 2002).  In one qualitative study, 
although CPOE was found to be beneficial for physician–pharmacy workflow, interpersonal 
communications were reported to increase (Niazkhani et al., 2010).  This was as a result of 
needing to perform extra tasks to coordinate work, such as with writing paper notes and 
initiating phone calls and face-to-face communication.  A second qualitative study 
investigating the perceived effects of CPOE on professional collaboration, workflow and 
quality of care reported that none of the professional groups involved in the medication 
process (physician, nurse and pharmacist) relied on the system to coordinate tasks (Aarts et 
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al., 2007).  Other modalities of communication were used by staff to coordinate inter-
dependent tasks. 
 
2.3.2.3 The impact of pharmacist messages in an electronic format  
Two studies in France investigated pharmacy messages that were targeted at physicians and 
sent via the CPOE system and the impact of these on the medication process.  The first 
study aimed to identify the types of interventions communicated and their impact on the 
prescribing process (Estellat et al., 2007).  The second to identify the characteristics of a 
prescribing error most predictive of their reproduction the next day (i.e. messages being 
overridden) (Caruba et al., 2010).  In both studies, the pharmacist could validate orders on 
the CPOE system with “accepted (agrees)” or “refused (disagrees)” symbols inserted next to 
the order line, as well as communicate messages (or “alerts”) electronically in response to a 
prescribing error.  Both studies reported a low acceptance rate of pharmacists’ alerts that 
were communicated via the CPOE system.  In the first of the two studies, pharmacists did 
not participate in ward rounds and provided advice to the physician only via the CPOE 
system (Estellat et al., 2007).  Out of the 81 alerts analysed, only 26% (n=21) resulted in a 
modification of therapy.  When physicians were asked why they had not accepted the 
pharmacy alert (i.e. modified the prescription) the most common response suggested that 
the physician did not agree with the pharmacist’s recommendation; “I think my order is 
clear enough for the nurse” (24%) and “due to disease progression, biology, or a specific 
context, it wasn’t required” (22%).  The authors proposed that the impact of pharmacists’ 
interventions were questionable owing to the high number of prescriptions that were not 
modified.  In the second study, the pharmacist visited wards to review electronic 
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prescription orders on Monday to Friday (Caruba et al., 2010).  A total of 96 alerts posted by 
pharmacists to physicians were analysed and 48% (n=46) resulted in an amendment of the 
prescription.  The authors rationalised the low level of acceptance because clinical 
pharmacy was a relatively new and expanding concept in France and despite the low 
acceptance, concluded that implementation of electronic alerts to communicate 
medication-related issues to the physician “could complement the pharmacists’ validation 
tasks and make the prevention of prescribing errors more efficient” (Caruba et al., 2010).  
 
Physician acceptance of pharmacists’ advice was investigated prospectively in a French 
teaching hospital (Bedouch et al., 2011), specifically investigating factors most predictive of 
acceptance.  In this study, 86.6% of assessable interventions were accepted by physicians.  
Slightly more interventions were communicated electronically via the CPOE system 
(n=257/448, 57.4%) compared to verbally.  The modality of communication was found to 
significantly affect the time to acceptance of requests (p<0.001); with the majority of 
interventions communicated verbally accepted by the physician within one hour.  The study 
found oral communication to be a predictive factor of intervention acceptance. 
 
2.3.2.4 Physician accessibility to pharmacy alerts  
The accessibility of pharmacist messages (“alerts”) communicated via a CPOE was identified 
as an issue in two studies investigating the impact of such messages on the medication 
process.  In one, a total of five clicks were reported to be required in the CPOE system for 
the physician to access and read the message (Caruba et al., 2010).  In a similar study where 
the reasons for physicians’ non-adherence with pharmacy alerts was investigated (Estellat et 
al., 2007), the third most common response was “It’s an omission, I haven’t seen it yet” 
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(16% (n=8/49)). Other explanations included: “I did not know how to view the text comment 
of the pharmacy alert” (8% (n=4/49)) and “the prescription was difficult to modify with the 
software” (10% (n=5/49)).  The authors recommended that display characteristics were 
important and “ergonomic improvements” (Estellat et al., 2007) were needed to ensure 
communications were more accessible. 
 
2.3.2.5 Clinical decision support: effect on communication 
The advanced functionality of CDS systems can, for example, allow the physician to review 
the medicines that are available (in stock) for prescribing within the hospital.  In a 
qualitative study investigating the effects of CPOE on interprofessional workflow in the 
medication process, access to CDS was found to decrease the number of interruptions for 
the physician from someone in pharmacy calling to discuss an alternative medicine rather 
than one that was unavailable (Niazkhani et al., 2010).  The system enabled physicians to 
enter a reason for their prescription order, therefore communicating a rationale to the 
pharmacist (or other healthcare professional) and preventing the need for a call to be made 
for clarification.  Fewer call-backs were also made to physicians for illegible or incomplete 
prescriptions in the study.   
 
A second study investigating the perceived impact of CPOE on professional collaboration, 
workflow and quality of care (Aarts et al., 2007), highlighted a pharmacist’s perceptions of 
CDS and how this might impact on their on the role.  The pharmacist communicated an 
understanding that some CDS functionality will replace the requirement for their 
interventions to be made as the system may detect many of the errors and alert the 
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physician instead.  As a result, contact with the physician may not be required to such an 
extent.  On the other hand, the same pharmacist stated that the role of the pharmacist may 
shift and “might become broader”, with a potential of increasing collaborative working.  This 
was supported by Estellat et al (2007), the authors of whom concluded that the 
development of further CDS, such as for drug-dose adjustment and availability of medicines, 
may prevent some prescribing errors and would enable pharmacists to “concentrate on the 
most relevant interventions” when reviewing and validating prescriptions (Estellat et al., 
2007). 
 
2.3.3 Study and reporting quality 
In this review, two of the three studies incorporating quantitative analysis of pharmacy 
alerts (Caruba et al., 2010; Estellat et al., 2007) had a low sample size (n=81 and 96 alerts 
respectively) collected over a short period of time, with an inevitable impact on the power 
of the study.  In one of these, the physicians’ reasons for not adhering with the pharmacists’ 
alerts were investigated using semi-structured interviews (Estellat et al., 2007).  The method 
adopted was the use of a multiple choice form with four possible reasons and a fifth reason 
as ‘other’ allowing for a free-text comment.  This gave the interviewee less scope to express 
their opinion or feeling on the subject and may inadvertently direct them to select an option 
that could remove accountability.  The third quantitative study examined a comparatively 
larger number of pharmacist interventions (n=448) and looked at the factors most 
predictive of their acceptance, such as the modality of communication used (Bedouch et al., 
2011).  In this study, on-ward integration of clinical pharmacists occurred at the same time 
as CPOE implementation.  As a result, the significance reported between electronic and 
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verbal communications with regards to physician acceptance may have been influenced by 
the recent pharmacy service provided at a ward level.  In the four qualitative studies 
comprising interviews, pharmacist participation was low (see Table 2.1).  One study 
recruited only one pharmacist, who was also the project lead for the CPOE implementation 
(Aarts et al., 2007).  This introduces a potential for bias compared to other participants, 
though this was not evident from the article.  In this same study, the recruitment of 
participants was made via an invitational consensus meeting, which may also introduce an 
element of bias.  This was acknowledged by the authors as a limitation, but it was also 
expressed that the risk was minimised owing to the variety of professional backgrounds.  In 
three studies, the methods for participant recruitment were not stated (Ash et al., 2004; 
Dykstra, 2002; Niazkhani et al., 2010).  One study re-examined data initially gathered in 
qualitative research looking into how CPOE alters the full range of communication within 
institutions and how communication influences its success (Dykstra, 2002).  The 
retrospective review was carried out by the author of the article, who was not named as a 
contributor in the original study (Ash et al., 1999).  When quotes were provided within the 
text, the profession or grade of the interviewee was not defined and occasionally, who they 
were referring to was not stated.   
 
2.4 Discussion 
In this review, I aimed to explore the impact of CPOE with integrated CDS on pharmacist-
physician communication in the hospital setting.  The review identified seven relevant 
studies, the small number of which demonstrates a gap in the research and knowledge 
relating to this subject.  Out of those studies included, several topics emerged that were 
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categorised to allow for a narrative review of the findings: computer entry: “a false 
communication”; interpersonal communication; the impact of pharmacist messages in an 
electronic format; physician accessibility to pharmacist alerts; and, the effect of clinical 
decision support on communication. 
 
This review highlighted how personal interactions can be reduced in a setting that utilises 
CPOE and CDS in one of two ways.  First, health technology such as CPOE can facilitate a 
workflow whereby the presence of healthcare professionals in the same space as each 
other, such as on the ward—is no longer necessary to carry out medication-related tasks.  
Second a reduction in the frequency of communications between the pharmacist and the 
physician as a direct result of the technology.   
 
Personal presence was found to change for two reasons.  First, an interaction with the 
computer to complete or review steps of the medication process can create a sense (and 
therefore assumption) that a communication has occurred with other members of the 
multidisciplinary team.  In the case of a pharmacist communicating an intervention via the 
CPOE system, submission of a message via the computer may lead to an assumption that 
the task has been completed and that a personal interaction with the physician is no longer 
necessary to follow-up or coordinate the task.  Second, the ability to interface with the 
computer from any location means that healthcare professionals do not need to be present 
in the same vicinity (e.g. on a ward) to carry out medication-related tasks and 
documentation.  Physicians can enter medication orders and pharmacists validate and 
review these orders at a distance from one another, which can reduce the opportunity for 
personal interactions, whether formal or informal in nature.  Evidence suggests that this 
35 
 
increased reliance on the computer to complete tasks and communicate can have an impact 
on the coordination of work between physicians and nurses (Beuscart-Zephir et al., 2005; 
Pirnejad et al., 2009; Pirnejad et al., 2008), which has the potential to increase the risk of 
miscommunication, with potential for error.  It is important that organisations and staff are 
aware of the potential for this unintended effect of the technology and put processes in 
place to account for this prior to implementation.  This may include the consideration of 
system design and choosing a system that provides the capability to allow healthcare 
professionals to more effectively coordinate their work within the system (e.g. two-way 
communication), as well as the provision of training to highlight the negative impacts. 
 
The frequency of interpersonal interactions between the pharmacist and the physician was 
reported to be reduced in the context of CPOE.  The technology has the capability to 
prevent certain medication errors (e.g. caused by illegible orders) and CDS can provide 
physicians with the information and guidance to support their prescribing, such as with the 
provision of formularies or protocols.  In both cases, CPOE and CDS can serve to replace 
many of the interventions formerly documented and communicated by pharmacists during 
the process of clinical check and medication review.  As systems provide more complex 
pharmacological information to guide the prescribing process, the number of encounters 
between the two professionals may fall.  In view of the fact that members of the healthcare 
team may also become more spatially distributed throughout the hospital, the physician 
may rely more on the computer for this guidance over time. 
 
Verbal communication was found to increase the acceptance rate of medication-related 
interventions—predictive of requests being translated into practice.  Taking this into 
36 
 
account, a shift towards a virtual modality of communication between the two professions 
may impact on the integration of pharmacists’ work within the clinical team, the physicians’ 
perception of their role and overall acceptance of their clinical interventions.  It is important 
that the potential barriers and disruptions to the flow of information between the 
pharmacist and physician are highlighted to staff (Georgiou et al., 2007) and that 
communication functions within systems are designed so that the intended recipient can 
easily access the information and increase the likelihood that it will be considered and 
actioned in practice.   
 
Effective communication between the pharmacist and physician could enhance coordinated 
exchange of information and more immediate resolution of drug-related problems and 
medication errors.  Optimising this exchange in the context of CPOE could increase 
collaborative working, which can benefit patient care.   
 
2.4.1 Limitations 
The topics identified in this review are limited by the small number of studies focusing on 
pharmacist-physician communication and collaborative work in the hospital setting.  
Furthermore, the primary aims of the studies included were not to determine the effect of 
CPOE or CDS on pharmacist-physician communication, but to investigate interprofessional 
collaboration and workflow generally, or the impact of pharmacist messages in such 





At the time of this review, few studies were identified that investigated how CPOE and CDS 
impacts on pharmacist-physician communication in the hospital setting.  Furthermore, no 
studies were identified that examined specifically how CDS impacts on what is 
communicated by pharmacists.  Taking the time to examine this relationship in the context 
of new technologies will allow for a better understanding about the interaction between the 
professionals and whether this has the potential to impact on the care of the patient.  Such 
an insight may enable channels of communication in existing CPOE systems to be enhanced 
so that interprofessional work can be optimised to benefit patient care.  The themes 











Chapter 3 CLASSIFYING ERRORS IN THE MEDICATION PROCESS: A 
NARRATIVE REVIEW OF THE METHODS ADOPTED IN THE HOSPITAL 
SETTING 
 
In this chapter, I describe the methods used to identify relevant studies that examine the 
incidence and prevalence of medication prescribing errors or drug-related problems in the 
hospital setting.  I examine the classification schemes adopted by researchers to categorise 
errors and identify whether the schemes have been through a process of validation.  I 
demonstrate that at the time of the review, there was no standard approach for classifying 
medication errors or drug-related problems, despite some published and validated schemes 
being available.  I conclude that developing a classification scheme that is tailored to the 
research question and local study environment is common practice. 
 
3.1 Background and research questions 
Analysing and monitoring the incidence, prevalence and potential cause of errors in 
healthcare is an essential component of patient safety.  The data can be incredibly powerful 
to an organisation when used appropriately—that is through the sharing of the information, 
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implementing change to minimise risks and optimise care and then re-examining the impact 
of that change.  The data could be even more powerful if the results of individual studies in 
a setting (e.g. hospital) could be combined to provide a national rate of error and if settings 
could be directly compared to one another to drive quality improvement.  The collation of 
such data would require organisations and authors of studies to adopt the same definitions 
of error, data collection techniques and classification schemes to categorise error types and 
severity (American Society of Hospital Pharmacists (ASHP), 1993; Franklin et al., 2010; 
Shawahna et al., 2011; World Health Organization, 2009). 
 
3.1.1 Terminology 
Drug-Related Problem (DRP); medication error; medication-related error; and Adverse Drug 
Events (ADE) are all referred to in the literature when referring to errors occurring during 
the medication process.  The terminology used often changes depending on the aims of the 
research and potentially who is conducting the study.  Furthermore, the definitions for 
these terms vary in the published literature. 
 
A DRP has been defined as “A circumstance that involves a patient’s drug treatment that 
actually, or potentially, interferes with the achievement of an optimal outcome” (Johnson & 
Bootman, 1995); a definition that has been adopted (albeit slightly modified) by the 
Pharmaceutical Care Network Europe (PCNE) Working Group on drug-related problems 
(Pharmaceutical Care Network Europe, 2012).  The definition has been criticised by some 
since the premise of the DRP is that there is a potential for harm, omitting other problems 
that may not necessarily pose a risk to the patient (van Mil, 2005).  This has led to sub-
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categorisation of the term when classifying problems to identify those that involve error and 
those that do not (Fijn et al., 2002; van den Bemt et al., 2000).   
 
Medication errors have been defined as “a failure in the treatment process that leads to, or 
has the potential to lead to, harm to the patient” (Ferner & Aronson, 2000)—a definition 
adopted by both the European Medicines Agency (European Medicines Agency, 2014) and 
the World Health Organization (World Health Organization, 2014).  In the US, the National 
Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) use the 
definition of "any preventable event that may cause or lead to inappropriate medication use 
or patient harm while the medication is in the control of the health care professional, 
patient, or consumer" (National Coordinating Council for Medication Error Reporting and 
Prevention (NCC MERP), 2012).  Both definitions make it clear that errors can occur at all 
stages of the medication process (e.g. prescribing, dispensing) and unlike DRPs, the latter of 
the two definitions emphasises that the error does not need to lead to patient harm (or 
potential for harm) as an outcome and that error can simply relate to the use of a medicine. 
 
Attempts have been made to standardise the definition of a prescribing error in the 
medication process.  A practitioner led definition was agreed by consensus as: “a clinically 
meaningful prescribing error occurs when, as a result of a prescribing decision or prescription 
writing process, there is an unintentional significant (1) reduction in the probability of 
treatment being timely and effective or (2) increase in the risk of harm when compared with 
generally accepted practice” (Dean et al., 2000).  Despite the publication of this definition, a 
systematic review conducted nine years later, in which 70% of the studies were conducted 
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after the definition was agreed, still found that the majority of studies developed their own 
definitions or modified existing ones (Dornan et al., 2009). 
 
3.1.2 Classification schemes 
Classification schemes allow for data and information to be organised using a standard 
approach and hopefully in a way that can avoid subjectivity in the process.  The WHO 
emphasises the importance of a single classification scheme for monitoring patient safety 
incidents, since the ongoing use of different taxonomies prevents effective sharing of data, 
which has a direct impact on learning opportunities (World Health Organization, 2012).  A 
single taxonomy is adopted in the UK, where the NRLS receive patient safety incident 
reports via a national online database.  The use of a single taxonomy to describe incidents 
within the database means that the information can be analysed on a national level to 
ascertain where risks exist and identify vulnerabilities in systems that may be contributing to 
patient harms. 
 
Attempts have been made to standardise the classification of DRPs or medication errors for 
research and audit purposes (Hohmann et al., 2012; National Coordinating Council for 
Medication Error Reporting Prevention, 1998; Pharmaceutical Care Network Europe 
Foundation, 2010).  Yet, evidence would suggest that many organisations and researchers 
continue to use their own schemes to meet local objectives for data collection (Dornan et 
al., 2009; Schaefer, 2002).  Eight principles have been published to facilitate the 
development of coding systems for DRPs (Schaefer, 2002), but a literature search conducted 
a couple of years later found that no system met all eight principles (van Mil et al., 2004) 
and few classification systems had been through a process of validation for their usability.   
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The aim of this study is to identify how medication errors and DRPs are classified in studies 
investigating their incidence and prevalence.  This will capture information provided by the 
authors on for the use of schemes to categorise errors and whether these have been 
through a process of validation.  The results of this review will inform the methodology for 
the categorisation of pharmacist-physician communications in the hospital setting. 
 
3.2 Method 
3.2.1 Methodological approach 
A systematic review of the literature was selected to identify studies specific to the research 
question.  The PICOS elements relating to the incidence and prevalence of medication errors 
and DRPs are as follows: 
 Population: hospital or secondary care 
 Comparison: medication errors or DRPs 
 Outcome: incidence or prevalence of medication errors or DRPs 
 Study design: retrospective and prospective studies 
An intervention was not specified in the search to avoid any restrictions relating to the 
research methods adopted by the authors in the studies.   
 
3.2.2 Study identification 
A search was performed on MEDLINE (1980 to week 9 2012), including In-Process & Other 




3.2.3 Search terms 
Subject headings were identified relating to each of the PICOS elements and for each 
database to increase the specificity of the search.  The subject headings were exploded to 
include narrower related terms where appropriate: medication error (exp) OR drug related 
problem; retrospective studies (exp) OR prospective studies (exp); AND incidence (exp) OR 
prevalence (exp); AND hospital (exp) OR secondary care.   
 
3.2.4 Inclusion/exclusion criteria 
Studies published in English were included in the review that focused on the incidence of 
medication-related error in the hospital setting relating to prescribing.  Studies were 
excluded if they were carried out in the community, ambulatory care or outpatient settings 
and where only one error type (e.g. dose omissions) or one class of medicine was being 
investigated.  Studies were also excluded if the article did not define the categories within 
the classification scheme (or make this available as supplementary information online).  In 
cases where studies appeared to meet the inclusion criteria, or where a decision could not 
be made based on the title or abstract alone, full-text copies were obtained.  Articles that 
cited or were cited by the included studies were screened to identify any further relevant 
studies not already captured in the search.  In addition, the references from reviews were 
searched. 
 
3.2.5 Review and emerging topics 
For each of the studies selected for inclusion, the following data were recorded: country and 
year of the publication, the aim of the study, the system used in the medication process (i.e. 
paper-based or computerised) and the terminology for error referred to.  For each study, 
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the categories (and any sub-categories) used to classify the errors were summarised and 
tabulated.  Where a classification scheme was referenced by a study, this was further 
investigated to examine validation processes to establish whether pre-determined 
specifications were met. 
 
3.3 Results 
3.3.1  Summary of the studies 
A total of 122 studies were identified, of which 71 were excluded based on the title and 
abstract.  The remaining 51 papers were reviewed in full-text and 31 of these were selected 


























Figure 3.1 – Flow chart for article selection for the narrative review  
Records identified from 
database search 
(n=176) 
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Adverse drug reactions (n=7) 
Ambulatory care (n=4) 
Causes of error (n=2) 
Detection (n=1) 
Diagnostics (n=2) 
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Error reporting rates (n=5) 
Missed doses (n=2) 
Medical error (n=6) 
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Prescribing behaviour (n=1) 
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3.3.2 Narrative review of the included studies 
A summary of the 31 studies included in the review is provided in Appendix 1.  The studies 
were conducted in 15 countries, with a high proportion carried out in the US (n=9/31) and 
UK (n=7/31).  The methods used for data capture were prospective (n=18/31) and 
retrospective analysis (n=13/31) and comprised reviews of medication orders (n=21/31), 
case notes (n=3/31) and voluntary incident reporting forms alone or in combination with 
medication order review (n=7/31).  The terminology used to describe the errors being 
investigated ranged, with the majority referring to medication errors (n=16/31) and 
prescribing errors (n=8/31) and some adverse drug events (n=3/31) and DRPs (n=1/31).  
There were also studies that used a combination of terms (n=3/31).  A CPOE system was 
used in eight of the study sites, two of which were pre-/post-intervention studies following 
implementation of the technology.  One national study in the US reported on error rates for 
496 hospitals, of which 25% utilised some form of CPOE (Pham et al., 2011). 
 
The categories used to classify errors varied widely between studies.  The number of 
potential categories in a single classification scheme ranged from four (Fijn et al., 2002; Vrca 
et al., 2005) to 20 (Devine et al., 2007) (Table 3.1).  Ten out of the 31 studies used sub-
categories to further describe the errors.  The main category of ‘Dose’ was used in all the 
studies, although this ranged from a single statement of ‘Wrong dose’, to one study 
separately categorising ‘Underdose’, ‘Overdose’, ‘No maximum dose stated’ and ‘Missing 
dose information’ (Dornan et al., 2009).  There were categories not mentioned in any other 



































































































No. of sub- 
categories 
(Lesar et al., 1997b)                Underdose 9 0 
(Wilson et al., 1998)                Transcription error 9 0 
(Ross et al., 2000) 
               Incorrect intravenous 
concentration 
11 0 
(Fijn et al., 2002)                Non-existing dosage form 7 29 
(Kozer et al., 2002)                Information 6 0 
(LaPointe & G., 2003)                Wrong dose or drug 8 0 
(Parthasarathi et al., 
2003) 
               Drug-disease interaction 8 27 
(Bobb et al., 2004)                Drug-food interaction 16 0 
(Chen et al., 2004)                Out of stock 12 0 
(Nebeker et al., 2005)                Wrong strength/ 
concentration 
14 16 
(Vrca et al., 2005)                 4 0 
(Barber et al., 2006)                Wrong diluent 12  
(Ashcroft & Cooke, 
2006) 
               Wrong strength 15 0 
(Colpaert et al., 2006)                Wrong duration 14 16 

































































































No. of sub- 
categories 
(Jayawardena et al., 
2007) 
               
Dose inappropriate for 
creatinine clearance 
8 0 
(Marcin et al., 2007)                 11 2 
(Madegowda et al., 2007)                
Pre-op medication not re-
started 
13 0 
(Engum & Breckler, 2008)                 10 0 
(Picone et al., 2008)                Adverse effect 11 0 
(Kunac & Reith, 2008)                Monitoring error  14 16 
(Pham et al., 2011)                Unauthorized drug  given 9 0 





















adverse drug reaction 
29 0 
(Ghaleb et al., 2010)                Use of abbreviations 8 0 
(Klopotowska et al., 2010)                Unnecessary drug use 9 0 
(Al-Jeraisy et al., 2011)                Undecided route 8 11 
(Franklin et al., 2011)                No indication 14 0 
(Hartel et al., 2011)                Wrongly transcribed  3 15 
(Jennane et al., 2011)                
Drug not prescribed 
despite indication 
6 0 
(Shawahna et al., 2011)                
Maximum dose not 
specified on when 
required 
9 9 
(Westbrook et al., 2012)                Not indicated 17 0 
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A total of 12 articles referred to other published studies to inform the classification scheme 
(Appendix 1).  Four studies adopted the use of the NCC MERP Taxonomy of Medication 
Errors, either in full (Colpaert et al., 2006; Kunac & Reith, 2008) or as a modified version of 
this (Marcin et al., 2007; Pham et al., 2011); two used a scheme developed by the author(s) 
in a previous study (Ghaleb et al., 2010; Shawahna et al., 2011); one referenced the 
American Society of Hospital Pharmacists (Wilson et al., 1998); one the ADE Prevention 
Study Group (LaPointe & G., 2003); and four a scheme adopted by other published studies 
(Barber et al., 2006; Fijn et al., 2002; Hartel et al., 2011; Kozer et al., 2002).  One of these 
published studies referenced a further study for its scheme (Cousins & Hatoum, 1991).  
Overall nine different schemes were identified, of which three had been through a process 
of formal validation according to the primary author(s) (Ghaleb et al., 2005; Pharmaceutical 
Care Network Europe, 2012; Shawahna & Rahman, 2009).  A Delphi technique was used by 
two studies to validate the scheme classification and one was validated during a working 




In this review I identified 31 studies investigating the prevalence, type and in some 
instances, the severity of errors in the medication process in the hospital setting.  The 
terminology for error, the methods for data collection and the classification scheme to 




The terminology referred in the studies did not appear to inform the number and type of 
categories used in the classification schemes.  For example, Dornan et al (2009) investigated 
prescribing error and used a classification scheme with 29 main categories, whilst another 
study only used four (Vrca et al., 2005).  Fijn et al (2002) investigated prescribing errors, but 
included categories in the classification scheme such as ‘sound-alike drug prescribed' and 
‘abbreviations for frequency/route’—categories that would not be considered prescribing 
errors by some practitioner led definitions (Dean et al., 2000).  These findings were 
consistent with previous research that found the definitions for prescribing error were often 
developed specifically for the study or were modified from existing ones (Bjorkman et al., 
2008; Dornan et al., 2009; Lisby et al., 2010). 
 
Despite published classification schemes being available in the literature, the majority of 
authors of studies did not refer to these as a reference for their method of data analysis.  
This may suggest that organisations prefer to collect data specific to the study environment 
and research question and that published schemes do not always fulfil these requirements.  
It is also important to note that organisations are likely to want to continue to use schemes 
that they have previously adopted so that direct comparisons can continue to be made for 
longitudinal analysis of error rates.  In those studies that did refer to a published 
classification scheme as evidence for the method, no authors provided a rationale for their 
choice.  Few of these had been through a process of validation, which is important for 
testing the accuracy and reliability of a method.  This may suggest that this is not always 
considered an important factor, perhaps because researchers will standardise how they 
categorise errors with the provision of training to ensure this is approached consistently and 
internal validation may take place for a proportion of these. 
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The categories selected to organise data within a scheme were found to vary widely, with 
some authors adopting very broad descriptions and others more detailed and often 
presented as sub-categories.  The more detailed the description of an error is, the more 
information that can be captured about the nuances of that error.  However, this needs to 
be balanced against continuing to ensure ease of use of the scheme and avoiding potential 
confusion between categories (Schaefer, 2002; World Health Organization, 2012).   
 
The use of a CPOE system can reduce the rate of medication prescribing errors, eliminating 
those associated with illegibility and incomplete information (Barber et al., 2006; Bates et 
al., 1998; Bates et al., 1999).  In this review, few studies were carried out in settings utilising 
CPOE, but in those that were, the classification schemes were not adapted to account for 
the new process of prescribing.  Two studies referenced a scheme that was developed for 
paper-based processes (Barber et al., 2006; Shawahna et al., 2011).  This may suggest that 
errors did not emerge in the studies that were believed to be solely related the use of the 
technology (e.g. selection errors), or did not occur at a rate that would warrant a new 
category to be added to a scheme. 
 
3.4.1 Limitations 
A defined search strategy was used in this review to identify relevant studies, which may not 
have captured every published study investigating medication errors or DRPs occurring in 
the medication process.  Furthermore, only articles published in English were included and 
the grey literature was not searched for similar studies.  However, I have no reason to 
believe that a much more comprehensive search strategy would have altered the 
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conclusions about the current state of medication error classification schemes reported in 
the literature.   
 
3.5 Conclusions 
Healthcare researchers adopt classification schemes to organise data into manageable and 
meaningful categories that can be analysed to inform quality improvement initiatives.  
There is no recommended standard for classifying medication errors or DRPs, although 
there are some published schemes available, which have been subjected to a process of 
validation.  A structured and consistent approach to capturing and classifying these would 
provide a powerful insight into their incidence and prevalence across a healthcare setting to 
better inform quality and safety improvement.  The uptake of such a standardised scheme 
may be encouraged if organisations had the opportunity to adapt elements (e.g. sub-











Chapter 4 DEVELOPING CONSENSUS ON HOSPITAL PRESCRIBING 
INDICATORS OF POTENTIAL HARMS AMENABLE TO CLINICAL 
DECISION SUPPORT 
 
In this chapter, I describe the eDelphi technique conducted to identify high-risk prescribing 
indicators that are relevant to the hospital setting and amenable to CDS.  I summarise the 
80 indicators that were agreed by consensus and their associated harms.  The indicators will 
be used to identify high-risk errors in the quantitative analysis of messages communicated 
by pharmacists to physicians via the CPOE system at UHBFT.   
 
A summary of this chapter has been published in the British Journal of Clinical 
Pharmacology.  I was also co-author on a similar study conducted for the paediatric setting, 
published in the same journal. 
 Thomas, S. K., McDowell, S. E., Hodson, J., et al. (2013) Developing consensus on 
hospital prescribing indicators of potential harms amenable to decision support. 
British Journal of Clinical Pharmacology, 76 (5): 797-809. 
 Fox, A., Pontefract, S., Brown, D., et al. (2016) Developing consensus on hospital 
prescribing indicators of potential harm for infants and children. British Journal of 
Clinical Pharmacology, 82 (2): 451-460.  
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4.1 Background and research aims 
Monitoring the types and rates of errors is crucial in understanding how processes can be 
improved to reduce the risk of patient harm and to examine whether an intervention to 
improve a process has had the desired impact.  Determining the potential harm of these 
errors and the subsequent burden to both the patient and the NHS can prove difficult.  
Indeed many studies choose to utilise their own severity scales for defining a level of harm.  
These tend to be subjectively assessed and scored by the researcher, with the potential for 
introducing bias, or request consensus is achieved from a number of healthcare 
professionals for every error found in the research (Dean & Barber, 1999; Dornan et al., 
2009), which can prove time consuming and costly. 
 
Untargeted prescription chart review for potential prescribing errors can lead to a plethora 
of low- or no-harm errors (Avery et al., 2012; Dornan et al., 2009).  Whilst newer processes 
exist for determining ‘actual’ harm occurrences—for example by looking at triggers that 
indicate harms such as the prescribing of antidote medicines or critical laboratory values 
(Griffin & Resar, 2009)—such processes require an intensive retrospective review of clinical 
records.  Determining the preventable nature of such harm is also prone to subjective 
interpretation.    
 
Prescribing indicators are agreed by a range of stakeholders to be a valid method to 
measure or monitor an area of prescribing, where there is a perceived direction in which the 
prescribing being measured should move over time (The Information Centre (Health Care), 
2012).  Previous work in general practice has identified a list of critical indicators of potential 
prescribing errors in the UK as a means of assessing the safety of general practitioner 
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prescribing (Avery et al., 2011).  In a similar manner, Inappropriate Prescribing (IP) criteria 
for older adults have been developed to facilitate chart review and identify the medications 
that may ‘potentially’ lead to adverse drug events (Gallagher et al., 2008; Laroche et al., 
2007).  However, this ‘screening’ tool is restricted to errors of omission and commission, is 
specific to a patient population and is not necessarily designed to measure prescribing over 
time.  In Australia, hospitals are encouraged to use the ‘Indicators for Quality Use of 
Medicines (QUM)’ – a set of 30 indicators designed to measure both processes and 
outcomes of medication use to inform system improvement (NSW Therapeutic Advisory 
Group, 2007).  These indicators are generally not specific to a medicine and capture data on 
quality rather than safety for optimal medication use rather than indicators of potential 
harms.  Therefore, at present, there remains no validated list of prescribing indicators that 
have been developed for the hospital setting, or that are associated with both the highest 
risk of patient harm and likelihood of occurrence. 
 
As CPOE becomes more widespread in the hospital setting, prescribing indicators should be 
considered that are amenable to CDS—that is the error to which each indicator refers has 
the potential to be prevented by such software.  The use of CDS provides an opportunity to 
alert prescribers to potential harms (Kaushal R, 2003; Pearson et al., 2009; Schedlbauer et 
al., 2009).  Such systems have been shown to substantially reduce medication error rates, 
but most studies have not been powered to detect differences in the rate of adverse drug 
events (Kaushal R, 2003).  As described in Chapter 3, the methods adopted by the 
researchers and the study outcomes also vary, making comparisons between them difficult.  
Developing indicators that are amenable to CDS allows for the effects of this technology to 
be quantified; this is important not only given the rate at which such technologies are being 
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implemented but also relevant because of the heterogeneity of system configuration and 
complexity. 
 
The aim of this research is to identify a list of prescribing indicators specific for the hospital 
setting that would aid the prospective collection of high-risk prescribing errors amenable to 
CDS.  The results will inform the methodology for identifying high-risk errors communicated 
by pharmacists to the physician via a CPOE system.  
 
4.2 Method 
4.2.1 Methodological approach 
The Delphi technique has been widely used in healthcare research as an approach to 
establish consensus in an area where published information is inadequate (Avery et al., 
2005; Gallagher et al., 2008; Jones & Hunter, 1995).  The method generally comprises a 
questionnaire sent to a group of experts who are asked to answer a series of questions over 
multiple rounds (Fitch et al., 2001).  After each round, the responses are gathered and 
tabulated by the researcher and sent back to the group for the questions to be answered 
again.  The responses from participants are anonymous during the process and the process 
continues until a level of agreement has been accomplished.  The Delphi method is useful 
when there is a defined question that needs to be answered and one that does not need to 
be informed by direct discussion between the expert participants and the researcher, as 
would occur using a Nominal Group Technique (NGT) (Fitch el al., 2001).  Unlike the NGT, 
the method is also less time-consuming for participants and may therefore encourage 
participation and a higher completion rate of the multi-stage process. 
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Given the specific aim of the study, the Delphi methodology was selected to gather the 
subjective judgements of experts regarding a defined list of prescriber indicators and to 
develop quantitative data from which to finalise this list.  An exploratory round were 
planned, followed by two rounds of an electronic Delphi (eDelphi), conducted via email for 
participants to score indicators to identify high- or extreme-risk indicators.  A consensus of 
at least 80% across the expert panel was planned to be achieved. 
 
4.2.2 Expert panel selection 
Participants were selected based on their clinical expertise in medication safety, as well as 
those with knowledge of CPOE systems who would be able to identify errors that are 
amenable to reduction by CDS software.  Some participants were identified from a 
conference held by a National Institute for Health Research programme grant for applied 
research: “Investigating the adoption, implementation and effectiveness of electronic 
prescribing systems in English Hospitals” [RP-PG-1209-10099] as well as personal contacts.  
An invitation was emailed to potential participants, along with a Participant Information 
Leaflet to provide an overview of the eDelphi study (Appendix 2).  A total of 32 experts were 
invited to participate in the process, of whom 20 agreed.  Panellists were pharmacists, 
clinical pharmacologists and physicians from geographically diverse areas in England, with a 
range of professional grades.  Consent to participate was implied, on account of each of the 




4.2.3 The eDelphi process 
In the first instance, the inclusion and exclusion criteria for the prescribing indicators were 
defined (see Table 4.1).  These criteria were used to construct an initial list of indicators 
based on clinical experience, searches of relevant UK resources and previous work 
conducted to define critical indicators of potential harm (Avery et al., 2011; Gallagher et al., 
2008; Joint Formulary Committee; Medicines and Healthcare products Regulatory Agency; 
National Patient Safety Agency; Phansalkar et al., 2012).  Where possible, the original 
evidence base or language used by others to describe the issues was adopted to provide the 
context of the indicators.  Each indicator was listed to state the trigger medicine(s) or class 
of medicine, the error process and the associated harm, for example: “Digoxin [medicine] 
prescribed concomitantly [process] with a diuretic [medicine] (Risk of hypokalaemia and 
subsequent digoxin toxicity [harm])”.  This was constructed to reduce the risk of 
misunderstanding and bias.  The prescribing indicators were listed in a table and then 
circulated among a team of researchers (a clinical pharmacologist, epidemiologist and 
researcher in applied health research) for comments and refinement before incorporation 
into a questionnaire for circulation to the participants for an exploratory round. 
Table 4.1 – Inclusion and exclusion criteria for the prescribing indicators 
 
Inclusion criteria Exclusion criteria 
The indicator describes a medicine prescribed in 
the general adult in-patient population 
 
The indicator relates to a medicine prescribed at 
a reasonable rate in the UK hospital 
environment 
The indicator describes a prescribing practice 
that is not routinely undertaken in the UK 
hospital setting 
 
The indicator is specific to a medicine used in a 
patient population other than adult inpatients 
(i.e. paediatric vaccination schedules) 
 
The indicator describes an error that would not 




Extraction of data required for the indicator 
(from hospital care records) is unlikely to be 
feasible 
 
The indicator describes a failure to monitor 
treatment 
 
The indicator describes errors relating to the 




The refined list of indicators was emailed to all participants enrolled in the study.  They were 
asked to review each of the indicators and to recommend any modifications they deemed 
necessary.  In addition, the opportunity was given for further indicators to be suggested that 
participants felt were missing from the initial list.  The responses from this round were 
assessed and those that had clinical merit were included in an updated list of indicators for 
round one of the eDelphi.  A rationale for excluding suggested indicators was provided to 
each of the participants to give a clearer understanding of the overall inclusion criteria.  For 
example, one participant suggested ‘Any use of naloxone or flumazenil’– the rationale 
provided to the participant stated, ‘This is a trigger to identify an adverse drug event, not an 
indicator of harm from a prescribing error’. 
 
4.2.3.2 Round one 
Round one of the eDelphi aimed to identify the most clinically significant indicators, defined 
as those which would have the greatest risk in a clinical setting.  Using a 5-point Likert scale, 
participants were asked to rank each indicator for the likelihood of it occurring in hospital 
and the severity of the most likely outcome should the error occur.  This scale was based on 
that used by the former UK National Patient Safety Agency NRLS (Table 4.1) (National 
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Patient Safety Agency, 2008)—now part of NHS Improvement— and therefore one that UK 
healthcare professionals were likely to be familiar with.  Acknowledging that participants’ 
previous areas of clinical practice (e.g. oncology) may influence the scoring, they were 
requested to take a more general view in the interpretation of each indicator.  
 
Table 4.2 – Scoring likelihood and severity of the errors occurring  







Do not expect 
it to occur but 
it is possible it 














Severity  1 2 3 4 5 
 
 








No risk of 
patient injury 
or harm and no  
intervention 
required 





















When all ratings from round one had been received, the likelihood and severity scores were 
converted into ‘risk scores’ using the NRLS Risk Matrix (Table 4.2) (National Patient Safety 
Agency, 2008).  The median scores for each indicator were then calculated across the 
participants in the study and the indicators divided into two groups: those where the 
median risk score was situated in the upper categories of ‘high’ or ‘extreme’ and those 
where the risk was ‘low’ or ‘moderate’.  The degree of consensus between the participants 
was defined as the proportion that gave a risk score in the same group as the median.  The 
mean consensus across all of the indicators was then calculated.  The target for consensus 
was defined as at least 80%, in order to ensure that the resulting list of indicators was 
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reliable.  This adhered to validated consensus method for developing appropriateness 
scenarios (Fitch et al., 2001).  
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1  Rare 
This will probably 
never occur 
2 Unlikely 
Do not expect it to 
occur but it is possible 





This will probably 
occur 
5 Almost certain 




Leads to death, multiple 
permanent injuries, or 
irreversible health effects 
5 10 15 20 25 
4 Major 
Major injury leading to long-
term incapacity/ disability 
4 8 12 16 20 
3 Moderate 
Moderate injury requiring 
intervention 
3 6 9 12 15 
2 Minor 
Minor injury or illness requiring 
minor intervention 
2 4 6 8 10 
1 Insignificant 
No risk of patient injury or 
harm and no 
intervention required 













4.2.3.3 Round two 
In round two, the full list of indicators were returned to each participant with their own 
individual scores for severity and likelihood shown, as well as the median scores from all 
members of the expert panel.  This gave the opportunity for participants to modify their 
scores in light of the judgments of the rest of the group or to retain their original viewpoints 
if they did not agree with the common opinion.  The median risk scores were then 
recalculated and the mean consensus between participants determined, as per round one.  
The final list of indicators comprised those where the median risk score and the scores of at 




The exploratory stage and two-round eDelphi was completed by all 20 participants.  The 
expert panel consisted of 11 pharmacists with a sum of 122 years hospital experience and 
nine physicians with a sum of 60 years hospital experience (Table 4.3).  All participants 
either worked in an academic institution or within an NHS hospital and all had an interest in 





Table 4.4 – Participant demographics 
 
Profession Grade Specialty Employer 
Pharmacist Senior Diabetes and endocrinology NHS hospital 
Physician Registrar Clinical pharmacology Academic institution 
Physician F2 physician Medicine NHS hospital 
Physician Consultant Clinical pharmacology NHS hospital 
Pharmacist Teacher practitioner Paediatrics NHS hospital 
Pharmacist  Senior General surgery NHS hospital 
Pharmacist  Lecturer  Palliative care NHS hospital 
Pharmacist Lecturer  Medication safety Academic institution 
Pharmacist Senior Oncology NHS hospital 
Pharmacist Lecturer  Medication safety Academic institution 
Pharmacist Lead pharmacist/lecturer Medication safety Academic institution 
Pharmacist Senior Electronic prescribing NHS hospital 
Physician F2 physician General medicine NHS hospital 
Pharmacist Senior Primary Care Interface*  
Physician F2 physician Medicine NHS hospital 
Physician Registrar Respiratory medicine NHS hospital 
Physician F1 physician Medicine NHS hospital 
Physician Registrar Clinical pharmacology NHS hospital 
Physician F2 physician Diabetes and endocrinology NHS hospital 
Pharmacist Lecturer  Pharmacy practice Academic institution 
F1 – Foundation Year 1 physician (junior, first year of practice post-qualification) 
F2 – Foundation Year 2 physician (junior, second year of practice post-qualification) 
*Works at the interface between community and hospital care 
 
In the first instance, 210 prescribing indicators were identified; 108 of these were from 
published studies using similar consensus techniques (Avery et al., 2011; Gallagher et al., 
2008; Phansalkar et al., 2012), 36 from safety warnings and alerts from UK authorities (Joint 
Formulary Committee; Medicines and Healthcare products Regulatory Agency; National 
Patient Safety Agency) and 66 from clinical experience.  In the exploratory round, a refined 
list of 89 indicators were sent to the participants and 71 additional prescribing indicators 
were suggested by the expert panel, of which 20 were selected for inclusion in round two 
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(making a total of 109).  Figure 4.2 the eDelphi process and results of each stage and table 





















Figure 4.1 – A summary of the eDelphi process and results at each stage  
Defining the problem What errors occur in hospital that may be amenable to clinical 
decision support?  
 What is the perceived likelihood of these errors? 
 What is the potential severity? 
Expert panel selection 
Exploratory round 
Round one eDelphi 
Expertise of panel defined: 
 Clinical expertise in medication safety 
 Knowledge of CPOE systems  
 Can participate in proposed time-scale proposed 
Participants asked to:  
 Review indicators and suggest modifications where necessary 
 Suggest additional indicators that are not listed 
Participants asked to rate each indictor for: 1) likelihood of 
occurrence; and 2) severity of the most likely outcome.  Risk scores 
from the severities and likelihoods were produced and the median 
calculated for each indicator. 
Indicators were classified as low/medium or high/extreme risk, 
based on the median.  Consensus was calculated for each indicator 





Round two eDelphi Indicators returned to participants with: 1) their own scores for 
severity and likelihood from round one; and 2) median scores from 
all members of the expert panel in round one.  Participants were 
given the opportunity to change their scores in light of the 
judgments of the rest of the group, or retain their original score if 
they did not agree with the common opinion.   
 
 210 indicators identified 
 89 suggested for exploratory round 
following review 
 71 indicators suggested by participants 
 20 accepted following review 
 109 indicators identified for round one 
 Mean consensus across all indicators is 
<80% 
 The eDelphi proceeds to round two 
 
Mean consensus of risk scores for the 
indicators is recalculated and found to be 
>80%, hence sufficient agreement. 
 80 indicators classified as high or extreme 
risk reached a consensus of 80% to make 
up the final list 
20 agreed to participate in all three rounds 
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Table 4.5 – Reasons for exclusion of suggested indicators in round one of the eDelphi 
 
Reason for exclusion No. 
Modified existing indicator 2 
Dependent on individual hospital guidelines 1 
Difficult to assess 9 
Medicine not prescribed on an in-patient basis 1 
Indicator already present in list 10 
Not amenable to CDS 6 
Specialty specific 4 
Relates to administration 8 
Relates to monitoring 7 
Trigger, not indicator 1 
Unnecessary duplication of treatment 1 
Total 50 
 
A total of 80 out of 109 prescribing errors were considered high or extreme risk by 
consensus when the scores for likelihood and severity were considered; these were included 
in the final screening tool (Appendix 3).  The indicators excluded in round two are 
summarised in Appendix 4.  There were 16 indicators that achieved 100 percent consensus 
and 65% (n=52/80) that achieved censuses of 90% or more. 
 
Of the 80 final indicators, the majority were synthesised from clinical experience (n=25), 
followed by those identified by the STOPP/START criteria (a screening tool for assessing the 
appropriateness of medicines or classes of medicines in older adults) (Gallagher et al., 2008) 
(n=23), Avery et al (2011) (n=12), Medicines and Healthcare products Regulatory Agency 
MHRA and NPSA warnings (N=14) and Phansalkar et al (2012) (n=6).  The indicators included 
a total of 41 different trigger medicines or classes of medicine, prescribed for: 
cardiovascular (n=22), central nervous system (n=28), endocrine (n=5), gastrointestinal 
(n=6), infection (n=12) and miscellaneous (n=7).  The most common medicines and classes 
named in the indicators were antibiotics (n=13), antidepressants (n=8), non-steroidal anti-
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inflammatory drugs (NSAIDs) (n=6), opioid analgesics (n=6), antiplatelets (n=5), 
methotrexate (n=4), low molecular weight heparins (LMWH) (n=4) and benzodiazepine (and 
like) medicines (n=4). 
 
Participants identified five indicators as ‘extreme risk’, calculated using the NPSA Risk 
Matrix.  Three of these involved anti-infective medicines (macrolides [with warfarin], 
gentamicin and amphotericin B), one involved a LMWH and one related to paracetamol.  
The most frequent error types identified as high or extreme risk were those classified as 
clinical contraindications (36.3%, n=29/80).  This included medicines prescribed in renal 
impairment (n=8), heart failure (n=4) and epilepsy (n=4), as well as those that should be 
avoided with abnormal blood results (n=4).  Drug-drug interactions were the second most 
common error type (28.8%, n=23/80), with antidepressants the most common interacting 
class of medicine (n=5). 
 
When indicators were ranked according to median severity scores only, two out of the 80 
indicators were given a score of 5: Catastrophic (see Figure 4.1): ‘Amphotericin B prescribed 
without stating the brand name and the dose in mg/kg (Risk of fatal overdose due to 
confusion between lipid based and non-lipid formulations)’ and ‘Oral methotrexate 
prescribed to a patient with an inappropriate frequency (Increased risk of toxicity)’. 
 
4.4 Discussion 
This eDelphi identified 80 high and extreme risk prescribing indicators that are relevant to 
the hospital setting, which also have the potential to be prevented by alerts and warnings in 
CDS software.  All 20 participants completed the exploratory round and both rounds of the 
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eDelphi, removing any bias potentially introduced by missing responses from people with 
specific expertise.   
 
The most frequently named medicines or classes of medicines in the final list were 
antibiotics, opioids and LMWHs.  This is consistent with those considered high-risk by the 
NPSA, identified in incident reports as the medicines with the highest percentage of 
medication incident reports with fatal and severe harm outcomes with clinical outcomes of 
death and severe harm (Cousins et al., 2012).  Indicators relating to antidepressants were 
also frequent, but are not listed by the NPSA as medicines with a high number of reports for 
fatal and severe harm.  Four of these were for selective serotonin re-uptake inhibitors 
(SSRIs), a class of drug with a high prescribing rate in the UK, with citalopram being one of 
the top 20 medicines dispensed by pharmacies in England at the time of the study (The NHS 
Health and Social Care Information Centre, 2012). 
 
In this study, the indicators were not restricted to one type of error.  The most frequent 
error types associated with the indicators were clinical contraindications (36.2%, n=29/80) 
and drug-drug interactions (28.8%, n=23/80).  In the US, a set of high-priority drug-drug 
interactions have previously been identified by an expert panel to help target CDS and 
create a list of interactions as a minimum standard for such systems (Classen et al., 2011; 
Phansalkar et al., 2012).  Interestingly, only six of the 23 drug-drug interactions identified by 
the expert panel in this eDelphi process were the same as those previously identified by 
Phansalkar et al (2012) showing there to be a difference in opinion between what the UK 
and the US would consider to be highly significant.  This may, in part, be due to the 
difference in the rate at which these medicines are prescribed in each country.  However, 
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when the scoring for the indicators were ranked according to median severity scores only, 
two indicators scored ‘5’ (catastrophic) and 26 scored ‘4’ (major); nine of these were drug-
drug interactions and only one was consistent with the list defined by Phansalkar et al 
(2012).  
 
The prescribing indicators were developed for the hospital setting and therefore include 
some medicines that are not likely to be prescribed in general practice (e.g. intravenous 
gentamicin).  However, just six such indicators out of the 80 include medicines that would 
only be prescribed on an inpatient basis and therefore 74 of the indicators have the 
potential to be applied to general practice.  Indeed eight of the final indicators were taken 
directly from Avery et al (2011), which were originally developed for GP systems and were 
subsequently scored as high or extreme risk in this eDelphi process.  
 
The indicators of harm identified provide an objective measure than can be implemented in 
the routine collection of high-risk prescribing errors in both paper-based and electronic 
processes.  The indicators can be used for both prospective and retrospective drug chart 
review.  The collection of standardised data allows for comparison to be made and 
conclusions drawn which can provide evidence for safety initiatives.  With the capital cost of 
installing a CPOE system in a hospital being in the region of £1.5 million, research into its 
effect and effectiveness are crucially important.  Investigating the rate of high-risk 
prescribing errors pre- and post- implementation in such cases is beneficial in providing 
evidence to support one of the primary objectives of implementing such a system—to 




The indicators can also be used to inform the development and optimisation of CDS, with 
the intention of minimising untargeted or non-specific alerting which can lead to an 
overburdening of the prescriber and causing alert fatigue, limiting its intended effects 
(Riedmann et al., 2011; van der Sijs et al., 2008a).  A Cochrane review in 2011 found that 
point of care computer reminders generally achieve small to modest improvements in 
provider behaviour (Shojania et al., 2009) and concluded that further research must identify 
key factors—related to the design—that reliably predict larger improvements in care from 
such expensive technologies.  The indicators developed here can help ensure that CDS 
target the errors that are more likely to occur and/or have the greatest potential for causing 
patient harm and may serve as a priority list for CDS software developers. 
 
4.4.1 Limitations 
Prior to the commencement of the eDelphi, 210 indicators were identified from both clinical 
experience and published literature.  Of these, 130 were excluded as it was felt they were 
neither prescribed at a reasonable frequency nor considered to be high-risk enough for 
inclusion.  This review process meant that many of the indicators sent to the participants 
could already be considered high-risk and may explain why the final list was not 
substantially smaller.  The same 20 participants took part in both the exploratory round and 
the two-round eDelphi, which may further explain why consensus was reached on a large 
number of indicators.  There may also be a risk that in the original identification step, some 
high-risk errors were missed, despite a robust review of the literature, or excluding some 
that other people would have considered important enough for inclusion.  However, the 
exploratory round prior to the eDelphi process was designed to reduce the risk of such 




All participants in the eDelphi were from geographically diverse areas in England.  However, 
the lack of expertise from further afield may make these indicators more applicable to the 
UK setting.  Indeed it may be of interest to see whether, for example, experts from other 
defined geographical regions (e.g. US and other European countries) would come to similar 
conclusions as UK healthcare professionals.  The indicators identified are all knowledge-
based errors and do not include those that may occur as a result of the use of the system.  
However, the methodology used in this study may be applied to capture this type of error in 
an organisation if the development were informed by error reports submitted over time. 
 
Lastly, with the development of any indicator or trigger to monitor quality or safety in 
healthcare, its relevance should be continuously reviewed and updated.  As new therapeutic 
agents are introduced and older ones go out of favour, the likelihood scores for their 
occurrence in clinical practice may well adjust and they would no longer qualify according to 
our methodology.       
 
4.5 Conclusions 
Prescribing errors with a high potential for causing patient harm have been identified by an 
expert panel.  These indicators provide a standardised and validated method for the routine 
collection of prescribing error data in both paper-based and electronic prescribing 
processes.  They can serve as a means to assess safety improvement, such as with the 
introduction of CPOE and CDS in UK hospitals.  This can also be of value in the optimisation 
of CDS embedded within CPOE systems.  The results of this study will be used to identify 
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whether pharmacists communicate with physicians via a CPOE system regarding high-risk 








Chapter 5 ELECTRONIC PHARMACIST-PHYSICIAN 
COMMUNICATIONS IN A HIGHLY COMPUTERISED HOSPITAL: 
DEVELOPMENT OF THE DATABASE 
 
In this chapter I introduce the ‘Prescribing Information and Communication System’ (PICS) in 
use at the University Hospital Birmingham NHS Foundation Trust and the review message 
function to facilitate pharmacist-physician communication.  I describe the method used to 
capture data relating to pharmacist-physician communications in PICS and provide a 
detailed description of how the data were coded to answer key questions.  Finally, I explain 
how various temporal, message and prescriptions factors were coded in the database and 
provide an evidence-base for why this was conducted.  
 
Sections of this methodology chapter have been published in PLoS ONE: Pontefract, S. K., 
Hodson, J., Marriott, J. F., et al. (2016) Pharmacist-Physician Communications in a Highly 





5.1.1 Digital health data and quality improvement 
The adoption of health information technology as Electronic Patient Records (EPRs) 
(sometimes referred to as Electronic Health Records) worldwide and across all sectors of 
healthcare has generated large volumes of digital data and as more systems are 
implemented, the volume of data being generated is increasing and at an exponential rate 
(Luo et al., 2016).  This explosion of information is commonly referred to as ‘Big data’ and is 
often described by the four V’s: Volume, Velocity, Variety and Veracity (Raghupathi & 
Raghupathi, 2014; Tan et al., 2015).  ‘Variety’ refers to the different forms of data; for 
example, data may be structured, such as with a list of pathology results or patient 
comorbidities, or unstructured such as with free-text documentation detailing a patient 
consultation or management plan.  ‘Veracity’ refers to the accuracy of data and therefore 
the quality of the information. 
 
The ability to digitise health information has revolutionised how quality improvement is 
approached in healthcare.  The value of this data increases with the ability to link data to 
other sources of information.  In some countries, the use of health data is mandated to 
drive quality—the HITECH Act in the US has developed objectives to ensure “meaningful use 
of data… to achieve significant improvements in care” (Blumenthal  & Tavenner 2010).  
 
The adoption of CPOE to facilitate the medication process has specifically enabled large 
quantities of data to be captured relating to the use of medicines.  For the first time, 
questions can be asked of the prescribing and administration of medicines that would not 
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have been feasible (or indeed in some cases possible) in paper-based processes.  For 
example, organisations can determine how timely medicines are being administered in 
hospital (Coleman et al., 2013), identify and quantity adverse effects to medicines 
(Mohamed et al., 2011) and target areas with CDS software to ensure or promote 
standardised care (Murdoch & Detsky, 2013).   
 
In this study, I introduce the development of a large database, created to analyse both 
structured and unstructured data relating to pharmacist-physician communications.  
 
5.1.2 Prescribing, Information and Communication System 
The Prescribing, Information and Communication System (PICS) is a locally developed CPOE 
system in use at the University Hospital Birmingham NHS Foundation Trust (UHBFT) since 
2004, although earlier parts of the system existed as early as 1998 (Nightingale et al., 2000). 
PICS is used for the prescribing and administration of medicines throughout all inpatient 
beds, with the exception of the Emergency Department and some complex systemic 
anticancer therapies prescribed according to defined treatment protocols.  It is also used to 
generate the discharge summary and prescription for patient discharge (known as ‘to take 
out’ prescriptions, or TTOs). 
 
At UHBFT, pharmacists screen inpatient and TTO prescription orders that are generated in 
PICS for their safety and appropriateness.  When the pharmacist is satisfied that an order for 
a medicine is appropriate, it is validated—a process undertaken to confirm an order is 
suitable for a patient and the action of which generates a green icon on screen to inform 
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other healthcare professionals it has been checked.  During review, the pharmacist may 
wish to query a discrepancy or error, or communicate information to support the order.  In 
PICS, a communication function exists that enables the pharmacist to communicate with the 
physician using an electronic ‘review message’—a free-text message of up to 255 characters 
that can be assigned to a patient’s individual prescription order (Figure 5.1–5.4).   
 
 
Figure 5.1 – Adding a review message to a medicine; the pharmacist highlights the 
medicine and selects ‘Rev’ [Review] 
 
 






Figure 5.3 – An ‘R’ icon highlights the presence of a review message on a prescription 
 
 
Figure 5.4 – Clicking on the ‘R’ icon reveals the free-text message 
 
For the purpose of this study, key features of the review message function are as follows: 
I. Delivery of the message is immediate as soon as the pharmacist commits it to the 
system; 
II. An ‘R’ icon identifies the presence of a message on screen (Figure 5.3). Clicking on 
the ‘R’ icon reveals the free-text message (Figure 5.4); 
III. The receipt of the message is dependent on when an intended recipient (i.e. 
physician) next looks at the patient’s prescription profile; 
IV. The message can be viewed by anyone and is not directed to a named person or 
team; 
V. The recipient can see the name of the pharmacist who has assigned the message; 
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VI. For each review message, there is an option for the recipient to ‘Sign-off’ the 
message, which would be considered acknowledgement that the information has 
been received.  Selecting ‘Sign-off’ removes the ‘R’ icon from the prescription. 
Messages can be signed-off by any healthcare professional.  For example, if a 
prescription has been amended as a result of a request, but the physician failed to 
sign-off a message, the pharmacist may do so to remove the ‘R’ icon from the 
screen; and, 
VII. The viewing and signing-off of messages is not mandated within the PICS system.   
 
 
Everyone receives training on the use of PICS, adapted for the professional group. 
Pharmacists also receive training on the hospital’s clinical pharmacy standards at the time 
that reflect those stated by the membership body, “Pharmacists intervene with prescribers, 
patients and other healthcare professionals to ensure medicines are safe and effective” 
(Royal Pharmaceutical Society, 2014). 
 
This process of prescription validation and pharmacist-physician communication via PICS is 
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5.1.3 Aim and key research questions 
The aim of this study was to capture pharmacist-physician communications assigned to 
prescription orders over a 12-month period and to code the data to enable descriptive and 
statistical analyses to address four key questions. 
1. What type of information is communicated by pharmacists via the review message 
function in PICS? 
2. Do physicians sign-off pharmacist review messages within PICS? 
3. What factors influence the sign-off and time taken to sign-off review messages? 
4. What factors influence the action and the time taken to action review messages? 
 
5.1.4 Ethics approval 
This study protocol was approved by the University Hospital Birmingham NHS Foundation 
Trust Research and Development Department [21st October 2013] and the University of 
Birmingham Ethics Committee [ERN_12-0127]. 
 
5.2 Developing the database 
5.2.1 Data capture 
The following data were requested from the Informatics Department at the University 
Hospital Birmingham NHS Foundation Trust: 
I. Review messages assigned by pharmacists to medicines orders between the 1st 
January 2012 and 31st December 2012; 
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II. The details of the prescription order on which each review messages was assigned; 
and, 
III. Details of any changes made to the order following a review message being assigned. 
 
For each review message captured, the following information was requested: 
I. Date and time the review message was assigned by the pharmacist to a prescription 
order in PICS; 
II. Date and time the order was generated by the physician; 
III. Grade of the pharmacist who assigned the review message (grade 6–8; grade 6 
pharmacists generally having 0–18 months experience; grade 7 having at least 18 
months experience; and 8 being the most senior).  In cases where a pharmacist had 
recently moved grades, it was requested that the lower grade was assigned; 
IV. Ward and speciality the patient was under the care of when the review message was 
assigned; 
V. The free-text of the review message; 
VI. Details of the medicine order on which the review message was assigned: name of 
medicine; route; dose; dose units; frequency; and the regularity of the prescription; 
VII. Status of the prescription (i.e. whether it was continued (C) or deleted (D) prior to 
the patient receiving a dose); 
VIII. Whether the review message was signed-off within the system; 
IX. Profession of the user who signed-off the message (pharmacist, junior physician, 
registrar, consultant, or non-medical prescriber); and, 




The data were presented in an Excel spreadsheet, with each data entry representing a 
different review message on an order and with a unique identifier for each, but unrelated to 
the patient’s personal data.  
  
In order to ascertain any patterns in the pharmacists’ use of the review message function 
over time, the following data were also requested between 1st January 2004 and 31st 
December 2014: 
I. Number of inpatient prescriptions; 
II. Number of prescriptions for discharge (TTOs); 
III. Number of inpatient episodes; and, 
IV. Number of review messages assigned by pharmacists. 
 
5.2.2 Cleaning the data 
The following review messages were excluded prior to coding for analysis: 
I. Messages generated and assigned by pharmacy technicians; 
II. Messages generated and assigned by pre-registration pharmacists; 
III. Blank messages (no message within the free-text field); 
IV. Duplicate messages that can occur when the ‘add’ button is clicked by the 
pharmacist more than once in quick succession, which commits the same message to 
the PICS database on more than one occasion.  These were identified using the 
‘Conditional Formatting’ function in Excel allowing duplicate cells to be highlighted; 
and, 
V. Incomplete messages identified using a filter function in Excel. 
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5.2.3 Coding the data 
The captured data were coded in Excel to identify a number of factors.  These were 
informed by the data available to code and a preliminary review of the data to determine 
any themes that were possible to code and that would be potentially beneficial to the 
analysis.   
i. Category of the medicine type; 
ii. Presence of a high-risk medicine; 
iii. The topic of the communication; 
iv. Review messages communicating information relating to a pre-defined high-risk 
error (Thomas et al., 2013); 
v. Review messages associated with a disparity between what the patient usually takes 
prior to admission and what they are currently prescribed (defined as the medicines 
reconciliation process); 
vi. Review messages that were not directly associated with the medicine orders on 
which they were assigned; and, 
vii. Messages that requested an action that could be determined from the data.  
 
The coding strategy and rationale for each of the above factors is described in more detail 
below. 
 
5.2.3.1 Category of medicine 
Antimicrobial and cardiovascular medicines are commonly associated with hospital 
prescribing errors (Bobb et al., 2004; Lewis et al., 2009).  In order to determine the types of 
medicines frequently discussed in communications, the medicines were categorised 
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according to those used in the UK British National Formulary (BNF) (Joint Formulary 
Committee).  In each case, the medicine name was searched using the online BNF and a 
main category and sub-category was assigned.  In cases where medicines or preparations of 
a medicine existed in more than one category (e.g. methotrexate as ‘Musculoskeletal and 
joint diseases’ and ‘Malignant disease and immunosuppression’), the first category as it 
appeared online in the BNF was assigned, considered the most common use for that 
medicine.  ‘Anaesthetics’, ‘Immunological products’ and ‘Emergency treatment of poisoning’ 
were all categorised as ‘Other’ owing to the small number of review messages assigned to 
medicines in these categories. 
 
5.2.3.2 High-risk medicine 
Although serious or fatal medication errors in NHS hospitals are relatively uncommon, it is 
accepted that certain high-risk medicines are associated with more severe harms (Cousins et 
al., 2012).  The presence of a high-risk medicine on a patient’s prescription profile may affect 
how a prescriber prioritises or reviews treatments and was therefore identified in the 
dataset so that any effect on physician sign-off or action can be investigated.   
 
The NPSA (now part of NHS Improvement) has identified common medicines or therapeutic 
groups of medicines that are associated with death or severe harm outcomes reported to 
the NRLS (Cousins et al., 2012) (Table 5.1).  Although a more recent systematic review of the 
literature has also identified ten medicines associated with hospitalisation or serious patient 
harm caused by medication errors (Saedder et al., 2014), the number of reports analysed in 
this study was lower than the number of NRLS reports and the study was not specific to the 




High-risk medicines and classes of medicines listed in Table 5.1 were identified using the 
BNF and coded in the database using a binary code [1: positive (medicine is associated with 
death or severe harms), 0: negative (medicine is not listed as being associated with death or 
severe harm).   
Table 5.1 – Common medicines or therapeutic groups of medicines associated with death 
or severe harm outcomes 
 
 High-risk medicines 
Adrenaline Methotrexate 
Amiodarone Non-steroidal anti-inflammatory drugs 
Antipsychotics Opioids 
Antibiotics (excluding topical) Phenytoin 
Benzodiazepines Potassium 
Insulins Warfarin 
Low molecular weight heparins Direct oral anticoagulants* 
*Direct oral anticoagulants were not included in the initial list, but have been added to account for 
these high-risk medicines 
 
5.2.3.3 Topic of communication 
In UK paper-based prescribing environments, pharmacists traditionally endorse or annotate 
the drug chart with information or instructions to support the medication process, aimed at 
both nurses and physicians.  Research into this form of communication has shown that it is 
conducted to facilitate administration or “subtly influence medical prescribing” (Liu et al., 
2014).  Yet, the day-to-day written discourse of pharmacists directly to physicians has not 
been investigated, particularly in the context of CPOE in the UK.  Identifying the topic of 
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pharmacists’ messages will not only provide insight into what pharmacists’ everyday 
practice actually entails, but will also help determine whether the theme of a 
communication influences a physician’s subsequent prescribing actions. 
 
Discourse by way of an entirely free-text electronic communication means that the general 
theme of a communication is not pre-defined for the recipient and is therefore not available 
as a pre-populated structured code to facilitate analysis for research.  Content analysis is a 
qualitative research method used to describe the key messages or elements of text data.  It 
comprises a “subjective interpretation of the content of text data” (Hsieh & Shannon, 2005) 
and subsequent identification of themes or patterns within the data.  This method is useful 
for quantifying unstructured data in a systematic way and thus enables statistical analyses 
to be performed (Green & Thorogood, 2009; pp 198-203).  There are various techniques 
described in the literature for conducting content analysis, the selection of which is 
determined by the aim of the study.  For example, content may be analysed inductively, a 
grounded or ‘conventional’ approach where there is no hypothesis and theory is generated 
or deductively, a directed approach where preliminary codes can help integrate concepts 
already identified (Bradley et al., 2007; Hsieh & Shannon, 2005).  Although the written 
discourse of pharmacists has not been directly investigated, the types of information or 
requests they might communicate to physicians is well documented and so this would 
support the latter of the two approaches.  For example, based on the review described in 
Chapter 3 we know that pharmacists identify prescribing errors in the course of their clinical 
work and communicate with prescribers to rectify these or to instigate further discussion.  
We also know that errors relating to dosing of medicines and omissions are most prevalent 
in the UK hospital setting and are likely to make up a proportion of pharmacists’ 
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communications (Dean et al., 2002b; Lewis et al., 2009; Ross et al., 2013).  Based on 
personal experience, pharmacists also provide supportive information and make proactive 
suggestions to optimise the use of medicines.  In addition, they may also recommend 
alternative treatment(s) for cost-effective reasons (Bourne & Choo, 2012).  In the context of 
CPOE, some communications may well relate to the use of the technology during the 
prescribing process, such as with selecting the wrong medicine from a drug dictionary or the 
wrong dose units (Brown et al., 2017; Castro. G. M., 2016; Estellat et al., 2007; Redwood et 
al., 2011). 
 
Content analysis of the free-text review messages were conducted to determine the various 
topics of communications.  The review messages were filtered according to each individual 
medicine name and read sequentially.  This ensured a systematic approach to the analysis, 
allowing for patterns of communication to be more easily identified for each medicine.  
Healthcare communications are made within a context (i.e. of a patient and their diagnosis) 
(Garner & Watson, 2007).  Without knowledge of this context, analysis can either identify 
and code what is explicitly stated in text (i.e. the latent content) or what is implied (i.e. the 
manifest content) (Abbott & McKinney, 2013).  Each of the messages were read objectively 
and coded with a description that summarised the explicit topic of the discourse (Abbott & 
McKinney, 2013; Saldana, 2013).  The process was conducted iteratively, where messages 
were constantly compared to each other to refine the codes or to generate new ones.  This 
method of constant comparison “combines the explicit coding procedure (…) and the style of 
theory development” (Glaser, 1967; pp 102).  Analysis commences immediately with this 
approach and not just at the end when the coding is complete.  To reduce inconsistency, a 
list of codes was maintained along with a description to define each. This was updated and 
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modified as the coding progressed and was used to prompt reflection on and refinement of 
the codes (Green & Thorogood, 2009; pp 202-203).  As the analysis progressed, fewer topics 
of communication emerged from the data and codes could be more easily assigned using 
the framework developed.  Upon completion of coding, a total of 129 different topics of 
communication had been identified among the review messages (Appendix 5). 
 
5.2.3.4 Theme of communication 
In order for the theme of communication to be quantified and considered a factor in any 
statistical analyses of the dataset, the individual codes needed to be organised into broader 
themes.  In qualitative analysis, a theme should effectively describe the semantic 
relationships between the codes within it.  The narrative review described in Chapter 3 was 
conducted to inform the coding process and to identify potential names or descriptions for 
themes.  This identified standards for a good coding system (e.g. “Problems defined should 
be clear and – if possible – leading to only one choice of coding”) (Schaefer, 2002) and four 
published and validated schemes for coding medication errors and/or drug-related 
problems: 
I. APS-Doc (Hohmann et al., 2012) 
II. NCC MERP (National Coordinating Council for Medication Error Reporting 
Prevention, 1998) 
III. PCNE Classification V 6.2 (Pharmaceutical Care Network Europe Foundation, 2010) 
IV. PI-Doc (Schaefer, 2002) 
 
To identify a scheme that could be used to organise the 129 communications into themes, I 
conducted an exploratory Delphi to establish a level of consensus of opinion (Jones & 
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Hunter, 1995).  A pharmacist and physician (JF, JJC) and I independently organised the 129 
topics into themes described by the four different schemes.  The results were compared to 
determine which scheme had the greatest level of consensus and which performed best at 
minimising the number of topics categorised as ‘Other’ (Table 5.2).   
Table 5.2 – Number of topics of communication that achieved consensus or no consensus 
when categorised into the four schemes 
 
 APS-Doc NCCMERP PCNE V6.2 PI-Doc 
No. of categories in scheme     10 11 8 9 
Full consensus (n/129) 67 (51.9%) 68 (52.7%) 48 (37.2%) 17 (13.2%) 
Partial consensus* (n=129) 50 (38.8%) 51 (39.5%) 68 (52.7%) 82 (63.3% 
Zero consensus (n/129) 12 (9.3%) 10 (7.8%) 13 (10.1%) 30 (23.3%) 
Full consensus categorised 
as ‘Other’ (n/129) 
28 (21.7%) 42 (32.6%) 13 (10.1%) 0 (0.0%) 
*Partial consensus, 2/3 participants agreed. 
 
Out of the four schemes, APS-Doc (Hohmann et al., 2012) was found to achieve both a high 
level consensus (51.9%, n=67/129) and performed well at minimising the number of codes 
categorised as ‘Other’.  As such, this scheme was identified to facilitate and inform the 
development of a bespoke scheme to categorise topics of pharmacist-physician 
communication in PICS. 
 
The APS-Doc scheme was modified to categorise the topics of communication into one of 
ten themes.  Each theme was then described, along with an example of the type of codes it 
would encompass (Table 5.3).  The 129 topics identified in section 5.2.3.3 were listed in a 
column in an Excel spreadsheet, along with the modified APS-Doc themes pre-populated in 
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a drop down list to facilitate coding.  Using a consensus technique, the same three 
participants (SP, JF, JJC) independently categorised each topic into a theme.  The results 
were combined and consensus determined.  Codes that did not achieve consensus were 
highlighted and participants were given the opportunity to reconsider their selection based 
on other participant’s (anonymised) selections.  Any disagreements after the second round 
were discussed in order to reach consensus. 
 
The first round of the eDelphi achieved a consensus of 69.0% (n=89/129) and a further 
28.7% (n=37/129) were agreed by two out of three participants (Table 5.2).  Only 2.3% of 
the codes (n=3/129) had zero consensus.  After the second round, consensus of 98.4% 
(n=127/129) was achieved and the remaining two codes were agreed by two out of three 
participants (SP, JJC).  These two codes were discussed and consensus on all themes was 
achieved.  This process of consensus resulted in the 129 codes categorised into ten themes 
of communication (Appendix 5), a summary of which is provided in Table 5.3.  The eDelphi 
process is summarised in Figure 5.6. 
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Table 5.3 – Modified APS-Doc: description of the themes and examples of the topics (codes) within each theme 
 
Main category Brief description Examples of medication-related topics of 
communications 
Example of pharmacist review 
message 
Contraindication Communication relates to a 
contraindication to treatment 
that requires attention or 
monitoring 
Physiological contraindication exists [Bisoprolol] Patient is currently 
hypotensive, please do not administer if 
patient is hypotensive. 
Contraindication exists owing to other disease 
state 
[Nitrofurantoin] eGFR is less than 60 = 
please change to trimethoprim. 
Contraindication exists owing to allergy or 
intolerance 
[Trimethoprim] Patient allergic to co-
trimoxazole - contains trimethoprim. 
Potential contraindication as a result of cross-
reactivity due to allergy status 
[Meropenem] Patient is allergic to 
penicillin, if beta lactam allergy, please 
review and consider alternative. 
    
Dose/ frequency Communication relates to the 
dose or frequency of a medicine 
The dose is too high or low for the patient or 
indication 
[Enoxaparin] Please consider dose 
reduction to 20 mg daily, patient’s eGFR= 
23. 
The wrong dose has been prescribed on 
conversion of the drug route/form 
[Citalopram] Pls review 20 mg tablet = 16 
mg (8 drops)-supplied for NG [nasogastric] 
administration. 
The wrong dose units have been prescribed [Vancomycin, 1 milligram] Please amend 
dose to 1 gram BD. 
The total daily dose has been divided 
inappropriately for the indication or patient 
[Senna] Pt usually takes ONE BD [twice a 
day], please review. 
The frequency is too high or low for the  patient 
or indication 
[Meropenem]  Please review dose of 
Meropenem, should be BD [twice a day] in 
view of eGFR. 
The regularity of the prescription needs 
reviewing (e.g.  when required to regular) 
[Lactulose, when required] Most effective 




Main category Brief description 
Examples of medication-related 
communications 
Example of pharmacist review  
message 
Drug form/route Communication relates to the 
form, preparation or route of 
administration of a medicine 
Inappropriate form of medicine for patient or 
indication 
[Lansoprazole capsules] This patient was 
prescribed Fastabs prior to admission. 
Inappropriate pharmacokinetic form for 
patient or indication (e.g. modified-released) 
[Propiverine] This dose is intended to be the 
XL preparation - please review. 
Inappropriate route for indication or medicine [Chloramphenicol ear drops] Patient was 
using chloramphenicol ointment for the right 
EYE, please review. 
Inappropriate use of multiple routes of 
administration 
[Ranitidine] Please prescribe IV or oral.  
Frequency not equivalent (IV must be TDS 
[three times a day]). 
Alternative route recommended for optimal 
treatment 
[Filgrastim] Please review route due to low 
platelets should be given IV infusion. 
Drug interaction Communication relates to a drug 
interaction that may require 
attention or monitoring 
Pharmacokinetic drug  interaction  
 
[Simvastatin] Please pause whilst on 
clarithromycin, increased risk of myopathy. 
  Pharmacodynamic drug  interaction [Tramadol] Increased risk of CNS toxicity 








Main category Brief description Examples of medication-related 
communications 
Example of pharmacist review 
message 
Drug selection Communication relates to the 
selection of the prescribed 
medicine 
Unsuitable for indication [Rifampicin] Micro results show 
rifampicin resistance - please review 
appropriateness of this drug. 
Wrong strength of medicine/preparation has 
been prescribed 
[Seretide® 250] Patient uses Seretide 125 
evohaler 2 puffs BD - please amend. 
No indication [Metronidazole] C diff negative.  Is this 
still needed? 
Use of two medicines with the same active 
substance 
[Paracetamol] Regular co-codamol 
prescribed please review prn [when 
required] paracetamol 
Use of two medicines in the same therapeutic 
group 
[Lactulose] Please review use of Laxido 
and lactulose - therapeutic duplication - 
both osmotic laxatives 
Sub-optimal drug choice according to guidelines [Cefotaxime] First-line treatment for 
meningitis is ceftriaxone 2 g BD.  
Wrong brand (preparation) selected for patient 
or indication 
[Ferrous sulphate] Pt takes ferrous 
fumarate 210 mg BD - Please review 
Wrong medicine prescribed as a result of a 
selection error in an electronic prescribing system 
[Clonazepam] Patient does not take 
clonazepam - see medical notes - patient 
is prescribed clobazam 20 mg on 
alternate evenings  




Communication relates to the 
use of the medicine or the 
administration process 
Timing of administration is inappropriate for the 
patient, medicine  or indication 
[Dexamethasone] Please amend timing of 
doses so that last dose each day is no 




Main Category Brief description Examples of medication-related 
communications 
Example of pharmacist review 
message 
  Medicine has not or is not being administered as 
intended 
Fluoxetine] Please review - patient 
refusing doses. 
  
Patient unable to take/use or be administered 
the medicine 
[Citalopram] Dr please review to change 
to drops as pt [patient] having difficulty 
swallowing. 
  Inappropriate medicine device for patient or 
indication 
[Seretide Accuhaler®] Please review to 
evohaler as per dhx [drug history]. 
  Dose is immeasurable for administration [Enoxaparin] Treatment dose enoxaparin 
= 1.5mg/kg 1.5*83 = 124.5 mg - round to 
120 mg. Please review dose. 
  Duration of prescription is unsuitable or no 
longer suitable 
[Phosphate effervescent] Please end as 






Main category Brief description Examples of medication-related 
communications 
Example of pharmacist review 
message 
Logistics Communication relates to the 
logistics of the medication 
process 
The medicine is not available for supply or 
administration 
[Calcichew D3 Forte®] Calcichew D3 forte 
is non-formulary, please switch to Adcal 
D3. 
 The prescription is incomplete  [Fentanyl, TTO] Needs CD [controlled 
drug] form. 
 The prescriber does not have authority to 
prescribe the medicine 
[Capecitabine] Only registrar or 
consultant to prescribe chemotherapy. 
 The prescription is for the wrong patient [Fentanyl] To be removed - written for 
wrong patient. 





Main category Brief description Examples of medication-related 
communications 
Example of pharmacist review 
message 
Omission Communication relates to an 
unintentional omission of 
treatment 
Omission of a medicine taken by a patient 
prior to admission 
Omission of a required medicine on the 
discharge prescription 
Omission of a treatment to optimise 
management 
 
Omission of a prophylactic  treatment 
[Salbutamol] Pt also uses Symbicort 
400/12. Please review. 
[Metronidazole] Please add to TTO. 
 
[Adcal D3] Please note low Hb 
[haemoglobin] - please could iron 
supplements be considered. 
[TEDS stocking] Enoxaparin also 





Communication of supporting 
information or request for 
supporting information 
Monitoring requirements for treatment [Amiodarone] Monitor TFTs [thyroid 
function tests]. 
Provision of information about the patient 
that may aid decision-making 
[Lansoprazole] Patient stopped taking 
this as it was ineffective.  He was 
taking correctly, compliantly and with 
no drug interactions that would 
prevent effect. 
Provision of information about the medicine 
that may aid stages of the medication process 
[Levetiracetam] Consider increasing 
after 1-2 weeks to 250 mg twice daily 
as per BNF dosing. 
Other supporting information [Enoxaparin] Low platelets please 
review. 
       
Other Communication relating to other 
medication-related issue that is 
not covered by the other 
categorises and descriptors 
  [.aprepitant] Aprepitant is in the PICS 

















Figure 5.6 – Flow chart to show rounds one and two of the eDelphi to achieve consensus 
 
5.2.3.5 High-risk error 
Assigning a severity to a patient safety incident or near miss event is an important step in 
the risk assessment process and common practice in the UK healthcare setting.  However, it 
requires agreement by consensus to determine a reliable mean score of severity—a time 
consuming process requiring up to four independent judges (Dean & Barber, 1999).  Coding 
the review messages to identify those that may relate to error and subsequently assigning a 
potential severity would require assumptions to be made of the data without context of the 
Round one eDelphi 
Delphi 
Round two eDelphi 
Delphi 
Participants (n=3) 
categorised the topics of 
communication categorised 
into themes using the 
modified APS-Doc scheme 
Consensus 69% (n=89/129) 
Zero consensus 2.3% (n=3/129) 
Themes returned to 
participants identifying 
those with full, partial and 
no consensus 
 
Participants given the 
opportunity to change their 
themes 
Participants discussed any 
disagreements (n=2/129) 
100% consensus achieved 
on how the 129 topics of 
communication are to be 
categorised 
Consensus 98.4% (n=127/129 
Consensus 100% (n=129/129 
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patient or the situation.  However, it would be beneficial to find out if pharmacists 
communicate information relating to high-risk errors via the CPOE system and if so, whether 
this factor influences subsequent outcomes.  In Chapter 4, I described a two-stage 
consensus technique to identify 80 high-risk prescribing errors (indicators) in the hospital 
setting [Appendix 3] (Thomas et al., 2013).  During the review of messages, communications 
relating to one of the 80 indicators were highlighted using a binary code [1: positive (error is 
one of the high-risk indicators), 0: negative (error is not one of the high-risk indicators).  
These were further categorised according to which one of the 80 indicators of error the 
communication related to.   
 
5.2.3.6 Messages relating to medicines reconciliation 
Errors of unintentional omission are repeatedly identified as the main type of medication 
error in UK hospitals, with the prevalence highest on admission (Cousins et al., 2012; Donyai 
et al., 2007; Dornan et al., 2009; Ross et al., 2013).  It was therefore expected that a 
proportion of messages communicated in PICS would relate to this discrepancy.  Medicines 
reconciliation “is the process of identifying an accurate list of a person's current medicines 
and comparing them with the current list in use, recognising any discrepancies and 
documenting any changes” (National Institute for Health and Care Excellence, 2015). 
Messages relating to this process on admission to hospital were identified using a binary 
code [1: positive (error relates to reconciliation on admission), 0: negative (information does 
not relate to reconciliation on admission].  Communications that discussed discrepancies at 
discharge were not coded as being related to medicines reconciliation, since the formal 





Findings from studies suggest that some clinical specialities may have higher prescribing 
error rates than others, for example, those that write fewer prescriptions such as surgical 
specialties (Dean et al., 2002b; Singh et al., 2009).  The speciality the patient was under 
when the message was communicated was identified.  The hospital specialities were 
categorised as shown in Table 5.4.  
Table 5.4 – Speciality the patient was under the care of when the review message was 
assigned 
 
Speciality Directorate within category 
General Medicine  
General Surgery  
Medical Admissions  
Trauma and Orthopaedics  
Critical Care and Burns Critical Care; Burns 
Medical Specialities Renal; Liver; Neurology; Cardiology; 
Haematology; Oncology; Ambulatory Care 
Surgical Specialities Ear, nose and throat; Cardiothoracic; 
Maxillofacial; Plastics; Urology; Vascular 
 
 
5.2.3.8 Association of message and prescription  
A review message in PICS can only be assigned to an active prescription order on a patient’s 
profile.  Should a pharmacist wish to communicate information via the CPOE system 
unrelated to any of the listed orders for a patient, they are forced to assign the message to 
one that it is not directly discussing it.  A good example of this would be a communication 
relating to an omission of treatment.  Identifying the number of messages that are 
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unrelated to the prescription order may inform system design relating to this.  As such, 
messages unrelated to the assigned medicine were identified using a binary code [1: 
positive (message relates to the medicine order on which it is assigned), 0: negative 
(message is not related to the medicine order on which it is assigned).   
 
5.2.3.9 Messages requesting an action 
The messages were reviewed to determine if they requested a measurable action that could 
be determined from the database.  For example, a message requesting a dose change to a 
specified alternative dose could be coded, whereas a message that provided supportive 
information (e.g. to monitor biochemistry) could not.  Messages requesting an action were 
identified using a binary code [1: positive (message requests a change in the prescription 
that is measurable from the database) 0: negative (message does not request a change in 
the prescription that is measurable from the database). 
 
When the coding of factors was complete, the database could be interrogated for analysis 
and additional data requested where necessary. 
 
5.3 Determining action 
5.3.1 Data capture 
The following data were identified from the database described and coded in section 5.2: 
i. Messages associated with the prescription on which it was assigned (see 5.2.3.8); 
and, 
ii. Messages that requested an action that could be determined from the data (5.2.3.9).  
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The data were separated into a separate Excel spreadsheet, along with the unique identifier 
for each line of coded data.  Data were requested from Informatics for each unique 
identifier on: 
i. Prescriptions that had a documented change in PICS after a review message had 
been assigned; 
ii. Details of the changed prescription: medicine name; route; dose; dose units; 
frequency; and the regularity of the prescription; and, 
iii. Date and time changes were executed in PICS. 
 
5.3.2 Coding the data 
The data were coded to identify whether the prescription was changed according to the 
pharmacists’ request in the review message.  Data were filtered by the subject of the 
communication (i.e. code) and the components of the new prescription order analysed.  
Data were coded as outlined in Table 5.5—a process that occasionally required application 
of clinical knowledge relating to the prescription order in question. 
Table 5.5 – Coding of next action data 
 
Action Code Binary code 
No further changes made to the prescription No action 0 
Changes to prescription, but request not actioned No action 0 






5.4 Inter-rater reliability 
In the development of the review message database, a proportion of the coding required 
qualitative content analysis.  Inter-rater reliability can provide a numerical score of 
agreement or consensus and is common practice in quantitative studies as a measure of 
consistency and therefore reliability.  However, its value in qualitative research is debated 
owing to the inherent subjectivity of the analysis  (Armstrong et al., 1997) and the varying 
methods adopted (Cook, 2012).  Despite its limitations, it was important to determine 
whether the messages in the database were reviewed and coded explicitly as intended and 
not implicitly, potentially influenced by prior experience and biases of a single reviewer.    
 
5.4.1 Method 
An independent statistician selected 5% (n=1,722) of the review messages at random using 
the ‘RAND()’ (random)  function in Microsoft Excel to generate a decimal (between 0 and 1) 
for each of the lines.  Those that were less than 0.05 (i.e. approximately 5% of the sample) 
were identified to be part of the validation set and prepared for independent review.  The 
dataset contained: 
i. Details of the prescription on which the review messages were assigned: name of 
medicine; route; dose; dose units; frequency; and regularity of the prescription; and, 
ii. The free-text review message. 
  
The rater was asked to code messages for three factors: 1) their relation to the medicines 
reconciliation process; 2) whether they were associated with the prescription on which they 
were assigned; and, 3) the theme of communication.  To facilitate coding of the theme of 
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communication, the rater was provided with the definitions of each theme (Table 5.3).  
Inter-rater agreement was calculated according to the percentage of times the raters 
agreed.  Any disagreements were identified and discussed to see whether they could be 
resolved by consensus.  After discussion, the final percentage agreement was determined.  
Any outstanding disagreements were assessed in further detail to check for any 
inconsistencies that may have indicated a problem with the coding process.   
 
5.4.2 Results 
A total of 1,722 review messages were independently coded for three factors: 1) their 
relation to the medicines reconciliation process; 2) whether they were associated with the 
prescription on which they were assigned; and, 3) the theme of communication.  The level 
of consensus between the two raters is shown in Table 5.6, describing agreement following 
the three steps in the process: 1) independent coding; 2) review of disagreements non-








 % (n/1722) 
Disagreement 
% (n/1722) 
 Message associated with the prescription   
1 Independent coding 98.0% (n=1687)  2.0% (n=35)  
2 Review of disagreements, non-blinded 98.5% (n=1697)  1.5% (n=25)  
3 Discussion 99.4% (n=1711)  0.6% (n=11)  
 Message relates to medicines reconciliation   
1 Independent coding 94.8% (n=1633)  (5.2% (n=89)  
2 Review of disagreements, non-blinded  96.6% (n=1663)  3.4% (n=59)  
3 Discussion 97.5% (n=1679)  2.5% (n=43)  
 Theme of communication   
1 
Independent coding with a summary of the 
themes (Table 5.4) 
86.9% (n=1497)  13.1% (n=225)  
2 
Independent coding with how all codes were 
categorised into themes (Appendix 5) 
98.3% (n=1693)  1.7% (n=29)  
3 Discussion 98.8% (n=1702)  1.2% (n=20)  
 
The assessment of inter-rater reliability showed substantial agreement across the three 
factors, all of which improved when additional resources were provided and with later 
discussion.  In cases where there were disagreements, these were then assessed in further 
detail to identify any commonality that would indicate a systematic error in the coding.  This 
highlighted some instances where codes required more detailed descriptors and, therefore, 
refinement of the description of the code in the methodology.  Examples of disagreements 
prior to discussion and subsequent agreement and final disagreements are provided in 




Table 5.7 – Examples of inter-rater disagreements prior to discussion and consensus was achieved 
 
 
Review message Code 
Second 
rater 
Comment on agreement 
Message associated with the prescription 
Pls [please] change discharge letter - 
changes have been made to regular meds 
Yes No This was coded as associated with the prescription, with 
changes made that now need to be reflected on the TTO. 
 
Pt [patient] on inhaler at home - Salbutamol 
evohaler - 2 puffs BD prn [twice a day when 
required] 
Yes No This message was assigned to a salbutamol prescription of a 
different preparation (nebules) indicating what should be 
prescribed as the patients ‘usual’ regimen.   
 
Message relates to medicines reconciliation 
Was on mst [morphine sulfate tablet brand] 
sachets? 
No Yes This message was assigned to a TTO prescription for codeine 
phosphate. The message was coded as unrelated to the 
medicines reconciliation process on admission.   
 
Patient not had any for weeks, not 
appropriate to give on TTO, please review 
No Yes This message was assigned to a TTO prescription and does not 
describe reconciliation on admission.  
 
Theme of communication    




The theme was coded as ‘Omission’ and the fine code as 
‘Takes as combination preparation but only single constituent 
prescribed’.  The second rater agreed with the fine code. 
 
Patient has a falls risk - please consider 





The theme was coded as ‘Contraindication’ and the fine code 
as ‘Drug-disease interaction – falls’.  The second rater agreed 
with the fine code. 
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Table 5.8 – Examples of messages with no inter-rater agreement 
 
 
Review message First coded Second rater Comment on disagreement 
Message associated with the prescription 
Please update thrombosis 
assessment 
Yes No This in an example of experience informing coding.  This 
message was coded as associated with the prescription since 
the medicine is being used for cancer, which would increase 
the risk of thrombosis. 
 
Please r/v whether required with 
Aspirin  
No Yes This message was likely associated with the aspirin 
prescription. This can be considered an error in coding. 
Message relates to medicines reconciliation 
Is this new? [Atenolol] Not in pts 
[patient’s] own meds and dose listed 
in notes is 50 mg daily 
 
No Yes This message does relate to reconciliation and can be 
considered an error in coding. 
 
Pt [patient] does not have nebuliser 
at home - please change to inhaler 
No Yes The rater felt that this does relate to reconciliation. The first 
coder argued that it concerns the discharge process. 
  
Theme of the communication    
Please review dates-needs to start 4 





The theme was coded as ‘Supporting Information’ and the fine 
code as ‘Information provision - Duration of treatment’. The 
rater disagreed that this related to the duration of treatment. 
 
Normally uses tamsulosin M/R 400 
micrograms capsules once daily 
Drug Use/ 
Administration 
Drug selection The theme was coded as ‘Drug Form/ Route’ and the fine code 
as ‘Change to MR formulation to be consistent with pre-
admission medicines’.  This was a coding error since the 
message was assigned to a different medicine. 
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After independent coding (step 1), the rate of consensus was lowest for the theme of 
communication, with a disagreement rate of 13.1%.  At this stage the rater had access to a 
list of the themes, a description of each and examples of subjects within the theme (Table 
5.4).  When this resource was expanded to include the full list of codes within each theme 
(Appendix 5) (step 2), disagreement fell to 1.7%.  This degree of change shows an 
agreement for the codes of communication to describe the contents of the review 
messages, but suggests that the second reviewer may have “packaged the themes 
differently” into major themes (Armstrong et al., 1997).  This finding is consistent with the 
difficulties already faced when attempting to gain consensus on the categorisation of 
communication themes described in Chapter 3 and in section 5.2.3.3. 
 
The initial coding of the dataset took just over 18 months, a long time for a single reviewer 
to be immersed in the data and to become familiar with the nuances of the free-text 
communications.  During this time, the codes were refined as messages were continuously 
compared to each other across the entire dataset.  A second rater is unlikely to view the 
messages in exactly the same way, since they did not have the opportunity to compare and 
refine codes over the same period of time.  It is also important to note that the approach of 
constant comparison “is not designed to guarantee that two analysts working independently 
with the same data will achieve the same results” (Glaser, 1967).  Despite this, the level of 





5.5 Strengths and limitations of the database 
The database of pharmacist-physician communications comprises over 34,000 free-text 
review messages, with additional information on the associated prescriptions and user 
interaction.  The volume and veracity of the database is a clear strength, the latter of which 
has been demonstrated with a high inter-rater reliability, despite the subjective 
interpretation of data necessary for content analysis.  In addition, the individual factors 
coded within the database give it variety to inform a more comprehensive descriptive and 
statistical analysis of electronic communications. 
 
The coding of the database was supported with both a clear rationale for each factor and 
evidence-base where possible.  In coding the theme of communication, where evidence did 
not exist to inform the process, additional research was conducted to gain consensus and 
improve the validity of the study.   
 
In the development of this database, free-text communications were reviewed and coded to 
identify the explicit subject of the discourse and not what may be implied.  The latter is not 
possible without knowing the individual pharmacists and running an analysis of their intent 
and the subsequent interpretation of the recipient.  In addition, a lack of context at the time 
of the message (i.e. of the patient and situation) makes this difficult.  Communications were 
also analysed and validated by pharmacists and not physicians who were the intended 
recipients of messages.   
 
The language used by pharmacists in their written discourse was not analysed in this study.  
For example, whether pharmacists wrote with due consideration of the recipient (the 
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physician) or how the discourse changes to position the recipient’s response (Gee, 2014).  A 
pharmacist’s discourse may change depending on their grade or prior experience, for 
example the use of ‘?’ before a written request has been suggested to counterbalance that 
an action is being requested (Liu et al., 2014).  This type of analysis could provide further 
explanation for the outcome of communications, but was outside the scope of this study.    
 
Finally, the communications were not analysed for their potential impact on patient safety.  
This is difficult to determine without context of the patient or the situation and would have 








Chapter 6 DESCRIPTIVE ANALYSIS OF PHARMACIST-PHYSICIAN 
COMMUNICATIONS 
 
In this chapter, I provide a descriptive account of the review message database captured 
over a 12-month period.  I describe the various temporal, message and prescription factors 
associated with the messages assigned to prescriptions in PICS by pharmacists and present 
the results using tables and graphs.  
 
Some of the results presented in the chapter have been published in a report published by 
NHS England: Office of the Chief Pharmaceutical Officer, M. D. (2016). Transformation of 
seven day clinical pharmacy services in acute hospitals. Case Study: Pharmacist-physician 






6.1 Data analysis 
In Chapter 5, various factors were introduced that were coded during the analysis of the 
database.  Each of these can be divided into temporal, message and prescription factors 
(Table 6.1). 
 
Table 6.1 – Factors coded for in the analysis of pharmacist review messages 
 
Temporal factor 
Day of the week messages are assigned 
Hour of day messages are assigned 
Time between prescription being generated and message being assigned 
 
Message factor 
Grade of the pharmacist 
Message assigned to a high-risk medicine 
Message associated with the prescription 
Message relates to the reconciliation process 
Theme of communication 
Message relates to a high-risk error 
 
Prescription factors 
Speciality the patient is under the care of in the hospital 
Type of medicine  
Regularity of medicine 
 
The data captured and the various factors coded in Microsoft Excel (Table 6.1) were 
summarised using descriptive statistics and represented graphically to highlight patterns or 
trends.  The changes in the numbers of patients, prescriptions and review messages 
assigned to each in PICS between 2009 and 2014 were analysed using linear regression 
models.  Totals and rates were calculated for each of the months and set as dependent 
variables in the regression models, with the month number as the independent variable.  
The coefficients of the resulting models were used to estimate the average annual increase 
in each of these outcomes. 
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The length of the messages as the number of characters was calculated using the LEN 
function in Microsoft Excel.  A non-parametric approach was used as the distribution of the 
data was skewed (Figure 6.1).  Data were reported as medians and interquartile ranges and 
comparisons between the grades of the pharmacists and the theme of communication were 
performed using the Kruskal-Wallis test.  Where significant differences were detected, post-
hoc pairwise comparisons between the categories were conducted using Dunn’s test.  All 
analyses were performed using SPSS 22 (IBM SPSS Inc., Chicago, IL, USA), with p<0.05 
considered significant.   
 





6.2 Use of the review message function 
Over the five-year period between January 2009 and December 2014, the number of patient 
admissions recorded in PICS increased from 52,977 to 89,899 per year.  The number of 
prescriptions generated for patients increased from 1,059,252 in 2009 to 1,625,307 in 
2014—a rise of 53.4%.  Upon conducting a linear regression analysis, the rate of increase 
was found to be significant, increasing by 652 each year (p<0.001).  Similarly, there was a 
significant increase in the number of prescriptions generated, increasing by 9,735 each year 
(p<0.001). 
 
Linear regression analysis found a significant increase in the rate of messages assigned to 
patients, with a 2.9 percentage point increase per annum (95% CI: 2.12–3.65, p<0.001), as 
well as a 0.2 percentage point increase per annum for messages assigned to prescriptions 
(95% CI: 0.18–0.25, p<0.001) (Figure 6.2).  Looking at the study period of 2012 (Figure 6.3), 
January and August had the highest rate of messages assigned to prescriptions, with 3.2% of 











Figure 6.3 – Percentage of patients and prescriptions with a review message assigned in 2012
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6.3 The Database 
Between 1st January 2012 and 31st December 2012 there were 71,994 inpatient episodes 
generated in PICS, for whom 1,291,773 prescriptions were generated.  Of these, 925,035 
were inpatient orders and 366,738 prescriptions for discharge (TTOs).  Pharmacist’s 
assigned 36,245 review messages to prescriptions.  After exclusions, the final database 














Figure 6.4 – Flow chart to show data that were excluded during the development of the 
database 
 
Review messages assigned 








Review messages for 























Each of the factors coded are described below. The frequencies of review messages relating 
to each factor are summarised in Appendix 6. 
 
6.3.1 Temporal factors 
The majority of messages were assigned to prescription orders between Monday and Friday 
(98.6%, n=34,039/34,506).  Nearly one quarter of these were assigned on a Monday alone 
(22.9%, n=7,899/34,506) and steadily declined over the weekdays to 17.8% 
(n=6,151/34,506) on a Friday (Figure 6.5).  Overall, a larger proportion of messages were 
assigned in the morning between 00:00–13:00 hours (61.5%, n=21,238/34,506), compared 
to the afternoon between 13:00–23:59 (13,268/34,506). 
 
Figure 6.5 – Number of review messages assigned by pharmacists by day of the week and 





Peaks were observed in the assignment of messages at 10:00 (18.7%, n=6,436/34,506), 
11:00 (17.8%, n=6,156/34,506) and 15:00 (10.8%, 3,712/34,506).  The time of day messages 
were assigned was consistent across the days of the week, with peaks observed between 
10:00–12:00 and 14:00–16:00 on a Monday to Friday and troughs around lunchtime at 
13:00 (Figure 6.6).  At the weekend, the majority of messages were assigned earlier in the 
day between 09:00–11:00. 
 
 
Figure 6.6 – Hour of day review messages were assigned across the days of the week 
Excludes n=3 that occurred between 0:00–1:00 on a Tuesday and n=1 between 02:00–3:00 on a 
Friday. 
 
Just over half of all the messages were assigned within the first 24 hours of the prescription 
being generated, with 25.8% within the first 12 hours (n=8,913/34,506) and 27.9% between 
12–23:59 hours (n=9,636/34,506).  A large proportion were then assigned within 1–6 days 
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of the prescription being initially generated (38.4%, n=13,278/34,506) and fewest assigned 7 
or more days later (7.8%, n=2,679/34,506).   
 
6.3.2 Message and prescription factors 
6.3.2.1 Grade of the pharmacist 
The 34,506 review messages were assigned to prescriptions by 55 different pharmacists 
identified though individual user logins—52 Full Time Equivalent (FTE) roles based on a 37.5 
hour working week.  Grade 7 pharmacists assigned the most messages overall (47.2%, 
n=16,302) and grade 8 the fewest (22.2%, n=7,672).  Grade 7 pharmacists also assigned the 
most messages per FTE (Table 6.2).  
 






No. of FTEs No. of review 
messages (%) 
Number of messages 
per FTE pharmacist* 
6 15  15 10,532 (30.5%) 702 
7 20 19.24 16,302 (47.2%) 848 
8 20 18.03 7,672  (22.2%) 426 
*Rounded to the nearest whole number 
 
6.3.2.2 Speciality  
The majority of messages were assigned to prescriptions for patient’s under the care of the 
Medical Specialities (29.8%, n=10,294/34,506) and General Medicine (8,429, 
n=8,429/34,506) and fewest for those under Critical Care and Burns (5.1%, n=1,744/34,506) 




Table 6.3 – Number of messages assigned to patient’s prescriptions by speciality 
 
Speciality No. of messages 
Proportion of 
total no. of 
messages (%) 
Medical Specialities 10294  29.8% 
General Medicine 8429 24.4% 
Medical Admissions 6663 19.3% 
Surgical Specialities 3388 9.8% 
General Surgery 2074  6.0% 
Trauma and Orthopaedics 1914  5.5% 
Critical Care and Burns 1744  5.1% 
Total 34506  
 
6.3.2.3 Association with the prescription 
On examination of the content of messages, 9.9% (n=3,406/34,506) were found to be 
unrelated to the prescription order on which they were assigned.  This occurred most 
frequently for patients under the care of Medical Admissions (36.6% n=1,245/3,406), 
accounting for 18.5% of all the messages assigned in this speciality.  Unrelated messages 
were assigned less frequently for those patients under Critical Care and Burns (1.4%, 






Figure 6.7 – Number of review messages assigned to prescription orders according to 




Nearly half of all the messages (47.3%, 16,355/34,506) were assigned to two categories of 
medicines: Cardiovascular (24.5%, n=8,458/34,506) and the Central Nervous System (22.9%, 
n=7,897/34,506).  This was still the case when only accounting for messages directly 
associated with the prescription (Figure 6.8).  Fewer messages were assigned to medicines 
categorised as Other (e.g. acetylcysteine, n=46/83), Malignant Disease and 





Figure 6.8 – Number of messages assigned to each category of medicine that were directly 
associated with the prescription 
CNS Central Nervous System; EEEO Eye, Ear, Nose and Oropharynx; GI Gastrointestinal; 
Malign/Immuno Malignant Disease and Immunosuppression; Muscu/Joint; Musculoskeletal and 
Joint Disease; OGU Obstetrics, gynaecology and urinary-tract disorders 
 
Just under one quarter of all the messages were assigned to ten different medicines in PICS 
(23.8%, n=8,227/34,506).  The most common being enoxaparin (a Cardiovascular medicine), 
accounting for 6.3% (n=2,179/34,506) of all the messages (see Table 6.4), with one in every 
twenty prescriptions for enoxaparin having a message assigned in 2012 (4.9%, 
n=2,179/44,028).  The second most common medicine was paracetamol (a Central Nervous 




Table 6.4 – Top ten medicines with review messages assigned  
 
Name of medicine  




of total no. 
of messages 
(%) 
Total no. of 
prescription 
orders in 2012 
Proportion of total 
prescriptions with 
a message (%) 
Enoxaparin 2179 6.3% 44,028 4.9% 
Paracetamol 1075 3.1% 103,847 1.0% 
Lansoprazole 890 2.6% 36,608 2.4% 
Simvastatin 831 2.4% 20,869 4.0% 
Aspirin 599 1.7% 33,024 1.8% 
Adcal D3 559 1.6% 13,330 4.2% 
Furosemide 544 1.6% 34,316 1.6% 
Tramadol 541 1.6% 28,232 1.9% 
Metformin  514 1.5% 10,734 4.8% 
Codeine phosphate 495 1.4% 35,444 1.4% 
Total 8227 23.8   
 
When considering only those messages that were directly associated with the prescription 
orders, the top four medicines remained the same (enoxaparin, paracetamol, lansoprazole, 
simvastatin), but aspirin and Adcal D3® no longer featured, replaced with Sando K® (an oral 
potassium chloride supplement) and lactulose (Table 6.5).  For aspirin and Adcal D3®, 77.7% 
(n=262/337) and 46.7% (n=178/381) of all messages assigned to these medicines were not 




Table 6.5 – Top ten medicines with review messages assigned that were directly 
associated with the prescription order 
 
Name of medicine 




total no. of 
messages (%) 





with a message 
(%) 
Enoxaparin 2012 6.5% 44,028 4.6% 
Paracetamol 977 3.1% 103,847 0.9% 
Lansoprazole 814 2.6% 36,608 2.2% 
Simvastatin 784 2.5% 20,869 3.8% 
Tramadol 525 1.7% 28,232 1.9% 
Furosemide 491 1.6% 34,316 1.4% 
Metformin  483 1.6% 10,734 4.5% 
Lactulose 465 1.5% 12,375 3.8% 
Codeine phosphate 440 1.4% 35,444 1.2% 
Sando-K 407 1.3% 12,083 3.4% 
Total 7398 23.8   
*n=31,100 total number of review messages associated with the prescription 
 
6.3.2.5 High-risk medicines 
Almost a third of all messages were assigned to medicines considered high-risk (29.1%, 
n=10,047/34,506).  In 93.0% of cases, the messages communicated information that was 
directly associated with that medicine (n=9,339/10,047).  The majority of the messages 
were assigned to prescriptions for antibacterials (30.9%, n=3,102/10,047), followed by 
LMWHs (21.8%, 2,195/34,506) and opioid analgesics (21.6%, 2,175/34,506) (Figure 6.9)—an 
order that did not change when only considering related messages.  In the year analysed, no 





Figure 6.9 – Number of messages assigned to a high-risk medicine or class of medicine 
DOACs Direct Oral Anticoagulants; NSAID Non-Steroidal Anti-Inflammatory Drugs; LMWHs Low 
Molecular Weight Heparins 
 
6.3.2.6 Free-text prescription entry 
The PICS system allows physicians to prescribe medicines that are not listed in the drug 
dictionary.  So called ‘dot drugs’ because a dot (.) is added prior to writing the name of the 
medicine, the free-text nature of the entry overrides all associated CDS.  Out of all the 
prescriptions analysed with a message assigned, 0.01% (n=364/34,506) were generated as a 
‘dot drug’.   The majority of the messages highlighted to the physician that the ‘medicine 
name had been prescribed to override all decision support’ (18.7%, n=68/364) and to 
change this to a drug dictionary entry, for example: “Aprepitant is in the PICS dictionary, 




6.3.2.7 Regularity of prescription 
Most messages were assigned to regular prescription orders (79.0%, n=27,276) (Figure 6.10) 
and fewest assigned to Once Only prescriptions (0.8%, n=266/34,506).  Proportionally, 
fewer messages assigned to As Required prescriptions (3.4%, n=128/3,541) that were 
unrelated to the prescription.  The most common medicine in this theme was lactulose 
(10.0%, n=367/3,669), with all messages assigned associated with the prescription. 
 
Figure 6.10 – Pie chart to show the regularity of the prescription orders on which 
messages were assigned 
 
6.3.2.8 High-risk error 
Overall, a small proportion of messages communicated information relating to one of the 80 
high-risk errors identified in Chapter 4 and summarised in Appendix 3 (Thomas et al., 2013) 
(3.8%, n=1,317/34,506).  The majority were assigned by grade 7 pharmacists (45.7%, 
n=602/1,317) and fewest by grade 8 (16.3%, n=215/1,317).  Of these 80, 45 were raised in a 
review message at least once. The most common high-risk error (Table 6.6), accounting for a 
quarter of all high-risk messages was, ‘Paracetamol prescribed at a dose of 4 g over a 24 
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hour to a patient under 50 kg’ (26.6%, n=350/1,317).  Proportionally, more messages related 
to a high-risk error in General Medicine (5.4%, 458/8,429) and fewest in Medical Admissions 
(2.1%, n=143/6,663).  Appendix 7 provides a summary of all high-risk errors and the 
frequency at which these were communicated.   
 
Table 6.6 – Most common high-risk errors communicated via the review message 
 






Paracetamol prescribed at a dose of 4 g over a 24 hour to a 
patient under 50 kg (Risk of hepatocellular toxicity) 
350 32.2 
   
Statin prescribed concomitantly with a macrolide antibiotic 
(Increased risk of myopathy) 
203 24.4 
   
Low molecular weight heparin prescribed to a patient with 
renal impairment without dose adjustment (Increased risk 
of bleeding) 
156 7.1 
   
Potassium chloride supplements continued for longer than 
is required  (reference range 3.5–5.3 mmol/litre) (Increased 
risk of hyperkalaemia) 
139 29.6 
   
Nitrofurantoin prescribed to a patient with eGFR < 60* 
ml/minute/1.73m2 (Risk of peripheral neuropathy and 
inadequate concentration in urine)  
102 57.6 
Total 950  
Total number of high-risk medicines 1,317  




6.3.2.9  Medicines reconciliation 
Nearly half of all messages communicated information relating to the reconciliation 
process—comparing the patient’s current treatment regimen to that taken prior to 
admission (44.3%, n=15,295).  The majority of these were assigned to patients under 
Medical Admissions (33.9%, n=5,180/15,295) (Figure 6.11).  Very few messages were 
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assigned by pharmacists at the weekend that related to this process (0.4%, 67/15,295) 
(Figure 6.12).   
 
Figure 6.11 – Messages relating to the medicines reconciliation process in each speciality 
 
 
Figure 6.12 – Messages relating to the reconciliation process by day of the week 
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Table 6.7 summarises the times taken to assign the messages, the majority of which were 
assigned within 24 hours (60.8%, n=9,301/15,295). 
 
Table 6.7 – Time since the prescription was generated and message relating to 
reconciliation assigned 
 
Time from prescription 








< 12 hours 4070 26.6% 
12:00–23:59 5231 34.2% 
1–6 days 5559 36.3% 
7+ days 435 2.8% 






 6.3.2.10  Theme of communication 
The analysis of the content of messages identified 129 topics of communication, categorised 
into ten themes (Chapter 5).  The most common theme of communication related to the 
Dose/Frequency (27.1%, n=9,361/34,506), followed by the provision of Supporting 
Information (23.0%, n=7,953/34,506) and then Drug Use/Administration (13.9%, 
n=4,790/34,506) (Figure 6.13).  Messages raising the logistics of the prescription order were 
least frequent (0.02%, n=622/34,506).  Appendix 8 provides a summary of the number of 
messages within each of the 129 topics.   
 
 






Looking at the grades of the pharmacists assigning the messages, those of grade 7 (n=20) 
assigned a higher proportion within each category compared to grade 8 (n=20) (see Table 
6.2).  The category where this was most prominent were messages relating to Omissions, 
with 54.2% (n=2,003/3,696) assigned by grade 7, compared to 8.2% (n=304/3,696) by grade 
8 (Figure 6.14). 
 
 






All themes of communications occurred across all specialities.   Looking at the proportions 
for each theme across specialities (Figure 6.15), messages relating to Dose/Frequency and 
Omissions stand out in the Medical Admissions compared to any other speciality (25.6%, 




Figure 6.15 – Proportion of messages by each theme assigned to prescriptions in 
specialities 
*<10% of messages  
 
The top ten topics of communication accounted for 44.8% of all the messages (Table 6.8).  
The most frequent was to provide information about a patient’s usual ‘at home’ dosing 
regimen (10.5%, n=3,638/34,506).  The second most common related to an omission of 
treatment, specifically one previously taken by the patients and not reflected on their 
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current hospital prescription (8.2%, n=2,828/34,506).  The most frequent topics are listed in 





Table 6.8 – Top ten topics of communication and the most common medicines within each topic 
 
Topic of communication 
Theme of 
communication 












Information is provided on the 
patient’s usual dosing regimen 
(no change requested) 








       
There is an omission according 
to the patient’s medication 
history 








       
The dose is too low compared 
to pre-admission 
Dose/ Frequency 1781 19.0% 5.2% Levothyroxine 
Furosemide 






       








       






































       












       
The dose is too low Dose/ Frequency 1029 11.0% 3.0% Enoxaparin 








The dose is too high compared 
to pre-admission 








       
There is a duplicate prescription 


















The Dose/Frequency theme was most commonly associated with communications relating 
to the medicines reconciliation process (28.0%, n=4,276/15,296) and the majority related 
directly to the prescription on which they were assigned (99.7%, n=9,336/9,361).  The most 
frequent Dose/Frequency topic related to a dose error perceived to be lower than that 
usually taken by the patient (19.0%, n=1,781/9,361)—assigned to 263 different medicines in 
PICS, with levothyroxine the most common (4.8%, n=86/1,781).  Messages relating to 
perceived errors of the dose or frequency being too high or low accounted for 85.3% of all 
communications in this theme (n=7,982/9,361) (see Appendix 8).  The most common 
medicines with Dose/Frequency problems identified and highlighted with a message were 
for enoxaparin (8.7%, n=811/9,361), paracetamol (5.8%, 548/9,361), lactulose (4.3%, 
406/9,361) and simvastatin (2.1%, 197/9,361).   For enoxaparin, the majority of messages 
highlighted a dose that was too low (16.5%, n=360/2179) or too high (15.1%, n=329/2179); 
for paracetamol the dose being too high (35.0%, n=380/1,086); for lactulose the frequency 
being too low (80.0%, n=380/475); and for simvastatin the dose being higher than that 
usually taken by the patient (13.8%, 115/831). 
 
Supporting information 
The most common Supporting Information message was to provide information about a 
patient’s usual regimen, accounting for almost half of these messages (45.7%, 
n=3,638/7,953).  For example, “dhx = 2 mg bd” [dhx being an abbreviation for the drug 
history, followed by the dosing schedule of twice a day).  The second most frequent topic 
provided information about the usual dosing regimen for a medicine (7.9%, n=629/7,953), 
for example: “Usually given 12-hourly” on a prescription for intravenous ondansetron.  A 
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proportion of these messages requested that various parameters were monitored (8.7%, 
n=692/7,953), for example “Monitor potassium please”, assigned to a prescription for an 
oral formulation of potassium chloride.   
 
Drug Use/Administration 
The most frequent topic relating to the Drug Use/Administration process was to request 
that a duration of treatment was added to the prescription order (21.7%, n=1,041/4,790).  
This was most frequent on prescriptions for Sando-K (13.0%, 135/1,041), for example: 
“Please specify end date”.  The second most common topic was to request a review of the 
duration of treatment (21.6%, n=1,036/4,790), which was mostly frequently assigned to 
enoxaparin prescriptions (10.6%, n=110/1,036).  For example: “Please review if still required 
as INR [International Normalised Ratio] is now within range”. 
 
Omission 
Messages relating to an omission of treatment accounted for 10.5% (n=3,661/34,506) of all 
messages.  The majority of these messages (86.3%, n=3191/3,696) were unrelated to the 
prescription on which they are assigned.  An omission of treatment on admission to hospital 
was the most common topic communicated in this theme (88.4%, n=2,830/3,191).  These 
were mostly sent by grade 6 pharmacists, with 75 messages per pharmacist per annum 
(40.0%, n=1128/2820,) and grade 7, with 77 messages per pharmacist per annum (54.7%, 
n=1543/149).  Grade 8 pharmacists assigned few messages relating to this type of omission, 




An analysis of the medicines with messages assigned relating to omission showed that 
47.3% (n=1,749/n=3,696) began with letters A to C in the alphabet, appearing first on a 
patient’s prescription profile as these are listed alphabetically on screen.  Out of the 505 
Omission messages that did relate to the prescription, the most frequent was to raise that a 
patient was on a combination preparation but only a single component had been prescribed 
(65.0%, n=328/505).  A third of these were assigned to Adcal (32.6%, n=107/328) and 
highlighted to the physician that a combination with vitamin D is usually taken by the 
patient: “Patient takes Adcal D3 two daily - please change”.   
 
Drug selection 
The most common topic within the theme of Drug Selection was to highlight that a duplicate 
medicine had been prescribed in light of an existing class of medicine (n=24.5%, 812/3,308).  
This occurred most frequently with tramadol (20.4%, n=166/812) and codeine phosphate 
(10.3%, n=83/812).  For example: “Patient also on morphine, please rationalise” assigned to 
a regular prescription for tramadol.  The second most common topic was to highlight to the 
physician that the patient takes a different class of medicine to that which has been 
prescribed (18.4%, n=608/3,308).  This occurred most frequently with lansoprazole (31.1%, 
n=189/608), followed by simvastatin (15.5%, n=94/608).  A small number of messages 
related to CPOE selection errors (n=11/34,506), assigned on nine different medicines.  For 
example, the prescription of ‘clonazepam’ when the pharmacist perceived that ‘clobazam’ 






The most common topic within the theme of Drug Form/Route was to request a change 
from a standard-release formulation to a modified-release formulation to be consistent with 
the patient’s usual regimen (34.1%, n=699/2,050).  This occurred most frequently on 
prescriptions for metformin (18.0%, n=126/699), followed by doxazosin (9%, n=63/699).  For 
example: “Patient normally takes MR tablets - please change” on a prescription for 
metformin.  The second most common was to request a change in the formulation of a 
medicine from a solid dosage form to a liquid or dispersible form (14.6%, n=299/2,050).  
This occurred most frequently on prescriptions for lansoprazole (17%, n=51/299) and 
paracetamol (10.7%, n=32/299). 
 
Contraindication 
Messages relating to a Contraindication accounted for 3.6% (n=1,249/34,506) of all the 
messages.  The majority of these related to a drug-disease interaction, with the medicine 
prescribed increasing the risk of falls (46.4%, n=580/1,249) and the pharmacist asking for a 
review in light of this.  For example: “Patient has a falls risk. Please consider using a less 
sedating antihistamine”, assigned to a prescription for chlorphenamine.  This message type 
was most frequently assigned to the opioid analgesics codeine phosphate (25.2%, 
n=146/580) and tramadol (17.2%, n=100/580).  The second most common topic within this 
theme related to drug-disease interactions as a result of patient comorbidities (26.3%, 
328/1,249).  These were mostly assigned to nitrofurantoin (30.8%, n=101/328), raising a 
contraindication with the patient’s level of renal function and the need to select an 
alternative antibiotic: “Please review, eGFR [glomerular filtration rate] <60 ml/minute.  
Nitrofurantoin ineffective because of inadequate urine concentrations. Consider switching to 
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trimethoprim 200 mg BD [twice a day] for three days”.  The remaining messages were 




Messages highlighting a drug interaction accounted for 21.8% of the messages 
(n=753/34,506).  The majority of these related to a pharmacokinetic interaction (n=74.8%, 
563/753), with the absorption, distribution, metabolism or excretion of one of the 83 
medicines affected by the concomitant treatment.  These messages were most commonly 
assigned to simvastatin (44.5%, n=251/563) and clarithromycin (7.8%, n=44/563) and in 
both cases the same interaction was raised: “Interaction between simvastatin and 
clarithromycin increased risk of myopathy.  Please consider pausing the simvastatin until 
course of clarithromycin is complete”.  Messages relating to a pharmacodynamic 
interactions —identifying synergistic or antagonistic effects or adverse effects—were 
assigned to 59 different medicines (25.2%, n=190/753), the most common being tramadol 
(14.7%, n=28/190) and ibuprofen (12.6%, n=24/190).  
 
Logistics  
Messages relating to the logistics of the prescription accounted for 1.8% of all the messages 
(n=622/34,506), the smallest proportion overall.  The most common topic within this theme 
was for the pharmacist to inform the physician that the medicine was not stocked in the 
hospital and requested for an alternative to prescribed (74.1%, n=461/622).  These 
messages were assigned to 195 different medicines.  The second most common topic also 
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related to stock of a medicine, but as a result of manufacturing delays as opposed to stock 
held by the pharmacy department (9.5%, n=59/622).   
 
Other 
The most common topic of communication coded as ‘Other’ related to an out-of-date 
discharge summary, with 68.5% (n=496/724) of requests asking for the TTO to be updated 
to reflect the inpatient regimen.  The second most common topic was to raise the use of a 
‘dot drug’ to generate the prescription (n=9.9%, n=72/724).  This shows that out of the 364 
‘dot drug’ prescriptions in the database, not all of them were identified by the pharmacist as 
a problem (see section 6.3.2.6, Free-text drug entry). 
 
6.2.2.11 Length of messages 
The maximum length of any review message assigned in PICS is 255 characters.  Overall, 
pharmacist’s messages contained a median of 45 characters (Interquartile range (IQR) 30–
68).  A post-hoc analysis found there was a significant difference in the median length of 
messages across the grades of pharmacists (p<0.001) (Table 6.9).  A pair-wise comparison 
showed a significant difference between grade 6 and 8 pharmacists (p<0.001) and grade 7 
and 8 pharmacists, with grade 8 pharmacists assigned shorter messages overall.  There was 
















6 47 29–72 
7 46 32–67 
8 40 27–64 
 
There was also a significant difference in the length of the review messages across the 
themes of communication (p<0.001) (Table 6.10).   
Table 6.10 – Median length of review messages by theme of communication 
 




Drug Interaction 72 53–96 
Logistics 61 42–87 
Contraindication 57 37–82 
Omission 57 40–78 
Drug Selection 50 35–72 
Dose/Frequency 46 35–64 
Drug use/Administration 43 27–65 
Drug Form/Route 42 28–59 
Other 36 18–59 
Supporting Information 34 20–58 
 
Messages communicating information about a Drug Interaction had the highest median 
length of 72 characters (IQR 53–96), compared to Supporting Information with a median 
length of 34 characters (IQR 20–58). 
 
6.3 Discussion 
In this study, 34,506 free-text review messages were analysed for their content, along with 
the associated prescriptions on which they were assigned.  Between 2009 and 2014, there 
was a year-on-year increase in the pharmacists’ use of the review message function.  Albeit 
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small (0.2 percentage points per annum), it may suggest an increasing dependence on the 
modality of communication over time.  On the other hand, the increase observed may be 
due to an increasing workload from the increasing number of inpatient episodes each year 
at the hospital, increasing number of medicines prescribed in the NHS (Health and Social 
Care Information Centre, 2016) and increasing roles such as medication history taking and 
medicines reconciliation.  In addition, pharmacists are taking on many more clinical tasks 
during the medication review process, such as with completing assessments to identify any 
medicines that may increase the risk of patient falls (National Institute for Health and Care 
Excellence, 2013).  A function to communicate information quickly and in a manner that is 
not dependent on the presence of the recipient may be selected to help manage workload, 
since it may decrease the time to complete a task.  Alternatively electronic communication 
may be used as a means to avoid challenging the physician directly about medication-
related problems (Liu et al., 2014).   
 
The majority of messages were assigned by pharmacists between a Monday and a Friday, 
highlighting the reduction in clinical pharmacy services over a weekend at the study site and 
possibly explaining the slightly higher proportion of messages assigned at the beginning of 
the working week.  The activity of pharmacists in identifying potential drug-related 
problems during the week may serve as evidence for implementation of seven day 
pharmacy services in the hospital setting.  Patient admissions do not stop over the weekend 
and although the rates of admission may be slightly lower during this time, evidence also 
suggests that patients are sicker and are at higher risk of death and readmission to hospital 
if admitted on a Saturday or Sunday (Freemantle et al., 2015).  On-going review of patients’ 
medications is essential for safe optimal patient care.  This would require a transformation 
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of acute hospital services, which includes seven day working so that medication review and 
reconciliation can continue throughout the week (Office of the Chief Pharmaceutical Officer, 
2016).   
 
The messages within PICS are restricted to 255 characters and although this may seem short 
to communicate medication-related information, pharmacists rarely used the allocated 
space.  Messages were found to have a median length of just 45 characters, a quarter of the 
maximum length in PICS and even half that of the Tweet length recommended by Twitter 
for maximal value and engagement (Lee, 2014).  Grade 8 pharmacists assigned shorter 
messages overall and messages relating to a drug interaction were longer than any other 
theme—likely because the pharmacist needs to state the name of two or more medicines to 
explain the interaction.  The consistent practice of assigning relatively short messages may 
be reflective of an increasing workload, with short messages used to save time in the long-
run.  It cannot be determined from this study whether this impacts on the interpretation of 
the messages by the physician and overall effectiveness of the communication.  
 
A large proportion of the messages related to the medicines reconciliation process and the 
true number is likely to be higher than that found given that the messages were coded 
based on an explicit statement from the pharmacist that the query or request related to the 
patient’s pre-admission regimen.  In contrast to other UK studies that show errors of 
omission to occur most frequently in this process (De Winter et al., 2010; Quélennec et al., 
2013; Urban et al., 2014), communications relating to the Dose/Frequency were most 
prevalent in this study.  The PICS CPOE system does not have a function to facilitate the 
medicines reconciliation process (e.g. integrated with community records, documentation 
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of discrepancies), so information and queries relating to this process need to be 
communicated to the physician via a review message or other means.  Programmes to assist 
the process have been shown to reduce the rate of discrepancies in the hospital settings 
(Zoni et al., 2012), but this technical capability is not one considered by many hospitals at 
system implementation, rather as an enhanced function as systems mature (NHS England, 
2013).  The frequency of these messages may highlight the difficulties faced by practitioners 
in determining a patient’s medication history on admission to hospital, largely as a result of 
poor or lack of sharing of information at the interface of care.  The time required to gather 
the necessary information from different sectors of care has been shown to be a barrier for 
effective reconciliation, as well as poor communication and documentation between and by 
teams relating to this task (Ross et al., 2013).  The study by Ross et al (2013) also found that 
these problems persisted when physicians discharged patients.  Although this was not a 
prominent theme in the messages in this study, such discrepancies at discharge are likely to 
be dealt with directly to avoid any delays in the process and as such would not be reflected 
in the database.  The majority of reconciliation messages were assigned between a Monday 
and a Friday—reflective of little or no ward-based reconciliation activity at the weekend—
and were mostly made in the Medical Admissions department.  Nearly two thirds of all 
reconciliation messages were assigned within 24 hours of the prescription being generated 
and thus adhered to the national standard (National Institute for Health and Care 
Excellence, 2015).  Medical Admissions could be an initial target for weekend services to 
achieve a timelier reconciliation process overall. 
 
Pharmacists communicated a range of medication-related information to the physician.   
The most common theme related to the Dose/Frequency of a medicine, many of which 
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could be considered prescribing errors by definition (Dean et al., 2000).  Although the 
frequency of communications cannot be extrapolated to a rate of error per se, the high 
prevalence of perceived dose and frequency errors observed is consistent with other UK 
studies investigating prescribing errors in the hospital setting (Dornan et al., 2009; Tully et 
al., 2009).  Messages relating to Dose/Frequency were most commonly assigned to 
enoxaparin, paracetamol, lactulose and simvastatin—four frequently prescribed medicines 
in the acute NHS sector.  For enoxaparin, paracetamol and lactulose, messages largely 
related to the dose or frequency being too low or too high (unrelated to the reconciliation 
process) and so are most likely to be knowledge-based mistakes (Reason, 1990; p 13).  This 
may highlight an area within the system where CDS can be optimised to better guide 
physicians through the prescribing process.  For simvastatin, the Dose/Frequency errors 
were largely as a result of a discrepancy compared to pre-admission regimens.  This may 
further highlight how a lack of information to inform the medication history can lead to 
knowledge-based mistakes, perhaps with a potential to encourage physicians to prescribe 
the most common dose until the information can be confirmed.   
 
Pharmacists used the review message function to provide a lot of supporting information— 
evidence that it is used for far more than requests for review.  In paper-based prescribing 
environments, pharmacists can annotate prescriptions to provide additional information to 
facilitate the medication process, such as with requests to monitor treatment (Liu et al., 
2014).  In the electronic prescribing environment, such written annotations are not possible, 
or annotations may be restricted and not easily added.  The number of these messages still 
being communicated in this way may suggest sub-optimal design to align with practice.  
Pharmacists may be accustomed to the process of annotating paper drug charts and so use 
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workarounds in the system to ensure that this is still possible in order to fulfil a professional 
standard outlined by the Royal Pharmaceutical Society for hospital pharmacy services, “Care 
contributions are documented and audited to demonstrate the impact of the service on 
patient outcomes and to help target resources” (Royal Pharmaceutical Society, 2012).  Most 
CPOE systems provide information about monitoring and some complex systems such as 
PICS are even integrated with laboratory data to drive patient specific decision support.  The 
continued provision of this information in a highly computerised environment may highlight 
a lack of pharmacists’ knowledge in relation to CDS, such as which alerts are presented to 
physicians at the point of prescribing and review.  Alternatively, it may show a lack of 
confidence in the CDS to effectively inform physicians about monitoring requirements, 
possibly because pharmacists are aware of the propensity for alerts to be overridden 
(McMullen et al., 2015; van der Sijs et al., 2010).   
 
Looking at the prevalence of messages by topic, informing the physician about a patient’s 
usual regimen, without asking for a direct change or review, was the most common topic 
out of all the messages.  The provision of information without a recommendation may 
indicate that the pharmacist is seeking clarification, although CPOE has previously been 
shown to reduce these types of queries with physicians in the hospital setting (McMullen et 
al., 2015).  Alternatively, pharmacists may be using the review message function to 
document the information for accountability and to make the information visible to all 
members of the healthcare team involved with the medication process.  Perceived errors of 
omission were the second most common topic and most common if those coded as 
supporting information are removed.  This is consistent with UK studies investigating 
medication prescribing errors (Dornan et al., 2009; Tully & Buchan, 2009) or medication-
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related patient safety incidents (Cousins et al., 2012), where errors of omission are generally 
observed the most.  The design of the review message function in PICS—to assign a message 
directly to a prescription—does not support an optimal communication for errors of 
omission, since the medicine in question is not present on a patient’s profile.  Prescriptions 
are listed alphabetically in PICS and the data in this study suggests that the messages were 
largely placed on medicines towards the top of the list (A–C in the alphabet), unrelated to 
the prescription.  This highlights the use of a workaround within the CPOE system, with the 
pharmacist finding a way of documenting the information electronically to fulfil a 
communication and complete a task.  Such workarounds can be important to inform system 
design (Cresswell et al., 2016). 
 
Although a few CPOE-related errors were identified as a result of ‘selection errors’, it was 
not apparent from the data whether communications were sent as a direct result of 
sociotechnical incidents.  This is difficult to determine with content analysis since it is 
dependent on the pharmacist stating that the problem identified may relate directly to the 
use of the system.  A study conducted in the same hospital site—one year prior to this 
database being captured—found that 15% of medication incidents occurred as a result of 
sociotechnical issues (Redwood et al., 2011).  To capture a more realistic rate of error and as 
a means of being able to monitor such incidents, pharmacists could be asked to make it 
explicitly clear in their communications when a sociotechnical incident is suspected.  
Alternatively, a tick-box field could be added to message functions to allow pharmacists to 




A proportion of messages were assigned to high-risk medicines, but few messages were 
found to relate to one of the 80 high-risk errors identified in Chapter 4 (Thomas et al., 
2013).  This may suggest that these errors did not occur frequently or more likely that 
pharmacists chose to communicate directly with the physician for such problems (Liu et al., 
2014).  It is not specifically stated in the UK standards on conduct, ethics and performance, 
which modality of communication pharmacists should select (General Pharmaceutical 
Society, 2012; p 12), rather that the “Information is appropriately shared with other health 
and social care professionals involved in the care of the patient”.  It is not stated in updated 
standards, which at the time of this study were not available for pharmacists (General 
Pharmaceutical Society, 2017).  The appropriateness of the modality is likely to depend on 
the pharmacists’ individual perception of the risk of an error, which will be informed by their 
past experiences and may therefore vary depending on their grade or length of time in 
practice.   
 
6.3.1 Strengths and limitations 
A strength of this study is the size of the database analysed.  Over 34,000 messages and 
associated prescriptions were captured and a wide range of factors were coded for analysis.  
A proportion of the database was also independently coded, with a high inter-rater 
reliability demonstrated.  
 
This study was conducted in a single-centre in England and so the results here may not 
reflect practice in other hospital settings that use CPOE systems, or pharmacist-physician 
communication in other countries.  The language used by pharmacists in their written 
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discourse was not analysed in this study.  This may change depending on the grade or prior 
experience of the pharmacist (Liu et al., 2014) and could provide a more in-depth insight 
into how experience affects communication and also what is communicated.  Messages 
were reviewed and coded to identify the explicit subject.  Latent analysis is not possible 
without knowing the individual pharmacists and running an analysis of their intent and the 
subsequent interpretation of the recipient.  By its very nature, coding free-text can 
introduce an element of subjectivity, but the inter-rater reliability study was reassuring and 
showed that the definitions of the codes were effective and therefore the coding consistent.   
 
Finally, verbal communication was not investigated; a modality shown to achieve timelier 
acceptance of requests (Bedouch et al., 2011) and may be occurring simultaneously 
between the pharmacist and the physician.   
 
6.3.2 Conclusions 
Pharmacists identified errors or discrepancies in the prescriptions of medicines and 
increasingly communicated these to the physician via the CPOE system.  This occurred less 
frequently at weekends, indicative that medication reviews and reconciliation activities 
were largely conducted on the wards between a Monday and Friday.  The implementation 
of a pharmacy service over the weekend could target the specialities found to have high 
numbers of messages assigned during the week, such as Medical Specialities. 
 
Messages relating to high-risk errors were not prominent in the database, which may 
suggest alternative means of communication for these, or a lower rate of occurrence at the 
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study site.  The errors and associated medicines could be used to target the optimisation of 
CDS to benefit patient care, with a positive impact on the workload of the pharmacist.  
Despite the message function being a request to review (“review message”), pharmacists 









Chapter 7 STATISTICAL ANALYSIS OF THE SIGN-OFF AND ACTION OF 
REVIEW MESSAGES 
 
In this study, I investigate how various temporal, prescription and message factors impact 
on the sign-off of review messages within PICS and whether requests were actioned by the 
physician.  I also analyse the time taken for these two tasks to be completed in practice.  I 
demonstrate that there may be a sub-optimal use of the review message function in the 
clinical documentation of a message being received and potentially highlight that the 
function is not performing as intended in achieving a timely transfer of information to 
generate an effect.  I describe how review messages assigned on a Friday and at the 
weekend take significantly longer to sign-off and action in practice, suggesting that such 
tasks may not be prioritised during on-call hours and that continuity of medication-related 
care during this time may be compromised. 
 
The method and results presented in this chapter have been published in PLoS ONE: 
Pontefract, S. K., Hodson, J., Marriott, J. F., et al. (2016) Pharmacist-Physician 
Communications in a Highly Computerised Hospital: Sign-Off and Action of Electronic 
Review Messages. PLoS ONE, 11 (8): e0160075.
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7.1 Statistical analysis 
The data captured and coded in Chapter 5 were split into dichotomous and continuous 
outcomes.   
For the dichotomous outcomes of sign-off and action, an initial univariable analysis was 
performed using Chi-square tests to compare the outcome rates across a range of temporal, 
message and prescription factors (Table 7.1–7.3) 
 
For the continuous outcomes (time taken to sign-off and time to action), the distributions 
were first assessed using histograms.  Neither variable was found to be normally distributed; 
hence parametric analyses could not be used (Figure 7.1).   
 
Figure 7.1 – Distribution of the times taken for review messages to be A) signed-off; and B) 
actioned as requested.  





Owing to the skewed distributions, comparisons of these outcomes across the factors were 
performed using a non-parametric method, with Mann-Whitney tests used for binary 
factors and Kruskal-Wallis for cases with more than two categories.  In addition, the 
continuous outcomes were dichotomised using ≤ 48 hours for time to sign-off and ≤ 24 
hours for time to action and analysed using Chi-square tests.   
 
After this initial analysis, a more comprehensive analysis of the data was performed.  This 
was a multivariable analysis that accounted for the effects of multiple factors 
simultaneously and also adjusted for potential correlation between outcomes for repeated 
review messages on the same prescription.  For example, if a physician signs off a review 
message on a patient’s PICS profile, they are likely to sign-off other review messages that 
exist on the profile at the same time.  Hence, review messages on the same profile could not 
be treated as independent.  Therefore the data were analysed using multivariable 
Generalised Estimating Equations (GEE) (Liang & Zeger, 1986) with binary logistic models.  
Initially, unstructured correlation matrices were used, which allowed the model to attribute 
a different degree of correlation between the outcomes for each pair of messages on a 
prescription. This approach gave the model the greatest flexibility in attributing within-
prescription correlations.  However, due to the number of individual correlations in the 
resulting matrices, in some cases the resulting model was too complex to be produced from 
the available data (i.e. non-convergence), resulting in potentially unreliable results.  Where 
this occurred, the model was repeated using an exchangeable correlation structure.  This 
was a more straightforward approach, where the same degree of within-prescription 
correlation was assumed for every pair of messages.  This solved the issues of non-
convergence in these cases, resulting in reliable models. 
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Separate models were produced for the two dichotomous outcomes (sign-off and action).  
For the continuous outcomes (time to sign-off and time to action), the dichotomised 
versions described previously were used as dependent variables, as valid models could not 
be produced from non-Gaussian distributed data.  Each model contained the temporal, 
message and prescription outlined and described in Table 7.1–7.3.  Any categories where no 
outcomes occurred were excluded from the associated models, as zero counts make Odds 
Ratios (ORs) incalculable.  In addition, correlations between the factors were assessed to 
identify potential multicollinearity.  This found that high-risk errors were highly associated 
with the Route/Form theme of communication, so this factor was excluded from the 
analysis.  For the analyses of action and time to action, the prescription status was also 
excluded since deleting a prescription before it could be administered was one of the 
behaviours being considered in the definition of an action (i.e. the outcome).  The resulting 
models found within-prescription correlation ranging from 0.557–0.780 for the outcomes 
considered, supporting the decision to use the GEE methodology. 
 
All analyses were performed using SPSS 22 (IBM SPSS Inc., Chicago, IL, USA), with p<0.05 
considered significant.  Odds ratios were plotted on a logarithmic scale to show symmetry of 




Table 7.1 – Temporal factors included in the GEE model 
 
Temporal factor Description Categories 
Day of the week Day of the week the review message was 
assigned by the pharmacist in PICS. 
Saturday and Sunday grouped together 









Hour of day  Hour of day the review message was 
assigned by the pharmacist in PICS. 
Grouped into morning and afternoon 




Time taken to assign 
review message 
The time between the prescriptions 
being generated in PICS, to a review 
message being assigned. 
Numbers were assessed using 
histograms and categorised to allow for 
an even spread across the parameters. 







Table 7.2 – Message factors included in the GEE model 
 
Message factor Description Categories 
Grade of pharmacist Grade of the pharmacist assigning the 




   
Message assigned to a 
high-risk medicine 
High-risk medicines were identified  No 
Yes 
 
Message assigned to a 
high-risk error 
High-risk errors were identified No 
Yes 
 
Message related to 
medicines reconciliation 
Communications were identified that 
related to a disparity between the 
patient’s current prescription and the 






Message associated with 
the prescription 
Messages were reviewed and identified 
as to whether they were associated with 






Communication theme Theme of communication in the review 
message.  Themes developed and 












   
Profession of person 
signing off the review 
message 








*NMP Non-medical prescriber; SPR Specialist registrar. NMPs were grouped with SPRs owing to 
small numbers (n=86).  
159 
 
Table 7.3 – Prescription factors included in the GEE model 
 
Prescription factor Description Factor 
Speciality  The speciality the patient was under the 
care of when the review message was 
assigned.  Medical Admissions were 
separated from General Medicine owing 
to the difference in pharmacist presence 
in this setting.   
Medical specialities: Renal; Liver; 
Neurology; Cardiology; Haematology; 
Oncology; Ambulatory Care.  Surgical 
specialities: Ear, nose and throat; 
Cardiothoracic; Maxillofacial; Plastics; 
Urology; Vascular 
Medical Admissions 






   
BNF Group The prescription medicine was 
categorised according to the chapters of 
the British National Formulary.  These 
were further categorised into a second 
level categorisation to facilitate 
descriptive analysis. 
Cardiovascular 
Central nervous system 
Endocrine 















   
Regularity of prescription The regularity of the prescriptions were 
further categorised 
Regular; Regular; Continuous infusion;  
Once only dose; When required: When 
required; When required infusion;  
TTO: Regular at home; When required at 






   
Prescription status D: Deleted (the prescription was deleted 
before any doses were administered).  







Of the 34,506 review messages analysed, 46.6% (n=16,025/34,506) were signed-off in PICS, 
the majority of which were by junior physicians (39.5%, n=6,329/16,025) and pharmacists 
(39.3%, n=6,302/16,025) (Figure 7.2).   
 
 






Most messages were signed-off between a Monday and Friday (98.8%, n=15,854/16,025).  
Of those that were signed-off at the weekend, a higher proportion were signed-off on a 
Saturday (63.7%, n=109/171) compared to a Sunday (36.3%, n=62/171).  The proportions of 




Figure 7.3 – Sign-off of messages by profession and by day of week 





The majority of messages were signed-off between 08:00–18:00 (95.1%, 15,244/ 16,025), 
with peaks in the rate observed between 10:00–11:00 and again at 15:00–16:00 by all 
professions (Figure 7.4).  Of those that were signed-off, 65.5% (n=10,502/16,025) were 
completed within 48 hours.   
 
 
Figure 7.4 – Sign-off of messages by professions by hour of day 
 
After accounting for those messages that were not directly associated with the prescription 
or where an action could not be determined, 9,991 were identified for further analysis to 
determine if they led to an action (Figure 7.2).  Of these, just over a third of the 
prescriptions were amended in-line with the pharmacists’ requests (35.8%, n=3,575/9,991) 

















Figure 7.5 – Flow chart to show the process of identifying messages that could be assessed 
for action or no action 
 
Where messages were actioned, the majority of the modifications to the prescriptions were 
made between a Monday and Friday (94.1%, n=3,364/3,575).   With exception of a Monday, 
a slightly higher proportion of messages were actioned in the morning shift between 00:00–
12:59, compared to the afternoon between 13:00–23:59 (Figure 7.6).  Peaks were observed 
in the action of messages at 11:00 and 16:00 (Figure 7.7), similar to those observed for sign-
off. 
  




Review messages for 
analysis of action 
(n=31,100) 
 
Review messages for 
analysis of action 
(n=9,991) 
 
ACTIONED as requested 
by pharmacist  
(n=3,575) 
 








No action requested (n=6,778) 






Figure 7.6 – Action of requests by day of week and shift  
 
 
Figure 7.7 Figure – Action of requests by hour of day  
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The results of this statistical analysis will be approached to consider each of the temporal, 
message and prescription factors in turn for each of the four outcomes: 1) sign-off of review 
messages; 2) time to sign-off in ≤ 48 hours; 3) action of requests; and, 4) time to action 
requests in ≤ 24 hours.  The GEE model described accounts for all factors in Table 7.1−7.3 
simultaneously.   
 
7.2.1 Temporal factors 
The results tables of the GEE analysis for temporal factors can be found in tables 7.4 and 7.5 
and Appendices 9–12. 
 
7.2.1.1 Day of the week review message assigned 
The rate of sign-off was significantly different across the days of the week (p=0.002), with 
messages less likely to be signed-off at the weekend (p=0.001, OR 0.706, 95% CI 0.570–
0.875) compared to a Monday (Figure 7.8[A]).  Where messages were signed off, this was 
significantly less likely to occur in ≤ 48 hours if they were assigned on a Friday (p<0.001, OR 
0.439, 95% CI 0.392–0.491) or at the weekend (p<0.001, OR 0.381, 95% CI 0.268–0.542) with 
median times to sign-off 42.5 hours (range: 1.6–96.5) and 47.1 hours (4.7–72.6) 
respectively, compared to 23.3 hours (2.4–69.4) on a Monday.  Messages assigned on a 
Thursday were signed off quicker than any other day of the week (p=0.008, OR 0.856, 95% 







Figure 7.8 – GEE model for day of the week 
A: Sign-off and time taken to sign-off in ≤48 hours; B: Action and time to action as requested in ≤ 24 hours. ORs (95% CI) from the GEE model described 




The rate at which messages were actioned did not change significantly across the days of 
the week (p=0.073, Figure 7.8[B]).  Where messages were actioned, this was less likely to 
occur in ≤ 24 hours if they were assigned on a Friday (p<0.001, OR 0.663, 95% CI 0.530–
0.828) or at the weekend (p=0.001, OR 0.276, 95% CI 0.130–0.585) relative to a Monday.  
The median time to action was 22.8 hours (range 1.9–94.1) and 37.3 (10.1–54.1) hours 
respectively, compared to 20.2 (2.2–48.2) hours on Monday. 
 
7.2.1.2 Hour of day review message is assigned 
The hour of day the pharmacist assigned the review messages did not have a significant 
impact on the rate of sign-off (p=0.086).  However those assigned in the afternoon (13:00–
23:59) were less likely to be signed-off in ≤ 48 hours (p=0.013, OR 0.911, 95% CI 0.846–
0.981), with a median time of 23.5 hours (95% CI 2.6–89.5) compared to 23.3 hours (2.1–
72.8) in the morning.  No significant difference was detected in the rate of action (p=0.847) 
or time to action (p=0.714) by time of day. 
 
7.2.1.3 Time between prescription being generated and message being assigned 
The time between the prescription being generated and the review message being assigned 
had a significant impact on the rate of sign-off (p<0.001).  Where messages were signed-off, 
this was significantly less likely to occur in ≤ 48 hours if they were assigned to prescriptions 
generated  7 or more days ago, compared to within the last 12 hours (p=0.001, OR 0.424, 
95% CI 0.365–0.492).  The former group took on average over twice as long to be signed-off, 
with a median time of 50.8 hours (range: 12.6–166.6) compared to 20.0 hours (1.2–48.2) 
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(Figure 7.9[A]).  Messages assigned within 1–6 days were more likely to be signed off 
(p<0.001, OR 0.892, 95% CI 0.837–0.949) compared to those assigned in < 12 hours.  
 
A similar pattern was observed for those that were actioned, with messages assigned to 
prescriptions that were generated 7 or more days ago significantly less likely to be actioned 
in ≤24 hours (p<0.001, OR 0.559, 95% CI 0.402–0.777), taking almost twice as long than 






Figure 7.9 – GEE model for the time since the prescription was generated to the message being assigned.  
A: Sign-off and time to sign-off in ≤ 48 hours; B: Action and time to action as requested in ≤ 24 hours. ORs (95% CI) from the GEE model described in 
Appendices 9–12. < 12 hours is the reference category
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Table 7.4 – GEE results for temporal factors for sign-off rates and time to sign-off in ≤48 hours 
 
 GEE of Sign-off Rates GEE of Time to Sign-off ≤ 48 hours % of Messages  Hours to Sign-off  
(Median, Range)  Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Signed-off 
Day of the week review message assigned  0.002*   <0.001*   
 
Monday 1 – 1 – 47.0% 23.2 (2.4–69.4) 
Tuesday 1.020 (0.953–1.093) 0.563 0.977 (0.877–1.088) 0.670 47.4% 23.3 (2.7–65.7) 
Wednesday 1.004 (0.935–1.079) 0.903 1.104 (0.984–1.237) 0.091 47.4% 23.1 (2.2–52.7) 
Thursday 0.937 (0.871–1.008) 0.081 0.856 (0.763–0.961) 0.008* 45.3% 22.6 (2.0–96.1) 
Friday 0.937 (0.872–1.008) 0.082 0.439 (0.392–0.491) <0.001* 45.4% 42.5 (1.6–96.5) 
Sat/Sun 0.706 (0.570–0.875) 0.001* 0.381 (0.268–0.542) <0.001* 36.6% 47.1 (4.7–72.6) 
Hour of day review message assigned  0.086   0.013*   
 00:00–12:59 1 – 1 – 46.7% 23.3 (2.1–72.8) 
13:00–23:59 1.043 (0.994–1.093) 0.086 0.911 (0.846–0.981) 0.013* 46.1% 23.5 (2.6–89.5) 
Time from prescription generated to message 
assigned  
<0.001*   <0.001* 
  
 
< 12 hours 1 – 1 – 45.6% 20.0 (1.2–48.2) 
12–23:59 hours 0.971 (0.911–1.035) 0.367 0.841 (0.758–0.934) 0.001* 47.6% 22.4 (2.0–70.8) 
1–6 days 0.892 (0.837–0.949) <0.001* 0.633 (0.572–0.701) <0.001* 46.0% 25.5 (3.1–92.9) 
7+ days 1.020 (0.926–1.124) 0.682 0.424 (0.365–0.492) 0.001* 47.2% 50.8 (12.6–166.6) 
*Significant at p<0.05 
Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Message factors ‘Messages assigned to high-risk error’ and ‘Messages 
associated with prescription’, which were excluded from the analysis owing to multicollinearity. SIGN-OFF: Profession of person signing off the message was 




Table 7.5 – GEE results for temporal factors for action rates and time taken to action in ≤24 hours 
 
 GEE of Action Rates GEE of Time to Action ≤ 24 hours % of Messages  Hours to Action  
(Median, Range)  Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Actioned 
Day of the week review message assigned  0.073   <0.001*   
 
Monday 1 – 1 – 35.7% 20.2 (2.2–48.2) 
Tuesday 1.078 (0.945–1.229) 0.263 0.831 (0.676-1.022) 0.079 37.8% 22.1 (2.4–47.3) 
Wednesday 0.923 (0.804–1.060) 0.256 0.948 (0.757-1.187) 0.640 34.6% 22.3 (2.4–48.0) 
Thursday 1.071 (0.932–1.231) 0.332 0.970 (0.779-1.208) 0.785 36.9% 21.4 (2.3–45.4) 
Friday 0.930 (0.808–1.070) 0.309 0.663 (0.530-0.828) <0.001* 34.2% 22.8 (1.9–94.1) 
Sat/Sun 0.754 (0.490–1.158) 0.197 0.276 (0.130-0.585) 0.001* 27.1% 37.3 (10.1–54.1) 
Hour of day review message assigned  0.847   0.714   
 00:00–12:59 1 – 1 – 36.7% 21.6 (2.2–49.2) 
13:00–23:59 0.991 (0.903–1.087) 0.847 0.973 (0.840-1.127) 0.714 34.3% 22.1 (3.1–69.1) 
Time from prescription generated to message 
assigned  
<0.001*   0.001* 
  
 
< 12 hours 1 – 1 – 31.2% 21.6 (3.1–44.2) 
12–23:59 hours 1.335 (1.186–1.503) <0.001* 1.036 (0.856-1.254) 0.719 39.5% 19.0 (1.9–45.6) 
1–6 days 1.241 (1.097–1.404) 0.001* 0.836 (0.686-1.019) 0.076 36.8% 22.7 (2.2–69.8) 
7+ days 1.099 (0.896–1.347) 0.364 0.559 (0.402-0.777) 0.001* 32.7% 40.3 (3.4–139.4) 
*Significant at p<0.05. Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Prescription Factor ‘Prescription status’ which 
was excluded from the analysis of action and time to action as this can be considered an outcome. ACTION: Categories with zero counts (BNF category 
‘Other’ and Regularity ‘As required’ and ‘Once-only’) were excluded from the analysis. TIME TO ACTION: Categories with zero counts (Communication 







7.2.2 Message factors 
The results tables of the GEE analysis for message factors can be found in tables 7.6 and 7.7 
and Appendices 9–12.  Messages associated with high-risk error were excluded owing to 
multicollinearity.  
 
7.2.2.1 Grade of pharmacist 
The sign-off rate was significantly different across the grades of the pharmacist (p=0.010), 
with messages assigned by grade 8 pharmacists least likely to be signed-off (p=0.004, OR 
0.899, 95% CI 0.835–0.967) compared to grade 6.  There was no significant difference found 
for grade 7 (p=0.506, OR 0.980, 95% CI 0.925–1.039).  Where messages were signed-off, 
there was no significant difference across the grades for the time taken in < 48 hours 
(p=0.368), with the median time to sign-off ranging from 22.4–25.5 (2.1–94.3) hours.   
 
The rate of action was also found to be significant across the grades (p=<0.001).  In contrast 
to sign-off, messages from the grade 8 pharmacists were the most likely to be actioned 
(p<0.001, 1.379 95% CI: 1.182–1.607 Vs. grade 6), whilst messages from grade 7 pharmacists 
that were actioned were most likely to be actioned in ≤24 hours (p<0.001, OR 1.408, 95% CI: 
1.167–1.698). 
 
Where messages were actioned, this was more likely to occur in <24 hours if they with 
assigned by grade 7 pharmacists (p<0.001, OR 1.408 (1.167–1.698), with a median time of 





7.2.2.2 High-risk medicine 
Messages assigned to high-risk medicines were significantly less likely to be signed-off 
(p<0.001, OR 0.841, 95% CI 0.789–0.895) or actioned (p=0.012, OR 0.848, 95% CI 0.745–
0.964) than those assigned to other medicines.  No significant association was detected 
between high-risk medicines and the time taken to sign-off or action (p=0.713 and p=0.707 
respectively).  The median time taken to action messages assigned to high-risk medicines 
was 20.2 hours (1.9–47.8) compared to 22.1 hours (2.4–57.1) for those that were not coded 
as high-risk. 
 
7.2.2.3 Medicines reconciliation 
Messages communicating information relating to a disparity between the current inpatient 
prescription and the patient’s pre-admission medicines were more likely to be signed-off in 
PICS (p<0.004, OR 1.082 (1.025–1.142) compared to those that did not.  Where messages 
were signed-off, this was also significantly more likely to occur in <48 hours (p<0.001, OR 
1.210, 95% CI 1.110–1.319), with a median time of 22.4 hours (1.9–70.2), compared to 21.8 
hours (1.9–66.8).  Messages were more likely to be actioned if they were related to 
medicines reconciliation (p<0.001, OR 1.278, 95% CI 1.144–1.428), however the rate of 
action in ≤24 hours was not found to change significantly, with a median of 23.1 hours (2.3–
67.9), compared to 24.7 hours (3.4-75.5) for messages unrelated to the reconciliation 
process. 
 
7.2.2.4 Communication theme 
The theme of communication had a significant impact on whether messages were signed-off 
(p<0.001).  With the exception of communications categorised as Other, all communications 
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were significantly less likely to be signed-off compared to Dose/Frequency, with those 
related to Contraindication the least likely to be signed-off.  Messages relating to a 
Contraindication were also least likely to be signed-off ≤48 hours (p=0.004, OR 0.721, 95% CI 
0.579–0.899 Vs. Dose/Frequency).  The rate of action was also found to differ significantly 
across the categories (p=0.014), with those relating to ‘Drug Use/Administration’ least likely 
to be actioned (p=0.035, OR 0.680, 95% CI 0.475–0.973) Vs. Dose/Frequency).  There was no 
significant difference in the time taken to action across the themes (p=0.581). 
 
7.2.2.4 Profession of signed user 
The profession of the signed user was considered in the GEE for time to sign-off.  Compared 
to pharmacists, messages were more likely to be signed-off by consultants (p=0.028, OR 
1.203, 95% CI 1.020–1.420) and junior physicians (P=0.001, OR 1.159, 95% CI 1.061–1.267), 





Table 7.6 – GEE results for message factors for sign-off rates and time to sign-off in ≤48 hours 
 
 GEE of Sign-off Rates GEE of Time to Sign-off ≤ 48 hours % of Messages Hours to Sign-off  
(Median, Range)  Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Signed-off 
Grade of the pharmacist  0.010*  0.368   
 
6 1 – 1 – 46.4% 25.5 (2.1–94.3) 
7 0.980 (0.925–1.039) 0.506 1.065 (0.972–1.167) 0.178 46.7% 22.4 (2.1–71.3) 
8 0.899 (0.835–0.967) 0.004* 1.068 (0.943–1.209) 0.300 45.9% 23.4 (2.4–71.8) 
Message assigned to a high-risk medicine  <0.001*   0.713   
 No 1 – 1 – 47.8% 23.1 (2.1–73.4) 
Yes 0.841 (0.789–0.895) <0.001* 0.982 (0.890–1.083) 0.713 43.0% 24.1 (2.7–75.4) 
Message relates to medicines reconciliation 0.004*   <0.001*   
 No  1 – 1 – 43.1% 23.3 (2.2–73.5) 
Yes 1.082 (1.025–1.142) 0.004* 1.210 (1.110–1.319) <0.001* 50.7% 25.1 (2.9–96.5) 
Communication theme <0.001*  <0.001*   
 Dose/Frequency 1  1 – 54.2% 23.2 (2.4–71.7) 
  Contraindication 0.498 (0.439–0.566) <0.001* 0.721 (0.579–0.899) 0.004* 33.5% 40.7 (2.9–120.0) 
 Drug Form/Route 0.640 (0.581–0.705) <0.001* 1.139 (0.969–1.339) 0.116 44.0% 22.6 (1.7–71.9) 
 Drug Interaction 0.733 (0.633–0.850) <0.001* 0.989 (0.777–1.261) 0.932 46.6% 27.0 (2.9–120.2) 
 Drug Selection 0.537 (0.494–0.584) <0.001* 1.119 (0.969–1.291) 0.126 35.6% 23.2 (2.2–72.1) 
 Drug Use/Admin 0.604 (0.562–0.649) <0.001* 0.863 (0.764–0.974) 0.017* 39.4% 23.6 (1.7–72.3) 
 Logistics  0.560 (0.471–0.665) <0.001* 0.957 (0.717–1.278) 0.767 37.1% 27.0 (3.7–89.7) 
 Omission 0.820 (0.764–0.880) <0.001* 0.043 (0.938–1.159) 0.437 50.1% 21.7 (2.0–66.8) 
 Other 0.864 (0.733–1.018) 0.080 0.566 (0.418–0.766) <0.001* 39.2% 24.9 (2.7–117.9) 
 Supporting Info 0.801 (0.755–0.850) <0.001* 0.956 (0.872–1.048) 0.339 48.4% 23.8 (2.1–92.9) 
Profession –  0.001*   
 Pharmacist – – 1 – – 23.7 (0.7–91.7) 
 Consultant – – 1.203 (1.020–1.420) 0.028* – 22.2 (3.1–67.9) 
 Junior – – 1.159 (1.061–1.267) 0.001* – 22.9 (2.7–70.9) 
 SPR/NMP – – 0.976 (0.867–1.099) 0.690 – 24.3 (4.2–78.2) 
*Significant at p<0.05. Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Message factors ‘Messages assigned to high-risk 
error’ and ‘Messages associated with prescription’, which were excluded from the analysis owing to multicollinearity. SIGN-OFF: Profession of person 
signing off the message was excluded from the analysis since there is no profession for messages that were not signed-off.  
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Table 7.7 – GEE results for message factors for action rates and time taken to action in ≤24 hours 
 
 GEE of Action Rates GEE of Time to Action ≤ 24 hours % of Messages Hours to Action 
(Median, Range) 
 Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Actioned 
Grade of the pharmacist  <0.001*   0.002*   
 
6 1 – 1 – 31.9% 25.2 (3.8–78.1) 
7 1.203 (1.061–1.365) 0.004* 1.408 (1.167-1.698) <0.001* 38.1% 20.4 (2.2–47.5) 
8 1.379 (1.182–1.607) <0.001* 1.293 (1.013-1.651) 0.039* 35.1% 20.2 (1.7–51.4) 
Message assigned to a high-risk medicine  <0.001*   0.707   
 No 1 – 1 – 36.4% 22.1 (2.4–57.1) 
Yes 0.848 (0.745–0.964) <0.001* 1.040 (0.846-1.279) 0.707 33.9% 20.4 (1.9–48.2) 
Message relates to medicines reconciliation 0.004*   0.859   
 No  1 – 1 – 30.3% 24.7 (3.4-75.5) 
Yes 1.278 (1.144–1.428) 0.004* 1.016 (0.852-1.212) 0.859 42.5% 23.1 (3.2-68.3) 
Communication theme <0.001*  0.581   
 Dose/Frequency 1  1 – 36.4% 21.6 (2.4–51.6) 
 Drug Form/Route 1.099 (0.941–1.285) <0.001* 0.992 (0.775-1.268) 0.992 33.9% 22.8 (1.4–72.0) 
 Drug Use/Admin 0.680 (0.475–0.973) <0.001* 0.946 (0.551-1.623) 0.839 25.2% 24.2 (3.5–52.7) 
 Logistics  1.936 (0.985–3.807) <0.001* 0.453 (0.148-1.386) 0.165 24.5% 51.4 (22.6–96.5) 
*Significant at p<0.05. Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Message factors ‘Messages assigned to high-risk 
error’ and ‘Messages associated with prescription’, which were excluded from the analysis of action and time to action owing to multicollinearity.  
Prescription Factor: ‘Prescription status’ was excluded from the analysis of action and time to action as this can be considered an outcome. 
ACTION: Categories with zero counts (BNF category ‘Other’ and Mode ‘As required’ and ‘Once-only’) were excluded from the analysis. 
TIME TO ACTION: Categories with zero counts (Communication theme: ‘Contraindication’, ‘Drug Interaction’; ‘Drug Selection’; ‘Omission’ ‘Other’ and 




7.2.3 Prescription factors 




The rate of sign-off (p<0.001) and time taken to sign-off (p<0.001) were found to differ 
significantly across the specialties (Figure 7.10[A]).  Where messages were signed-off, this 
was significantly less likely to occur in ≤48 hours if they were assigned to patients in Trauma 
and Orthopaedics (TNO) than those in Medical Admissions, taking on average over twice as 
long (p<0.001, OR 0.419, 95% CI 0.349–0.502)—median: 51.3 hours versus 20.5 hours.  
There was a significant difference in the rate of messages being actioned (p<0.001) across 
the specialities (Figure 7.10[B]).  Messages were least likely to be actioned in ≤24 hours if 
they were assigned to prescriptions for patients in TNO compared to Medical Admissions 
(p=0.004, OR 0.598, 95% CI 0.422–0.848), with median times of 28.3 hours (range: 7.2–







Figure 7.10– GEE model for speciality. A: Sign-off and time taken to sign-off in ≤48 hours; B: Action and time to action as requested in ≤ 24 
hours 
ORs (95% CI) from the GEE model described in Appendices 9-12. Medical Admissions is the reference category. CC: Critical Care; Med: 
Medicine; Surg: Surgery; Spec: Specialities; TNO: Trauma and Orthopaedics
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7.2.3.2 Category of medicine 
The rate of sign-off of messages was found to be significant across the categories of 
medicine (p<0.001), with those assigned to Cardiovascular medicines more likely to be 
signed-off compared to all other categories of medicine.  Where messages were signed-off, 
the time taken ≤48 hours was also found to be significant (p<0.001).  Anti-infective 
medicines (Infection category) stood out amongst all the categories, being twice as likely to 
be signed-off in ≤48 hours (p<0.001, OR 2.062, 95% CI 1.775–0.563) compared to 
Cardiovascular medicines, with a median time to sign-off of 19.9 hours (1.3–47.7) compared 
to 24.8 hours (3.0–95.7). 
 
The rate of action and time to action was also significant across the categories (p <0.001, 
p=0.001), with anti-infectives most likely to be actioned (p=0.013, OR 1.246, 95% CI 1.048–
1.482) compared to Cardiovascular, followed by those assigned to Central Nervous System 
medicines (p=0.020, OR 1.162, 95% CI 1.024–1.320).  Messages assigned to anti-infectives 
were actioned nearly four times faster than messages assigned to Cardiovascular medicines 
(p<0.001, OR 2.055, 95% CI 1.546–2.732), with a median time to action of 6.0 hours (1.2–
26.4) compared to 23.0 hours (3.4–68.8). 
 
7.2.3.3 Regularity of prescription 
The regularity (or mode) of the prescription had a significant impact on the rate of sign-off 
(p<0.001), with all modes less likely to be signed-off compared to messages on Regular 
prescriptions.  However, where messages were signed-off, this was found to occur 
significantly quicker for those assigned to Once-only (p=0.001, OR 11.077, 95% CI 2.581–
47.533) and TTO prescriptions (p<0.001, OR 2.818, 95% CI 2.321–3.421)—with a respective 
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median time to sign-off of 1.8 hours (0.1–20.2) and 2.1 hours (0.3–26.2), compared to 23.7 
hours (2.5–73.8) for Regular medicines.  As required prescriptions took significantly longer 
(p=0.004, OR 0.813, 95% CI 0.780–0.935), with a median time of 30.9 hours (3.7–119.9).  
 
Since messages on Once-only and TTO prescriptions were less frequent and rarely specified 
actions, prescriptions of these types were excluded from the analysis of action.  The analysis 
found that the messages assigned to ‘As required’ prescriptions were significantly less likely 
to be actioned than those on Regular prescriptions (p<0.001, OR 0.374, 95% CI 0.317–
0.442).  There was no significant difference in the time taken to action in ≤24 hours 
(p=0.468). 
 
7.2.3.4 Prescription status 
Messages assigned to Deleted prescriptions were significantly less likely to be signed-off 
than those for Completed prescriptions (p=0.005, OR 0.898, 95% CI 0.832–0.968).  However, 
a higher proportion were signed-off in ≤48 hours (p<0.001, OR 1.739, 95% CI 1.520–1.989)—
median time of 5.3 hours (0.8-44.1) compared to 24.0 hours (2.5–76.2) for prescriptions that 
were continued.  Prescription status was not included in the analyses of action and time to 




Table 7.8 – GEE results for prescription factors for sign-off rates and time to sign-off in ≤48 hours 
 
 GEE of Sign-off Rates GEE of Time to Sign-off ≤ 48 hours % Messages Hours to Sign-off  
(Median, Range)  Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Signed-off 
Speciality <0.001*   <0.001*   
 
Medical Admissions 1 – 1 – 52.5% 20.5 (1.7–48.2) 
Critical Care and Burns 2.038 (1.796–2.314) <0.001* 0.954 (0.786–1.157) 0.630 63.0% 23.9 (3.0–72.4) 
General Medicine 1.111 (1.024–1.205) 0.011* 0.775 (0.681–0.883) <0.001* 49.2% 24.9 (2.4–94.5) 
 General Surgery 0.558 (0.498–0.625) <0.001* 0.807 (0.664–0.981) 0.031* 33.3% 23.0 (1.4–76.6) 
 Medical Specialities 0.840 (0.780–0.906) <0.001* 0.809 (0.714–0.917) 0.001* 41.5% 23.2 (2.2–72.4) 
 Surgical Specialities 0.837 (0.763–0.919) <0.001* 0.735 (0.630–0.857) <0.001* 41.9% 23.9 (2.5–76.9) 
 TNO 1.090 (0.970–1.226) 0.147 0.419 (0.349–0.502) <0.001* 47.0% 51.3 (19.3–167.5) 
BNF category <0.001*   <0.001*   
 
CVS 1  1  51.3% 24.8 (3.0–95.7) 
CNS 0.955 (0.891–1.023) 0.189 1.256 (1.131–0.884) <0.001* 44.4% 23.7 (2.3–78.1) 
Endocrine 0.993 (0.904–1.091) 0.883 1.323 (1.143–0.875) <0.001* 51.0% 21.4 (1.6–65.5) 
EEEO 0.765 (0.650–0.901) 0.001* 1.138 (0.880–1.136) 0.325 43.3% 22.6 (1.9–75.5) 
GI 0.894 (0.815–0.981) 0.018* 1.032 (0.896–1.116) 0.663 45.9% 24.1 (2.5–90.1) 
Infection 0.991 (0.905–1.086) 0.852 2.062 (1.775–0.563) <0.001* 45.7% 19.9 (1.3–47.7) 
 Malign/Immuno 1.054 (0.830–1.337) 0.667 1.484 (0.998–1.002) 0.051 49.2% 22.6 (2.6–66.6) 
 Muscu & Joint  0.842 (0.724–0.980) 0.027* 1.416 (1.100–0.909) 0.007* 42.3% 23.3 (2.4–68.6) 
 Nutrition and blood 0.796 (0.729–0.868) <0.001* 1.022 (0.892–1.121) 0.756 43.9% 24.2 (2.7–89.6) 
 Obs, Gynae, & Uro 0.791 (0.656–0.955) 0.015* 1.289 (0.953–1.049) 0.100 45.6% 22.9 (2.5–66.1) 
 Other 0.511 (0.328–0.796) 0.003* 2.521 (0.912–6.969) 0.075 28.6% 9.6 (0.5–42.3) 
 Respiratory 0.702 (0.634–0.778) <0.001* 1.246 (1.058–1.468) 0.008* 41.4% 22.3 (1.4–71.2) 





Table 7.8 – Continued 
GEE of Sign-off Rates  GEE of Time to Sign-off ≤48 hours % Messages 
Signed-off 
Hours to Sign-off 
(Median, Range) Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value 
Regularity of prescription <0.001*  <0.001*   
 Regular 1  1 – 50.5% 23.7 (2.5–73.8) 
  As Required 0.538 (0.495–0.586) <0.001* 0.813 (0.780–0.935) 0.004* 32.8% 30.9 (3.7–119.9) 
 Once-Only 0.319 (0.235–0.433) <0.001* 11.077 (2.581–47.533) 0.001* 22.2% 1.8 (0.1–20.2) 
 TTO 0.436 (0.397–0.478) <0.001* 2.818 (2.321–3.421) <0.001* 29.5% 2.1 (0.3–26.2) 
Prescription status 0.005*  <0.001*   
 Continued 1 – 1 – 47.0% 24.0 (2.5–76.2) 
 Deleted 0.898 (0.832–0.968) 0.005* 1.739 (1.520–1.989) 0.028* 42.4% 5.3 (0.8–44.1) 
*Significant at p<0.05. Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Message factors ‘Messages assigned to high-risk 
error’ and ‘Messages associated with prescription’, which were excluded from the analysis owing to multicollinearity.  SIGN-OFF: Profession of person 
signing off the message was excluded from the analysis.  
CVS Cardiovascular; CNS Central Nervous System; EEEO Eye, Ear, Nose and Oropharynx; GI Gastrointestinal; Malign/Immuno Malignant Disease and 




Table 7.9 – GEE results for prescription factors for action rates and time taken to action in ≤24 hours 
 GEE of Action Rates GEE of Time to Action ≤ 24 hours % Messages Hours to Action  
(Median, Range)  Odds Ratio (95% CI) p-value Odds Ratio (CI) p-value Actioned 
Speciality <0.001*   0.093   
 
Medical Admissions 1 – 1 – 44.9% 19.9 (2.2–36.0) 
Critical Care and Burns 0.921 (0.718–1.180) 0.515 0.831 (0.585-1.180) 0.301 38.0% 19.7 (0.7–72.6) 
General Medicine 1.038 (0.884–1.218) 0.651 0.832 (0.658-1.052) 0.124 37.3% 23.8 (2.2–70.8) 
 General Surgery 0.750 (0.602–0.934) 0.010* 0.767 (0.551-1.068) 0.116 32.8% 22.1 (1.9–73.4) 
 Medical Specialities 0.706 (0.610–0.816) <0.001* 0.857 (0.684-1.073) 0.179 29.1% 20.4 (2.2–48.0) 
 Surgical Specialities 0.585 (0.483–0.709) <0.001* 0.714 (0.519-0.981) 0.038 25.9% 24.0 (4.1–90.2) 
 TNO 1.192 (0.945–1.504) 0.139 0.598 (0.422-0.848) 0.004 38.1% 28.3 (7.2–110.9) 
BNF category <0.001*   0.001*   
 
CVS  1  1  37.5% 23.0 (3.4–68.8) 
CNS 1.162 (1.024–1.320) 0.020* 1.205 (0.987-1.471) 0.067 36.2% 21.4 (1.9–54.5) 
Endocrine 1.132 (0.944–1.356) 0.180 1.158 (0.879-1.527) 0.297 41.8% 21.7 (2.6–48.1) 
EEEO 0.872 (0.646–1.176) 0.369 0.806 (0.499-1.302) 0.378 34.4% 24.5 (4.1–97.4) 
GI 0.771 (0.648–0.917) 0.003* 0.941 (0.709-1.249) 0.674 26.1% 23.2 (2.6–75.7) 
Infection 1.246 (1.048–1.482) 0.013* 2.055 (1.546-2.732) <0.001* 37.8% 6.0 (1.2–26.4) 
 Malign/Immuno 0.918 (0.555–1.519) 0.740 0.958 (0.442-2.075) 0.913 34.6% 23.4 (2.3–51.0) 
 Muscu & Joint 1.204 (0.888–1.632) 0.232 1.142 (0.713-1.830) 0.580 38.6% 22.0 (2.2–48.2) 
 Nutrition and blood 0.815 (0.677–0.981) 0.030* 1.116 (0.830-1.500) 0.467 36.2% 21.4 (3.4–51.8) 
 Obs, Gynae, & Uro 0.892 (0.603–1.320) 0.568 0.921 (0.504-1.682) 0.788 36.9% 23.4 (2.4–44.4) 
 Respiratory 0.906 (0.734–1.119) 0.358 0.893 (0.645-1.238) 0.498 36.7% 24.0 (2.4–69.6) 
 Skin 0.546 (0.297–1.005) 0.052 1.493 (0.495-4.501) 0.477 19.5% 19.2 (2.2–54.0) 
Regularity of prescription <0.001*  0.468   
 Regular 1  1 – 41.50% 21.6 (2.2–51.6) 
  As Required 0.374 (0.317–0.442) <0.001* 0.896 (0.666-1.206) 0.468 18.60% 24.2 (2.2–90.2) 
*Significant at p<0.05. Results from GEEs accounting for all factors in tables 7.1–7.2, with the exception of Prescription Factor ‘Prescription status’ which 
was excluded from the analysis of action and time to action as this can be considered an outcome. ACTION: Categories with zero counts (BNF category 
‘Other’ and Regularity ‘As required’ and ‘Once-only’) were excluded from the analysis. TIME TO ACTION: Categories with zero counts (Communication 
theme: ‘Contraindication’, ‘Drug Interaction’; ‘Drug Selection’; ‘Omission’ ‘Other’ and ‘Supporting Information’ were excluded from the analysis. CVS 
Cardiovascular; CNS Central Nervous System; Eye, Ear, Nose and Oropharynx; GI Gastrointestinal; Malign/Immuno Malignant Disease and 




In this study, thousands of free-text communications were analysed that were written by 
pharmacists to physicians and sent via the CPOE system in a large acute hospital.  The 
extensive audit system allowed several factors to be considered that might influence the 
sign-off and action of messages and the time taken.  
  
The low rate of sign-off (n=46.6%) may suggest that this function is not always utilised by 
the physician as acknowledgment that the information from the pharmacist has been read 
and/or actioned.  Those messages that were analysed for action would be considered 
interventions by the assigning pharmacist since they requested a “change in a patient’s 
management or therapy” (Dooley et al., 2004).  A lower rate of action was observed 
(n=35.8%) than might have been expected compared to other pharmacist intervention 
studies in the context of CPOE, where acceptance rates have been found to range from 
86−90% (Bedouch et al., 2011; Bourne & Choo, 2012; Ibáñez-Garcia et al., 2016).  This may 
suggest that communication via the CPOE system is sub-optimal at the study site and 
messages are not being received as intended.  Alternatively, messages may have been 
considered by the physician and a decision made that, in the most part, an action was not 
necessary (Niazkhani et al., 2010).  When messages were signed-off or actioned, this did not 
always occur in a timely manner, with two thirds of messages (65.5%) signed-off within 48 
hours and just over half (57.0%) actioned within 24 hours.  A delay in the acceptance of 
interventions has previously been observed when they were requested via a CPOE system 
compared to verbal communication (Bedouch et al., 2011), which may suggest physicians do 
not always prioritise medication-related tasks communicated electronically (Brown, 2014).  
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The findings may be explained by a number of system and process factors, which are 
discussed below. 
 
7.3.1 Process factors 
It is perhaps not surprising that various time-related factors affected the sign-off and action 
of messages.  Over the weekend when the wards are likely to be staffed by a reduced 
number of physicians, the rate of sign-off was lower and the time taken to both sign-off and 
action messages was found to increase on Fridays and at weekends.  A separate study in the 
same hospital setting found that junior physicians took significantly less time to generate 
prescriptions in the CPOE system at the weekend (Coleman et al., 2015).  Together with our 
findings, this may suggest that on-call / covering physicians spend less time interacting with 
a patient’s prescription profile over the weekend or do not prioritise review messages when 
services are typically reduced both inside and outside the hospital (Freemantle et al., 2015).  
The delay could also be explained by the physicians’ lack of confidence to act on requests 
without consulting more senior colleagues, or on behalf of another clinical team.  The fact 
that messages communicated on a Friday also took longer to action may relate to the 
messages being assigned after the consultant ward rounds (which typically occur in the 
morning); messages may not be seen until the next routine review of the patient.  However, 
a reduction in the presence of ward pharmacists at the weekend (and perhaps in the 
afternoon) should not be discounted as a contributing factor here; their presence may act as 
a visual or verbal prompt for physicians on weekdays to pay attention to medication-related 




Typically, the longer a prescription had existed for a patient, the longer it would take for a 
message to be signed-off or actioned.  Physicians may enter a patient’s PICS profile more 
frequently to monitor response or to optimise treatment to new prescriptions, increasing 
the opportunity of seeing a message for an action to occur.  The pharmacist may also direct 
their attention to new orders in their prioritisation of tasks, influencing the time to action 
with additional verbal requests to the physician as they await a response to their message 
(Wu et al., 2013).  This finding may highlight a need to encourage regular review of all 
prescriptions during a patient’s admission.   
 
The grade of the pharmacist was found to be predictive of both action and action within 24 
hours, with physicians less likely to sign-off messages assigned by the highest grade 
pharmacists, but more likely to action their requests.  This factor has previously been found 
to be a significant predictor of physician acceptance of interventions (Barber et al., 1997).  In 
the UK, grade 6 (relatively newly qualified) pharmacists typically rotate every 3 months to 
gain experience across a range of specialities.  As pharmacists move to higher grades, they 
are more likely to work within a single speciality and have a more consistent presence on a 
ward, allowing more time for physicians to better understand and appreciate the knowledge 
and skills the pharmacist can provide to the team (Liu et al., 2010).  This is likely to promote 
collaborative working, which may influence physicians’ response to pharmacists’ requests 
and how these are prioritised.   
 
Messages assigned to high-risk medicines were, perhaps worryingly, less likely to be signed-
off or actioned.  Although the majority of prescriptions are generated by junior physicians in 
NHS Hospitals (Lewis et al., 2014), in most cases they are not the decision maker and follow 
187 
 
instructions by senior medical colleagues (Dearden et al., 2015; Ross et al., 2012).  As such, 
the physician may be cautious to make changes to a prescription until consulting more 
senior colleagues, leaving messages on screen for others in the team to view.  However, if 
this were the case, a delay in the time taken for both outcomes would be expected, which 
was not observed.  In contrast, messages relating to the medicines reconciliation process 
were more likely to be signed-off and actioned.  Given that these requests involve amending 
a prescription to reflect a patient’s ‘usual’ regimen, the physician is not being asked to make 
a decision about a new prescription per se.  As such, they may perceive these as more 
straightforward and without the need to consult more senior colleagues.  The difference in 
the rate of sign-off and action according to the medicine category may provide further 
evidence that physicians find certain requests and medications—such as those relating to 
cardiovascular medicines—easier to take action on, possibly because of their familiarity with 
the associated regimens.  Messages regarding the Dose /Frequency of medicines were 
significantly more likely to be signed-off compared to all other types of messages, with the 
lowest rate observed for contraindicated medicines.  This finding did not correlate with the 
action, suggesting that some requests were not deemed necessary.  These findings relating 
to high-risk medicines, medicines reconciliation and the theme of the message, may all be 
reflective of the prescribers’ confidence to alter regimens.  This may serve as evidence that 
electronic communication should only be used for non-urgent requests (Edwards et al., 
2009), while others require face-to-face or direct (collaborative) discussion between the 
pharmacist and the physician, which would provide opportunity to gain more context of the 




Finally, there was a significant difference in the rate of sign-off and action according to the 
specialty the patient was under the care of.  At the study site, the Medical Admissions 
ward—used as the reference category—has fairly consistent staff presence across the day 
and night compared to the on-call cover systems on medical and surgical wards.  A 
pharmacist is present all day Monday–Friday on this ward (as they are for Critical Care and 
Burns), unlike Surgical Specialities where the pharmacist will visit on a daily basis, but will 
not be present all day.  Physicians are likely to be more familiar with the pharmacist in these 
settings and as such a mutual understanding of each other’s expectations regarding 
medication-related tasks is likely to have developed.  For example, the pharmacist may 
actively encourage physicians to engage with the review messages before the end of their 
shift.  A low acceptance rate of interventions has previously been observed in a hospital 
where the pharmacists communicated entirely via the CPOE system and did not participate 
in ward rounds (Estellat et al., 2007).  Adopting a process of minimal face-to-face 
communication would not be considered collaborative, or promote such working.  In 
contrast, a study investigating  the impact of CPOE in the “team-orientated” Critical Care 
setting found it did not have a negative impact on the quality of communication in the long-
term (Hoonakker et al., 2013).   
 
7.3.2 System factors 
Review messages in PICS may be considered a type of alert to the physician, albeit a passive 
one that is non-interruptive. Human factor variables found to influence acceptance of alerts 
are: 1) display characteristics (i.e. proximity of the alert to the event); 2) textual information; 
and 3) prioritisation (Seidling et al., 2011).  The sign-off function is intended to serve as an 
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indication that a message has been received, read and acknowledged.  However, the rate of 
sign-off would indicate that it may not be used as intended.  A failure to sign-off a message 
means it remains on a patient’s prescription order and as such, may unnecessarily 
contribute to a message burden on screen.  This may have an unintended consequence of 
reducing the effectiveness of messages, with new messages indistinguishable from the old.  
Messages may become invisible or are no longer obvious to the physician and so may be 
overlooked (Caruba et al., 2010; Estellat et al., 2007).  This may provide some explanation as 
to why a large majority of messages were signed-off by pharmacists themselves (39.3%, 
n=6,302/16,025), actively removing the ‘R’ icon from the screen on the physicians’ behalf to 
ensure any remaining messages still require acknowledgement.  This finding suggests that 
further training is required to promote optimal use of the system—interprofessional 
sessions would also enable practitioners to share their expectations on the use of the 
system. 
 
In PICS, a pharmacist is unable to assign a priority to a review message to identify those that 
require more urgent acknowledgment or response.  Without this information the physician 
is unable to appropriately prioritise medication-related requests over other tasks.  This may 
provide some explanation for the observed delay in the sign-off and action of some 
messages.  On the other hand, it was reassuring to find that messages assigned to anti-
infective medicines were more likely to be actioned within 24 hours compared to other 
medicines.  Again this suggests that physicians prioritise the review of some medicines over 
others; in the particular case of anti-infectives, it may be as a result of national campaigns to 




The review message function does not allow for bi-directional communication and so the 
physician is not obliged to respond in order to gather information about the query.  
Therefore, aside from signing-off a message, the physician cannot provide an explanation 
for their subsequent action (or inaction).  CPOE systems with CDS software that allows 
clinicians to provide an explanation as to why alerts have been over-ridden have been found 
to be more likely to succeed than those that did not (Roshanov et al., 2013). Therefore 
designing systems with bi-directional communication may increase the physician’s 
awareness of messages, which over time could inform its optimal use.  For example, it may 
reduce the total number of messages assigned by pharmacists as they understand what 
information is useful to the physician and how best this should be communicated.  Two-way 
communication would also increase collaborative working, integral to the effectiveness of 
this modality of communication.   
 
7.3.3 Strengths and limitations 
The aim of this study was to investigate the effectiveness of pharmacist-physician 
communications when sent via a CPOE system.  As previously described (see 6.3.1), a 
strength of this study is the size of the database, with over 34,000 messages available for 
analysis, 16,025 of which were eligible for analysis of time to sign-off and 9,991 for action.  
The language used by pharmacists in their written discourse was not analysed in this study.  
This may change depending on the grade or prior experience of the pharmacist (Liu et al., 
2014) and could provide further explanation for the outcome of communications in this 




In the analysis, prescribing errors were not identified, since this would have required 
assumptions to be made of the data without context of the patient or the situation at the 
time.  Therefore only those messages analysed for action can be directly compared to 
intervention studies.  Further targeted qualitative research is required to understand why 
messages are not consistently signed off or actioned in PICS and why the function does not 
appear to be used as intended by system developers. 
 
7.3.4 Conclusions 
The capability to communicate in an ad hoc asynchronous manner in hospital has benefits 
for both the pharmacist and physician—fewer interruptions reduce the need for the 
physician to multi-task, which can reduce procedural and clinical errors in a busy and 
pressured environment.  However, in this study a lower rate of sign-off and action was 
observed than might have been expected, suggesting uni-directional communication via the 
CPOE system may not be optimal.  An established pharmacist-physician collaborative 
working relationship is likely to influence the prioritisation and response to messages, since 
a more desirable outcome was observed in settings and with grades of pharmacists where 
this was more likely.  Designing systems that can facilitate collaborative communication, 













Chapter 8 A QUALITATIVE ANALYSIS OF PHARMACIST-PHYSICIAN 
COMMUNICATIONS IN A HOSPITAL CPOE ENVIRONMENT 
 
 
In this chapter, I describe the qualitative research methods used to investigate 
communication between pharmacists and physicians at UHBFT and Guy’s and St Thomas’ 
NHS Foundation Trust.  I introduce five themes that emerged from the analysis of the data 
and consider these in relation to the communication load of pharmacists and the 
effectiveness of communication.  Finally, I interpret the findings in the context of the 
literature and propose new ideas to explain why CPOE was found to impact on 
communication between the professional groups.    
 
8.1 Background and research questions  
Healthcare has been described as a “complex adaptive system” (Plsek & Greenhalgh, 2001; 
Sturmberg et al., 2012), where staff will adapt very quickly in response to changes such as 
new technology and will organise their work so that they can continue to meet targets and 
achieve desired outcomes.  It is strongly recommended that healthcare organisations work 
closely with designers and suppliers when planning to implement new technology such as 
CPOE.  This ensures that staff are effectively engaged in the process from the start and can 
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consider the local environment in the design and implementation (Cresswell et al., 2013a; 
Gagnon et al., 2014).  During this process, the organisation will have considered the benefits 
of implementing the new technology, such as on safety and productivity, but the 
sociotechnical implications are often harder to predict.  “Work as intended” and actual 
“work as done” (Blandford et al., 2014) can be very different in practice and are not easily 
identifiable from the analysis of quantitative data generated from CPOE systems.  Examining 
the sociotechnical factors associated with the implementation of new technology allows the 
intended and actual use to be better aligned.  
 
Qualitative research methods enable the context of the hospital environment to be 
considered when evaluating the impact of new technology.  This includes the organisational, 
professional and social factors that can impact on the use and acceptance of new systems 
(Boonstra & Broekhuis, 2010; Kaplan, 2001).  The methods allow us to determine how and 
why sociotechnical factors may change or evolve over time, by examining the habitual 
adjustments staff make (consciously or unconsciously) to continue to achieve the desired 
outcomes as the technology embeds into the culture of the organisation. 
 
The aim of this study is to explore pharmacists’ and physicians’ perceptions of their 
interprofessional communication in the context of CPOE and CDS and to validate the 
findings using ethnographic non-participant observation.   
The analysis will be framed by known topics from a systemic review of the literature 
described in Chapter 2 (Thomas & Coleman, 2012) and the quantitative analysis described in 
Chapters 5–7 (Pontefract et al., 2016).   
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8.2 Method: Focus Groups 
8.2.1 Methodological approach 
There are two potential research methods available for generating qualitative data to meet 
the objective of this study: interviews and focus groups.  Focus groups were selected as the 
method for gathering the data.  Unlike one-to-one interviews, focus groups allow for data to 
be generated on the collective views of participants (Morgan, 1998a; pp 9-16).  Opinions 
and experiences of participants can be shared within a group discussion and contextualised 
to determine similarities or differences.  This is important given that the subject being 
investigated is the direct or indirect communication between two professional groups.  
Since pharmacists and physicians work alongside each other as part of the healthcare team, 
participants should also feel that they can talk openly, avoiding the need for interviews to 
be conducted separately to avoid conflict. 
 
8.2.2 Ethics approval 
This study protocol received favourable opinions and approval by the Research and 
Development Department at both UHBFT [21st October 2013] and Guys and St Thomas’ NHS 
Foundation Trust [27th August 2015].  The study was also approved by the University of 
Birmingham Ethics Committee [ERN_12-0127]. 
 
8.2.3 Data collection 
8.2.3.1 Setting 
Focus groups were conducted with pharmacists and physicians in two hospitals sites: 
UHBFT, the setting of the quantitative study described in Chapters 5-7; and Guy’s and St 
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Thomas’ NHS Foundation Trust (GSTFT).  The latter comparator site was selected, based on 
the pre-defined criterion that the hospital had recently (within the last 12 months) 
implemented a CPOE system.   
 
University Hospitals Birmingham NHS Foundation  
As previously described, UHBFT uses a locally developed CPOE system called PICS, which has 
been in use at the hospital since 2004, although earlier parts of the system existed as early 
as 1998 (Nightingale et al., 2000).  PICS is used for the prescribing and administration of 
medicines throughout all inpatient beds, with the exception of the Emergency Department 
and some complex systemic anticancer therapies prescribed according to defined treatment 
protocols.  It is also used to generate the discharge summary and prescription for patient 
discharge (known as ‘to take out’ prescriptions, or TTOs).  Despite being highly digitised, 
with PICS holding pathology data and documentation of vital observations (e.g. blood 
pressure) and clinical assessments, the medical notes remain paper-based throughout the 
hospital. 
 
Guys and St Thomas’ NHS Foundation Trust 
Despite a digital drive for NHS hospitals to become paperless, very few hospitals 
implemented CPOE during the period of this overall programme of study.  The GSTFT was 
identified through the National Institute for Health Research programme grant for applied 
research, ‘Investigating the adoption, implementation and effectiveness of electronic 
prescribing systems in English Hospitals’ [RP-PG-1209-10099].  As it was known that the 
Trust had recently implemented the system, the electronic prescribing pharmacist was 
contacted and invited to participate in the study.   
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In contrast to UHBFT, GSTFT have three commercial CPOE systems in use across the 
hospital.  The Intensive and High Dependency Care Unit (ICU) was the first department to 
digitise the prescribing process, implementing the CareVue® electronic patient record in 
2004.  The discharge process across the hospital was next to be digitised in 2006, with all 
discharge prescriptions generated using the iSoft® system.  Lastly, between 2014 and 2015 
the MedChart® system was implemented for all other inpatient departments.  A summary of 
the technology used in each site is provided in Table 8.1.   
Table 8.1 – Summary of electronic patient records available at UHBFT and GSTFT 
 
Description UHBFT GSTFT 
CPOE system PICS CareVue®; MedChart®, 
iSoft® 
   
Commercial or ‘home 
grown’ 
Home grown Commercial 
   
Electronic discharge  PICS  iSoft® 
   
Medical notes Paper-based ICU: Electronic and 
integrated in CareVue® 
Rest of hospital: e-Noting 
separate to MedChart® 
   




   
Other function to 
communicate with 
physician 
Nil Alerts that can appear when 
the physician generates a 
prescription 
   
Simultaneous access Staff can access records and 
make changes in the system 
at the same time 
Staff can access the system 
at the same time, but are 
unable to make changes at 
the same time 
   
Pharmacist proposing 
of prescriptions 
Can propose prescriptions 
for physician authorisation  
Can propose prescriptions 
for physician authorisation 





8.2.4 Participant recruitment 
Pharmacists and physicians were eligible to participate in the study provided they were 
qualified in their field and had regularly prescribed or validated inpatient prescriptions 
within the CPOE system within the preceding six months.  For both professions, no 
restrictions were placed on the grade of the professional or number of years of experience.  
Between 6–8 participants was set for each focus group, to allow for discussion to be 
generated and for everyone to have an opportunity to contribute in the allocated time 
(Morgan, 1998b; pp 71-73). 
 
Both pharmacists and physicians were invited to participate in the study via email.  The 
email provided a background to the research question, dates that the focus group(s) would 
be held on and a copy of the Participant Information Leaflet for further information 
(Appendix 13).  This ensured that potential participants were appropriately informed and 
could ask questions prior to accepting the invitation, or had the opportunity to prepare 
questions to ask before the focus group commenced.  In both sites, emails were sent by 
members of staff who were familiar to the professional groups.  At UHBFT, physicians were 
emailed directly by the Postgraduate Centre Manager for Education and the pharmacists by 
the Deputy Director of Pharmacy.  At GSTFT, the Deputy Director of Pharmacy (the 
nominated research facilitator required by the hospital for research and development 
approval) emailed potential participants.  In each case, I was copied into emails so that 





At the beginning of the focus group, participants were provided with another copy of the 
Participant Information Leaflet, along with a Consent Form and given some time to read 
these to ensure they were fully informed about the research.  Participants were asked to 
acknowledge that they had read and understood all the information presented in the 
Consent Form by initialling each of the statements listed (Appendix 14).  The same Content 
Form and Participant Information Leaflet was used for all four focus groups as the focus of 
the research did not change throughout the study.  
 
8.2.6 Conducting the focus groups 
Topics identified through the systemic review of the literature described in Chapter 2 
(Thomas & Coleman, 2012) and the quantitative analysis described in Chapters 5–7 
(Pontefract et al., 2016) were listed in a guide for the facilitators, along with related prompt 
questions and the overall research question (Table 8.2).  This ensured that specific topics 
were integrated into the discussion and could be used to refocus “off-topic remarks” 
(Gubrium & Holstein, 2001; pp 147) that were not related to the research.   
Table 8.2 – Topic guide to facilitate the conducting of the focus group 
 
Theme Example of questions 
Unidirectional communication [Physician] What are your thoughts on the review 
message function for conveying medication-
related information?  
[Pharmacist] Can you tell me about any methods 
you might use to check that the information 
communicated within the review message has 
been received as intended?  
  
Interpersonal communication What are your thoughts on the frequency of 
interpersonal communication between the 




Electronic messages What are your thoughts on the electronic 
message in terms of conveying urgency of the 
communication?  
  
Physician accessibility to electronic review 
messages 
What are your thoughts on the accessibility of the 
review message within the PICS system?   
  
Clinical decision support 
 
 
[Pharmacist] Can you tell me whether you 
think/feel that the presence of CDS affects the 
type of information you communicate to the 
physician?  
[Physician] Can you tell me your thoughts on how 
the presence of CDS might affect the messages 
received by pharmacists?   
  
Acknowledgement of messages [Pharmacist] What are your thoughts on how 
messages are ‘signed-off’ (acknowledged) within 
PICS?  
[Physician] Are there any instances where you 
might consider leaving the message on screen 
and not signing it off?  
 
Four focus groups were conducted across the two sites; three at UHBFT and one at GSTFT 
(Table 8.3).  Both uni-professional and mixed focus groups were conducted at UHBFT, each 
with a range of professional grades.  The focus group at GSTFT was conducted at a later date 
to allow some time for a preliminary analysis of the data to be conducted and for 
observational research to be performed at UHBFT (see section 8.3). 
Table 8.3 – Demographics of the focus groups 
 
Focus group Date Setting Professional group 
1 16th June 2014 UHBFT Pharmacists 
    
2 23rd June 2014 UHBFT Physicians 
    
3 1st July 2014 UHBFT Pharmacists and Physicians 
    




It is important to consider the composition of focus group participants in the research 
design process, as the data generated by the interaction between individuals is dependent 
on the group dynamic (Kitzinger, 1995).  The uni-professional focus groups allow for similar 
or shared experiences to be discussed between participants and to explore issues in more 
depth.  In this case, the views on communication with the other professional group may also 
be expressed openly without fear of offending someone.  However, although the uni-
professional groups may appear homogenous (i.e. same professional training), introducing 
participants with a range of experience to a single focus group also provides an opportunity 
to discuss how opinions and perspectives differ and how these may have been influenced 
over time.  The introduction of mixed focus groups, which in this case sees two different 
professional groups interact, provides an opportunity for participants to discuss the barriers 
and facilitators to communication and to challenge each other’s views.  In each case, the 
group interactions allow for views to be challenged, debated and even rationalised among 
the group and may even lead to changes in views as a result (Kitzinger, 1994).   
 
I moderated the four focus groups.  This involved opening and directing the discussion, 
ensuring all participants had the opportunity to participate and that the discussions were 
not dominated by any individual(s) in particular.  In addition, interruptions would be 
prevented or minimised to avoid problems with audio recordings and transcription (Fern, 
1982; Gubrium & Holstein, 2001; pp 146).  Each of the focus groups was facilitated by an 
independent academic researcher, known to me as staff at the University (CH at UHBFT and 
SS at GSTFT).  Conscious of my background as a pharmacist and having occasionally worked 
at UHBFT, independent facilitation was important to ensure that I did not inadvertently lead 
the discussion, which could potentially lead to confirmation bias in both the analysis and 
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interpretation of the data (Mays & Pope, 2000).  The facilitators were selected based on 
their previous experience of qualitative research, their understanding of the role of the 
hospital pharmacist, knowledge of CPOE systems and, their independence from the study 
site.  They were provided with a background to the study, had explained to them any 
common terms that may emerge during the focus group (e.g. CPOE terminology) and were 
provided with the topic guide (Table 8.2) to facilitate the discussion.  A second independent 
academic member of staff (HB at UHBFT and HV at GSTFT) was also present in the groups to 
undertake administrative tasks of collating signed consent forms, setting up the recording 
equipment and taking notes to facilitate transcribing of the data.  
 
Prior to the start of the focus group, an opportunity was provided for any final questions to 
be asked of the moderator.  The recorder was started and it was further reiterated that 
participants were free to leave at any time and that everyone had consented to the focus 
group being recorded.  The aim of the study was repeated and the moderator, facilitator 
and administrator introduced themselves and explained their role in the process.  
Participants were then asked to introduce themselves by providing the following 
information: 
i. Profession (pharmacist or physician); 
ii. Number of years qualified; and 




Every focus group commenced with the same opening question to “capture the interest of 
the participants” (Gubrium & Holstein, 2001; pp 148); this was broad and related to the 
overall research question: 
 
“What are your thoughts on communicating with the [physician /pharmacist/each 
other] in the context of electronic prescribing”?   
  
Each focus group lasted between 1–1.5 hours and was recorded so the data could be 
transcribed at a later date.  
 
8.2.7 Peer debriefing 
Immediately after each focus group, the moderator, facilitator and administrator gathered 
to reflect on and discuss the interview in a debriefing meeting (Table 8.4).  The debriefs 
were conducted to discuss the organisation and running of the focus group, whether any 
aspects needed be improved for subsequent groups and to discuss the interpretation of the 
data to probe its relevance to the research question (Given, 2008; pp 603-605).  In each 
case, any topics identified that may warrant further discussion were documented and added 
to the topic guide to focus data collection for subsequent groups.  A second debriefing was 
also conducted after each focus group with the academic qualitative supervisor.  In addition 
to discussing the above points and gaining feedback, this particular debrief provided further 
opportunity to discuss initial thoughts and impressions, identify any gaps in the data and 




Table 8.4 – Dates of peer debriefing following focus groups 
 
Focus group Date of focus group Date of debrief 1* Date of debrief 2* 
1 16th June 2014 16th June 2014 17th June 2014 
    
2 23rd June 2014 23rd June 2014 27th June 2014 
    
3 1st July 2014 1st July 2014 23rd July 2016 
    
4 25th Feb 2016 25th Feb 2016 29th Feb 2016 
*Debrief 1: facilitator and administrator; Debrief 2: Academic supervisor (Sabi Redwood) 
 
8.2.8 Data analysis 
Focus group data were transcribed verbatim, but did not take account non-verbal 
communication such as laughter.  Participants were anonymised using a letter to represent 
their profession (P: Pharmacist; D: Doctor), a number to identify the statements of 
individuals and a letter to represent the location (B: UHBFT; G: GSTFT).  Prior to any formal 
coding of the data, each of the transcripts was read in full and on multiple occasions to 
become familiar with the content.  Initial thoughts and reactions to the data were 
documented and early ideas about connecting themes were noted using mind maps.  This 
early process of analysis was important to understand the dataset as a whole, which would 
facilitate formal coding and thematic analysis at a later date.  The transcripts were uploaded 
into NVivo 10, a Computer Assisted Qualitative Data Analysis Software designed to facilitate 
coding and theming of such data.  The following attributes were assigned to each focus 
group and the individual participants so that, where applicable, the characteristics may be 
considered when comparing concepts during the analysis: 
 Setting (UHBFT or GSTFT); 
 Profession (pharmacist/physician); 
 Length of time qualified (<1 year, 1–3 years, 4–10 years, more than 10 years); and 
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 Experience with paper-based prescribing systems (Yes/No).  
The data were analysed using an integrative method of both deductive and inductive 
analysis.  The deductive approach was conducted using a framework of codes (Table 8.5) 
that were identified from both a systematic review of the literature described in Chapter 2 
(Thomas & Coleman, 2012) and the quantitative study of pharmacist-physician 
communications described in  Chapters 5-7 (Pontefract et al., 2016).  This framework 
analysis enabled already known concepts to be integrated into the analysis (Bradley et al., 
2007).   
 
Table 8.5 – Framework to inform deductive analysis of focus group data 
 
Origin of theme Theme 
Systematic review A false communication 
 Interpersonal communication 
 The impact of pharmacist messages in an electronic format 
 Physician accessibility to pharmacist alerts 
 The effect of CDS on communication 
  
Quantitative analysis Pharmacist assignment of review messages 
 Physician action of review messages 
 
An inductive analysis of the data was conducted to identify new or emerging concepts that 
had not already been highlighted during the research.  This was particularly important given 
that few studies had been identified in the initial review of the literature (Chapter 2).  In the 
analysis, the data were initially fine coded to capture detailed descriptions of the data.  The 
codes were then arranged into the most salient or common themes that were observed 





8.2.9 Confirmability: verification of codes 
Approximately one quarter of the text data from two focus groups were selected at random 
from UHBFT (uni-professional; pharmacists) and GSTFT (mixed; pharmacists and physicians).  
An academic qualitative researcher with an interest in CPOE and medication safety (SS), was 
asked to review the transcripts with the research question in mind and apply codes to 
describe the data.  The codes were then discussed and compared with the themes and 
codes already generated.   
 
The approach taken to request that a proportion of the transcripts were coded by an 
independent researcher was not conducted to guarantee validity of the analysis (Cook, 
2012), but to provide an insight that may be useful for checking methodological or 
confirmation bias.  Importantly, it provided an opportunity to discuss and refine the 
descriptions used for codes and themes going forward. 
 
8.2.10 Transferability of the findings 
Optimising the transferability of the findings was considered in the design of the focus 
group research.  First, participants in both sites were randomly selected to participate in the 
study and with a range of professional grades so that the sample could be more 
representative of a larger population of professionals in each site.  Second, GSTFT was 
selected as a contrasting site to UHBFT in relation to: the CPOE systems in use; the relative 
length of time it had been in use; and, the lack of functionality for pharmacists to 
communicate requests and information electronically assigned to a prescription.  
Importantly, comparing sites that had adopted CPOE technology at different times allows 
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for the “stability and change in sociotechnical relations” to be investigated (Pollock & 
Williams, 2010), helping to identify short and long-term impacts of implementing new 
technologies, such as with adjusting professional roles and routines.  
 
GSTFT was also selected based on its shared features with UHBFT in: providing care for 
acute inpatients; the provision of specialist services (e.g. critical care); and, presence of 
ward based pharmacists.  The distinct similarities and differences were intended to allow for 
emerging concepts to be compared between sites to inform interpretation of the data 
(Green & Thorogood, 2009; Silverman, 2016).   
 
8.3 Method: Non-participant observation 
8.3.1 Methodological approach 
Qualitative observational research in the context of health information technology can allow 
for the dynamic between social and technical processes to be investigated across a range of 
dimensions, including the hardware and software, human-computer interaction and 
workflow and communication (Siting & Singh, 2010).  Observation was therefore selected as 
a means of data triangulation to compare and further explore the findings from the 
quantitative study of pharmacist-physician communications at UHBFT (Chapters 5–7) and 
the themes identified from a preliminary analysis of the focus group data at the same site 
(Reeves et al., 2008; Mays & Pope, 2000).  Observational research can be conducted overtly, 
where there is a mutual understanding between the observer and participant regarding the 
aim of the study, or covertly where the opposite is true (Mays and Pope 1995).  Given that 
pharmacists and physicians at the study site had been invited to participate or had 
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participated in the focus groups, overt observation was necessary.  Pharmacists were 
selected as participants because they instigate the use of the review message function at 
UHBFT and data from the focus groups suggested that their requests are frequently 
followed up directly with the physician.  Although observation of the physician would be 
valuable to gain an insight into their response to the messages via the CPOE system, there 
was concern that conducting this overtly could alter the behaviour of the physician—the so 
called “Hawthorn effect”—with a potential to impact on the validity of the findings 
(Roethlisberger & Dickson, 1961, cited in Goodwin et al., 2017).  In addition, since the 
receipt and review of messages sent by the pharmacist is one of many tasks potentially 
carried out by the physician on a daily basis, the observation time dedicated to the study 
would need to be substantially increased to capture a degree of interaction with the 
messages that could facilitate exploration.   
 
8.3.2 Ethics approval 
This study protocol received favourable opinion and was approved by the Research and 
Development Departments at both the UHBFT [21st October 2013] and GSTFT [27th August 
2014].  The study was approved by the University of Birmingham Ethics Committee 
[ERN_12-0127]. 
 
8.3.3 Data collection 
Pharmacists were observed performing their routine clinical duties in the hospital setting at 
UHBFT.  Observations were particularly focused on the pharmacists’ use of the review 
message function, documentation of information to coordinate care with other staff and 




Two broad settings were selected for the study, where pharmacists spend the majority of 
their time: the wards and the dispensary.   
 
Wards 
Pharmacists at UHBFT are predominately ward-based and each is responsible for a number 
of named wards that they will visit every weekday.  Grade 6 pharmacists are responsible for 
named wards for a period of approximately three months and grade 7 pharmacists for four 
months.  Pharmacists spend the majority of the day covering their allocated wards, although 
most grade 6 pharmacists are generally required to return to the dispensary from 16:00 
onwards (although there are exceptions to this, specifically if they are assigned to the 
Admissions or Oncology wards).  The total time spent on the wards can vary depending on 
the number of wards a pharmacist is required to cover in the course of a day, taking into 
account additional wards that they may need to visit to cover annual leave.  The ward 
pharmacists spend their time reviewing patients’ prescriptions generated in PICS, undertake 
or confirm medication histories and communicate with other members of the healthcare 
team about medication-related issues.  To gain an insight into how the pharmacists’ tasks 
and role may differ across specialities, observations were scheduled on a range of wards: 
Admissions; General Medicine; Critical Care; Liver and Renal. 
 
Dispensary 
Pharmacists are required to spend some time in the dispensary on a weekly basis.  This 
would typically be for one of four designated time slots on one day in the working week 
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(Table 8.6).  To gain insight into how the time of day may impact on the pharmacists’ tasks, 
each of the above time slots were planned to be observed at least once.   
 
Table 8.6 – Pharmacist cover in the dispensary, divided into four time slots 
 
Time Description of pharmacist cover 
09:00-11:00 The morning is generally covered by one senior pharmacist of at least 
grade 7 
  
11:00-13:00 One pharmacist will generally be allocated to cover this time slot, unless 
it is very busy and with exception of a Thursday when two pharmacists 
will be present.  At 13:00 on a Thursday, junior physicians attend periods 
of protected study and as such are not available to be contacted. Two 
pharmacists are allocated prior to this to ensure workload can be 
managed and any queries chased with the physicians beforehand. 
  
13:00-15:00 Generally covered by one pharmacist of at least grade 7, except for when 
it is very busy 
  
15:00-17:00 Often two or three pharmacists to manage workload prior to the end of 
the working day 
 
In this dispensary, pharmacists spend their time on the following clinical tasks: 
 Missed doses: PICS can highlight when a patient has missed a dose of a medication 
and generates an order to be automatically printed in pharmacy.  It is the 
responsibility of the pharmacist to manage these orders by checking that the 
prescription is appropriate before the medication is supplied and ensuring that the 
missed doses are dealt with in a timely manner; 
 Discharge prescriptions (TTO): the pharmacist will check that the prescription is 
complete and appropriate for the patient; 
 General out of stock (non-urgent) medicine request; 
 Non-stock requests: from wards that do not have a pharmacist assigned; and, 
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 Requests for stock requests from off-site departments: (e.g. hospices, rehabilitation 
units). 
 
8.3.4 Participant recruitment 
As for the focus groups, pharmacists were eligible to participate in the observation study 
providing they were qualified in their field and had regularly prescribed or validated 
inpatient prescriptions within the hospital CPOE system within the preceding six months.  
There were no restrictions placed on the grade of the professional or number of years of 
experience.  Pharmacists were invited to participate in the study via email, which was sent 
from the Deputy Director of the Department.  Since the observational research planned was 
to be overt in nature, the email provided a background to the research question and a copy 
of the Participant Information Leaflet for further information (Appendix 13).  This ensured 
that potential participants were appropriately informed and could ask questions prior to 
accepting the invitation or had the opportunity to prepare questions to ask before the 
observation commenced.  The email also detailed the period of time over which the 
observations would ideally take place.  I was copied into the email so that potential 
participants could respond to me directly and ask any questions.  Participants were selected 
to ensure that a range of professional grades, wards (specialities) and shifts (time of day) 
could be observed. 
 
8.3.5 Consent 
Approximately one week before the observations were planned to commence on the wards, 
the relevant ward managers were emailed to inform them about the research and to 
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request permission to conduct the observation.  The email provided a background to the 
research question, the planned time for the observation and attached a copy of the 
Participant Information Leaflet for further information.  In addition, all pharmacy staff 
(including pharmacists, technicians, administrators and technical officers) were informed 
about the research during a pharmacy team briefing.  It was made clear that the 
observations would not be filmed or recorded and that written field notes taken would not 
contain any patient information.  It was also explained that the research was funded by the 
National Institute for Health Research and that the study had been approved by the Trust 
Research and Development Department. 
 
Prior to the observation commencing, the pharmacist participant was given the opportunity 
to read the Participant Information Leaflet and ask any questions.  It was explained that 
they were being observed for their workflow, communication and interactions with other 
healthcare professionals (mostly physicians).  It was also emphasised that individual 
performance was not being assessed and that written field notes would be taken during the 
observation, but that these would not include any patient data and that the observation 
would not be filmed or recorded.  Finally, it was explained to the participant that they may 
withdraw from the observation at any stage and that they could request to have any 
information from the observation removed from the analysis without repercussion.  Verbal 
consent was confirmed from each participant before the observation commenced. 
 
In any situations where a patient was present during the observation of the pharmacist, the 
observer introduced themselves and explained that they were a researcher observing the 
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pharmacist on the ward and requested verbal consent to continue.  If there was a situation 
where the patient objected, the observer would remove themselves from the consultation. 
 
8.3.6 Conducting the observation 
The aim of the observational research was collect data that could be used to triangulate the 
findings from the quantitative study and the focus group.  A total of 21 hours was planned 
over 11 days across the two settings at UHBFT, with the intention that this could be 
increased if new concepts emerged that needed further investigation.  I conducted the 
observations along with two academics from the University of Birmingham: HV, a 
pharmacist who had previously worked at UHBFT; and HB, a research associate with a 
background in investigating CPOE and patient safety who had previously acted as an 
administrator for the focus groups.  Multiple observers were selected to collect data to 
improve the reliability of the study (LeCompte & Goetz, 1982) since it allowed for different 
perspectives to be gained.  Importantly, this also enabled more hours of clinical time to be 
observed.  The participants were cognisant of the research question and aims.  The 
observers were informed that they could also share their professional background with the 
participant and could interact to ask questions to gain context or further explanation of 
events as needed.  However, participants were not formally interviewed and recorded. 
 
In both the ward and dispensary setting, the observations were targeted (Table 8.7 and 8.8) 
to look for concepts that were identified in the quantitative study described in Chapter 5–7 
(Pontefract et al., 2016) and from the preliminary analysis of data generated by the focus 
groups.  However, observers were also informed that they could document observation that 
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they felt were relevant to pharmacist-physician communication that had not already been 
identified and described to them.   
 
Table 8.7 – Themes for targeted ethnographic observation on the wards 
 
WARDS 
Theme Sub-theme Example 
Interpersonal 
communication 
Synchronous communication Synchronous communication (or attempts 
made to) with the physician (i.e. both the 
pharmacist and physician participating in 
the communication at the same time, e.g. 
face-to-face) 
Difficulties getting hold of the physician 
Informing a physician about a review 
message being placed on PICS for their 
attention 
 Communication from the physician 
Asynchronous communication 
via PICS  
Communication via the review message 
Communication in the medical notes 
Collating tasks to handover to 
the physicians  
Process of collecting tasks over a period of 
time to handover in a single interaction 
   
Theme of 
communication 
Clinical decision support Errors generated by default orders  
Documentation Pharmacist messages for 
communicating with other 
pharmacy staff 
Time spent on task, duplication of tasks 
Use of the P-note 
(endorsement) 
Use of P-note to document information  
   
Proposals Pharmacist use of the 
proposal function 
Frequency of medicines being proposed 
 Informing physician of medicines 
proposed 
   
Professional 
roles (training) 
Pharmacists as informal 
trainers of the system 
Being asked about how to use PICS 





Table 8.8 – Themes for targeted ethnographic observation in the dispensary 
 
DISPENSARY   





Synchronous communication (or 
attempts made to) with the physician 
(i.e. both the pharmacist and physician 
participating in the communication at 
the same time, e.g. face-to-face) 
Difficulties getting hold of the physician 
Informing a physician about a review 
message being placed on PICS for their 
attention 
Communication from the physician  
Asynchronous 
communication via PICS  
Communication via the review message  
Difficulties getting hold of the physician 
   
Theme of 
communication 
TTO supply problems, 
controlled drugs 
prescription problems 
Incomplete controlled drug 
prescriptions that require handwritten 
annotation 
   
Closing the loop 
of 
communication 
Pharmacist following up 
on whether interventions 
have been actioned 
Method adopted and frequency 
conducted 
   
Professional 
roles (training) 
Pharmacists as informal 
trainers of the system 
Receiving phone calls from physicians 
to find out how to use PICS 
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Observers were reminded to observe and record a range of dimensions of observation, such 
as: “objects” (e.g. availability of hardware); “activities” (of staff); “actions” undertaken by a 
member of staff; “goals” of the healthcare professionals at work; and “feelings” expressed 
by participants or those around them (Spradley, 1980, cited in Reeves et al., 2008).  An 
‘Observer’ badge was worn throughout each observation.  In the ward setting, the observer 
introduced themselves to the nurse in charge to remind them of their presence and that the 
observation had been permitted by the ward manager.  At the start of each observation 
period, the start time and the setting (ward name /dispensary) were documented along 
with the grade of the participant.  During the period of observation, the observers made 
written notes to document their perspective of the events observed (Pope, 2005), along 
with their thoughts and reflections of the setting and interactions within it and, where 
applicable, the perspectives of those observed.  The observers were informed that they 
could take recording equipment, but that this should only be used to record any immediate 
reflections when the observation had finished.   
 
Each observation was planned to last approximately two hours and at the end of the 
observation, the finish time was documented so that a total time could be calculated.  The 
observers typed up their notes along with any recorded reflections, as soon as possible after 
each session. 
 
8.3.7 Peer debriefing 
The observers attended regular debrief meetings to discuss and reflect on what they had 
observed and experienced.  This provided an opportunity to discuss the targeted themes, 
any new dimensions, disconfirmations to the themes and for the observers’ to provide their 
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own interpretation of the data.  This part of the process was particularly important given 
that multiple observers were conducting the research.  The debrief meetings also provided 
an opportunity to discuss the organisation and running of the observations, raise any ethical 
issues or problems encountered and any aspects that may need to be improved for 
subsequent observations.  Debrief meetings were also conducted with the academic 
qualitative supervisor to discuss the above points. 
  
8.3.8 Data analysis 
The observers’ typed field notes and reflections from each observation were uploaded into 
NVivo 10 to facilitate analysis.  The following attributes were assigned to each source: 
 Observer initials (SP, HB, HV); 
 Grade of the pharmacist participant (6,7,8); and, 
 Setting (ward speciality, dispensary). 
Since the observational study was primarily conducted to triangulate the findings from the 
quantitative study and focus group study, the data were analysed into the themes and sub-




A total of 27 people participated in the focus groups across the two hospital sites, 20 at 
UHBFT (B) and 7 at GSTFT (G). There were 16 pharmacists and 11 physicians (see Table 8.9) 
and the majority of participants (n=21/26) had worked with paper-based prescribing 
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systems in the past.  The participants varied in their level of experience, from relatively 
newly qualified pharmacists and physicians who had been qualified for less than 2 years 
(n=8), to those who had been practising for 2–3 years (n=5), 4–10 years (n=9) and for more 
than 10 years (n=5) in their professional role.  A full summary of the participant 
demographics is provided in Appendix 15. 
 
Table 8.9 – Demographics of focus group participants 
 
 UHBFT GSTH Total 
Pharmacists    
No. of pharmacists 11 5 16 
Experience with paper-based 
prescribing 
10 5 15 
Length of time qualified:    
<2 years 2 0 2 
2–3 years 3 1 3 
Qualified 4–10 years 3 3 7 
Qualified >10 years 3 1 4 
    
Physicians    
No. of physicians 9 2 11 
Experience with paper-based 
prescribing 
4 2 6 
Length of time qualified:    
<2 years 5 0 5 
2–3 years 1 0 1 
4–10 years 2 1 3 
>10 years 1 1 2 
 
 
At UHBFT, 15 pharmacists who were eligible to participate in the study were observed for a 
total of 20 hours, 7.25 hours of which were in the dispensary and 12.75 on the wards (Table 









Observer Grade of 
participant 
Date Time  
(hours) 
Dispensary 09:00–11:00 SP Grade 8 23rd Feb 2015 2.0 
11:00–13:00 HV Grade 6 
Grade 7 
Grade 8 
24th Feb 2015 1.75 
13:00–15:00 SP Grade 6 
Grade 8 
25th Feb 2015 1.50 
15:00–17:00 HB Grade 8 
Grade 8 




HV Grade 6 26th Feb 2015 2.00 
General 
Medicine 
SP Grade 6 26th Feb 2015 1.50 
Critical Care HB Grade 7 2nd Mar 2015 1.50 
Renal/Liver HV Grade 8 2nd Mar 2015 2.00 
Admissions HB Grade 7 5th Mar 2015 2.00 
Liver/GI SP Grade 7 5th Mar 2015 1.75 
Admissions SP Grade 6 10th Mar 2015 2.00 
Subtotal 12.75 
Total observation time 20.00 
GI: Gastrointestinal 
All three professional grades of pharmacists were observed, with more grade 8 pharmacists 
observed overall (n=6), the majority of which were seen in the dispensary (n=5).  Equal 
numbers of grade 6 (n=3) and grade 7 (n=3) pharmacists were observed on the wards.  Each 
of the four allocated time slots in the dispensary were observed once, along with a range of 
specialities on the wards: General Medicine (3.5 hours); Admissions (3.75 hours); Critical 




8.4.2 Thematic analysis 
In the analysis of focus group and observational data, five prominent themes emerged: 
Professional roles; Interpersonal communication; Documentation; Flow of information; and 
Decision-making (Figure 8.1).  
 
 
Figure 8.1 – Themes and sub-themes identified in the qualitative analysis of pharmacist-
physician communication  
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8.4.2.1 Professional roles 
Technical expertise 
The use of a CPOE system within the hospital setting introduced a new ‘technical’ expert 
role for the pharmacist.  Pharmacists reported that they were contacted by physicians to 
find out how to complete complex tasks within the system, such as how to prescribe 
“infusions” [P10.B; D8.B] or a titration regimen over a period of days.  This was confirmed by 
the physicians and was observed in both the dispensary and the ward setting.  One 
pharmacist covering a dispensary slot received four phone calls from physicians requesting 
advice, two of which related to the use of the system, specifically the prescribing of syringe 
drivers.  These requests contributed to ad hoc direct and indirect communication between 
the two professional groups, which would not have existed in paper-based processes. 
 
“I suppose that is one of the things that electronic prescribing does introduce, which 
is the technical aspects of knowing how to use the system. That’s what we do often 
get asked, “How do I do this” which you never would have had obviously if you were 
just writing it” [P15.G]. 
 
Requests for technical expertise did seem to occur less frequently when practitioners were 
using systems that provided more complex CDS, such as with standardised order sets in the 
Critical Care setting.  In any case, there was an assumption from the physicians that 
pharmacists were experts on all functions of the system—most likely because of their 
association with managing medicines generally.  Although there were occasions when 
pharmacists could explain first-hand how to use elements of the system, there were also 
times when they would have to “figure out” [P4.B] the system so that they could provide 
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the guidance requested.  This was highlighted by the pharmacists taking on a “nurturing” 
[P1.B] role when physicians were new to the hospital and were unfamiliar with the system.   
 
Pharmacists used the assumed technical expert role to their advantage to explain functions 
of the system that were important for medication-related communication, such as with the 
review messages at UHBFT.  Although it was unclear whether this was conducted in 
anticipation of any questions they may receive from physicians later on about the use of the 
message function, pharmacists were certainly aware that the training may not be optimal 
and that physicians were expected to learn about the system on the job and “pick it up” 
[P5.B] over time.   
 
“But I also think you are aware that they’re just literally thrown in one minute and 
you do have to be a bit more [training]” [P1.B]. 
 
The pharmacists did not report to dislike the requests for technical expertise, but seemed 
accepting of the role.  It was also suggested by pharmacists that they “should teach them” 
[the physicians] [P2.B] in a more formal role. 
 
“[…] I think that’s just part of the pharmacists’ and doctors’ roles changing all the 
time and electronic prescribing is just another one of these changes […]” [P12.G]. 
 
Although the physicians’ role did not change to one of a technical expert to support other 
staff, they were still expected to gain new technical skills to effectively prescribe for and 
manage patients within the CPOE system.  This was amplified in a hospital where multiple 
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systems were in use, where “the difficulty for junior doctors is becoming an expert in a 
multitude of systems […]” [D11.G].  Given that hospital CPOE systems vary across the UK, the 
role of technical expert adopted by pharmacists is likely to continue—at least while 
physicians continue to move between hospitals during their clinical training. 
 
Professional restrictions  
In paper-based prescribing environments, the drug chart is a focal point for physicians, 
pharmacists and nurses to communicate medication-related information.  Working on 
paper, pharmacists would traditionally annotate (or endorse) prescription orders with 
information to “fine tune” [P9.B] them.  Pharmacists reported they had, “a tendency to 
scribble all over it [the prescription] if it was a paper chart to try and make it right.” [P2.B], 
such as adding an extra time of day, “if it was the wrong time, you just crossed it out and put 
a circle at the correct time” [P1.B]; annotating “MR” [modified-release] [P1.B], or amending 
the route of administration. 
 
“Yes I would have just have gone, oh that should be three times a day, extra circle, or 
No you don’t want that IM [intramuscular] you want that sub-cut” [P14.G]. 
 
Within a CPOE system, practitioners are assigned user rights depending on their role and/or 
level of experience.  For example, physicians can generate prescriptions, pharmacists can 
verify these and nurses can administer the medicines.  In view of the restriction placed on 
professional groups, pharmacists across both sites reported that they were unable to amend 
and fine tune prescriptions in the same way as they would have done on paper.  This led to 
frustrations among the pharmacists, since without prescribing rights (i.e. as an independent 
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prescriber), the technology had removed their power to make amendments that they 
deemed appropriate and importantly ones that they felt confident in performing.   
The restriction was reported to, “lengthen the process a bit” [P1.B], which was described as 
a “faff” [P14.G] for tasks that they felt capable of completing and increased the need to 
intervene with the physician compared to paper-prescribing environments. 
 
“I think yes we probably are making more interventions than we would if it was a 
paper chart. Because we’d just write on it rather than making this big thing over it” 
[P7.B].   
 
Pharmacists perceived the types of amendments to be low risk, referring to these as 
“niggly” and “bitty” [P14.G].  The only exception to this was the ICU setting at GSTFT, where 
non-prescribing pharmacists could “make certain amendments and state ‘prescriber 
contacted’ for really small amendable things” [P16.G].  Physicians agreed that pharmacists 
should be able to amend prescriptions for the benefit of patients, which highlighted a trust 
and confidence in their ability to perform the task.   
 
“[…] And the problem is, it’s the patient who suffers at the end of it, so rather than 
sitting there slipping notes to each other and blaming each other for causing 
problems,  is to actually say, “We will sort out all the low level stuff” and actually sit 
there and talk to each other about the more important things” [D7.B]. 
 
Even with prescribing rights, pharmacists did not always feel comfortable with making 
changes to a prescription without informing or discussing with the physician.  One 
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pharmacist described that it felt “rude to change something” [P9.B] and as such would 
document that the change had been made with the use of a P-note (or endorsement note), 
or discussed it with the physician and then, “document that discussion” [D11.G]. 
 
Prescription review 
It was acknowledged across both sites that using CPOE had eliminated some types of 
prescribing errors that would ordinarily occur in paper-based prescribing processes, such as 
those caused by “illegibility” [P1.B] of prescriptions, “spelling mistakes” [P7.B] and errors of 
transcribing as a result of “drug re-writes” [P4.B]—the need to re-write a drug chart onto 
another as a result of the limited administration capacity of the chart on paper.  Pharmacists 
and physicians no longer needed to review prescriptions for these errors, which formed part 
of their routine tasks when working in paper-based process.  However, pharmacists 
reported these had been replaced by a “completely different error set” [P16.G] that they 
would actively and routinely monitor for.  For example, GSTFT uses multiple prescribing 
systems; ICU use a different system (CareVue®) compared to the rest of the hospital 
(MedChart®) and a separate system was in place to generate all prescriptions for patient 
discharge (iSoft®).  As patients transition from ICU to another ward (“step down care”) or 
vice versa (“step up care”), medicines need to be transcribed from one system to another.  
Both pharmacists and physicians were mindful that this introduced a new type of 
transcribing error at the interfaces of care: 
 
“Even within this Trust, there are different systems and it’s the interface between the 
systems that has the most frequent problems.  For me I have to deal more and more with 
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the step down medications than I did when most of the wards were operated on paper 
charts.” [D11.G] 
 
For the pharmacist, the presence of multiple CPOE systems changed the focus of their initial 
prescription review, with part of this process now dedicated to checking for transcribing 
errors.  This added to their workload, leaving less time to review and make 
recommendations to optimise treatment regimens. 
 
“[…] On critical care anyway, I do a lot more medicines optimisation trying to make sure 
patients are on the right doses. What I found working in other areas, you’re doing the 
step-down check, it’s all error checking. Then you’re doing the discharge and it’s error 
checking. And then you might get to do some medicines optimisation somewhere in-
between that role“ [P16.G].  
 
The use of multiple systems also increased the physicians’ workload, as they needed to 
replicate prescriptions for patients at transfer.  A physician described the inability for 
systems to “talk to each other” as a “fundamental safety problem” [D10.G] when stepping 
up or down patient care from the ICU.   
 
Errors of transcribing at the transition of care were not raised as a problem at UHBFT, where 
a single CPOE system was in use.  This removed the opportunity for such errors to occur and 
the need for pharmacists to routinely review for their presence.  Nevertheless, in contrast to 
GSTFT, transcribing issues were raised at UHBFT in relation to the use of paper medical 
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notes along-side CPOE systems, although arguably this issue would still exist in paper 
prescribing processes:  
 
“I think quite, well not quite often, but sometimes I will look at the clerking and their 
clerking is perfect, but when you look at PICS, they’ve then made the mistake when 
they’ve gone to put it on PICS” [P1.B]. 
 
The difference between the two sites highlights the importance of interoperability between 
health information systems—particularly in a single site—and how this can impact on both 
workload and the type of tasks staff need to perform.   
 
Errors of omission were still reported to occur in both hospitals, possibly driven by the lack 
of interoperability with community CPOE systems.  As such, pharmacists continued to 
routinely review prescriptions for the presence of these errors.  At both sites, pharmacists 
are able to ‘propose’ prescriptions for a physician (i.e. of the omitted medicine), to generate 
the order for their authorisation.  This task, now performed routinely as part of the 
prescription review process with CPOE, would not take place in the paper-based 






8.4.2.2 Interpersonal Communication 
Remote access to information 
The ability to access patient and prescribing information remotely via the CPOE system was 
beneficial for both pharmacists and physicians.  Time saving was raised as a particular 
benefit, since remote working could be used to review more patients in a defined or finite 
period of time, such as at weekends.  Some pharmacists also used remote working to 
improve their efficiency, such as to “[…] collate information, look at patients, [and] see what 
needs doing” [P6.B] prior to attending the ward.  Although the ease of access to information 
has the potential to encourage regular remote working away from clinical environments 
such as the wards, this was not apparent from the data.  On the contrary, pharmacists were 
aware that working remotely could have a negative impact on interactions with patients, 
relatives of patients and physicians and so chose to avoid this where possible.   
 
When pharmacists worked in the dispensary, they are remote from patients and staff.  In 
this environment, pharmacists found it harder to make decisions during their clinical review 
of prescriptions without knowledge of the patient, or being able to speak to the patient 
about their medicines.  At UHBFT, the use of paper medical notes made remote decision-
making even harder, since context could not be easily gained from the CPOE system about 
what decisions had been made during the admission and why. 
 
Physicians reported that pharmacists were visible on the wards and when in contact and 
communicating, a familiarity between the two professions was observed at UHBFT.  
Physicians acknowledged the value of having a, “stable pharmacist on the ward” [D7.B] and 
being able to, “access everything to do with pharmacy through that one person” [D5.B], 
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reporting that tasks could be completed in a, “more timely” [D6.B] manner when they knew 
who to talk to.  This provides further evidence that the ability to work remotely has not 
contributed to actual remote working and that interpersonal interaction is important to gain 
familiarity and build working relationships.  
 
Clinical Decision Support 
Many CPOE systems provide CDS to guide practitioners through the various stages of the 
medication process and to improve clinical decision-making.  This can vary in complexity, 
from being able to provide access to online resources, to more complex active support that 
can alert practitioners to inappropriate or sub-optimal prescriptions.  The CPOE systems in 
use at UHBFT and GSTFT provide CDS at the point of prescribing.  In both sites, the 
physicians reported that the technology reduced the need to ask as many clinical questions 
of the pharmacist. 
 
“I think from that perspective we probably have to approach the pharmacist less in 
terms of infusion concentrations and drug doses because most things are integrated 
into the system. So that makes things easier. I don’t know if it makes us make errors 
less frequently”. [D11.G]  
 
Pharmacists were still observed to receive clinical queries on the wards and in the 
dispensary via the telephone, particularly relating to the monitoring and review of 
medicines (e.g. when to take samples to monitor drug concentrations).  These interactions 




The CDS was found to impact on both the frequency and type of interactions that were 
initiated by the pharmacist to the physician.  Although it was acknowledged across both 
sites that using CPOE had removed some types of prescribing errors, the technology was 
found to increase the likelihood of certain error types in the prescribing process that would 
require intervention.  Many CPOE systems have the capability to propose order sets when a 
medicine is selected from a dictionary.  This decision support provides the prescribing 
practitioner with the, “full set of information required for a prescription” (NHS England, 
2015) to generate a complete prescription, such as the dose, strength, route and frequency.  
This would ordinarily exist for commonly prescribed medicines such as paracetamol or 
perhaps those considered high-risk where a deviation from the standard that may put the 
patient at risk of harm.  The CDS is designed to promote accurate prescribing and may also 
allow prescriptions to be generated in a timelier manner.  However, an unintended 
consequence of these ‘default’ orders has been highlighted, which is the generation of an 
inaccurate prescription through the inadvertent acceptance of the proposed order not 
intended by the prescriber.  Physicians at UHBFT quoted that, “[…] Easily 30–40% of notes 
[review messages] are about doses that are different to the standard PICS dose” [D5.B].  
Both professional groups could recount medicines or types of medicines that most likely 
contained an error as a result of these order sets, with examples listed such as, “calcium 
tablets, like Adcal® or Adcal D3®” [D3.B], “statins” [D4.B] and “furosemide” [P4.B].  This type 
of error was reported as a particular problem on the Admissions wards and so their value in 




“Where the defaults are useful is probably not when you’re taking a drug history 
because you don’t want somebody to just input the usual dose range, you want it to 
be specific for the patient.” [P10.B] 
 
Although interventions relating to default orders were not directly observed on the Medical 
Admissions ward at UHBFT, they were seen to occur on other wards and also by pharmacists 
in the dispensary.  For example, a pharmacist in the dispensary bleeped and subsequently 
spoke to a physician about a prescription for atorvastatin 10 mg for a patient who usually 
takes 40 mg according to the drug history on PICS.  In this case, the physician confirmed that 
the dose prescribed was an error and authorised that the pharmacist could change this on 
their behalf.  On questioning, the pharmacist confirmed that 10 mg was the default dose 
proposed by the system. 
 
Despite awareness that default orders had the potential to provoke certain prescribing 
errors and impact on workload to rectify these, the benefit of the CDS was also emphasised 
in helping to reduce higher risk prescribing errors.  Physicians were particularly grateful that 
it helped prevent, “[…] huge doses or tiny doses of an inappropriate drug” [D5.B] and 
reduced the risk of ‘slips’ in the prescribing process—where their intentions are appropriate 
but actions are not executed as planned (Reason, 1990; p55)—as a result of external factors 
such as tiredness.  Physicians also found the CDS beneficial in specialist areas of medicine, 
where, “defaults are quite useful because they’re generally tailored” [P10.B].   
 
It did not become clear during the study why order sets were inaccurately selected and 
generated by physicians, although poor access to medication-related information and the 
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pressure of time were suggested by one pharmacist as potential factors.  The former was 
emphasised by a physician who stated that if the default order did not exist within the CPOE 
system and the exact dosing regimen for a patient was unknown at the point of prescribing, 
they would likely prescribe the most common dose anyway. 
 
“[…] I guess if I don’t know, then I would just pick a common dose and wait for 
someone to correct me at day time hours…Probably still going to go for 2.5 mg of 
bisoprolol or 62.5 micrograms of digoxin, which as you say, may well be wrong, but 
that’s probably the same dose I’m going to prescribe with or without the clinical 
support system.” [D1.B] 
 
Since all elements of a prescription order within a CPOE must be complete for it to be 
generated—compared to paper prescriptions where an order can be partially completed 
until further information is available—errors generated as a result of default orders may, in 
part, also occur as a result of system restrictions.   
 
A second type of error reported to occur as a direct result of CDS was that of ‘selection’, 
where the wrong medicine or wrong combination of medicine/formulation or device is 
selected from a drug dictionary, often because the first on the list is selected.  Although 
these errors did not occur to the same extent as default orders, they still required 
intervention from the pharmacist to rectify the prescription. 
 
“Aspirin dispersible is the first thing that comes up, if they’re on EC [enteric coated] 
because they’re on a blister pack, they won’t change that, it will be dispersible […] 
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and Seretide®, the first thing is Accuhaler because it is alphabetical, so they’ll just 
leave it as Accuhaler” [P5.B]. 
 
The errors found to occur as a result of CDS increased the need for pharmacists to intervene 
and initiate a communication with the physician to rectify the prescription.  Overall, it was 
found to increase interpersonal interactions between the two professions.  The inability for 
pharmacists to be able to amend and tidy up prescriptions within the CPOE system further 
contributed to the need to intervene directly or indirectly with the physician (section 
8.4.2.1: Professional restrictions).   
 
Length of interactions 
The electronic documentation of requests at UHBFT meant that pharmacists did not need to 
explain every request directly to the physician, but rather they could direct the physician to 
a specific patient (or bed number) and ask for the messages to be reviewed accordingly. 
 
“Yes, it’s quite good that you can say ‘go and see beds 9, 10 and things’ but you don’t 
have to be specific about every single thing, you just say ‘bed 13 has got four review 
notes on, go and read them’, unless it’s something really serious.” [P1.B] 
 
This process of communication was only used by pharmacists for requests that they 
perceived to be low risk and therefore lower priority.  Physicians at UHBFT reported that 
being directed to patients to read requests was beneficial for their time, rather than “stood 
over” [D5.B] whilst the changes were made or the pharmacist needing to wait whilst they 
wrote the information down.  In contrast, at GSTFT where messages could not be assigned 
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to individual prescription orders within the CPOE system, requests were communicated and 
discussed with the physician and if not completed straight away, were added to the their 
task list.  
 
Irrespective of the ability to assign a message to a prescription, pharmacists at both sites 
adopted a workflow that intentionally reduced the number of times they needed to interact 
with the physician.  They would routinely collate the lower priority tasks to communicate to 
the physician all at the same time at the end of their shift on the ward.  Pharmacists 
described that they did not want to, “pester them constantly” [P2.B] and at UHBFT assigned 
review messages to avoid having to, “nag someone about it” [P3.B], “follow them” [P4.B] or 
avoid “biting at someone’s ear” [P3.B].  This demonstrated an awareness of how frequent 
interruptions may impact on the physicians’ workflow and potential workload.  The 
increased need for the pharmacist to intervene as a direct result of errors generated 
through the use of decision support as well as the inability to fine tune prescriptions, may 
further encourage them to adopt a workflow that minimises interruptions.  Pharmacists 
used analogies such as the, “school teacher” [P1.B] and the “drug police” [P9.B] to describe 
how physicians may perceive them—feelings likely intensified by the number of low-risk 
errors they need to communicate that previously did not exist in paper-based processes. 
 
“But I bet from your point of view, you’re like ‘for god’s sake, all the pharmacists can 





Accountability and responsibility 
Pharmacists at UHBFT not only used the review message function to communicate 
information indirectly to the physician, but also as a formal documentation of their requests 
and discussions to be held within the patient’s clinical record.  This was perceived to be 
beneficial for the accountability of the pharmacist, particularly compared to interventions 
made solely through, “word of mouth” [P2.B] where documentation of the intervention or 
interaction may not exist at all.  It was also described as superior to paper notes used in 
paper-based prescribing processes, where intervention messages may not be filed in the 
medical notes or go missing: 
 
“You know you have told them but it’s also documented somewhere for definite that 
you told them to review something and they can’t say ‘oh you didn’t tell us about 
this’ so it’s kind of good for us from that communication point of view, that we’ve got 
a trail to say that we did tell them about something” [P1.B]. 
 
The written (typed up) information in a review message was preferred by the physicians, as 
it was perceived to reduce the risk of errors through misinterpretation or misremembering 
information that was relayed verbally.   
 
“There are three drugs they need to change by the end of this ward round and I’ll 
probably forget one of them or I can’t remember whether she said 15 or 50 [mg]. So 




The review message communication also meant that physicians did not need to rely on their 
written task lists or handover sheets transcribed from earlier conversations with the 
pharmacist, which were reported by one physician as, “notoriously unreliable” [D5.B] and 
often, “adulterated by other clinicians” [D5.B].  The documentation of the review messages 
was therefore also used as a, “safety net” [P1.B] by pharmacists to document information or 
to back-up information relayed verbally to the physician and to provide more detailed 
information. 
 
Although most transactions within the CPOE system are visible to other users, or can be 
captured from a large audit database, there is no way of identifying if a member of the 
prescribing team has read a review message (e.g. such as with a “seen by” or “read by” 
annotation).   
 
“PICS tells you who has changed a prescription as well and deleted one which is good. 
It would be nice if it perhaps showed if someone’s read a review note just so there’s 
some sort of accountability” [P3.B]. 
 
A lack of accountability in this case may impact on the physician’s motivation to see the 
request through and in a timely manner.  In addition, since the review message is assigned 
to a prescription and not directed to a named person or team, physicians reported that this 
implied a, “broad team responsibility” [D2.B].  The inability to assign responsibility for a 
request means that a single person or team does not need to take, “ownership of it” [D2.B], 
which can lead to an assumption that someone else in the team will pick it up who may be 
better informed to deal with it.  Should a physician choose to amend a prescription or 
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generate a new prescription, the ability to determine accountability for these changes was 
perceived as beneficial.  However as all actions are either visible or can be captured from a 
large audit database, it was suggested that maybe, “people are conscious of ‘oh this might 
come back to me’, you know, ‘my name is against this forever’, so maybe that’s why doctors 
are more scared to action our notes [messages] perhaps” [P2.B].  The lack of accountability 
to identify when messages have been read and by whom, in combination with no assigned 
responsibility for dealing with the requests, means that messages can be ignored without 
repercussion.  This was perceived to impact on the overall effectiveness of the electronic 
communication, leading to either no action or lack of a timely action. 
 
Coordinating work 
The documentation of review messages facilitated communication between the pharmacists 
at UHBFT and was used as a means of, “handing over to other people” [P2.B] to coordinate 
care.  First, as the messages are accessible to all users of the CPOE system, pharmacists 
were reassured that any outstanding requests would be followed up by another pharmacist 
where necessary (e.g. if the patient is moved to a different ward).  The review message icon 
on screen made requests visible and accessible, without which “follow-up would be harder” 
[P1.B].  Second, the review message helped pharmacists identify which patients had been 
reviewed, facilitating prioritisation of work and avoiding duplication, which would be “time 
consuming” [P5.B].  Pharmacists were observed to read messages as part of their routine 
workflow on PICS, hovering over or clicking on any existing review message icons to inform 
their tasks.  On occasion, pharmacists were also seen to sign these off if the request had 
been actioned or dealt with, which removed the icon from the screen and the prompt to 
follow-up.  This suggests that the documentation of review messages is used for more than 
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simply communicating information to physicians, but also to display activities and actions to 
coordinate care amongst the pharmacy team.   
 
Pharmacists at UHBFT also reported to document information using the ‘pharmacy 
message’ function within the CPOE system.  Here, they would write down the confirmed 
medication history of the patient (as there is currently no dedicated function within the 
system to do so) and document any medication-related, “interventions for audit purposes” 
[P5.B].  Despite an element of duplication, this was also perceived as beneficial to 
coordinate work between the pharmacists.  Not only were all the ward pharmacists 
observed to look at the pharmacy messages to inform their review of a patients’ 
prescription, but they were also used by pharmacists in the dispensary to verify 
prescriptions that needed to be supplied.  The pharmacy messages (as the name would 
suggest) were not perceived to be a pharmacist-physician communications and although 
some pharmacists “taught” [P5.B] physicians to look at it in an attempt to coordinate care, 
this practice was not consistent, which was confirmed by the physicians.  The fact that 
technicians can also write in the pharmacy messages to coordinate work with the 
pharmacist may contribute to its hidden use, as “there could be a potential for error” [P2.B]. 
If the information was used by a physician before had been verified by a pharmacist.  With 
this in mind, it is not surprising that the need for a dedicated “tab” [P10.B] to document the 





8.4.2.4 Flow of information 
Pharmacist as sender of information 
Pharmacists modified both the modality and timing of communication based on their 
perception of the urgency of the request and therefore the associated risk to the patient.  
Pharmacists consistently reported that direct and immediate communication would be used 
to communicate with the physician for urgent cases and that multiple forms of 
communication would be used to ensure the information was exchanged in a timely manner 
to ensure quick action. 
 
“If it’s urgent, we would speak to a doctor. If they’re not there, you would phone, you 
would email and make sure they get a response back to whatever. You would not go 
home that day without making sure... you know you’ve communicated with the 
doctor about something urgent” [P9.B]. 
 
This was confirmed by the physicians, who agreed that direct communication was always 
used and reiterated that an extra step was needed for these types of communication, such 
as, “old fashioned bleeping and talking to each other” [D4.B].  Remote working, such as 
when covering the dispensary, made contacting the physician more difficult at times and 
was observed to be time consuming for the pharmacist when bleeps were not answered 
and alternative means of contact needed to be sought.  This process was not perceived to 
be any different to how pharmacists would work in paper prescribing environments, except 
that identifying who to contact was easier via the CPOE system.  Initiating direct 
communication on the wards was far easier in comparison, although there were times when 
this was observed to be harder, such as in the afternoon when junior physicians were in 
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teaching and when physicians need to move between wards to see patients who were 
outliers.  All these tasks were made more difficult for new rotational pharmacists who were 
unfamiliar with the setting and teams. 
 
Pharmacists at UHBFT reported that the review message would never be used as a single 
modality of communication for urgent requests, but that information may still be 
documented in the review message for accountability and to avoid misinterpretation of the 
request at the point of prescribing (see 8.4.2.3, Accountability and responsibility): 
 
“Yeah, but you could say ‘I’ve put a review note on that’, like you’d contact them 
straight away. Because over the phone it might get confusing, they might get the 
wrong dose over the phone or something, whereas if it’s written down, it’s more 
solid” [P4.B]. 
 
Avoiding the review message for urgent requests may emphasise the pharmacists’ lack of 
confidence in this modality of communication to alert physicians to requests that require 
immediate attention.  Confidence in the effectiveness of system alerts was also highlighted 
by the pharmacists’ approach to inform the physician about omitted medicines, which may 
or may not be regarded as urgent depending on the medicine.  The pharmacists at UHBFT 
would not only propose the medicine for the physician, which would create a “flashing” 
alert tab on a patient’s profile, but would also issue a repeat communication by assigning a 
review message to the first available prescription on a patient’s prescription profile to direct 
the physician to look at the ‘proposed’ flashing medicines tab.  The repeat communication 
suggests that the pharmacists were aware of the potential for alerts to be overlooked and as 
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such adopted a, “workaround” [P10.B] to reinforce their request, since there was no other 
means of communicating information about a medicine that does not exist on a patient’s 
profile. 
 
Pharmacists at both sites adopted the same workflow for communicating non-urgent 
requests with the physician.  The details of each request would be written down as a 
personal prompt to, “pick it all up at the end of the day” [P14.G] with the physician and 
would be communicated at the same time at the end of their shift on the ward (see 8.4.2.2, 
Length of interactions).  Although it was not clear from the focus group data how these were 
documented as reminders for the pharmacist to follow-up, observation at UHBFT showed 
that this was always conducted on paper.  At UHBFT, the requests were also documented as 
a review message, which as discussed, served as an additional prompt for the pharmacist to 
help coordinate care, document accountability and provide more detailed information for 
clarity.   
 
Since the action of non-urgent requests in both sites was dependent on the verbal handover 
and prompt from the pharmacist, the amendments to prescriptions likely occurred at similar 
times—towards the end of the pharmacists shift on a ward when these were all 
communicated.  This may suggest that the electronic communication of requests has no 
impact on the time to action.  The only difference being that the pharmacists at UHBFT have 





Physicians as the recipients of information 
The CPOE system at UHBFT does not actively alert physicians when a review message is 
assigned by a pharmacist, rather it passively highlights the presence of a message with an 
icon on a patient’s prescription.  The physicians’ receipt of a message is influenced by their 
awareness of the presence of a message on a patient’s profile, which was found to be 
dependent on: 1) being prompted by the pharmacist; 2) the visibility of the message on the 
screen; and, 3) the physician’s perception of what the messages would request based on 
previous experience of the content of these.   
 
First and as discussed above, pharmacists at UHBFT prompt physicians to read messages on 
screen to ensure the information is communicated effectively.  Since physicians are aware 
that this will largely take place during the day and, that pharmacists will inform them 
directly of urgent cases, there is little motivation to read messages without direction to do 
so.  One physician admitted that when the pharmacist was not around on a particular day, 
they, “don’t review the drugs properly or it happens sporadically” [D5.B].  This was reported 
to be particularly true at weekends when pharmacists were not ward-based to follow-up 
requests directly with the physician. 
 
“So any review notes you put on, sort of late on a Friday are not conveyed to a doctor 
and will get missed until Monday. If there’s a patient you have to see, if you’re 
worried about them you might look at it [the review message], but at the same time 
since it’s probably going to be “Please change this Adcal prescription”, you may well 
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not do, because I’m interested in the fact that this patient’s very septic. I’m not 
bothered about their simvastatin or whatever” [D8.B].  
 
“I generally haven’t come across a review note [message] that cannot wait a 
weekend. I mean they’re generally relating to medications which it’s just not a 
disaster if you have missed two days” [D1.B]. 
 
At UHBFT, the presence of a review message is identified by a small grey ‘R’ icon on an 
individual prescription order on a patient’s profile (see 5.1.2).  Pharmacists emphasised that 
the review messages may not be highly visible and that this is likely to contribute to the 
overall effectiveness of the communication being received.  Both professionals used words 
such as “subtle” [D8.B] and “little” [D8, P3.B] to describe the icon, indicative that the 
visibility is not perceived as optimal.  The use of the letter ‘R’ in the design was also 
questioned since physicians may not be aware that this refers to ‘Review’. 
 
“I’m just thinking about the R, if it said ‘review’ on it, maybe they’d be more inclined 
to actually look into it, because R could mean anything. They don’t necessarily know 
it means you need to review this medication” [P7.B]. 
 
The visibility of the review message was compared to the, “sticky note” [P10.B] that would 
be placed on a drug chart in a paper-based prescribing environment—described as being 
more “glaringly obvious” [P6.B] for the physician.  The disadvantage of these notes was also 
raised though, with there being a tendency for the notes to physically, “fall off” [D5.B], as 
well as the inability to audit the process to, “measure it appropriately” [D7.B].  
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Finally, the inability to ascertain the priority of a request was raised as an issue, since all 
review message icons are visibly the same.  Pharmacists use the review message to 
communicate and document information on a range of themes—some simply providing 
supporting information and others requesting an action such as an amendment to a dosing 
regimen (see section 6.3.3.11).  Irrespective of the topic of the request, the physician is 
required to click onto each message icon to read the information, determine a priority and 
act accordingly.  Although suggestions were made about really urgent messages being 
designed to have a clear priority, this was considered in the context of other interruptive 
“flashing” [D9.B, D7.B] alerts within the CPOE system and how these already had an impact 
on workload and workflow.  Considering that pharmacists use the review message function 
to facilitate handover with others (see 8.4.2.3, Coordinate work), document information and 
discussions for accountability (see 8.4.2.3, Accountability and responsibility) and only 
communicate non-urgent requests, it is understandable that with repeated exposure to 
messages over time and no means of ascertaining a priority, the physicians’ response to the 
messages wanes. 
 
“The more messages there are, the less likely they are to be actioned and if the first 
one you click on is rubbish, how likely is it that you’re going to go down the list?” 
[D7.B]  
 
Pharmacists acknowledged that numerous review messages assigned to a patient’s profile 
could have a negative impact on overall effectiveness of the function of communication, 
giving reason for the physician to, “glaze over them” [P5.B], or causing them to feel 
overwhelmed.   
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Closing the communication  
Pharmacists and physicians at both study sites emphasised the importance of face-to-face 
communication and that a, “two-way system” [D9.B] was more beneficial for conversation 
and discussion.  Pharmacists at GSTFT were more inclined to handover medication-related 
requests directly, as there was no means of communicating a written message and assigning 
this directly to a prescription.  The non-urgent requests could be rectified there and then or 
potentially noted down by the physician for attention at a later date.  This approach 
increased the opportunity for discussion and the length of the interaction (see 8.4.2.2, 
Length of interactions).  Importantly, the pharmacist (as the sender of the information) also 
gained immediate feedback on their request, allowing the communication, in the most part, 
to be closed.  In contrast, at UHBFT, the directing of the physician to review named patients 
or bed numbers was found to impact on the pharmacist in two ways.  First, as the sender of 
the information, the pharmacist was left in a position of having to wait for their request to 
be actioned and monitor when this has been completed.  Second, where no action was 
perceived to have occurred on follow-up, the pharmacist would feel ignored and “deflated” 
as a result [P1.B].  
 
“But yeah, it’s a bit deflating at times, going back to what, it’s just like ‘day 3, still not 
done it’, so you feel like you’re in a way wasting your time, because you’re not seeing 
as many of the new patients because you’re reminding them again about the ten 




“You know, it takes such a long time sometimes to do a review note. It does. It took 
ages getting this drug history and at the end of it you leave these reviews. When 
nothing is done about it, you’re like ‘What was the point of me wasting my time 
doing this when you’re not going to do anything about it” [P7.B]. 
 
The uncertainty as to whether requests have been considered is further exaggerated by the 
physicians’ poor use of the ‘sign-off’ function within the system.  Sign-off is intended to be 
used by physicians to remove the ‘R’ icon from a prescription when the request has been 
dealt with or the information considered (see 5.1.2).  Pharmacists reported that, “only a few 
doctors” [P5.B] actually signed-off messages and found that they would sometimes be 
signed-off, “to get rid of it [from the screen]” [P4.B], but not do anything about it.  This was 
certainly observed on a General Medicine ward, with one pharmacist suggesting that the 
poor use of the sign-off function may reflect the physicians’ knowledge of how it should be 
used (i.e. as a means to acknowledge the request and close the communication).  However, 
the poor use of the sign-off function may also be intentional, as a result of a lack of 
knowledge about the system as a clinical patient record (see 8.4.2.1, Technical expertise; 
8.4.2.3, Accountability and responsibility).  Concern was raised by some physicians about the 
availability of the documented messages if they were signed-off, with one physician 
describing the sign-off as messages ,“falling off” [D2.B] the system and potentially getting 
lost. 
 
For the physician as the recipient of the information, the review message function does not 
enable two-way communication, as either a free-text or a tick box to state the outcome of 
the request.  As such, they are unable to provide feedback or a rationale back to the 
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pharmacist and close the communication.  Physicians reported this as difficult, 
acknowledging (in the uni-professional focus group) that this can appear that the 
information has been ignored and that they, “can’t be bothered to process” [D4.B] the 
request.  Physicians reported a desire to provide feedback and since this was not possible 
within the system, adopted a workaround to enable this. 
 
“I will quite often, when I sign-off a drug and I think there might be some question as 
to why I have changed or signed-off, I will put a P note saying ‘as per pharmacist 
review notes’... because then when the next clinician comes in they won’t necessarily 
immediately know why and they won’t know how to get to the old review notes and 
if there’s a P note there it might be more obvious to them.” [D5.B] 
 
8.4.2.5 Decision-making 
Awareness of context 
Pharmacists and physicians reported difficulties gathering information relating to the 
context of prescribing decisions that had already taken place.  The CPOE systems in both 
sites were described as effective in providing the information needed to determine ‘what’ 
had changed over time and was described as a, “massive improvement” [D1.B] compared to 
paper drug charts, which were difficult because they only last a finite period of time (i.e. 2–4 
weeks).  However, the reasons ‘why’ often prompted a need to intervene with the physician 




“I think that’s why we end up putting a lot more review notes on as well. Because I 
know I have chased a lot of doctors about when inhalers have been switched and I 
know now that obviously on one ward I covered that yeah, they have probably done 
this intentionally, but because there’s nothing written down, you still have to go and 
ask and leave a review note. So I think that kind of wastes everyone’s time a little bit 
as well. So I think the documentation in the note, if that was clear it would be useful.” 
[P8.B] 
 
 On reading the review messages from pharmacists, physicians at UHBFT reported their 
difficulty in determining whether prescriptions for a patient were generated with intention, 
or whether errors were actually present.  This uncertainty was reported to stem from poor 
or no documentation of medication-related changes in the medical notes, which had the 
potential to lead to uninformed changes to be made to prescriptions and also contribute to 
delays in actioning requests. 
 
“By the time they get to the ward they, it does cross your mind that maybe this 
prescribing error was on purpose... maybe it was changed deliberately in CDU 
[Clinical Decision Unit] in some way and you know you look through the notes and 
you’ve got no real way of telling, so I’ll change it on the assumption that it was mis-
prescribed for whatever reason, maybe just because the PICS default or something 
else […]” [D8.B]. 
 
Although some physicians reported that they documented information in the medical notes, 
it was also acknowledged that this was not consistent practice.  The use of paper medical 
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notes alongside CPOE, described as a, “half-way position” [D5.B], was believed to be a 
contributing factor to this, since the notes were not present in the workflow when 
interacting with the CPOE system.  As further evidence of this, the documentation of 
medication-related changes was not raised as an issue by the pharmacists working within 
the ICU setting at GSTFT where both the CPOE and electronic notes are available within the 
same system.  Here, the prescribing pharmacists working within the ICU setting explained 
that any changes they made would ordinarily be backed up with a discussion—a routine 
confirmed to be the case by a physician— with exception of “obvious” or “straightforward” 
amendments to prescriptions that may just be documented in the electronic notes. 
 
In an attempt to provide context, some (but not all) physicians and prescribing pharmacists 
at UHBFT adopted a workaround to communicate a rationale for their prescription changes, 
making them visible to others with using the P-note previously described. 
 
“[…] I occasionally use P-notes myself if I pause something, so if I pause something I 
put a P-note saying why I’ve paused it because otherwise two weeks later it’s still 
paused and no one knows why. But they’ve got to scroll through the notes if it’s not 
clear.”  [D8.B] 
 
This particular workaround has a clear disadvantage when there is a need to communicate a 
rationale relating to a prescription that has been stopped and so is not present on a 
patient’s prescription profile to assign a P-note.  Interestingly the workaround to provide 
the information was consistently reported to occur within the CPOE environment and not in 
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the medical notes separate to the system.  This may suggest a preference for all the 
information to be held within a single place—within the CPOE system.  
 
It was unclear whether pharmacists and physicians faced the same difficulties in the paper 
prescribing environment.  Given that fewer communications may be needed to determine 
‘what’ has changed over time, the overall frequency of communications may be lower or no 
different.  However, the strong desire for a, “timeline” [D2.B] of medication-related changes 
and facility for, “highlighting anything that’s happened to that drug in the history” [D5.B] 
emphasises the importance of an audit trail to access appropriate and relevant information 
and the potential for this to have a positive impact on workload.   
 
Responsibility 
For more junior physicians, the act of generating a prescription is often under the direction 
of a more senior member of the team.  Physicians described that prescribing at the request 
of another physician was hard at times, as they would need to generate prescriptions that 
they were not necessarily comfortable with.  The confidence to amend these prescriptions 
was suggested by pharmacists as a potential reason why requests were not actioned—
unprompted by the physicians and raised in the uni-professional focus group. 
 
“[…] especially if they’ve been on a ward round with a consultant. They’re a bit scared 




The responsibility for a prescription that originated under the direction of someone else, 
whether new or amended, was a concern for the more junior physicians.  The role of the 
decision-maker and the person generating the actual prescription initiated discussion about 
the need for review messages to be directed at a named person more appropriate to deal 
with the request (i.e. the decision-maker or consultant with overriding responsibility).  
However, this was also contested since a facility to direct a message to a particular person 
would mean that the request is no longer visible for everyone interacting with PICS to see, 
which may further reduce the likelihood that the message will be seen and a timely action 
taken.  A function in the CPOE system to highlight when prescriptions were recommended 
by someone else was also suggested, such as a, “third party action”. 
 
“I wish there was a third party action. I often find that consultants or registrars 
prescribe drugs that I’m not comfortable prescribing. I’m logged into PICS or they’ll 
say ‘Prescribe that’ and I’m logged in and I’m like ‘OK...’ [nervously]” [D5.B]. 
 
Physicians reported the use of the P-note as a workaround to document where the direction 
for a prescription originated from, such as with, “prescribed at the request of…” [D2.B] 
annotated.  As previously discussed, the physician would also provide an annotation when 
changes had been made at the request of the pharmacist: (see section 8.4.2.4: Closing the 
communication).  It was unclear whether this was conducted to remove responsibility from 
the prescriber back to the decision-maker or the pharmacist, or to facilitate the direction of 




Knowledge of the patient 
Knowledge of the patient was an important factor for physicians when making prescribing 
decisions at the request of a pharmacist.  Decision-making was found to be particularly 
affected during on-call hours, such as overnight or at weekends, where knowledge of all the 
patients potentially under a physician’s care was not possible.  First, in this situation, 
physicians were wary about amending prescriptions that were generated by another team, 
rationalising that it was not their, “duty” [D2.B] to respond to requests and these were best 
left to someone who, “might know something more about the patient” [D3.B].   
 
“I mean there are occasions when, usually ward cover situations, where you’re just 
sort of covering an acute out-of-hour episode and prescriptions relating to their sort 
of chronic medications, I tend to leave them. I don’t feel that I am in a position to say 
‘why is this amlodipine 5 mg rather than 10 [mg] when he has been taking 10’. There 
might be a very good reason for it. I don’t feel I’m in a position to know the patient to 
sign-off that note [review message] in which case I’ll leave it”. [D1.B] 
 
Second, taking responsibility for these requests was difficult given the lack of context of 
medication-related decisions documented within the CPOE system and medical notes, 
which may be considered even more important for informing physicians about patients not 
known to them.  The pressures of on-call, “fire-fighting the sick ones” [D3.B], explained why 
review messages were not prioritised by physicians, except in situations where the acute 
presentation of a patient may be medication-related.  The fact that review messages are 
only used by pharmacists to communicate non-urgent requests [see section 8.4.2.4, 
Pharmacist as sender of information] and that there is no way of identifying the priority of a 
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message [see section 8.4.2.4, Physicians as the recipient of information], are both likely to 
contribute to the reduced response of physicians during on-call hours at UHBFT. 
 
8.5 Discussion 
Understanding the unintended and unanticipated effects of new technology allows those 
individuals and teams working in the delivery of care to be in a unique position—one of 
power to plan for the change and adapt accordingly.  The unanticipated effects become 
anticipated, which can promote a more proactive approach to patient safety.  In this study, 
the use of CPOE in the hospital environment was found to impact on the communication 
load of pharmacists, which in turn had a direct impact on the workload of the physician.  
The effectiveness of communications sent electronically (asynchronously) via the CPOE 
system were found to be largely affected by their design.  An asynchronous approach to 
communication was also found to have a potential impact on interpersonal interactions and 
coordinated care. 
 
8.5.1 Communication load 
From the physicians’ perspective, the demand for technical guidance with the CPOE system 
increased interpersonal communication, but the number of clinical queries were perceived 
to fall.  From the pharmacists’ perspective, the need to communicate with the physician had 
increased owing to the loss of power to amend prescriptions in an electronic format; the 
occurrence of prescribing errors as a result of interactions with CDS (e.g. the unintended 
selection of default order sets) and interoperable systems; and the difficulty ascertaining 




Figure 8.2 – Impact of CPOE on pharmacists’ communication load
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In the hospital setting, physicians were found to rely on pharmacists to provide technical 
expertise when they needed assistance with medication-related tasks within the CPOE 
system.  This was found to continue in an environment with a well-established CPOE system 
in use and increased when physicians were new to the hospital and unfamiliar with the 
technology.  Pharmacists associated the increased workload from technical queries to gaps 
in the physicians’ knowledge of the system and the time allocated to training.  The informal 
role of technical expert assumed by the physician and subsequently adopted by the 
pharmacist has previously been described by McMullen et al (2015), who found that 
pharmacists became, “informal trainers” of systems post-implementation of CPOE and 
spent time showing physicians how to efficiently use the system (McMullen et al., 2015).  Of 
course, the demands for technical expertise are likely to be greater immediately after the 
implementation of a system but in contrast to the findings in this study, McMullen et al 
(2015) also found that the support demanded from physicians, “diminished with time” and 
experience.  This reduction in requests may be a reflection of the depth of training provided 
to practitioners pre-implementation compared to the on-going training provided long-term 
(i.e. during the induction of new staff).  
 
Training has been identified as a key consideration for successful implementation and on-
going use of CPOE (Cresswell et al., 2013b; Joint Commission, 2014) and although a range of 
training methods are used by hospitals to deliver this to staff (Brown et al., 2017), 
interprofessional training has not been identified as an approach.  It is part of the hospital 
pharmacists’ role to ensure that prescribers are, “supported in their everyday activities by 
readily-accessible information and guidance” (Royal Pharmaceutical Society, 2014; Standard 
5.1, p 15).  The continued demand for informal interprofessional education from the 
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pharmacists suggests that physicians find it beneficial and that pharmacists are generally 
well-placed and accessible to perform the task.  This ad hoc guidance is likely to fall over a 
weekend though, since ward-based pharmacy services are still rare in hospitals in England 
(Office of the Chief Pharmaceutical Officer, 2016).  A study to investigate socio-technical 
incidents occurring at UHBFT found that these occurred more frequently on a Sunday 
compared to the rest of the week (p<0.013) (Redwood et al., 2011), which may reflect the 
lack of informal training and support available at this time.  Informed by their own 
experience of the system and the types of queries received on a regular basis, pharmacists 
may be able to provide a greater depth of training, but further research is required to 
determine if this would be beneficial and how this should be formally embedded into 
organisations.    
 
Insufficient training can lead to sub-optimal use of systems—the use of the technology in a 
way that is not intended (i.e. workarounds) or underuse of system functions— which may 
increase the risk of error (Baysari et al., 2012; Mozaffar et al., 2017; Redwood et al., 2011).  
This was perceived to be a contributing factor for the sub-optimal use of some system 
functions at UHBFT, particularly those relating to the coordination of tasks.  Physicians’ 
inadequate use of the ‘sign-off’ function to indicate that a review message had been 
acknowledged, led to uncertainty for the pharmacist about whether a communication had 
been received.  As such, requests communicated via the review message often remained on 
their task list to follow-up, which added to their workload.  Sub-optimal use was not also 
raised by the physicians, which may reflect a lack of knowledge or poor awareness of how 
and why other professional groups interact with the system, the expectations of others and 
how to work with the system to coordinate work.  Cresswell et al (2013) recommend that 
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“the most effective training is tailored to the individual roles of users, without being too 
restrictive as this can undermine understanding of how the whole system functions”.  
Although this may be true in ensuring routine tasks can be completed in the system to 
deliver everyday care, it may not consider the use of the system in relation to 
interprofessional communication or how best to use system functions to coordinate care.  
Such knowledge of the system may only really be gained through interprofessional training, 
so that practitioners can develop skills together in the context of CPOE and, “learn with, 
from and about each other to improve collaboration and the quality of care” (Atkins, 2002).  
Knowledge of how others use the system may have the potential to reduce informal 
requests for guidance and reduce workload generated as a result of poor coordination of 
tasks.  
 
Pharmacists were found to assess the urgency of their requests for the physician and adjust 
their communication so that it was appropriate to the situation.  Significant requests that 
required prompt action were dealt with immediately and directly with the physician.  
However, for non-urgent requests, pharmacists favoured a workflow that minimised 
interruptions for the physician.  They were reported (and were observed) to collate non-
urgent requests and communicate all these to the physician at the end of the day (or their 
shift on the ward).  The analysis of a situation and “appropriate obtrusiveness” (Schmidt, 
2002) approach was perceived to be no different to how they would have worked in paper-
based environments.  This was found to be in contrast to some studies that show hospital 
work to be more task driven and dependent on interruptive communication to that these 
can be completed in a timely manner (Coiera & Tombs, 1998; Edwards et al., 2009; Popovici 
et al., 2015).  Based on this, pharmacists placed an emphasis on facilitating the workflow of 
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the physician, rather than removing tasks from their own workload and working memory.  
At UHBFT, with the capability to communicate requests asynchronously and electronically, 
pharmacists also adopted a modality of communication that could minimise the length of 
time of the interruption.  Interruptions that are unrelated to the task being completed can 
lead to multi-tasking (Edwards et al., 2009), impact on working memory (Coiera & Tombs, 
1998; Parker & Coiera, 2000) and shorten overall time spent on tasks (Mark et al., 2008; 
Westbrook et al., 2010).  The review message function enabled the pharmacist to 
communicate information indirectly—independent of the location and activity of the 
physician (Wu et al., 2013)—and removed the need for a detailed verbal hand-over of the 
request through directing physicians to review named patients or bed numbers at a time 
that was convenient for them.  In addition to this being beneficial for the physicians’ time 
and workflow, the written requests were preferred by the physicians as they did not need to 
rely on their working memory (Parker & Coiera, 2000),  and thus reducing the risk of 
information being misremembered or misinterpreted.  Although the desire to minimise the 
length of interruptions was conducted with the best intentions, it does have the potential to 
reduce opportunities for informal interaction (Harrison et al., 2007) and formal discussion, 
both of which are essential to gain context and to promote collaborative working practice.   
 
The non-interruptive workflow routinely adopted by pharmacists suggests that they are 
socially aware and sensitive to the activities or tasks being carried out by physicians, which 
may encourage them to engage at a more appropriate time to minimise interruptions 
(Bardram & Hansen, 2010; Heath et al., 2002).  Developing a social awareness is easier when 
working in close proximity to other healthcare professionals (such as on the ward).  The 
CPOE system enables remote access to information and often the capability for multiple 
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practitioners to access a single patient record at any one time.  It has been known for some 
time that this has the unintended potential to encourage remote working, causing 
practitioners to be spatially distributed from one another, which can reduce 
interprofessional interactions (Barber et al., 2007; Barber et al., 2006; Campbell et al., 2006; 
Dykstra, 2002; Harrison et al., 2007) and have a negative impact on social awareness.  In this 
study, the capability to access information remotely via the CPOE system did not appear to 
affect the proximity of practice of the pharmacist and physician.  On the contrary, 
pharmacists and physicians emphasised the importance of working together in the same 
space and were fully aware that CPOE had the potential to encourage remote working, 
which they reported to actively avoid.  The presence of the pharmacist was also found to be 
important for prompting the review of prescriptions, which may otherwise not be prioritised 
(Brown et al., 2014).  Proximity of practice to the patient and their relatives was also 
stressed, as this was considered essential to gather information and gain context.  As such, 
in the context of CPOE, pharmacists maintained an awareness of the activities of the 
physicians and this was perceived to be no different to paper-based processes.   
 
CPOE systems can enforce or reinforce professional standards and boundaries (Niazkhani et 
al., 2008), for example, by restricting actions according to profession or grade.  The 
restrictions placed on pharmacists to amend or “fine tune” prescriptions was found to 
increase the communication load for the pharmacist, compared to the freedom they had on 
paper to make minor adjustments to treatment regimens.  The pharmacists’ written 
endorsements on paper drug charts have been found to “subtly influence medical 
prescribing”(Liu et al., 2014) and are conducted with the intention to benefit patient care, 
either for the safety of the prescription or to align treatment to the patient’s usual regimen 
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so that the hospital admission reflects their medicine-taking behaviour at home (e.g. 
adjustment of times or days or doses).  Previously made known to the physician by a 
different coloured pen or an allocated space on the chart, the pharmacist would 
traditionally make amendments on behalf of the physician for low risk and low significance 
errors that they felt competent to action, which reduced the need to intervene with the 
physician.  In the context of CPOE, it was not always possible for pharmacists to amend the 
electronic prescriptions and even prescribing pharmacists were wary to do so without 
informing the physician, possibly because the amendment is less apparent on screen than it 
would have been on paper (Niazkhani et al., 2008).  This restriction increased the workload 
for pharmacists, as there was now a need to communicate—at UHBFT there was also the 
added need to follow-up that the task had been actioned since the pharmacist would not 
necessarily wait for these to be completed at the time of handover.  The low significance of 
these fine tuning requests is likely to further encourage a non-interruptive approach to the 
communication, with wanting to avoid distracting the physician for menial tasks.  The 
demand for these tasks to be completed over time may also have an impact on the 
pharmacists’ professional identity—including “the perception of themselves as 
professionals” (Morrow et al., 2011)—with a feeling that it may promote a belief that they 
spend time tidying up prescriptions as the “drug police”, rather than as experts in 
medicines.  Although the frustrations of these errors may seem small in one or two settings, 
they are likely being faced by pharmacists in all hospitals settings that utilise CPOE systems.  
The change in communication load highlights the importance for systems to be flexible and 
designed to account for existing work processes (i.e. in a paper-based environment).  
However, the very fact that systems have not allowed pharmacists to make changes may 
cast doubt on whether pharmacists were previously acting outside the scope of their 
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practice when working in paper-based processes.  Standards clearly state that pharmacists 
should “intervene with prescribers” (Royal Pharmaceutical Society, 2014; Section 6.2, p16), 
to ensure the safe and effective use of medicines.  Further clarification may be required 
from professional bodies as to the extent to which prescription orders in a CPOE system can 
be amended by non-prescribing pharmacists and how prescribing pharmacists should 
approach these in the hospital setting.  It is also important that physicians are engaged in 
this process and consulted on when setting these standards.  Finally, where amendments 
are possible by the pharmacist, these should be clearly visible to other practitioners (e.g. in 
colour).  Amendments made to paper drug charts have been found to influence prescribing 
(Liu et al., 2014) and the potential for learning to be gained from this day-to-day feedback 
should not be overlooked.  It is important that physicians see the types of fine tuning and 
low risk amendments that are being made to prescriptions so that they can adjust their 
practice to avoid these in the future (Ferguson et al., 2017).  
 
The use of CPOE in the hospital setting has been found to reduce the likelihood of a 
medication error occurring by almost half (Radley et al., 2013) and reduce the rate of 
preventable adverse drug events (Nuckols et al., 2014).  The use of integrated CDS software 
is considered to be the main reason for these benefits (Kaushal R, 2003).  Although 
pharmacists and physicians in this study acknowledged that CPOE could remove some 
medication errors, they were also aware of errors relating to the use of the technology, 
particularly CDS and could name common medicines associated with these.  A systematic 
review conducted to investigate the types and causes of prescribing errors within CPOE 
systems found that CDS in the form of default orders (sometimes referred to as auto-
complete or auto-populated orders) and drop-down menus can lead to prescribing errors 
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through the acceptance or selection of an incorrect order (Brown et al., 2017; Singh et al., 
2009).  The occurrence of these errors at the study sites was found to add to the 
communication load of the pharmacist and therefore the workload for the physician; those 
relating to default orders were perceived to contribute the most.  The use of default orders 
to “nudge” practitioners along an appropriate course, such as generic versus brand 
prescribing, have been shown to be effective at instilling and maintaining a required 
standard of prescribing (Malhotra et al., 2016).  However, nudging towards a regimen that 
has the potential to vary depending on the patient and/or the indication for treatment may 
be less beneficial in practice.  The fact that default orders were perceived to contribute to a 
proportion of communications (and tasks for the physician) suggests that the decision 
support is leading to a sub-optimal use.  Access to information and time were suggested as 
potential contributing factors for the occurrence of the errors.  A lack of information may 
cause the physician to consciously accept the inaccurate order until the information is 
known.  It was unclear from the data how frequently this may occur in practice, but it is 
likely that a lack of interoperability with electronic patient records (e.g. medical notes) and 
with records from other settings (i.e. the community) increases the likelihood of these, since 
the information is not available to the physician in a single location to aid their decision-
making.  In the presence of CPOE, the physician may be inclined to accept a default order 
and generate a prescription without knowledge that it is correct, compared to not 
prescribing a medicine until all the details are confirmed in a paper-based system.  
Physicians may be encouraged to continue with system defaults to remove the task of 
prescribing from their workload and may feel reassured that an error would be identified by 
a pharmacist before it is administered to the patient (Dornan et al., 2009).  In addition, 
unlike on paper where a prescription can be partly generated with the unknown details left 
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blank—acting as a visual clue to return to the chart when the information is known—this is 
not possible within a CPOE system (Niazkhani et al., 2009). 
 
A lack of time may result in physicians completing tasks quickly so that they can move on to 
the next.  The acceptance of incorrect orders when information about the patient’s history 
is known, may suggest that physicians are not only interacting with the system quickly, but 
also without conscious thinking.  “Consciousness is tuned to picking up departures from 
intention” (Mandler, 1975, cited in Reason, 1990; p 10), therefore, prescriptions that are 
generated not entirely as intended (e.g. incorrect dose) may occur as a result of automatic 
unconscious thinking, where less attention is paid to the detail of the order and with little or 
no effort applied to the review—so called “System 1” thinking (Kahneman, 2011; p 20-21).  
Kahneman (2011) describes how some activities can become “automatic through prolonged 
practice” (Kahneman, 2011; p 22) and that System 1 thinking has learned associations.  
Default orders are often configured for frequently prescribed medicines (e.g. “statins”). 
Over time, physicians will become familiar with the most common dosing regimens for 
medicines and may also gain knowledge of these through the frequent and regular use of 
the system.  Taking this into account, orders may be accepted as correct through association 
(i.e. of the most common regimen), without conscious thinking to check that the regimen is 
consistent with the patient’s needs—omitting an “attentional check” (Reason, 1990; p 61) to 
ensure the populated prescription on screen matches the patient’s medication history when 
generating the prescription.  The use of default orders in systems may have the unintended 
effect of encouraging this System 1 thinking when generating a prescription, leading to an 
over-reliance on the CPOE system to make decisions and active failures (as slips) to occur 
(Reason, 1990; p 57).  The use or design of default order sets in systems requires further 
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investigation to minimise the risk of active failures occurring (van der Sijs et al., 2006), 
particularly for those regimens that have the potential to vary according to the patient and 
indication for treatment.  Although some of the errors may seem insignificant because they 
are expected and likely to be caught, there is a risk that ‘default fatigue’ could lead to these 
escalating and becoming significant if they are not proactively managed (Furniss et al., 
2011). 
 
Interoperability of patient records is important to enable the seamless delivery of care.  
Timely access to information to inform decision-making has clear socio-economic benefits 
for organisations (EHR IMPACT, 2009; Lederman & Parkes, 2005; Walker et al., 2005).  It is 
not surprising then that interoperability is a key recommendation in the plan to digitise the 
NHS in England (National Information Board, 2014; Wachter, 2016).  A lack of 
interoperability between inpatient systems at GSTFT was found to impact on the role of the 
pharmacist, their communication load and the demands of the physician.  As well as the 
obvious duplication of tasks conducted by physicians when moving patients in or out of the 
ICU setting, pharmacists were required to dedicate time to review prescriptions for the 
presence of transcribing errors and intervene where necessary.  This was reported to take 
them away from other professional tasks such as the optimisation of treatment regimens.  
Pharmacists and physicians were aware of the risks associated with multiple CPOE systems 
and described the lack of interoperability as a “fundamental safety problem”.  The use of 
paper medical notes alongside CPOE systems was also found to be problematic, largely 
associated with the lack of information potentially driving the default orders previously 
described.  Interoperability of electronic patient records and CPOE systems within the same 
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hospital and across care settings is likely to reduce the communication load of pharmacists 
and the subsequent workload of physicians to amend prescriptions. 
  
The CPOE systems at the study sites were found to facilitate the easy capture of information 
relating to ‘what’ treatments had changed for patients over time (e.g. during an admission), 
but the reasons ‘why’ remained largely unknown, since systems did not provide the 
capability to document a rationale and for this to be accessed retrospectively.  Gaining 
context of prescribing decisions was found to be problematic for both pharmacists and 
physicians and this led to uncertainty on the pharmacists’ part, with the need to 
communicate with the physician to clarify the status of prescriptions.  On receipt of a 
request from the pharmacist, physicians reported that they would often struggle to make 
decisions, since a lack of documentation and poor access to information made it difficult to 
determine whether the prescription was as intended, or whether there was an unintended 
discrepancy.  This has the potential to lead to, “second order errors”, where a correct 
prescription is amended and an error is generated as a result.  The reduced interaction with 
using asynchronous communication may also further affect physician decision-making.   
Requests were also reported to be left for someone else to deal with who may be more 
familiar with the patient in question.  The use of electronic patient records has previously 
been found to impact on physicians’ clinical reasoning, because, although systems can 
provide a lot of patient data, it is not always easy to gain enough knowledge of the patient 
to inform decision-making (Elrouby and Tully 2017; Varpio et al., 2015a).  In this study, 
physicians expressed a need for a function within the CPOE system to provide a, “timeline” 
of events, so that prescriptions changes over time could be viewed to ascertain the patient’s 
treatment journey.  This is consistent with a study that found clinicians want to, “build the 
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patient story” (Varpio et al., 2015b) when delivering care and reported that the electronic 
patient records fragmented information, which made the story difficult and time consuming 
to construct.  The ability to retrieve a retrospective account of what has happened is 
important for physicians (Reddy et al., 2001) and this study suggests that it is also important 
for the pharmacist.  Bardram and Hansen (2010) argue that, “workplace awareness depends 
on collecting, processing, distributing, displaying and sharing information about the 
constantly changing work context”.  At UHBFT, pharmacists and physicians reported the use 
of a workaround within the CPOE system to display their actions relating to prescribing 
decisions, so to share these with other healthcare professionals.  This in turn enables other 
practitioners to collect the information to inform decision-making.  Although workarounds 
are often seen as discrepant, they can be conducted to achieve organisational goals and can 
highlight areas where CPOE systems function sub-optimally (Cresswell et al., 2016).  This 
workaround shows that pharmacists and physicians need to share and collect information to 
coordinate work, which in turn will facilitate decision-making.  Given the pressured 
environment of the hospital setting, it is important that staff involved with the medication 
process can gather sequential information quickly and accurately when interacting with 
electronic patient records.  A function within CPOE systems to facilitate this would be 
beneficial, detailing what changes have been made, why and by whom.  This would help 
avoid uncertainty at the point of prescription review.  As previously discussed, it is also 




8.5.2 Effectiveness of the communication 
Physicians and pharmacists across both study sites emphasised the importance of direct 
communication and that this should not be replaced by asynchronous modalities.  This was 
particularly true for requests that were urgent, or perceived to be urgent by the pharmacist.  
Close proximity of practice—found to be unaffected by the use of CPOE at both sites—was 
considered important to increase the opportunity for informal interactions.   
 
The effectiveness of the review message communications—where messages are received in 
a timely manner by a physician who can take action accordingly—was found to be 
influenced by a number of factors relating to the documentation of the request and the flow 
of information.  Figure 8.3 summarises the factors found to impact on the receiving and 







Figure 8.3 – Factors found to impact on the receiving and action of review messages sent via the CPOE system
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The use of electronic messages was found to have clear benefits for the physician, such as 
reduced interruptions to their workflow—important for reducing the risk of clinical and 
procedural errors (Edwards et al., 2009; Popovici et al., 2015; Westbrook et al., 2010).  
However, it has the disadvantage of reducing the length of interpersonal interactions, which 
is important for discussion to gain context, to develop professional relationships and to 
promote collaborative working (Liu et al., 2010; McDonough, 2001).  It was suggested by 
participants that when asynchronous methods are adopted, such as the review message, 
“two-way” communication would be beneficial, since feedback was considered important.  
A uni-directional message means that physicians are unable to provide a rationale for their 
decision-making.  Should a request be ignored for valid reasons, clinical or otherwise, this 
cannot be explained to the pharmacist and may appear that their input has been ignored or 
not considered.  This has the potential to impact on the professional relationship, as well as 
the lack of feedback contributing to the pharmacists’ workload with the need to follow-up 
requests with the physician.  Incorporating bi-directional communication into CPOE systems 
could enhance the effective flow of information, which in turn can help manage workload 
and enhance coordinated care (Ighani et al., 2010; Reddy et al., 2005).   
 
Human factor principles applicable to the design of alerts in CPOE systems have been 
described to include: visibility; confusability with other system messages or alerts; and the 
ability to determine a priority (Phansalkar et al., 2010).  The effectiveness of the review 
message at UHBFT as a form of communication was reported to be affected by these 
factors.  First, the visibility of the message on screen was perceived to be sub-optimal since 
the size and colour did not distinguish it from other types of messages.  Using an image or 
word that is associated with the profession is likely to prompt more immediate recognition, 
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as well as an enhanced awareness of the work of the pharmacist.  Second, there is no facility 
to assign a priority (or severity) to requests, so those that are perceived to be more 
significant are not highlighted as such.  In the present system, the approach taken by 
pharmacists to use direct communication for amendments they perceive to need immediate 
attention is entirely appropriate.  Although ‘priority’ is recommended by Phansalkar et al 
(2010) as a design feature for alerts and it was discussed as a possible improvement to the 
system, there is a potential risk of encouraging the use of asynchronous communication 
methods for urgent requests.  On the other hand, it could increase the chance of messages 
being reviewed out of hours when the pharmacist is not ward-based and serving as a visible 
prompt for the physician to follow-up medication-related reviews.  It is important to be 
aware that the addition of a design feature to assign a priority may also have the 
unintended effect of causing habitual behaviours (Baysari et al., 2017; Phansalkar et al., 
2010), or “alert fatigue” (Khalifa & Zabani, 2016; van der Sijs et al., 2006) where the 
physicians’ response to the alerts falls over time.  
 
The application of electronic messages in CPOE systems has the benefit of allowing certain 
activities to be recorded in the patients’ electronic record.  As previously discussed, this was 
found to be beneficial for facilitating the coordination of work between pharmacists—
providing a platform through which requests could be followed-up—and reduced the risk of 
information being misremembered or misinterpreted by the physician.  Unlike requests that 
are discussed or handed over verbally, the assignment of a message also generates a clinical 
documentation that is visible and that can be retrieved at a later date.  This was perceived 
to be useful for accountability, since it provided evidence that the task had been 
communicated by the pharmacist, which in turn could be used for organisational audit and 
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monitoring.  However, the design of the review message at UHBFT was not found to be 
effective in assigning a responsibility to the task, as the message was not directed to a team 
or person.  This was considered to impact on the effectiveness of the communication, since 
without being forced to take ownership, the messages may be more likely to be overlooked.  
This, combined with a poor awareness of context to easily build a “patient story” (Varpio et 
al., 2015b), is likely to impact on the physicians prioritisation of review messages and may 
encourage requests to be left for others to deal with who have more knowledge of the 
patient.  Pharmacists recommended that ‘read by’ requests might be useful so that 
accountability could be determined.  The use of “technovigilance” (Dixon-Woods et al., 
2013) in this way, to use the audit capability of the CPOE system to monitor the physicians’ 
transactions within a system and determine accountability, may have the unintended effect 
of causing physicians to completely avoid entering the message field; further reducing the 
effectiveness of the communication.   
 
8.5.3 Strengths and limitations  
This qualitative study was designed to ensure rigour during the investigation and analysis of 
data and to optimise the reliability of the findings.  However, as for any research, there are 
limitations that need to be addressed.  The focus groups were conducted in only two 
hospital sites in England.  Although the salient themes I have discussed emerged in both 
settings and provide evidence of data saturation, the findings should be interpreted in the 




This study was designed with consideration of my own experience and assumptions as a 
pharmacist working in hospital and with CPOE systems.  Focus groups were facilitated by a 
second independent researcher and a proportion of the data were independently coded.  
The observational research was also conducted by multiple investigators.  These steps were 
taken to reduce the risk of methodological or confirmation bias during the investigation and 
to gain a range of perspectives.  There are many methods that can be applied to assess 
reliability of qualitative research and there are differences in opinion as to how this should 
be best approached or approached at all (Cook, 2012).  As such, the approach taken here 
may be open to criticism and perceived as a limitation.  
 
Non-participant observation was conducted at UHBFT of hospital pharmacists performing 
their routine clinical work on the wards and in the dispensary.  This method was adopted to 
provide further data to explain the themes that emerged in the analysis of the focus group 
data at the site.  Physicians were not observed directly, but were observed when interacting 
with the pharmacist, both directly and indirectly.  As for the focus groups, data saturation 
was achieved as no new topics or themes emerged and so further observation beyond the 
20 hours conducted was not scheduled.   
 
8.5.4 Conclusions 
The use of CPOE was found to increase the communication load of pharmacists in the 
hospital sites investigated, which also had a direct impact on the physicians’ workload.  This 
increase in workload inevitably reduces the time pharmacists can spend on other tasks, such 
as spending time with patients to discuss their medication and reviewing prescriptions to 
optimise treatment regimens.  For the physician, the increase in workload may also lead to 
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multi-tasking, with an increased risk of clinical or procedural errors occurring.  In view of 
this, it is important that factors such as system restrictions, system-related errors, 
interoperability and context of prescribing decisions are considered in the design of systems 
and how organisations choose to configure these for local use.   
 
The use of CPOE increased interactions between the professionals as a result of technical 
guidance sought from the physician.  Although these interactions are beneficial for building 
working relationships, the reliance on pharmacists as technical experts highlight that 
training may not be sufficient.  This can result in sub-optimal use of systems, with the 
potential to increase the risk of errors.  Organisations needs to ensure that adequate 
training is provided for staff so that they can complete transactions within systems that are 
relevant to their role and can communicate and coordinate care in the context of the 
technology. 
 
The capability to communicate information asynchronously and specific to a prescription 
order in the CPOE environment was perceived to be beneficial to facilitate a non-
interruptive workflow.  The messages helped reduce the length of interruptions for the 
physician, allowed for the documentation of requests for accountability and, reduced the 
risk of misremembering or misinterpreting information communicated verbally. However, 
the message function investigated could be improved with the addition of bi-directional 
communication.  This has the potential to increase professional interactions, which can 
promote the sharing of information to coordinate work, facilitate awareness of context and 
promote collaborative working.  The function would also benefit pharmacists’ workload, as 
they receive timely feedback relating to their requests, potentially reducing the need to 
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follow-up the status of these with the physician.  This is something organisations should 









Chapter 9 DISCUSSION 
 
In this chapter, I assimilate the findings from the systematic review of the literature and the 
quantitative and qualitative analysis of pharmacist-physician communications.  Through a 
process of triangulation, I aim to present an integrated view of the findings to explain how 
the use of CPOE and CDS technologies in the hospital setting have an impact on pharmacist-
physician communication. 
 
9.1 Background to the research question 
The implementation of CPOE technology has been shown to have many benefits for patients 
and healthcare professionals, in particular a reduction in some types of medication errors 
and associated harms.  Evidence also suggests that systems have the potential to cause 
unintended and unanticipated consequences, such as on workflow and the quality of 
communication between staff.  A systematic review of the literature (Thomas & Coleman, 
2012) found that few studies had investigated the impact of this technology on 
communication between the pharmacist and physician in the hospital setting—a 




The aim of this research was to understand how the use of CPOE and CDS technology may 
impact on pharmacist-physician communication.  The objectives of the research outlined in 
Chapter 1, were to: 
1. Determine the effectiveness of uni-directional electronic communications sent via a 
CPOE system in a large acute hospital and identify factors that may influence this; 
2. Ascertain the perceptions of pharmacists and physicians of their interprofessional 
communication in the context of the technology; and, 
3. Observe pharmacists routine clinical work and their professional interactions in the 
context of the technology. 
 
9.2 Triangulation of findings and recommendations 
The findings from the systematic review, quantitative analysis and qualitative analysis will 
be discussed in three themes: 1) interpersonal interactions; 2) communication load; and, 3) 
effectiveness of communication. 
 
9.2.1 Interpersonal interactions 
It was not clear from the review of the literature how CPOE and CDS would impact on 
interpersonal communication (section 2.3.2.5).  Although it was noted that it had the 
potential to reduce opportunities for interaction because of the increased use of the 
computer to perform tasks (Ash et al., 2004); there was also evidence to suggest that it 
could increase interactions owing to the need to coordinate tasks, which was not possible 
via the computer (Niazkhani et al., 2010).  In this study there was no evidence to suggest 
that access to CPOE—with or without a means of electronic communication—affected the 
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presence of the pharmacist on the wards.  Pharmacists and physicians were mindful that 
CPOE systems could encourage remote working and only chose to work away from the 
wards where it was felt necessary for the delivery of the service (e.g. weekends).   
 
Data analysed between January 2009 and December 2014 showed a year-on-year increase 
in the pharmacists’ use of the review message function to communicate with physicians at 
UHBFT (section 6.2.1).  In isolation, this finding could suggest an increasing preference to 
use asynchronous methods of communication, confirming that the technology has the 
potential to reduce interpersonal interactions.  However, qualitative data captured from 
both pharmacists and physicians suggest that the increased use is much more strategic than 
simply an over reliance on the modality compared to more direct methods.  First, 
pharmacists were found to favour a non-interruptive workflow in both hospital study sites, 
primarily to facilitate the work of the physician.  They routinely collected tasks that they 
perceived to be of relative low-risk and would communicate these directly with the 
physicians towards the end of their shift on the ward.  Though this was not perceived to be 
any different as to how they would have worked in paper-based processes, the added 
capability to assign a review message meant that pharmacists could also reduce the length 
of disruption to the physician’s workflow—relying on the review message to provide the 
detail needed for the physician to review the request and take action at a time convenient.  
The preference to avoid distracting the physician is beneficial to workflow and can reduce 
the risk of procedural and clinical errors occurring (Popovici et al., 2015; Westbrook et al., 
2010).  Second, pharmacists and physicians were clear that the technology was not relied 
upon to communicate requests relating to high-risk errors and that these were routinely 
communicated directly and immediately with physicians so that any problems could be 
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rectified early.  Although a small proportion of messages at UHBFT (3.8%, see 6.2.3.3 and 
Appendix 7) were found to relate to one of the 80 high-risk errors identified in Chapter 4 
(Thomas et al., 2013), the communication of these via the CPOE system was to ensure 
clinical documentation for accountability and audit, rather than as the sole means of 
transferring the information.  The process of duplicating the communication as a review 
message provides an effective safety net—avoiding the need for the physician to rely on 
memory or written task lists to recall verbal information.  This shows that pharmacists not 
only routinely assess the potential risks of prescription orders on patient safety, but also 
that they evaluate the effectiveness of communication methods to select an appropriate 
modality based on this—choosing interpersonal interaction when tasks needed to be 
completed quickly.  Finally, the documentation of messages was also used as an effective 
way of helping to coordinate work between members of the pharmacy team.  In contrast to 
the findings from the systemic review that found staff did not rely on systems to coordinate 
tasks (section 2.3.2.2), pharmacists used various messaging function within the CPOE system 
to do just this.  The presence of the message icon provided an effective prompt to follow-up 
on tasks, facilitate handover and effectively monitor the stages of the medication process.  
The same coordination of work was not apparent among the physicians, possibly because 
they were unaware that messages could be accessed retrospectively. 
 
Direct communication is important for developing effective working relationships.  Although 
CPOE did not discourage direct communication, the ability to communicate with electronic 
messages assigned to prescriptions had the potential to reduce the length of interactions 
between staff, since the detail of requests no longer needed to be verbally handed over.  It 
is important that pharmacists and physicians remain mindful of the potential for systems to 
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reduce interpersonal interaction, particularly as systems increase in complexity and become 
integrated with other Electronic Patient Records (EPRs), making access to information easier 
and remote working more feasible.  This has implications for educators working in 
undergraduate health education, as there is a responsibility to familiarise students with the 
technology they will work with and the associated processes they will work in upon 
qualifying.  Incorporating the use of EPRs (such as CPOE) with an interprofessional approach 
would enable students to acquire the non-technical skills to work alongside the technology 
and each other to develop effective communication techniques.  Training relating to the use 
of the technology should also continue to be interprofessional at postgraduate level so that 
staff understand the role of others in the context of the medication process and the 
technology.  This mutual understanding is essential for achieving integration in 
multidisciplinary teams and successful engagement (Atkins, 2002; Keller et al., 2013; Luetsch 
& Rowett, 2015). 
 
9.2.2 Communication load 
Over a 12-month period, pharmacists at UHBFT assigned 36,245 review messages to 
prescriptions in the CPOE system, 34,506 of which were analysed for the quantitative study.  
The process of writing a message, physician review (and potential action) and pharmacist 
follow-up takes time and the population of multiple messages on a patient’s prescription 
profile was found to have a negative impact on the overall effectiveness of the message 
function.  Although a proportion of the message load has been rationalised above in relation 
to documentation and coordination of tasks (9.3.1: Interpersonal interactions), factors have 
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been identified throughout the research which have a direct impact on the communication 
load of the pharmacist.   
 
Just under half of all messages were found to relate to the reconciliation process, a larger 
proportion of which identified discrepancies in the dose and frequency of medicines 
compared to patient’s pre-admission regimens.  Given that the coding of messages was 
based on the pharmacist clearly stating a comparison to pre-admission regimens, this is 
likely to underestimate the true number of discrepancies.  This finding may highlight the 
difficulties faced by healthcare professionals in accessing relevant and accurate patient 
information at transitions of care, particularly in ascertaining an up-to-date and complete 
medication history.  The number of dose/frequency discrepancies compared to 
unintentional omissions of treatment—more commonly seen in this process—may also 
highlight that information at transitions of care is incomplete.  Not only does this present an 
on-going risk for patients, but it also adds to the daily workload of pharmacists and 
physicians in the delivery of care—time that could be spent with patients in working to 
optimise treatment regimens.  The implementation of interoperable EPRs across sectors of 
care and at transitions of care (e.g. in the same hospital) is already a priority for the NHS 
(National Information Board, 2014; Wachter, 2016) and this finding highlights this as a 
priority for patient safety.   
 
Pharmacists reported that a proportion of review messages they sent intended to clarify the 
status of prescriptions.  This may account for the 10.5% of messages assigned to 
prescriptions providing ‘Supporting Information’ about a patient’s usual regimen, but that 
did not make a direct request for a change to be made in case the prescription was actually 
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generated as intended.  This communication load was found to occur largely as a result of 
not being able to gather information about why prescription changes had been made during 
a patient’s admission, since the prescribing decisions and associated rationale were not well 
documented.  This process was considered easier in a paper-based process, where the 
information is less fragmented in comparison (Cresswell et al., 2014; Varpio et al., 2015a).  A 
capability for both physicians and pharmacists to document medication-related changes 
within the CPOE systems and the rationale for these, could provide the context needed for 
healthcare professionals to “build a patient story” (Varpio et al., 2015b), necessary to inform 
their decision-making.  This information can inform the ongoing care of the patient in 
helping to improve communication at transitions of care. 
 
The restrictions systems can place on professional groups means that pharmacists cannot 
amend (or fine tune) electronic prescriptions in the same way as they would have done on 
paper charts.  This was considered another contributing factor for their increased 
communication load.  An example of this is the annotation of “MR” (modified-release) on 
paper, when the standard-release formulation is incorrectly prescribed.  Messages 
requesting the physician ‘Changes the formulation to a modified-release form, to be 
consistent with pre-admission’ occurred 697 times over the 12-month period.  Similarly, 
requests to ‘Change the formulation from a modified-release to standard-release form, to 
be consistent with pre-admission’ occurred 93 times.  These two examples alone accounted 
for 2.3% of all the messages and provide evidence of how this loss in power to make 
changes can impact on workload.  The routine practice of annotating paper drug charts can 
reduce the need to intervene with the physician and ensures that patients can adhere to 
their usual medication routine soon after admission to hospital.  In the paper-based setting, 
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pharmacists are also reassured that their amendments are clearly visible to the 
multidisciplinary team.  However, it is important to note that this practice is not outlined in 
professional standards for hospital pharmacists in the UK (Royal Pharmaceutical Society, 
2014).  To align the practice on paper to that on the computer, pharmacists would need to 
be able to continue to make changes to electronic prescriptions, but professional standards 
may be necessary to ensure this is documented to ensure consistent and safe practice.  In 
addition, to reflect the visibility of changes in paper processes for audit and feedback 
purposes (Ferguson et al., 2017), systems would also need to be designed so that any 
changes can be easily identified on screen by the multidisciplinary team.   
 
In the review of the literature (section 2.3.2.5), it was not entirely clear how the use of CDS 
would impact on the frequency of communications.  One study found that it could decrease 
the number of interruptions for the physician (Niazkhani et al., 2010), largely because the 
system can force adherence to a formulary of medicines available in the hospital.  There was 
also a perception that CDS would replace the pharmacists’ need to intervene owing to its 
ability to prevent certain prescribing errors and provide guidance for physicians (Aarts et al., 
2007).  Consistent with these findings, CDS was appreciated by users since it helped to 
prevent slips in the prescribing process and therefore remove the need for some clinical 
interventions by the pharmacist.  It was also found to reduce communications directed from 
the physician to the pharmacist as a result of the guidance received from the system.  
However, the qualitative research also highlighted some negative effects of CDS on the 
accuracy of patients’ prescriptions and therefore on the communication requirements of 
pharmacists.   
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Default order sets—“a full set if information to complete a prescription proposed by CDS” 
(NHS England, 2015)—were identified as a particular problem, since accepting these led to 
inaccurate prescriptions being generated inadvertently.  Pharmacists and physicians 
highlighted specific medicines where this was considered to be a problem, namely “Adcal 
D3®”, “furosemide” and “simvastatin”.  Simvastatin and furosemide were found to be 
amongst the top ten medicines to have a message assigned that was directly associated 
with the prescription.  For simvastatin, a third of messages related to a discrepancy 
compared to the patient’s usual pre-admission regimen, almost half for furosemide and a 
third for Adcal D3®.  For these three medicines alone, the communications accounted for 2% 
of all the messages.  This correlates with the suggestion that these specific medicines often 
had dosing errors and that a proportion of these were likely as a result of default order sets.  
It may also explain why the majority of discrepancies relating to the reconciliation process 
were dose/frequency errors, in contrast to errors of omission more commonly reported in 
the literature (Quélennec et al., 2013; Urban et al., 2014). The Francis Inquiry Report 
(2013)—an independent inquiry into care provided by a large NHS hospital in England—
recommended that, “systems should be designed to include prompts and defaults where 
these will contribute to safe and effective care and to accurate recording of information on 
first entry” (Francis, 2013).  The use of default orders should be reviewed owing to their 
propensity to cause error and impact on patient safety.  The use of defaults are most 
beneficial for medicine regimens that do not vary between patients (such as complex 
infusions based on the patient’s weight in the ICU setting), or where elements of the 
regimen do not vary between patients (e.g. frequency, time and route for simvastatin).  
Partial population of prescription orders would ensure that the components of the 
prescription that should not vary are correct and that the physician applies conscious 
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thinking to add the missing (variable) information for each patient—an approach that may 
reduce the risk of developing habitual routines of accepting alerts (Baysari et al., 2017; 
Phansalkar et al., 2010).  The CDS could also be configured to include minimum and 
maximum ranges to reduce the risk of harm from input errors.  An alternative approach 
could be to implement an alert to encourage the physician to double check the prescription 
against the intended or required regimen.  However, over time the effect of these may 
diminish as it becomes one of many alerts that physicians need to deal with (van der Sijs et 
al., 2008b).   
 
A second error reported to occur as a result of CPOE and CDS were those of selection.  The 
quantitative study found that these were mainly as a result of incorrect drug/formulations 
and drug/device combinations in the drug dictionary, rather than the inadvertent selection 
of a look-a-like drug name.  For example, when aspirin “dispersible” is prescribed instead of 
the “EC [enteric coated]” formulation taken by the patient; or when the wrong device (e.g. 
for inhaled therapy) is prescribed for a patient— just two examples of error that accounted 
for 1.4% of all the messages.  Combination errors such as this have previously been found 
likely to occur in CPOE systems (Gerrett et al., 2009).  To minimise the risk of selection 
errors occurring, drug dictionaries could be designed to contain only one variable (i.e. name 
of medicine), rather than multiple components of the information needed, such as including 
the device or formulation.  Forcing prescribers to consciously select the additional elements 
of the prescription in a separate field would encourage a second check against the intended 
or required prescription, which should minimise the risk of error.  Although selection errors 
of the ‘wrong drug’ were not found to be prevalent in the database, the true number may 
be much higher.  These errors are likely to pose a higher risk to patient safety and so are 
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more likely to be rectified directly and immediately with the physician.  Tall man lettering—
where sections of a word are capitalised to highlight distinct differences with look-alike 
words—could be considered for specific names of medicines that look-alike on screen, or 
sound-alike when acting on a verbal request (Gerrett et al., 2009), that are frequently 
observed to cause error.  Although systems can be optimised to reduce the risk of error 
inducing interactions, such as with Tall man lettering and avoiding default regimens, it is 
also important that all healthcare professionals are aware of the potential for systems to 
cause error.  The use of CPOE and CDS should be integrated into undergraduate health 
education to ensure the future workforce is digitally competent and aware of the 
unintended consequences of systems—necessary to optimise and improve the use of 
technology in healthcare to benefit patient care (Wachter, 2016). 
 
Finally, a large proportion (9.2%) of the messages assigned to prescriptions was made to 
inform the physician that a medicine had been omitted.  Qualitative data suggested that a 
review message would routinely be assigned to the top medicine on the patient’s profile list 
to inform the physician and request (where applicable) to pay attention to prescriptions 
proposed on behalf of the physician within the CPOE system.  This was confirmed in the 
quantitative analysis, with nearly half of all these messages assigned to medicines starting 
with letters A to C.  The review message was used as a workaround to provide information 
that was unrelated to the prescription and occasionally to direct the physician to review 
another function within the system.  Workarounds have the potential to create situations 
prone to error, but can also be a sign of resourcefulness and highlight functions of the 
technology that require modification (Cresswell et al., 2016; Koppel et al., 2005).  This 
particular workaround may highlight a problem with the visibility of proposed medicines 
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within the system at UHBFT and the need for a dedicated function so that pharmacists can 
communicate contextual information solely related to omissions of treatment.  The ability 
to flag information to the physician about an omitted medicine or a specific function 
dedicated to omitted medicines, would reduce the number of unrelated messages 
populating a patient’s prescription profile, which may reduce the risk of message fatigue, 
particularly to those assigned to the top medicine on a patient’s prescription profile.  
 
9.2.3 Effectiveness of the communication 
The process of communication is dependent on the modality of communication, any “noise” 
in the process that may affect the message being received (e.g. number of messages) and 
the facility to provide feedback (see Figure 1.1) (Lunenburg, 2010).  In this study, an 
effective communication via the CPOE system was one where information is received by the 
intended recipient (physician) in a timely manner (within 24 hours) to achieve a response.  
The expected response is not necessarily one to act to adhere to the request of the 
pharmacist, as this may not always be appropriate—rather it is an action to consider the 
information and review the prescription order in question.   
 
9.2.3.1 Receipt of the information 
The effectiveness of electronic communication via the CPOE system is firstly dependent on 
the information being received.  The review of the literature identified that the ergonomics 
of electronic communications is important to ensure accessibility is optimised (section 
2.3.2.4).  This was raised as a factor at UHBFT since the visibility of messages was perceived 
to be sub-optimal, which could affect accessibility.  This could be improved by their 
286 
 
presence being distinguishable from other types of messages in colour and size and icons 
designed to relate to the profession initiating the communication (Phansalkar et al., 2010).  
A second factor considered important for the initial receipt of messages was the number of 
message icons on a patient’s prescription profile.  It was evident from the focus group data 
that multiple messages on a patient’s prescription profile could have a negative impact on 
the effectiveness of the message function and lead to a sense of being over-alerted and 
“burdened”.  Nearly a quarter of all the messages assigned to prescriptions provided 
‘Supporting Information’ and a proportion of these requested that the physician monitors 
specific parameters—information that is largely provided by the CDS when prescriptions are 
first generated.  From the recipient’s perspective, this increases the number of message 
icons on a patient’s prescription profile that provide information not deemed necessary, 
with the unintended effect of encouraging habitual behaviour to avoid paying attention to 
all messages in the longer-term.  To optimise the effectiveness of electronic communication, 
message functions should be reserved for making explicit requests and recommendations 
and alternative functions used to provide supporting information.  Pharmacists should also 
consider their modality of communication for patients that require multiple interventions—
discussing these directly with the physician and rectifying these collaboratively to ensure 
desirable outcomes are achieved and in a timely manner.  This would prevent the physician 
from feeling overwhelmed by multiple requests at the point of prescribing, promote 
collaboration and help reduce the risk of message fatigue.  These changes in practice would 
need to be supported with training and may also require a change to local protocols.  A 
function to assign a priority to messages was also suggested as a way of identifying the 
messages on screen that needed attention (section 8.5.2).  Although this may be useful to 
help physicians prioritise work when out-of-hours, it may encourage pharmacists to use the 
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system for higher-risk communications, with the unintended effect of reducing 
interpersonal interaction and increasing the risk that these requests may be overlooked.  
 
The receipt of messages was also perceived to be influenced by whether a responsibility was 
assigned to deal with the request (i.e. to a named person or team) or for responsibility to be 
identified based on who has received the information.  One of the recommendations for 
safer clinician communication in the context of EPRs is for the status of the communication 
to be visible, such as “sent, delivered, opened, acknowledged” (Office of the National 
Coordinator for Health Information Technology, 2014).  In this study, it was not possible to 
determine from the data the number of messages that were received and read by 
physicians, since there is no function to capture this within the system (i.e. read by receipts).  
Without a function to identify this, responsibility cannot be assigned to an individual (i.e. 
who has opened the message) to acknowledge the information and take action.  
Implementing the capability to monitor the status of communications could encourage 
interaction between the sender and the recipient of the information.  In addition, the data 
captured from this capability can provide the organisation with a greater insight into the 
effectiveness of communications over time, which can help inform training of healthcare 
professionals and provide evidence for the effect of any changes.  Of course, this 
functionality may have the opposite effect and encourage intended recipients (i.e. 
physicians/prescribers) to avoid reading messages altogether, which needs to be taken into 
account when monitoring the impact of changes.  
 
Finally, receipt of requests was found to be influenced by the presence of the pharmacist to 
prompt physician review.  This was supported by findings from the quantitative analysis, 
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which found that the time taken for physicians to action requests significantly increased 
over the weekend (compared to a Monday) when the pharmacist was not ward-based to 
follow these up and decreased in settings covered by a pharmacist for the majority of the 
day (e.g. Medical Admissions). These findings highlight the importance of a seven day ward-
based pharmacy service to support prescribers (and other staff) through the medication 
process and reinforces this recommendation made by NHS England to transform services in 
acute hospitals (Office of the Chief Pharmaceutical Officer, 2016).  The presence of the 
pharmacist can prompt timelier review of medication-related problems, increase the 
opportunity for direct interaction with the physician and increase the physician’s familiarity 
with a number of pharmacists as they move across numerous patients and wards out-of-
hours, both of which can promote collaborative working.  In the first instance, staff resource 
could be allocated at weekends to those areas where a high activity in the assignment of 
messages is observed (Medical Specialities), a higher prevalence of high-risk errors (General 
Medicine) and where most discrepancies are identified through reconciliation (Medical 
Admissions).  
 
9.2.3.2 Actioning the request 
Just over a third of messages led to an action as requested by the pharmacist and just over 
half of these were actioned within 24 hours.  Upon receipt of a request, an action in 
response to a pharmacists’ request was found to be dependent on the physician’s ability (or 
confidence) to make a decision and this was found to be largely dependent on their access 
to information about a patient.  This was further emphasised when physicians were asked to 
make decisions about patients that were not directly under their care, such as at weekends 
when the time taken to action messages increased (compared to a Monday).  Messages 
289 
 
relating the reconciliation process were more likely to be actioned, in contrast to those 
assigned to high-risk medicines.  The former of the two may be easier for physicians to 
rectify with the information provided by the pharmacist, compared to requests relating to 
the latter, where consulting colleagues to confirm the status of the prescription may be 
chosen as a safer course of action.  The time taken for some requests to be actioned 
supports the use of the message function for low-risk requests only—a practice adopted by 
the pharmacists, aware that messages can be overlooked.  It also supports the limited use of 
the function in areas of the hospital that may not be well supported by a regular ward-based 
pharmacist. 
 
Awareness of the context of prescribing over time was found difficult (sometimes 
impossible) to gather in the CPOE system, since there was no dedicated function within the 
systems to encourage this documentation in a single place.  Some physicians and prescribing 
pharmacists at UHBFT adopted workarounds to communicate rationale for changes they 
had made so these were visible to other staff.  A function to document a chronological 
timeline of medication-related changes within the CPOE system would allow for a more 
comprehensive overview of a patient’s management (van der Linden et al., 2012).  Access to 
this information could help physicians make decisions about patients who are not directly 
under their care (such as at weekends), enable requests to be actioned in a timelier manner 
and reduce the risk of second order errors.  Pharmacists would also benefit from access to 
the information, reducing the need to request clarification for prescribing decisions.   
 
The messages assigned by pharmacists had a median length of only 45 characters, a quarter 
of the possible length of 255 characters.  This did not appear to affect the clarity of the 
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communication, with messages being understood by the physicians (and other 
pharmacists), as well as being easily understood during the analysis of content for the 
development of the database.  Fewer characters will inevitably reduce the time required to 
write and read the messages and may, therefore, facilitate a less interruptive workflow.  
However, the level of detail provided to inform decision-making is questionable.  For 
example, the majority of messages themed as providing ‘Supporting Information’ 
communicated information about a patient’s usual regimen taken at home, without an 
explicit request to make a change to the prescription.  This may highlight an issue regarding 
the completeness of written communications and the need to clearly state the desired 
outcome, i.e. the recommendation.  Although this was not raised during the focus groups, 
the provision of this information could provide more context to the request for the recipient 
of the message and, as such, the physician may feel better informed to act.  ‘SBAR’ 
(Situation, Background, Assessment and Recommendation) is a method of structuring a 
communication to ensure that the information is complete and the desired response 
(recommendation) is clear (Dayton & Henriksen, 2007).  This approach helps focus the 
sender of the information to make clear the purpose of the communication and the desired 
outcome, which also makes it easier for the recipient to act.  ‘SBAR’ can also encourage a 
more consistent approach between healthcare staff (Leonard et al., 2004) and its use has 
been shown to positively correlate with in-hospital survival when text messages are sent 
between nurses and physicians (Wong et al., 2017).  Although not directly analysed in this 
study, all four elements of SBAR would likely not be possible in just 45 characters.  Training 
pharmacists to use SBAR for their written communications could encourage a more 
appropriate use of the message function, reserving it only for those with explicit 
recommendations and not just the provision of information.  The structured communication 
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would encourage pharmacists to provide more context (S: Situation; B: Background), which 
may facilitate physician decision-making.  Communication functions could be designed to 
prompt each of the four elements to ensure clear exchange of information. 
 
The grade of the pharmacist was found to influence the acceptance of review messages, 
with those assigned by grade 8 more likely to be actioned and those assigned by grade 7 in a 
timelier manner (≤24 hours).  This is interesting considering the messages assigned by grade 
8 pharmacists were significantly shorter in length than those assigned by grades 6 and 7 and 
they assigned proportionally fewer than any other grade.  Grade 8 pharmacists are more 
likely to be assigned to the same setting over a long period of time, compared to grade 6 
pharmacists who frequently rotate across specialities.  One possible explanation is that 
personal presence is important for developing working relationships and that this is 
important when being asked to respond to requests and make decisions.  This reinforces the 
importance of ward-based pharmacists being part of the multidisciplinary team—even more 
important when a pharmacist is new to a setting or ward.  Ward rounds provide a platform 
through which to build a working relationship with the team and gain more context about 
the patients under their care.  Pharmacists’ attendance would increase the opportunity for 
personal interaction, encourage collaborative working and potentially increase the 
effectiveness of requests communication asynchronously.  
 
9.2.3.3 Closing the communication 
There is evidence to suggest that physicians do not always implement the pharmacists’ 
advice in practice (Estellat et al., 2007; Mannheimer et al., 2006), which may be for valid 
clinical reasons.  Unfortunately, given the lack of functionality to provide feedback within 
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the CPOE system at UHBFT, the reasons why requests were not actioned remain unknown, 
as they often do to the pharmacists assigning the message.  The review of the literature 
(section 2.3.2.1) found that two-way communication was perceived as beneficial since it 
could allow for better coordination of tasks and help maintain an awareness of the stages of 
the medication process (Ash et al., 2004; Dykstra, 2002).  Consistent with these findings, 
uni-directional communication was found to impact on the pharmacist’s workload, since 
there was a need to follow-up the outcome of requests owing to uncertainty about whether 
they had been received and acknowledged (8.4.2.4).  Physicians expressed a desire to be 
able to respond to messages so that the pharmacist did not feel their requests were 
ignored.  Incorporating two-way communication into CPOE systems could enhance the flow 
of information, which in turn could help manage workload and enhance the coordination of 
care.  The written feedback also encourages documentation, which can provide further 
context for decisions-making in the medication process (Chused et al., 2008). 
 
The sign-off of messages is intended to be used by physicians to remove the ‘R’ icon from a 
prescription when the request has been dealt with or the information considered.  A low 
rate of sign-off of messages was observed with the CPOE system at UHBFT, with just under 
half signed-off as would be intended by system design and desired by the pharmacist as a 
form of feedback.  In addition, over a third of these messages were also found to be signed-
off by pharmacists themselves.  In isolation, this would suggest that the review message 
function is not always utilised by the physician as an acknowledgment that the information 
from the pharmacist has been read and/or actioned and could highlight a sub-optimal 
communication.  However, the focus groups identified a gap in knowledge relating to the 
use of the review message function—specifically concern among physicians that the 
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messages would disappear if they were signed-off and would therefore not be available as a 
form of clinical documentation to provide context for any changes made to prescriptions for 
other practitioners.  The training provided to healthcare professionals on the use of CPOE 
systems should include interprofessional communication and how to coordinate care in this 
environment.  This knowledge is best gained through interprofessional training, so that 
practitioners can understand how each other use the system to communicate and their 
expectations of use.  Figure 9.1 summarises the process of communication in the context of 
CPOE with the capability to send uni-directional electronic communications and the factors 
affecting each of the steps identified.   Note that an action may be the decision to take ‘no 
action’ in this context. 
 
Figure 9.1 – Process of communication in the context of CPOE and electronic messaging at 
UHBFT 
9.2.4 Summary of recommendations 
Figure 9.2 summarises the recommendations at each of the steps of the communication 
process.  This is further detailed in Table 9.1, including potential outcomes of each of the 




Figure 9.2  – Summary of recommendations to optimise communication at various stages of the process 
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Table 9.1 – Summary of recommendations and potential outcomes 
Stage in process Factor Recommendation Outcome 
Receipt of the 
message 
Visibility of the message Optimise the design of the message icon so that 
it is clearly associated with pharmacy 
Reduce the risk of confusability of the message icon 
with other message functions 
Responsibility to 
respond 
Messages designed to that the status can be 
determined (e.g. opened, acknowledged) 
Encourages ownership of the message and facilitates 
follow-up 
Frequency of messages Integration and interoperability of electronic 
patient records 
Reduce frequency of messages requesting 
clarification 
 Timeline of medication-related changes and 
associated rationale 
Reduce frequency of messages requesting 
clarification 
 Ability to amend electronic prescriptions Reduce frequency of messages to request low-risk 
(fine tuning) of prescriptions 
 Review the extent to which orders provide 
default information  
Reduce the risk of errors from default orders 
 Tallman lettering in drug dictionaries Reduce the risk of selection errors 
 Drug dictionary restricted to medicine name 
only 
Reduce the risk of selection errors 
Direct reminders Seven day ward-based pharmacy service Pharmacist available to prompt review of messages 
    
Action of 
requests 
Awareness of context Timeline of medication-related changes and 
associated rationale 
Knowledge to build the patient story  
  Use of SBAR communication Knowledge to build the patient story 
 Knowledge of patient Timeline of medication-related changes and 
associated rationale 
Knowledge to build the patient story  
  Interoperable electronic patient records Knowledge to build the patient story 
 Familiarity with the 
sender 
Pharmacists attendance at ward rounds Promote collaborative working 
 Recommendation Use of SBAR communication Knowledge to build the patient story 
    
Feedback Capability to provide 
feedback 




9.2.5 Barriers to the implementation of recommendations 
Some of the technological recommendations I have made will not be within the control of 
local hospital sites to implement.  Hospitals with locally developed (‘home grown’) systems, 
such as that used at UHBFT, will have more power to configure systems to apply the 
technological changes.  However, such organisations may be constrained by staff time and 
the finances required to support this.  Hospitals using commercial systems may have less 
immediate control, but changes may be possible in the longer-term if organisations work 
collaboratively with their software developers (Cresswell et al., 2014).  The re-design or 
introduction of new capabilities within CPOE systems will require staff training to ensure 
optimal use (Baysari et al., 2012; Mozaffar et al., 2017; Redwood et al., 2011) and 
depending on the complexity of the change, this may require additional resource.  The 
recommendation to introduce communication and coordinated care tasks into training and 
for this to be approached interprofessionally, would also require existing training 
programmes to be modified, which would require staff resource.   
 
Some recommendations may require a change of culture in organisations.  For example, the 
introduction of pharmacists at ward rounds may face barriers from healthcare professionals 
who are already in attendance and from the pharmacy department in relation to the time 
required to be allocated for such activities.  The implementation of a seven-day pharmacy 
service may also face barriers, such as workforce capability and funding (Office of the Chief 
Pharmaceutical Officer, 2016).  However, it is positive that both these recommendations are 
strongly supported by NHS England and are outlined as necessary steps to meet the clinical 
standards outlined for seven day services, particularly ‘Standard 8: Ongoing Review’ (NHS 
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England, 2016).  This may provide the stimulus needed to make the initial steps to transform 
clinical pharmacy services in the NHS. 
 
Finally, the use of SBAR communication would require much broader education and 
training, targeting both undergraduate pharmacy and technician students and the qualified 
pharmacy workforce.  To achieve this nationally, it may need to be reflected in standards 
published by the General Pharmaceutical Council.  The current workforce would also need 
to be trained.  Re-designing communication functions to prompt each of the four elements 
of the communication tool could facilitate implementation. 
 
9.3 Strengths and limitations 
The strengths and limitations of the studies have been presented at the end of each chapter 
throughout the thesis, the main points of which are summarised here. 
 
One of the main strengths of this research is the methodological design.  A sequential 
mixed-methods approach was adopted, comprised first of a quantitative analysis of 
pharmacist messages assigned to prescriptions in a large acute hospital, followed by 
qualitative research using focus groups and observation of pharmacists on the wards and in 
the dispensary, to both complement and expand on the findings (Holman, 1993; p29-36; 
Venkatesh et al., 2013).  This approach allows for a deeper exploration of concepts and was 
considered particularly important for investigating communication, where a quantitative 
analysis of messages alone would not be able to provide context in which these were sent 
and why.    
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The quantitative analysis of pharmacist-physician communications comprised over 34,000 
written messages, including detailed information relating to their associated prescriptions 
and where applicable, subsequent actions.  The volume and veracity of the database is a 
strength of the study and, despite the subjective interpretation of messages during the 
content analysis, a high inter-rater reliability was demonstrated.  Nevertheless, the study 
was conducted in a single-centre (UHBFT) using a locally developed CPOE system and as 
such the results may not necessarily reflect the practice of pharmacists in other hospital 
settings that use CPOE and electronic communication.  The free-text review messages were 
analysed and coded to identify the explicit subject of the discourse and not the latent 
content (i.e. what is implied).  Latent analysis is not possible without knowing the individual 
pharmacists and running an analysis of their intent and the subsequent interpretation of the 
recipient.  A lack of context at the time of the message (i.e. of the patient and the situation) 
also makes this analysis difficult and prevents further investigation into whether an error 
had actually occurred and the potential impact of this on patient care and safety.   
 
The focus groups were conducted in two hospitals and the observational research of 
pharmacists undertaking their usual clinical duties in one of these—both in the same 
country.  Despite evidence that data saturation was achieved, the findings may not be 
transferable to all hospitals or countries outside of England.  First, the impact of the factors 
identified in this study may vary according to the complexity of the systems in use.  Second, 
clinical pharmacy services vary between countries, where even in those with well-
established healthcare, the main task of the pharmacist still focuses on dispensing 
(Perraudin et al., 2011).  A strength of this study was the steps taken to reduce the risk of 
methodological and confirmation bias.  The data were independently coded by a second 
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researcher and an independent researcher was introduced to facilitate the focus groups to 
ensure the discussion was not inappropriately bias. Multiple researchers were also recruited 
to observe the pharmacists at work.  This was conducted to improve the reliability of the 
study, to gain different perspectives and interpretation of the findings, as well as to increase 
the number of hours of observation over a period of time. 
 
Finally, verbal communication between the pharmacist and physician was not investigated, 
though this was occasionally observed during the observational research.  The proportion of 
interventions made directly compared to asynchronously is unknown, but the focus group 
data did provide a good insight into this and why the modality of communication is selected 
over other methods. 
 
9.4 Future work 
9.4.1 Ongoing dissemination 
In the first instance, it is essential that the findings from this research are fed back to 
hospitals, organisations and system developers that are in a position to influence change.  
This can be achieved through publication and with posters and presentations at National 
and international conferences.  Dissemination is a requirement of the NIHR fellowship and is 
actively encouraged during annual reviews.  The final qualitative chapter in this thesis will 
be prepared and submitted for publication to complete the dissemination of both the 




The findings from this research have been fed back to the Director of Pharmacy at UHBFT 
and the CPOE team at the hospital so that technical changes to the system can be 
considered.  Plans have also been made to present the findings to the Royal Pharmaceutical 
Society Boards of England, Wales and Northern Ireland and an invitation has been accepted 
to further present this to the ‘Pharmacy Digital Forum’, a group that feedback to the country 
boards on matters relating to information technology. 
 
9.4.2 Implementation and ongoing research 
One of the recommendations to reduce the communication load of pharmacists was to 
permit changes to electronic prescriptions, in the same way that this would be conducted 
on paper.  I suggested the development of standards to ensure this practice is implemented 
consistently and safely.  This would require for consensus to be reached, with expert input 
from both pharmacists and physicians using a nominal group technique or Delphi (McMillan 
et al., 2016).  The implementation would need to be piloted and closely monitored and the 
changes pharmacists make auditable.  As preliminary work to inform this recommendation, I 
have submitted a Year 4 research project to the Master of Pharmacy (MPharm) degree at 
the University of Birmingham to investigate the amendments pharmacists make to 
prescriptions in a paper-based prescribing environment.  The themes identified in this study 
(commencing October 2017) will provide valuable data to inform a Delphi process with input 
from pharmacists and physicians of varying experience and specialisms from across the 
country.  
 
Integration of EPRs into undergraduate education has been recommended throughout this 
discussion, specifically in relation to improving digital competence in the use of the 
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technology and the use of SBAR when communicating electronically.  To raise awareness of 
both the benefits and unintended consequences of CPOE, three lectures have been 
integrated into the MPharm degree at the University of Birmingham, all of which I 
developed and deliver on an annual basis.  In Year 1, I introduce the digitisation of 
prescriptions in the community and hospital setting and present the policies and reports 
that have driven and are driving, a paperless NHS.  In Year 3, I introduce the benefits and 
unintended consequences of the technology and discuss pharmacist-physician 
communication in the context of CPOE, which encompasses the importance of SBAR 
communication.  Although this teaching is beneficial to students at Birmingham, a wider 
approach is needed to achieve an impact on practice.  In July 2016, the Prescribing Lead at 
the University of Manchester and I established a National working group to focus on the 
education of undergraduate healthcare professionals in acquiring the clinical, social and 
technical skills to safely prescribe and manage medicines with and alongside EPRs.  As a 
group comprising 12 academic institutions, representation from NHS England, NHS Digital 
and system suppliers, we have explored and developed key principles for the education of 
undergraduate healthcare students in the context of EPRs and outlined associated 
competencies.  This work was accepted for oral presentation at the European Association 
for Clinical Pharmacology and Therapeutics (24–27 June 2017) and has recently been 
endorsed by the Royal Pharmaceutical Society.  The principles and competencies will be 
prepared for publication, which is the first step in the process of integrating EPRs into 
undergraduate health education related to medicines safety.  These will be used to develop 
simulated patient records and associated scenarios, which we plan to make available to 
medical educators nationally via a web-based community of practice.  I have initiated 
applications to apply for funding to support the on-going work related to this project.  To 
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gain a greater insight into the perceptions of healthcare students regarding the current and 
future digitisation of patient records in the NHS I have also submitted an additional two Year 
4 MPharm research projects.  After a focused review of the literature, the students will 
conduct qualitative interviews with medical, pharmacy and nursing students about 
electronic patient records.   
 
The technological changes recommended here will need ongoing evaluation to monitor 
their impact and to identify unintended and unanticipated consequences that may 
compromise communication and put patients at risk.  Analysis of electronic communications 
can provide an insight into how modifications affect communication load, particularly 
relating to lower-risk errors and the use of CDS.  An ethnographic study of physicians’ 
interactions with the CPOE system and communications at the point of prescribing would 
provide further insight into how the organisational, individual, social and technical factors 
interact (Redwood et al., 2011). 
 
The rate of high-risk errors amendable to CDS at UHBFT was found to be low.  This is 
potentially because such errors are discussed directly with the physician to ensure they are 
rectified in a timely manner.  In view of this, the analysis of pharmacist messages cannot be 
used as a reliable method to determine the true incidence of high-risk errors in a hospital 
setting.  Further research would be beneficial to understand the occurrence of these errors 
in NHS hospitals.  This could be achieved through a prospective analysis of inpatient 
prescription orders or a retrospective review of prescribing data captured from CPOE 
systems.  The findings from this research could be used to inform organisations about the 
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potential for patient harms from prescribing and guide the design and configuration of 
systems to optimise CDS to reduce the rate of high-risk errors. 
 
Finally, it would be beneficial to conduct research into the modalities of communication 
available in CPOE systems used by NHS hospitals.  Communication is a capability assessed by 
NHS England in the annual ‘Digital Maturity Assessment’ (NHS England, 2015).  Data from 
this assessment could help identify systems that can be optimised, but also exemplar 
systems that could be used to conduct further comparative research.  Importantly, this 
research could inform the generalisability of the findings described in this thesis. 
 
9.5 Final conclusions 
The aim of this research was to understand how the use of CPOE and CDS in the hospital 
setting have an impact on pharmacist-physician communication.  The technology was found 
to change the focus and frequency of communications between the pharmacist and the 
physician.  The latter of the two causing an increased workload for the two professionals.   
The electronic documentation of the medication process does not entirely reflect the work 
that would have been conducted on paper-based systems (i.e. drug charts).   The technology 
largely removes the ability for pharmacists to amend prescriptions, which on paper helped 
clarify information for the physician to inform the administration or monitoring of 
medication and importantly allowed for prescriptions to be fine-tuned to reflect the 
patient’s requirements.  The loss of this capability means that such amendments are now 
the remit of the physician and are required to be communicated by the pharmacist.  The 
system restriction increases workload and, owing to the additional step in the process, can 
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lead to delays in amendments being made.  This has the potential to impact on the patient’s 
treatment regimen during admission and their seamless transition at the interface of care. 
 
CDS-related errors were found to increase communication load for the pharmacist and 
subsequent workload for the physician.  The design and/or local configuration of systems 
with respect to functions such as default orders need to be reviewed as a matter of priority 
to ensure patients are aligned to their usual or intended regimens soon after admission.   
The time dedicated to rectifying such errors can then be directed to more proactive tasks 
such as optimising treatment regimens for patients to improve outcomes. 
 
The ability to communicate asynchronously via the CPOE system and assign messages 
directly to prescriptions is beneficial for the work of both the pharmacist and physician.  The 
capability provides a means of clinical documentation, serving as a visual prompt at the 
point of prescribing and as a reminder of the details of the request.  The visibility of 
messages to all members of the healthcare team also facilitates a non-interruptive workflow 
and more effective coordination of tasks—though the latter will be dependent on its 
effective integration into training.  It is important that asynchronous modalities of 
communication do not replace direct interactions—rather it is used as an alternative 
modality for low-risk communications that do not warrant immediate attention and the 
need to interrupt the physician.  Communication functions can be optimised with the 
capability for the recipient to provide feedback.  This would not only facilitate the 
documentation of the decision-making process, but would be beneficial for encouraging 




Finally, the use of CPOE did not encourage remote working of the two professionals.  
Pharmacists and physicians continued to ensure they were patient-facing and present on 
the wards to interact with other healthcare professionals.  It is important that this way of 
working is maintained by organisations so that CPOE does not encourage a move to remote 
working.  The personal presence is important for professional interaction and for consulting 
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Appendix 1 – Characteristics of studies identified in the narrative review  
Author, Year Country Study type Study Aim 
Medication 
process 
Terminology used Source of classification scheme 
Lesar et al., 
1997b  
US Prospective analysis of 
medication-prescribing 
errors  
To report a programme for detecting, 





Wilson et al., 
1998) 
UK Prospective review of  
adverse incident 
reports 
To investigate the incidence and 
outcome of medication errors 
 
Paper-based Medication errors Based on (American Society of 
Hospital Pharmacists (ASHP), 1993) 
Ross et al., 2000 UK Retrospective review of 
medication errors  
To investigate the incidence and 
types of medication errors and the 
impact of error prevention programmes  
Paper-based Medication errors Not defined 
Fijn et al., 2002 Netherlands Retrospective case-
control study 
comparing 
prescriptions with and 
without errors 
To explore a method to assess predictors 
of prescribing error 
Paper-based Prescribing errors Based on other published studies 
(Kozer et al., 
2002) 
Canada Retrospective review of 
inpatient drug chart 
To investigate the incidence and type of 
medication errors and determine factors 
associated with risk of errors 
Paper-based Medication errors Classified according to the system 
described by (Lesar et al., 1997a) 
 
LaPointe & G., 
2003 
US Prospective review of 
medication orders 
To investigate the type of error, stage in 
the process and professionals involved 
Paper-based Medication errors The ADE Prevention Study Group 
Parthasarathi et 
al., 2003 
India Prospective review of 
inpatient drug charts 




Not defined  
Bobb et al., 2004) US Prospective analysis of 
medication orders 
To investigate prescribing errors averted 
by pharmacists and the likely impact of 
CPOE  
Paper-based Prescribing errors Not defined 
Chen et al., 2004) Taiwan Retrospective review of 
incident forms 
To investigate the incidence and type of 
medication errors 
CPOE Medication errors Not defined 
Nebeker et al., 
2005 
Canada Prospective review of 
case notes 
To investigate the frequency and type of 
ADEs after CPOE 





Author, Year Country Study type Study Aim 
Prescribing 
process 
Definition used Source of classification scheme 
Vrca et al., 2005) Croatia Prospective review of 
inpatient drug charts 
To determine the incidence and type of 






UK Retrospective analysis 
of medication-related 
incidents reports 
Frequency and type of incidents in the 
medication process and the reporting 
profession  
 
Paper-based Medication errors Not defined 
Barber et al., 
2006) 
UK Prospective evaluation 
of medication orders 
To prospectively evaluate the impact of a 




Medication error Based on a published study by (Dean 
et al., 2002b) 
Colpaert et al., 
2006) 
Belgium Prospective review of 
inpatient prescriptions 
To determine the impact of CPOE on the 






NCC MERP Taxonomy of Medication 
Errors 
Devine et al., 
2007) 
US Retrospective review of 
prescriptions 
To characterise the epidemiology of 
prescribing errors pre-/post-
implementation of CPOE 
Paper-based Medication error Based on published studies 
Jayawardena et 
al., 2007 
US Retrospective study of 
electronic prescriptions 
To investigate the impact of a CPOE 
system on the rate and type of 
prescription errors 
CPOE Prescription errors Not defined 
Marcin et al., 
2007) 
US Retrospective review of 
case notes 
 
To identify the incidence, nature and 
outcomes of medication errors 
Paper-based Medication errors Modification of NCC MERP Taxonomy 
of Medication Errors 
Madegowda et 
al., 2007 




To investigate the number, type and 
severity of errors reported by three 
nursing shifts 
 
Paper-based Medication errors Self-developed 
Engum & 
Breckler, 2008 
US Retrospective review of 
voluntary reports of 
medication error 
To review the number and type of 
medication errors across specialities 
Paper-based Medication errors Not defined 
Picone et al., 
2008) 
US Retrospective review of 
voluntary incident 
reports 
To describe medication errors and the 
factors predictive of errors 
Paper-based Medication errors Not defined 





observational study of 
inpatient drug charts, 
incident reports and 
attendance at MDTs 
 
To evaluate the incidence and 








Author, Year Country Study type Study Aim 
Prescribing 
process 
Definition used Source of classification scheme 
Pham et al., 2011 US Cross-sectional study of 
medication errors 
reports from the 
emergency 
departments 
To investigate the frequency, types, 




Medication errors Modification of the NCC MERP 
Taxonomy of Medication Errors 
Dornan et al., 
2009b 
UK Prospective chart 
review 
 
To explore the causes of prescribing 
errors made by foundation trainees 
Paper-based Prescribing errors Not defined 
Ghaleb et al., 
2010 
UK Prospective review of 
inpatient drug charts 
To determine the incidence and nature 
of prescribing and medication 
administration errors 
Paper-based Prescribing errors Based on a previous study by the 
same author (Ghaleb et al., 2005) 
Klopotowska et 
al., 2010 
Netherlands Prospective study of 
electronic prescriptions 
To investigate the impact of a hospital 
pharmacist on prescribing errors and 
related patient harm 
CPOE Prescribing errors and 
related ADEs 
Not defined 
Al-Jeraisy et al., 
2011 
Saudi Arabia Retrospective review of 
inpatient drug charts 
and patient notes 
To investigate the 
incidence and types of medication 




Based on published studies 
Franklin et al., 
2011 
UK Prospective study of 
prescribing errors 
identified by ward 
pharmacists 
To compare the prevalence and causes of 
prescribing errors in three hospitals  
Paper-based Prescribing errors Not defined 
Hartel et al., 2011 Switzerland Retrospective review of 
inpatient drug charts 
To investigate the frequency and type of 
medication errors in the medication 
documentation process 
Paper-based Medication errors Based on a published study by 
(Barker et al., 2002) 
Jennane et al., 
2011 
Morocco Prospective review of 
inpatient drug charts 
To determine incidence, type and 
outcomes of medication errors 
Paper-based Medication errors Not defined 
Shawahna et al., 
2011 
Pakistan Prospective review of 
inpatient drug charts  
To investigate the incidence of 
prescribing errors pre-/post-
implementation of CPOE 
Paper-based and 
CPOE 
Prescribing errors Based on a published study by 
(Shawahna & Rahman, 2009) 
Westbrook et al., 
2012 
Australia Prospective analysis of 
medication orders 
To investigate the effectiveness of two 
CPOE systems in reducing prescribing 




Prescribing errors Not defined 
ADE; Adverse drug events  
338 
 
Appendix 2 – Participant Information Leaflet for the eDelphi study 
 
Identifying and establishing consensus on prescribing safety indicators in 





Prescribing safety indicators have been well researched in primary care. However, the development 
of such indicators in the secondary care setting is limited. We wish to establish a consensus on the 
prescribing indicators judged by experts to have a significant risk of translating into actual patient 
harm in UK secondary care. These indicators will be used to evaluate whether the introduction of 
electronic prescribing (ePrescribing) systems results in a reduction in clinically important errors. 
This research is part of a larger mixed methods project funded by the National Institute for Health 
Research to investigate the implementation, adoption and effectiveness of ePrescribing systems in 
English hospitals.  
 
The eDelphi process 
We will use an electronic Delphi (eDelphi) technique to gain consensus on the opinions of experts 
through a series of questionnaires. The technique has been used previously in healthcare research to 
establish consensus. We have derived an initial list of 90 prescribing safety indicators through 
literature searching and clinical experience for consideration by the panel of experts.    
The eDelphi will be undertaken by email in three rounds: 
Round 1 A list of indicators will be sent out to participants, who will be asked to suggest 
critical indicators that they think are missing. 
Round 2 Responses from Round 1 will be analysed and collated into a second, larger list of 
indicators, which will be sent by email to participants. This spreadsheet will have a 
scoring functionality, where participants will score the likelihood of the error 
occurring and the seriousness of the error should it occur using a 5-point Likert 
scale. 
Round 3 Participants will receive a second spreadsheet containing their initial score and the 
median score for each indicator. Participants will be asked if they want to change 
their score in response to the median value. A comments section will allow 
respondents to justify/comment on their scoring decision. 
 
Participants will be given 7–10 working days to reply during each round.  
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Appendix 3 – High or extreme risk prescribing indicators, with median scores from the eDelphi shown for the severity and likelihood, with a calculated 
risk score  
 











Low molecular weight heparin prescribed without the patient's weight being 
used to calculate the treatment dose (Risk of subtherapeutic or 
supratherapeutic dosing) 
Cardiovascular Dosing 3 4 3 95% 
Low molecular weight heparin prescribed at a dose exceeding the maximum as 
stated in the product literature (Risk of bleeding increased) 
Cardiovascular Dosing 4 3 3 90% 
Digoxin prescribed at a dose >125 micrograms daily to a patient with renal 
impairment (Increased risk of digoxin toxicity) 
Cardiovascular Dosing 3 3 3 95% 
Digoxin prescribed at a dose of >125 micrograms daily to a patient with heart 
failure who is in sinus rhythm (Increased risk of digoxin toxicity) 
Cardiovascular Dosing 3 3 3 95% 
Amiodarone prescribed to a patient with abnormal thyroid function tests 
(Increased risk of thyroid disorders) 
Cardiovascular Clinical 
contraindication 
3 3 3 80% 
Non-cardioselective beta-adrenoceptor blocking drug prescribed to a patient  
with COPD (Increased risk of bronchospasm) 
Cardiovascular Clinical 
contraindication 
3 3 3 85% 
ACE inhibitor or angiotensin-II receptor antagonist prescribed to a patient with 
a potassium level >5.0 mmol/litre (Can cause or exacerbate hyperkalaemia) 
Cardiovascular Clinical 
contraindication 
3 3 3 80% 
Verapamil prescribed to a patient with NYHA Class III or IV heart failure (Risk 




4 3 3 95% 
Low molecular weight heparin prescribed to a patient with renal impairment 
without dose adjustment (Increased risk of bleeding) 
Cardiovascular Dosing 3 4 3 100% 
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Warfarin prescribed to a patient with a concurrent bleeding disorder 
(Increased risk of bleeding) 
Cardiovascular Clinical 
contraindication 
4 2 3 100% 
Aspirin prescribed to a patient with a past medical history of peptic ulcer 
disease without antisecretory drugs or mucosal protectants (Increased risk of 
peptic ulceration and risk of bleeding) 
Cardiovascular Clinical 
contraindication 
4 3 3 95% 
Antiplatelet  prescribed to a patient with a concurrent bleeding disorder 
(Increased risk of bleeding) 
Cardiovascular Clinical 
contraindication 
4 3 3 100% 
Digoxin prescribed concomitantly with a diuretic (Risk of hypokalaemia and 
subsequent digoxin toxicity) 
Cardiovascular Drug-drug 
interaction 
3 4 3 100% 




3 4 3 95% 
Potassium-sparing diuretic (excluding aldosterone antagonists) prescribed to a 
patient also receiving an ACE inhibitor or angiotensin-II receptor antagonist 
(Increased risk of severe hyperkalaemia) 
Cardiovascular Drug-drug 
interaction 
3 3 3 90% 
Amiodarone prescribed concomitantly with simvastatin 40 mg or above 
(Increased risk of myopathy) 
Cardiovascular Drug-drug 
interaction 
3 3 3 85% 
Verapamil prescribed to a patient concomitantly a with beta-adrenoceptor 
blocking drug (Increased risk of adverse cardiovascular effects) 
Cardiovascular Drug-drug 
interaction 
4 3 3 90% 
Warfarin prescribed concomitantly with a NSAID (Increased risk of bleeding) Cardiovascular Drug-drug 
interaction 
4 3 3 100% 




4 3 3 95% 
Clopidogrel prescribed to a patient concomitantly with omeprazole or 
esomeprazole (Antiplatelet effect of clopidogrel potentially reduced) 
Cardiovascular Drug-drug 
interaction 
3 4 3 95% 
Macrolide antibiotic prescribed concomitantly with warfarin without 




4 4 4 95% 
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Low molecular weight heparin omitted to be prescribed for prophylaxis 
(Increased risk of thrombosis) 
Cardiovascular Omission of 
prophylactic 
treatment 
4 4 4 95% 
Lithium dose not adjusted or omitted in a patient with a lithium concentration 
above the therapeutic range  (> 1.0 mmol/litre)  (Risk of lithium toxicity) 
Central Nervous 
System 
Dosing 4 3 3 100% 
Paracetamol prescribed at a dose of 4 g over a 24 hour to a patient under 50 
kg (Risk of hepatocellular toxicity)† 
Central Nervous 
System 
Dosing 4 4 4 94% 
Benzodiazepine or benzodiazepine-like drug prescribed to a patient with COPD 





3 3 3 90% 
Antipsychotic, other than risperidone, prescribed to a patient for the 
management of the behavioural and psychological symptoms of dementia 





4 3 3 100% 
Tricyclic antidepressant prescribed to a patient with dementia (Increased risk 





3 3 3 90% 
Selective serotonin re-uptake inhibitor prescribed to a patient with epilepsy 





3 3 3 95% 
Selective serotonin re-uptake inhibitor prescribed to a patient with a history of 
clinically significant hyponatraemia (non-iatrogenic , sodium <130 mmol/litre 





3 3 3 95% 
Prochlorperazine prescribed to a patient with parkinsonism (Risk of 





3 3 3 80% 
NSAID prescribed to a patient with chronic renal failure (Increased risk of 





3 3 3 95% 
NSAID prescribed to a patient with a history of peptic ulcer disease or 
gastrointestinal bleeding without  antisecretory drugs or mucosal protectants 





3 3 3 80% 
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NSAID prescribed to a patient with a history of heart failure (Risk of 





3 3 3 85% 
Lithium prescribed in conjunction with newly prescribed NSAIDs without dose 





4 3 3 100% 
Lithium therapy prescribed in conjunction with newly prescribed  loop or 
thiazide diuretics without dose adjustment or increased monitoring (Increased 





4 3 3 100% 
Tricyclic antidepressant prescribed at the same time as a Monoamine Oxidase 





4 2 3 80% 
Tramadol prescribed concomitantly with a Monoamine Oxidase Inhibitor 





4 2 3 84% 
Selective serotonin re-uptake inhibitor prescribed concomitantly with 





3 4 3 100% 
Selective serotonin re-uptake inhibitor prescribed concomitantly with aspirin 
without appropriate prophylaxis with antisecretory drugs or mucosal 





3 3 3 95% 
Citalopram prescribed concomitantly with other QT prolonging drugs 





3 3 3 85% 
Tramadol prescribed concomitantly with antiepileptics (Increased risk of 





3 4 3 100% 
Nefopam prescribed concomitantly with antiepileptics (Increased risk of 





3 3 3 80% 
Phenytoin and enteral feeds prescribed to a patient concomitantly (Reduced 





3 3 3 85% 
More than one paracetamol-containing product prescribed to a patient at a 





4 3 3 95% 
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Benzodiazepines prescribed long-term (i.e. more than 2–4 weeks) (Risk of 
dependence and withdrawal reactions) 
Central Nervous 
System 
Duration 3 4 3 85% 
Benzodiazepine or benzodiazepine-like drug prescribed long-term to a patient 
with depression (Risk of dependence and withdrawal reactions) 
Central Nervous 
System 
Duration 3 3 3 85% 
Benzodiazepine-like drugs (e.g. Zopiclone) prescribed long-term (i.e. more 
than 2–4 weeks) (Risk of dependence reactions) 
Central Nervous 
System 
Duration 3 4 3 85% 
Antipsychotic prescribed long-term (i.e. > 1 month) to a patient with 
parkinsonism  (Increased risk of worsening of extra-pyramidal side effects) 
Central Nervous 
System 
Duration 3 3 3 85% 







3 4 3 85% 
Prescribing of incorrect or inequivalent morphine (opiate) dose via multiple 
routes. (Risk of toxicity) 
Central Nervous 
System 
Route 3 4 3 100% 
Glibenclamide prescribed to an older adult with Type 2 diabetes mellitus 
(Increased risk of hypoglycaemia) 
Endocrine Clinical 
contraindication 
3 3 3 80% 
Metformin prescribed to a patient with eGFR < 30 ml/min/1.73m2 (Increased 
risk of lactic acidosis) 
Endocrine Clinical 
contraindication 
3 3 3 90% 
Pioglitazone prescribed to a patient with heart failure (Risk of exacerbation of 
heart failure)  
Endocrine Clinical 
contraindication 
3 3 3 85% 
Soluble insulin prescribed to a patient on a when required basis (Increased risk 
of serious episodes of hypoglycaemia and nocturnal hypoglycaemia post dose)   
Endocrine Frequency 3 3 3 90% 
Insulin prescribed to a patient at an inappropriate time, allowing for an 
administration without food (except once daily long-acting insulins) (Increased 
risk of hypoglycaemia) 
Endocrine Timing of dose 4 3 3 95% 
Domperidone prescribed at a total daily dose exceeding 30 mg/day in adults > 
60 years old (Increased risk of QTc prolongation, serious ventricular arrhythmia 
and sudden cardiac death)  
Gastrointestinal Dosing 4 3 3 95% 
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Diphenoxylate, loperamide, codeine phosphate prescribed as antidiarrhoeal 
agents for treatment of severe infective gastroenteritis (e.g. bloody diarrhoea, 
high fever, or severe systemic toxicity) (Increased risk of exacerbation or 
protraction of infection) 
Gastrointestinal Clinical 
contraindication 
3 3 3 85% 
Metoclopramide prescribed to a patient with parkinsonism (Risk of 
exacerbating parkinsonism symptoms) 
Gastrointestinal Clinical 
contraindication 
3 4 3 85% 
Colestyramine prescribed to a patient at the same time as any other oral 




3 4 3 90% 
Orlistat prescribed at the same time of day as oral antiepileptics (Orlistat can 
reduce the absorption of antiepileptics, leading to loss of seizure control)  
Gastrointestinal Drug-drug 
interaction 
3 3 3 90% 
Diphenoxylate, loperamide, or codeine phosphate prescribed as antidiarrhoeal 
agents for treatment of diarrhoea of unknown cause (Increased risk of 
exacerbating constipation with overflow diarrhoea) 
Gastrointestinal Indication 3 3 3 85% 
Penicillin containing compound prescribed to a penicillin allergic patient 
without reasoning (e.g. a mild or non-allergy such as diarrhoea or vomiting 
entered as an allergy where the indication for penicillin is compelling) (Risk of 
hypersensitivity reactions) 
Infection Allergy 4 3 3 100% 
Gentamicin dose calculated based on actual body weight rather than ideal 
body weight in an obese patient (BMI > 30 kg/m2) (Risk of excessive dosing and 
toxicity) 
Infection Dosing 4 4 4 100% 
Amphotericin B prescribed without stating the brand name and the dose in 
mg/kg (Risk of fatal overdose due to confusion between lipid based and non-
lipid formulations) 
Infection Drug name 5 3 4 90% 
Cephalosporin antibiotic prescribed to an older adult (except under the 




3 3 3 85% 
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Gentamicin prescribed to a patient with renal impairment without dose 
adjustment (Increased risk of toxicity) 
Infection Dosing 4 3 3 95% 
Gentamicin prescribed to an adult patient with normal renal function in a dose 
exceeding 7 mg/kg/day (Increased risk of toxicity) 
Infection Dosing 4 3 3 90% 
Vancomycin prescribed intravenously to a patient with renal impairment 
without dose adjustment (Increased risk of toxicity) 
Infection Clinical 
contraindication 
4 3 3 95% 
Quinolone antibiotic prescribed to a patient with epilepsy (Increased risk of 
seizure threshold being reduced) 
Infection Clinical 
contraindication 
3 3 3 100% 
Nitrofurantoin prescribed to a patient with eGFR < 60 ml/minute/1.73m2 (Risk 
of peripheral neuropathy and inadequate concentration in urine) † 
Infection Clinical 
contraindication 
3 3 3 90% 
Quinolone prescribed to a patient who is also receiving theophylline (Possible 
increased risk of convulsions ) 
Infection Drug-drug 
interaction 
3 3 3 95% 
Atazanavir prescribed concomitantly with a proton-pump inhibitor 
(Concentration of atazanavir potentially reduced, reducing therapeutic effect) 
Infection Drug-drug 
interaction 
3 3 3 95% 
Vancomycin prescribed intravenously over less than 60 minutes (Rapid 
infusion of vancomycin can cause severe reactions) 
Infection Intravenous rate 3 3 3 90% 
Brand specific prescribing of tacrolimus preparations (Brands vary in their 
dosing and pharmacokinetics) 
Misc Drug name 4 3 3 85% 
Methotrexate prescribed to a patient with a clinically significant drop in white 
cell count or platelet count (Risk of bone marrow suppression) 
Misc Clinical 
contraindication 
4 3 3 95% 
Methotrexate prescribed to a patient with abnormal liver function tests (Risk 
of liver toxicity) 
Misc Clinical 
contraindication 
4 3 3 83% 
Potassium chloride supplements continued for longer than is required  
(reference range 3.5–5.3 mmol/litre) (Increased risk of hyperkalaemia) 
Misc Clinical 
contraindication 
4 3 3 100% 
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3 3 3 89% 
Weekly dose of an oral bisphosphonate prescribed daily (Risk of 
hypocalcaemia)  
Misc Frequency 3 3 3 89% 
Oral methotrexate prescribed to a patient with an inappropriate frequency 
(Increased risk of toxicity) 
Misc Frequency 5 2 3 89% 
†Additional indicators recommended by panellists in the exploratory round and included in round one (n=13) 
‡Indicators where the text was suggested to be modified by panellists in the exploratory round for round one (n=2) 
Median risk scores: 1: Low risk; 2: Moderate risk, 3: High risk; 4: Extreme risk 
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Appendix 4 – Indicators not considered high or extreme risk by consensus of at least 80% 
Prescribing safety indicator (harm) 
Proton-pump inhibitors prescribed at the same time as antacid formulations (Reduced therapeutic effect of the proton-pump inhibitor) 
Thiazide diuretic prescribed to a patient with a history of gout (Increased risk of exacerbating symptoms in pre-existing gout) 
Thiazide prescribed to a patient with chronic kidney disease (CKD) stage 3 (eGFR< 45/ml/min/1.73m2) or above (Increased risk of adverse effects) 
Beta-adrenoceptor blocking drug prescribed to a patient with asthma (Increased risk of bronchospasm and acute deterioration) 
Aliskiren prescribed concomitantly with ACE inhibitors or angiotensin-II receptor antagonists (Increased risk of serious adverse cardiovascular and renal outcomes) 
Aliskiren prescribed to a patient with severe renal impairment, eGFR< 30 ml/min/1.73m2 (Risk of hyperkalaemia) 
Long-acting inhaled antimuscarinic prescribed concomitantly with a short acting nebulised antimuscarinic (Increased risk of additive adverse effects) 
SSRI prescribed concomitantly with pethidine (Increased risk of serotonin syndrome) 
Selective Serotonin Re-uptake Inhibitors prescribed at the same time as Monoamine Oxidase Inhibitors (Increased risk of serotonin syndrome) 
Metoclopramide prescribed to a patient <20 years (except in cases of severe intractable vomiting of known cause, or due to cytotoxics/radiotherapy)(Increased risk of 
extrapyramidal side-effects)  
Two concomitant opiate analgesics that are not in line with the WHO pain ladder (Injudicious use of two opiates) 
Aspirin prescribed to a child < 16 years (except in Kawasaki's disease) (Increased risk of Reye's syndrome)  
Vancomycin prescribed intravenously for the treatment of Clostridium difficile infection (Intravenous vancomycin has limited therapeutic effect) 
Oral quinolone antibiotic prescribed at the same time as iron (Reduced absorption of quinolones) 
Triazole antifungal prescribed at the same time as fentanyl (Increased risk of opiate toxicity) 
Rifampicin prescribed concomitantly with ritonavir (Ritonavir concentration can be reduced, reducing its effect) 
Bisphosphonate prescribed to a patient with an inappropriate timing (Increased risk of adverse effects and possible reduced absorption if given after food) 
Bisphosphonate prescribed to a patient at the same time of day as calcium (Bisphosphonate absorption reduced by calcium salts) 
Methotrexate prescribed on the same day as folic acid (Reduced efficacy of methotrexate) 
Allopurinol prescribed concomitantly with azathioprine (Allopurinol enhances effect of azathioprine and increases risk of toxicity) 
Allopurinol prescribed concomitantly with mercaptopurine (Allopurinol enhances effect of mercaptopurine and increases risk of toxicity) 
Calcium resonium prescribed when the potassium concentration is within the desired reference range (3.5–5.3 mmol/litre) (Risk of hypokalaemia) 
Potassium chloride infusions exceeding 40 mmol/litre given via the peripheral route (Peripheral administration risks venous pooling, which can lead to sudden high 




Prescribing safety indicator (harm) 
Selective COX-2 inhibitor NSAID prescribed to a patient with cardiovascular disease (Increased risk of thrombotic events) 
More than one NSAID prescribed to a patient at a time (Increased risk of bleeding) 
Allopurinol prescribed at a dose exceeding 100 mg in a patient with renal impairment (Risk of accumulation and subsequent toxicity) 
Live vaccine prescribed to an immunosuppressed patient, including those on corticosteroids (Increased risk of reaction or infection) 
Two loop diuretics prescribed concomitantly (Increased risk of adverse effects) 
Long-acting beta-2-agonist inhaler prescribed to a patient who is not also on an inhaled corticosteroid (Evidence base - not in line with British Thoracic Society guidelines) 
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Appendix 5 – Themes and detailed codes for pharmacist-physician communications 
Major theme Code 
Contraindication The drug is cautioned or contraindicated as a result of patient comorbidities 
The drug is cautioned or contraindicated as a result of recent test results 
The drug should be used with caution as the patient is at risk of falls 
The patient has reported an intolerance to the drug 
The patient is allergic to the drug 
There is a potential for cross-reactivity 
 
 
Dose/Frequency Change the prescription to be given on a ‘when required’ basis as the patient is refusing  
Change the regular prescription to on a ‘when required’ basis 
The dose is higher than the pre-admission dose 
The dose is lower  than the pre-admission dose 
The dose is too high 
The dose is too low 
The dose requires review 
The dose/strength has been documented incorrectly 
The frequency is too high 
The frequency is too high compared to pre-admission 
The frequency is too low 
The frequency is too low compared to pre-admission 
The frequency of dosing requires review 
The prescription should be documented as a 'continuous' frequency 
The prescription should be for a one-off dose only (i.e. not regular) 
The total daily dose is correct, but split incorrectly throughout the day 
The wrong dose units have been prescribed 






Drug Form/Route A change in formulation is required because the patient has an enteral feeding tube 
A change in formulation is required to be consistent with the patient’s pre-admission form 
An alternative route of administration is recommended 
Change the formulation from a liquid to a solid dose form 
Change the formulation to a modified-release form, to be consistent with pre-admission meds 
Change the formulation to a standard release form, to be consistent with pre-admission meds 
Change the formulation to enteric-coated, to be consistent with pre-admission meds 
Change the formulation to liquid or soluble form 
Change the formulation to modified-release 
Change the route from intravenous to oral 
Change the route from oral to intravenous 
Change to standard release 
The route is incorrect for the drug 
The route of administration is inappropriate for the indication 
The route requires review 
The use of multiple routes is not appropriate for the drug 
 
 
Drug Interaction There is a pharmacodynamic drug-drug interaction 
There is a pharmacokinetic drug-drug interaction 
 
 
Drug Selection A combination has been prescribed, but the patient is only on a single component 
Recommends an alternative treatment 
The drug choice does not adhere to guidelines 
The drug has been prescribed incorrectly by brand or generic name, not consistent with the eP 
system practice 
The drug is no longer indicated 
The patient is on a different brand of the drug and this should be ‘brand specific’ when prescribed 
The patient is on a different drug of the same class that has been prescribed 
The patient is on the drug, but takes it as a different brand (Adcal D3 versus Calcichew D3) 
The patient takes the drug as a different salt (e.g. ferrous sulphate, not fumarate) 
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The strength prescribed is higher than that used pre-admission 
The strength prescribed is lower than that used pre-admission 
The strength prescribed is too high 
The strength prescribed is too low 
The wrong drug has been prescribed as a result of a selection error 
There is a duplicate prescription with a drug of the same class 
There is a duplicate prescription with the same drug 





A change in formulation is required because the patient has swallowing difficulties 
A duration is needed on the prescription 
An alternative drug is recommended because it cannot be crushed/opened for administration 
An alternative drug recommended as it is not suitable for enteral feeding tubes 
Change the drug device to be consistent with pre-admission meds 
Doses have been missed for no obvious reason 
Review the prescription as the patient is refusing it 
The dose prescribed is immeasurable 
The drug cannot be administered as there is no intravenous access 
The drug has been prescribed at the wrong time of day (according to practice/BNF 
recommendations) 
The drug is to be re-started 
The drug is to be stopped (or paused) 
The drug should be prescribed as a reducing regimen 
The duration of treatment requires review 
The patient has never taken or used the drug that has been prescribed 
The patient no longer takes or uses the drug prescribed 
The prescription is inappropriate for discharge (e.g. intravenous form) 
The route of administration requires further information (e.g. which eye?) 






Logistics Information requested relating to controlled drug prescription writing requirements 
Informing physician that the prescription was validated and signed-off in error 
The physician’s grade does not give him/her authority to prescribe the drug 
The drug has been prescribed for the wrong patient 
The drug is not available as it does not exist as prescribed 
The drug is not available due to a manufacturing delay 
The drug not available as it is not stocked in the hospital 
The maximum frequency is required to be documented on the ‘when required’ prescription 
 
 
Omission Recommends a drug is started to optimise treatment (e.g. thiamine) 
The patient takes a combination preparation, but only a single component of this has been 
prescribed 
There is an omission according to the patient’s drug history 
There is an omission of required treatment (i.e. anti-emetics prior to chemotherapy) 
There is an omission on the ‘To Take Out’ (TTO) prescription 
Venous thromboembolism (VTE) prophylaxis has been omitted and requires initiation 
 
 
Supporting Information Additional information is provided on the patient’s drug history 
Endorsement (e.g. with meals) 
Information is provided on a patient’s test result(s) (e.g. potassium concentration) 
Information is provided on the administration, reconstitution or supply of a medicine 
Information is provided on the dosing regimen going forward (anticipatory) 
Information is provided on the duration of treatment 
Information is provided on the indication for treatment 
Information is provided on the patient’s allergy history 
Information is provided on the patient’s usual dosing regimen (but no change/review requested) 
Information is provided on the potential adverse effects of treatment 




Information is requested on the indication for treatment 
Information is requested on the requirement of the drug on discharge 
Information provided on the patient's response to treatment 
Informing physician that the patient is non-adherent with treatment 
Monitor blood pressure/pulse 
Monitor for adverse effects of treatment 
Monitor for beneficial effects of treatment 
Monitor glucose concentration 
Monitor pain control 
Monitor the patient’s biochemical parameters 
Monitor the patient’s haematological parameters 
Monitor the patient’s liver function tests 
Monitor the patient’s thyroid function tests 
Monitor the patient’s weight 
Request for falls assessment to be updated 
Request is made for the patient’s weight to be taken and documented 
Request is made for the venous thromboembolism assessment to be updated 
Requests serum/plasma concentration taken 
The pharmacist documents a discussion with the physician relating to the prescription 
 
 
Other Recommends prophylactic treatment is commenced (other than VTE, e.g. proton-pump inhibitor 
for a patient on a non-steroidal anti-inflammatory drug) 
Request is made for the TTO to be updated 
Request patient is counselled on treatment 
Request that the drug history is clarified 
Requests input from another healthcare professional (e.g. speech and language assessment) 
The drug name has been prescribed such that it overrides all decision support 




Appendix 6 – Frequency of review messages assigned by factor 
  





Day of the week review message assigned  
Monday 7899 22.9%  
Tuesday 7373 21.4%  
Wednesday 6441 18.7%  
Thursday 6175 17.9%  
Friday 6151 17.8%  
Sat/Sun 467 1.4%  
 Hour of day review message assigned 
00:00–12:59 21238 61.5%  
13:00–23:59 13268 38.5%  
 Time from prescription generated to message assigned 
< 12 hours 8913 25.8%  
12–23:59 hours 9636 27.9%  
1–6 days 13278 38.5%  
7+ days 2679 7.8%  
 Grade of pharmacist 
6 10532 30.5% 
7 16302 47.2% 
8 7672 22.2% 
 Message assigned to high-risk medicine 
No 24459 70.9% 
Yes 10047 29.1%  







Free-text drug entry   
No 64142 99.9% 
Yes 364 0.01% 
Message related to medicines reconciliation 
No 19211 55.7%  
Yes 15295 44.3%  
Communication theme 
Contraindication 1249 3.6%  
Dose/Frequency 9361 27.1%  
Drug Form/Route 2050 5.9%  
Drug Interaction 753 2.2%  
Drug Selection 3308 9.6%  
Drug Use/Administration 4790 13.9%  
Logistics 622 1.8%  
Omission 3696 10.7%  
Other 724 2.1%  









 Speciality    
Medical Admissions 6663 19.3%  
Critical Care and Burns 1744 5.1%  
General Medicine 8429 24.4%  
General Surgery 2074 6.0%  
Medical Specialities 10294 29.8%  
Surgical Specialities 3388 9.8%  
TNO 1914 5.5%  
Medicine type    
Cardiovascular 8458 24.5%  
Central nervous system 7897 22.9%  
Endocrine 2665 7.7%  
Eye, Ear, nose and oropharynx 772 2.2%  
Gastrointestinal 3091 9.0%  
Infection 3573 10.4%  




Musculoskeletal and joint 
disease 
872 2.5%  
Nutrition and blood 3421 9.9%  
Obstetrics, gynaecology and 
urinary-tract disorders 
526 1.5%  
Other 112 0.3%  
Respiratory 2417 7.0%  
Skin 395 1.1%  
High-risk medicine    
Amiodarone 232 2.3%  
Antibiotics 3102 30.9%  
Antipsychotics 398 4.0%  
Benzodiazepine 545 5.4%  
DOACs 0 0.0%  
Insulin 229 2.3%  
LMWH 2195 21.8%  
Methotrexate 37 0.4%  
NSAID 345 3.4%  
Opioid 2175 21.6%  
Phenytoin 136 1.4%  
Potassium 469 4.7%  
Warfarin 184 1.8%  
 Regularity prescription 
Regular 27276 79.0%  
As Required 3669 10.6%  
Once-Only 266 0.8%  
TTO 3295 9.5%  
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Appendix 7 – High-risk errors communicated via the review message 
Prescribing indicator of high risk-error 
No. of 
messages 
Paracetamol prescribed at a dose of 4 g over a 24 hour to a patient under 50 kg (Risk of hepatocellular toxicity) 350 
Statin prescribed concomitantly with a macrolide antibiotic (Increased risk of myopathy) 203 
Low molecular weight heparin prescribed to a patient with renal impairment without dose adjustment (Increased risk of bleeding) 156 
Potassium chloride supplements continued for longer than is required  (reference range 3.5–5.3 mmol/litre) (Increased risk of 
hyperkalaemia) 
139 
Nitrofurantoin prescribed to a patient with eGFR < 60 ml/minute/1.73m2 (Risk of peripheral neuropathy and inadequate concentration in 
urine)  
102 
Low molecular weight heparin prescribed without the patient's weight being used to calculate the treatment dose (Risk of subtherapeutic 
or supratherapeutic dosing) 
74 
More than one paracetamol-containing product prescribed to a patient at a time (Maximum dose exceeded) 48 
Low molecular weight heparin omitted to be prescribed for prophylaxis (Increased risk of thrombosis) 28 
Selective serotonin re-uptake inhibitor prescribed concomitantly with tramadol (Increased risk of serotonin syndrome) 23 
Amiodarone prescribed concomitantly with simvastatin 40 mg or above (Increased risk of myopathy) 16 
Penicillin containing compound prescribed to a penicillin allergic patient without reasoning (e.g. a mild or non-allergy such as diarrhoea or 
vomiting entered as an allergy where the indication for penicillin is compelling) (Risk of hypersensitivity reactions) 
14 
Domperidone prescribed at a total daily dose exceeding 30 mg/day in adults > 60 years old (Increased risk of QTc prolongation, serious 
ventricular arrhythmia and sudden cardiac death) 
13 
Macrolide antibiotic prescribed concomitantly with warfarin without appropriate dose adjustment or increased INR monitoring (Increased 
risk of bleeding) 
13 
Warfarin prescribed concomitantly with a NSAID (Increased risk of bleeding) 12 
Quinolone antibiotic prescribed to a patient with epilepsy (Increased risk of seizure threshold being reduced) 12 
Clopidogrel prescribed to a patient concomitantly with omeprazole or esomeprazole (Antiplatelet effect of clopidogrel potentially reduced) 11 
Colestyramine prescribed to a patient at the same time as any other oral medication (Risk of poor clinical effect owing to reduced 
absorption of medications) 
9 
ACE inhibitor or angiotensin-II receptor antagonist prescribed to a patient with a potassium level >5.0 mmol/litre (Can cause or exacerbate 
hyperkalaemia) 
8 
Antiplatelet  prescribed to a patient with a concurrent bleeding disorder (Increased risk of bleeding) 8 
Tramadol prescribed concomitantly with antiepileptics (Increased risk of seizures in patients with uncontrolled epilepsy) 8 
Low molecular weight heparin prescribed at a dose exceeding the maximum as stated in the product literature (Risk of bleeding increased) 7 
Quinolone prescribed to a patient who is also receiving theophylline (Possible increased risk of convulsions ) 6 
Vancomycin prescribed intravenously to a patient with renal impairment without dose adjustment (Increased risk of toxicity) 6 
Insulin prescribed to a patient at an inappropriate time, allowing for an administration without food (except once daily long-acting 




Benzodiazepines prescribed long-term (i.e. more than 2–4 weeks) (Risk of dependence and withdrawal reactions) 4 
Selective serotonin re-uptake inhibitor prescribed concomitantly with aspirin without appropriate prophylaxis with antisecretory drugs or 
mucosal protectant (Increased risk of gastrointestinal bleeding) 
4 
Pioglitazone prescribed to a patient with heart failure (Risk of exacerbation of heart failure)  4 
Selective serotonin re-uptake inhibitor prescribed to a patient with a history of clinically significant hyponatraemia (non-iatrogenic , 
sodium <130 mmol/litre in the previous 2 months) (Increased risk of hyponatraemia) 
4 
NSAID prescribed to a patient with a history of peptic ulcer disease or gastrointestinal bleeding without  antisecretory drugs or mucosal 
protectants (Increased risk of peptic ulceration and bleeding) 
3 
NSAID prescribed to a patient with chronic renal failure (Increased risk of deteriorating renal function) 3 
Selective serotonin re-uptake inhibitor prescribed to a patient with epilepsy (Increased risk of seizure threshold being reduced) 3 
Potassium-sparing diuretic (excluding aldosterone antagonists) prescribed to a patient also receiving an ACE inhibitor or angiotensin-II 
receptor antagonist (Increased risk of severe hyperkalaemia) 
2 
Gentamicin prescribed to a patient with renal impairment without dose adjustment (Increased risk of toxicity) 2 
Metformin prescribed to a patient with eGFR < 30 ml/min/1.73m2 (Increased risk of lactic acidosis) 2 
Methotrexate prescribed concomitantly with trimethoprim (Increased risk of haematological toxicity) 2 
NSAID prescribed to a patient with a history of heart failure (Risk of exacerbation of heart failure) 2 
Regular opiates prescribed without concurrent use of laxatives (Risk of severe constipation)‡ 2 
Antipsychotic prescribed long-term (i.e. > 1 month) to a patient with parkinsonism  (Increased risk of worsening of extra-pyramidal side 
effects) 
2 
Aspirin prescribed to a patient with a past medical history of peptic ulcer disease without antisecretory drugs or mucosal protectants 
(Increased risk of peptic ulceration and risk of bleeding) 
1 
Gentamicin dose calculated based on actual body weight rather than ideal body weight in an obese patient (BMI > 30 kg/m2) (Risk of 
excessive dosing and toxicity) 
1 
Soluble insulin prescribed to a patient on a when required basis (Increased risk of serious episodes of hypoglycaemia and nocturnal 
hypoglycaemia post dose) 
1 
Metoclopramide prescribed to a patient with parkinsonism (Risk of exacerbating parkinsonism symptoms) 1 
Lithium prescribed in conjunction with newly prescribed NSAIDs without dose adjustment or increased monitoring (Increased risk of 
toxicity) 
1 
Tramadol prescribed concomitantly with a Monoamine Oxidase Inhibitor (Increased risk of serotonin syndrome) 1 






Appendix 8 – Number of messages relating to each code  
Code No. of messages 
Information provision - Patient dosing pre-admission (no change) 3638 
There is an omission according to the patient’s drug history 2820 
The dose is lower  than the pre-admission dose 1781 
The dose is too high 1358 
The frequency is too low 1052 
A duration is needed on the prescription 1041 
The duration of treatment requires review 1036 
The dose is too low 1029 
The dose is higher than the pre-admission dose 906 
There is a duplicate prescription with a drug of the same class 812 
The frequency is too low compared to pre-admission 708 
Change the formulation to a modified-release form, to be consistent with pre-admission meds 699 
The frequency is too high 698 
Information is provided on the usual dosing regimen for the drug (but no change/review requested) 629 
Venous thromboembolism prophylaxis has been omitted and requires initiation 620 
The patient is on a different drug of the same class that has been prescribed 608 
The drug should be used with caution as the patient is at risk of falls 580 
There is a pharmacokinetic drug-drug interaction 564 
The patient no longer takes or uses the drug prescribed 558 
Request is made for the ‘To Take Out’ (TTO) to be updated 496 
The drug not available as it is not stocked in the hospital 461 
The frequency is too high compared to pre-admission 450 
The dose requires review 439 
There is a duplicate prescription with the same drug 374 
The patient has never taken or used the drug that has been prescribed 360 
Request is made for the patient’s weight to be taken and documented 350 
Change the drug device to be consistent with pre-admission meds 349 
The drug choice does not adhere to guidelines 344 
Information is provided on the duration of treatment 339 
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Information is provided on the dosing regimen going forward (anticipatory) 335 
The patient takes a combination preparation, but only a single component of this has been prescribed 333 
The drug is cautioned or contraindicated as a result of patient comorbidities 328 
There is an omission on the TTO prescription 321 
The drug is to be stopped (or paused) 316 
Change the regular prescription to on a ‘when required’ basis 310 
Change the formulation to liquid or soluble form 299 
A change in formulation is required to be consistent with the patient’s pre-admission form 288 
Timing of the dose (hour or day) requires adjusting to be consistent with the patient’s usual regimen pre-
admission 
271 
Monitor the patient’s biochemical parameters 271 
The drug is no longer indicated 268 
The total daily dose is correct, but split incorrectly throughout the day 257 
Recommends an alternative treatment 240 
Information is provided on a patient’s test result(s) (e.g. potassium concentration) 234 
Information is provided on the administration, reconstitution or supply of a medicine 218 
The pharmacist documents a discussion with the physician relating to the prescription 216 
There is a pharmacodynamic drug-drug interaction 190 
Information is requested on the indication for treatment 190 
Recommends a drug is started to optimise treatment (e.g. thiamine) 179 
Requests serum/plasma concentration taken 175 
Information is requested on the requirement of the drug on discharge 167 
A change in formulation is required because the patient has an enteral feeding tube 165 
The drug should be prescribed as a reducing regimen 163 
Review the prescription as the patient is refusing it 158 
The drug is cautioned or contraindicated as a result of recent test results 151 
There is a duplicate treatment prescribed for the same indication 150 
There is a dosing error as a result of when the route/form has been changed 146 
Change the route from intravenous to oral 143 
Monitor the patient’s haematological parameters 140 
Additional information is provided on the patient’s drug history 138 
360 
 
The patient is on a different brand of the drug and this should be ‘brand specific’ when prescribed 138 
Change the formulation to enteric-coated, to be consistent with pre-admission meds 134 
The drug has been prescribed at the wrong time of day (according to practice/BNF recommendations) 131 
A change in formulation is required because the patient has swallowing difficulties 123 
The dose prescribed is immeasurable 122 
The patient is allergic to the drug 114 
The route is incorrect for the drug 110 
Change the formulation to a standard release form, to be consistent with pre-admission meds 93 
The patient is on the drug, but takes it as a different brand (Adcal D3 versus Calcichew D3) 93 
The frequency of dosing requires review 83 
Information is provided on the potential adverse effects of treatment 77 
Endorsement (e.g. with meals) 75 
The drug name has been prescribed such that it overrides all decision support 72 
The patient takes the drug as a different salt (e.g. ferrous sulphate, not fumarate) 69 
The strength prescribed is lower than that used pre-admission 65 
The drug is not available due to a manufacturing delay 59 
The strength prescribed is higher than that used pre-admission 55 
The patient has reported an intolerance to the drug 54 
The pharmacist directs the physician to read the drug history or prescription endorsements 54 
The maximum frequency is required to be documented on the ‘when required’ prescription 53 
The prescription is inappropriate for discharge (e.g. intravenous form) 53 
Request that the drug history is clarified 49 
Change the prescription to be given on a ‘when required’ basis as the patient is refusing 46 
Monitor blood pressure/pulse 45 
The dose/strength has been documented incorrectly 44 
The drug is to be re-started 41 
Recommends prophylactic treatment is commenced (other than VTE, e.g. proton-pump inhibitor for a patient 
on a non-steroidal anti-inflammatory drug) 
37 
A combination has been prescribed, but the patient is only on a single component 35 
Monitor for adverse effects of treatment 32 
The wrong dose units have been prescribed 31 
361 
 
The drug is not available as it does not exist as prescribed 28 
Informing physician that the prescription was validated and signed-off in error 28 
The route requires review 26 
Request is made for the venous thromboembolism assessment to be updated 26 
There is a potential for cross-reactivity 22 
An alternative drug is recommended because it cannot be crushed/opened for administration 21 
Change the route from oral to intravenous  20 
An alternative route of administration is recommended 19 
There is an omission of required treatment (i.e. anti-emetics prior to chemotherapy) 17 
The prescription should be for a one-off dose only (i.e. not regular) 17 
Change the formulation from a liquid to a solid dose form 17 
Informing physician that the patient is non-adherent with treatment 16 
Information requested relating to controlled drug prescription writing requirements 16 
An alternative drug recommended as it is not suitable for enteral feeding tubes 15 
Change the formulation to modified-release 13 
Monitor glucose concentration 13 
Doses have been missed for no obvious reason 12 
The route of administration is inappropriate for the indication 12 
The wrong drug has been prescribed as a result of a selection error 11 
The drug has been prescribed incorrectly by brand or generic name, not consistent with the eP system 
practice 
10 
Requests input from another healthcare professional (e.g. speech and language assessment) 10 
The drug cannot be administered as there is no intravenous access 10 
The route of administration requires further information (e.g. which eye?) 9 
The strength prescribed is too low 7 
Change to standard release 7 
Information is provided on the patient’s allergy history 7 
Request patient is counselled on treatment 6 
Monitor pain control 6 
The prescription should be documented as a 'continuous' frequency 5 
Information provided on the patient's response to treatment 5 
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The use of multiple routes is not appropriate for the drug 5 
The physicians grade does not give him/her authority to prescribe the drug 4 
Information is provided on the indication for treatment 4 
Monitor the patient’s thyroid function tests 4 
Monitor for beneficial effects of treatment 3 
Request for falls assessment to be updated 2 
Monitor the patient’s liver function tests 2 
The strength prescribed is too high 2 
Additional information is provided on the patient’s drug history 1 
Monitor the patient’s weight 1 






Appendix 9 – Chi-Square and generalised estimating equation results for sign-off rates of review messages  
Considering: 1) Temporal; 2) Message and; 3) Prescription factors.  The results from the GEE have been reported alongside the Chi Square to allow for comparisons. Chi 
analysis shown is before any exclusions as a result of zero numbers and multicollinearity. 
1) Temporal factors   Chi-Square GEE 





Number signed off 
%(n) 
p-value Odds Ratio (95% CI) p-value 
Day of the week review 
message assigned 
      <0.001*   0.002* 
Monday 7899 47.0% (n=3715)  1   
Tuesday 7373 47.4% (n=3494)   1.020 (0.953–1.093) 0.563 
Wednesday 6441 47.4% (n=3055)   1.004 (0.935–1.079) 0.903 
Thursday 6175 45.3% (n=2798)   0.937 (0.871–1.008) 0.081 
Friday 6151 45.4% (n=2792)   0.937 (0.872–1.008) 0.082 
Sat/Sun 467 36.6% (n=171)   0.706 (0.570–0.875) 0.001* 
Hour of day review message 
assigned 
      0.309   0.086 
00:00–12:59 21238 46.7% (n=9909)   1   
13:00–23:59 13268 46.1% (n=6116)   1.043 (0.994–1.093) 0.086 
Time taken to assign review 
message 
      0.025*   <0.001* 
< 12 hours 8913 45.6% (n=4068)   1   
12–23:59 hours 9636 47.6% (n=4587)   0.971 (0.911–1.035) 0.367 
1-6 days 13278 46.0% (n=6105)   0.892 (0.837–0.949) <0.001* 












2) Message factors   Chi-Square GEE 





Number signed off 
%(n) 
p-value Odds Ratio (95% CI) p-value 
Grade of pharmacist 
      0.561   0.010* 
6 10532 46.4% (n=4889)   1   
7 16302 46.7% (n=7611)   0.980 (0.925–1.039) 0.506 
8 7672 45.9% (n=3525)   0.899 (0.835–0.967) 0.004* 
Message assigned to a high-
risk medicine 
      <0.001*   <0.001* 
No 24459 47.8% (n=11703)   1   
Yes 10047 43.0% (4322)   0.841 (0.789–0.895) <0.001* 
Message assigned to a high-
risk error 
      0.387   # 
No 33189 46.4% (n=15398)   # # 
Yes 1317 47.6% (n=627)   # # 
Message relates to medicines 
reconciliation 
      <0.001*   0.004* 
No 19211 43.1% (n=8272)   1   
Yes 15295 50.7% (n=7753)   1.082 (1.025–1.142) 0.004* 
Message associated with 
prescription 
      <0.001*   # 
No 3406 52.6% (n=1793)   # # 










      <0.001*   <0.001* 
Dose/Frequency 9361 54.2% (n=5073)   1   
Contraindication 1249 33.5% (n=419)   0.498 (0.439–0.566) <0.001* 
Drug Form/Route 2050 44.0% (n=902)   0.640 (0.581–0.705) <0.001* 
Drug Interaction 753 46.6% (n=351)   0.733 (0.633–0.850) <0.001* 
Drug Selection 3308 35.6% (n=1177)   0.537 (0.494–0.584) <0.001* 
Drug Use/Administration 4790 39.4% (n=1885)   0.604 (0.562–0.649) <0.001* 
Logistics 622 37.1% (n=231)   0.560 (0.471–0.665) <0.001* 
Omission 3696 50.1% (n=1851)   0.820 (0.764–0.880) <0.001* 
Other 724 39.2% (n=284)   0.864 (0.733–1.018) 0.080 




3) Prescription factors Chi-Square GEE 





Number signed off 
%(n) 
p-value Odds Ratio (95% CI) p-value 
Speciality 
      <0.001*   <0.001* 
Medical Admissions 6663 52.5% (n=3501)   1   
Critical Care and Burns 1744 63.0% (n=1099)   2.038 (1.796–2.314) <0.001* 
General Medicine 8429 49.2% (n=4147)   1.111 (1.024–1.205) 0.011* 
General Surgery 2074 33.3% (n=690)   0.558 (0.498–0.625) <0.001* 
Medical Specialities 10294 41.5% (n=4267)   0.840 (0.780–0.906) <0.001* 
Surgical Specialities 3388 41.9% (n=1421)   0.837 (0.763–0.919) <0.001* 
TNO 1914 47.0% (n=900)   1.090 (0.970–1.226) 0.147 
BNF category 
      <0.001*   <0.001* 
Cardiovascular 8458 51.3% (n=4336)   1   
Central nervous system 7897 44.4% (n=3510)   0.955 (0.891–1.023) 0.189 
Endocrine 2665 51% (n=1360)   0.993 (0.904–1.091) 0.883 
Eye, Ear, nose and 
oropharynx 
772 43.3% (n=334)   0.765 (0.650–0.901) 0.001* 
Gastrointestinal 3091 45.9% (n=1418)   0.894 (0.815–0.981) 0.018* 
Infection 3573 45.7% (n=1634)   0.991 (0.905–1.086) 0.852 
Malignant disease and 
immunosuppression 
307 49.2% (n=151)   1.054 (0.830–1.337) 0.667 
Musculoskeletal and 
joint disease 
872 42.3% (n=369)   0.842 (0.724–0.980) 0.027* 




526 45.6% (n=240)   0.791 (0.656–0.955) 0.015* 
Other 112 28.6% (n=32)   0.511 (0.328–0.796) 0.003* 
Respiratory 2417 41.4% (n=1000)   0.702 (0.634–0.778) <0.001* 
Skin 395 35.2% (n=139)   0.579 (0.462–0.727) <0.001* 
366 
 
Regularity of prescription 
      <0.001*   <0.001* 
Regular 27276 50.5% (n=13788)   1   
As Required 3669 32.8% (n=1205)   0.538 (0.495–0.586) <0.001* 
Once-Only 266 22.2% (n=59)   0.319 (0.235–0.433) <0.001* 
TTO 3295 29.5% (n=973)   0.436 (0.397–0.478) <0.001* 
Prescription status 
      <0.001*   0.005* 
Continued 30557 47.0% (n=14350)   1   
Deleted 3949 42.4% (n=1675)   0.898 (0.832–0.968) 0.005* 
Message factors ‘Message associated with the prescription’ and ‘High-risk error’ were excluded from the GEE owing to multicollinearity. 
Categorical data reported as %(n), with p-value from Chi-Square test. 




Appendix 10 – Chi-Square and generalised estimating equation results for time to sign-off ≤ 48 hours review message 
Considering: 1) Temporal; 2) Message and; 3) Prescription factors.  The results from the GEE have been reported alongside the Chi Square to allow for comparisons. Chi 
analysis shown is before any exclusions as a result of zero numbers and multicollinearity. 
 
1) Temporal factors    Chi-Square Test Generalised Estimated Equations 
    Time to Sign-Off ≤ 48 hours  Time to Sign-Off ≤ 48 hours 
  
Total no. of 
messages 
Median time to 
Sign-Off (hours) 
p-value 
No. signed off ≤ 
48 hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Day of the week review 
message assigned 
      KW<0.001*   <0.001*   <0.001* 
Monday 3715 23.2 (2.4–69.4)  67.7% (n=2515)  1   
Tuesday 3494 23.3 (2.7–65.7)   68.9% (n=2409)   0.977 (0.877–1.088) 0.670 
Wednesday 3055 23.1 (2.2–52.7)   70.1% (n=2166)   1.104 (0.984–1.237) 0.091 
Thursday 2798 22.6 (2.0–96.1)   67.4% (n=1885)   0.856 (0.763–0.961) 0.008* 
Friday 2792 42.5 (1.6–96.5)   51.5% (n=1439)   0.439 (0.392–0.491) <0.001* 
Sat/Sun 171 47.1 (4.7–72.6)   51.5% (n=88)   0.381 (0.268–0.542) <0.001* 
Hour of day review message 
assigned 
      MW<0.001*   0.001*   0.013* 
00:00-12:59 9909 23.3 (2.1–72.8)   66.5% (n=6590)   1   
13:00-23:59 6116 23.5 (2.6–89.5)   64.0% (n=3912)   0.911 (0.846–0.981) 0.013* 
Time taken to assign review 
message 
      KW<0.001*   <0.001*   <0.001* 
< 12 hours 4068 20.0 (1.2–48.2)   74.8% (n=3044)   1   
12-23:59 hours 4587 22.4 (2.0–70.8)   68.1% (n=3122)   0.841 (0.758–0.934) 0.001* 
1-6 days 6105 25.5 (3.1–92.9)   61.1% (n=3733)   0.633 (0.572–0.701) <0.001* 






2) Message factors    Chi-Square Test Generalised Estimated Equations 
    Time to sign-off ≤ 48 hours  Time to sign-off ≤ 48 hours  
  
Total no. of 
messages 
Median time to 
sign-off (hours) 
p-value 
No. signed off  
≤ 48 hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Grade of pharmacist 
      KW<0.001*   <0.001*   0.368 
6 4889 25.5 (2.1–94.3)   61.2% (n=3000)   1   
7 7611 22.4 (2.1–71.3)   67.7% (n=5154)   1.065 (0.972–1.167) 0.178 
8 3525 23.4 (2.4–71.8)   66.6% (n=2348)   1.068 (0.943–1.209) 0.300 
Message assigned to a high-risk 
medicine 
      MW0.003*   0.07   0.713 
No 11703 23.1 (2.1–73.4)   65.9% (n=7718)   1   
Yes 4322 24.1 (2.7–75.4)  64.4% (n=2784)   0.982 (0.890–1.083) 0.713 
Message relates to a high-risk 
error 
      MW0.003*   0.026*   # 
No 15398 23.3 (2.2–73.5)   
65.7% 
(n=10117) 
0.026* # # 
Yes 627 25.1 (2.9–96.5)   61.4% (n=385)   # # 
Message relates to medicines 
reconciliation 
      MW<0.001*   <0.001*   <0.001* 
No 8272 24.3 (2.6–91.6)   62.6% (n=5176)   1   
Yes 7753 22.4 (1.9–70.2)   68.7% (n=5326)   1.210 (1.110–1.319) <0.001* 
Message associated with 
prescription 
      MW<0.001*   <0.001*   # 
No 1793 21.8 (1.9–66.8)   70.4% (n=1263)   # # 
Yes 14232 23.6 (2.2–75.1)   64.9% (n=9239)   # # 
Communication theme 
      KW<0.001*   <0.001*   <0.001* 
Dose/Frequency 5073 23.2 (2.4–71.7)   67.0% (n=3398)   1   
Contraindication 419 40.7 (2.9–120.0)   54.9% (n=230)   0.721 (0.579–0.899) 0.004* 
Drug Form/Route 902 22.6 (1.7–71.9)   68.1% (n=614)   1.139 (0.969–1.339) 0.116 
Drug Interaction 351 27.0 (2.9–120.2)   60.7% (n=213)   0.989 (0.777–1.261) 0.932 
Drug Selection 1177 23.2 (2.2–72.1)   65.8% (n=775)   1.119 (0.969–1.291) 0.126 
Drug 
Use/Administration 
1885 23.6 (1.7–72.3)   65.0% (n=1226)   0.863 (0.764–0.974) 0.017* 
369 
 
Logistics 231 27.0 (3.7–89.7)   60.2% (n=139)   0.957 (0.717–1.278) 0.767 
Omission 1851 21.7 (2.0–66.8)   70.6% (n=1307)   0.043 (0.938–1.159) 0.437 
Other 284 24.9 (2.7–117.9)   59.9% (n=170)   0.566 (0.418–0.766) <0.001* 
Supporting 
Information 
3852 23.8 (2.1–92.9)   63.1% (n=2430)   0.956 (0.872–1.048) 0.339 
Profession of signed user 
      KW<0.001*   <0.001*   0.001* 
Pharmacist 6302 23.7 (0.7–91.7)   63.2% (n=3980)   1   
Consultant 1091 22.2 (3.1–67.9)   69.6% (n=759)   1.203 (1.020–1.420) 0.028* 
Junior 6329 22.9 (2.7–70.9)   67.7% (n=4284)   1.159 (1.061–1.267) 0.001* 





3) Prescription factors Chi-Square Test Generalised Estimated Equations 
    Time to sign-off ≤ 48 hours  Time to sign-off ≤ 48 hours  
  
Total no. of 
messages 
Median time to 
sign-off (hours) 
p-value 
No. signed off  
≤ 48 hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Speciality 
      KW<0.001*   <0.001*   <0.001* 
Medical Admissions 3501 20.5 (1.7–48.2)   74.8% (n=2619)   1   
Critical Care and 
Burns 
1099 23.9 (3.0–72.4)   66.1% (n=726)   0.954 (0.786–1.157) 0.630 
General Medicine 4147 24.9 (2.4–94.5)   62.0% (n=2570)   0.775 (0.681–0.883) <0.001* 
General Surgery 690 23.0 (1.4–76.6)   64.1% (n=442)   0.807 (0.664–0.981) 0.031* 
Medical Specialities 4267 23.2 (2.2–72.4)   65.9% (n=2812)   0.809 (0.714–0.917) 0.001* 
Surgical Specialities 1421 23.9 (2.5–76.9)   63.8% (n=907)   0.735 (0.630–0.857) <0.001* 
TNO 900 51.3 (19.3–167.5)   47.3% (n=426)   0.419 (0.349–0.502) <0.001* 
BNF category 
      KW<0.001*   <0.001*   <0.001* 
Cardiovascular 4336 24.8 (3.0–95.7)   61.5% (n=2668)   1   
Central nervous 
system 
3510 23.7 (2.3–78.1)   64.8% (n=2273)   1.256 (1.131–0.884) <0.001* 
Endocrine 1360 21.4 (1.6–65.5)   70.4% (n=958)   1.323 (1.143–0.875) <0.001* 
Eye, Ear, nose and 
oropharynx 
334 22.6 (1.9–75.5)   65.0% (n=217)   1.138 (0.880–1.136) 0.325 
Gastrointestinal 1418 24.1 (2.5–90.1)   62.8% (n=890)   1.032 (0.896–1.116) 0.663 




151 22.6 (2.6–66.6)   71.5% (n=108)   1.484 (0.998–1.002) 0.051 
Musculoskeletal and 
joint disease 
369 23.3 (2.4–68.6)   68.0% (n=251)   1.416 (1.100–0.909) 0.007* 
Nutrition and blood 1502 24.2 (2.7–89.6)   62.6% (n=940)   1.022 (0.892–1.121) 0.756 
Obstetrics, 
gynaecology and 





Other 32 9.6 (0.5–42.3)   81.3% (n=26)   2.521 (0.912–6.969) 0.075 
Respiratory 1000 22.3 (1.4–71.2)   67.8% (n=678)   1.246 (1.058–1.468) 0.008* 
Skin 139 23.8 (2.5–81.7)   64.7% (n=90)   1.257 (0.856–1.843) 0.243 
Regularity of prescription 
      KW<0.001*   <0.001*   <0.001* 
Regular 13788 23.7 (2.5–73.8)   65.2% (n=8994)   1   
As required 1205 30.9 (3.7–119.9)   55.7% (n=671)   0.813 (0.780–0.935) 0.004* 




TTO 973 2.1 (0.3–26.2)   80.2% (n=780)   2.818 (2.321–3.421) <0.001* 
Prescription status 
      MW<0.001*   <0.001*   <0.001* 
Continued 14350 24.0 (2.5–76.2)   64.1% (n=9199)   1   
Deleted 1675 5.3 (0.8–44.1)   77.8% (n=1303)   1.739 (1.520–1.989) <0.001* 
Message factors ‘Message associated with the prescription’ and ‘High-risk error’ were excluded from the GEE owing to multicollinearity. 
Categorical data reported as %(n), with p-value from Chi-Square test.  Continuous data reported as: median (lower quartile, upper quartile, with p-value from Mann-
Whitney (MW) or Kruskal Wallis (KW) test. 
*Significant at p<0.05. 









Appendix 11 – Chi-Square and generalised estimating equation results for action as requested of review messages 
Considering: 1) Temporal; 2) Message and; 3) Prescription factors.  The results from the GEE have been reported alongside the Chi Square to allow for comparisons. Chi 
analysis shown is before any exclusions as a result of zero numbers and multicollinearity. 
1) Temporal factors  Chi-Square Generalised Estimating Equations 







p-value Odds Ratio (95% CI) p-value 
Day of the week review 
message assigned 
      0.037*   0.073 
Monday 2314 35.7% (n=826)   1   
Tuesday 2111 37.8% (n=797)   1.078 (0.945–1.229) 0.263 
Wednesday 1828 34.6% (n=633)   0.923 (0.804–1.060) 0.256 
Thursday 1821 36.9% (n=672)   1.071 (0.932–1.231) 0.332 
Friday 1784 34.2% (n=611)   0.930 (0.808–1.070) 0.309 
Sat/Sun 133 27.1% (n=36)   0.754 (0.490–1.158) 0.197 
Hour of day review message 
assigned 
      0.015*   0.847 
00:00-12:59 6333 36.7% (n=2322)   1   
13:00-23:59 3658 34.3% (n=1253)   0.991 (0.903–1.087) 0.847 
Time taken to assign review 
message 
      <0.001*   <0.001* 
< 12 hours 2715 31.2% (n=846)   1   
12-23:59 hours 2965 39.5% (n=1171)   1.335 (1.186–1.503) <0.001* 
1-6 days 3633 36.8% (n=1336)   1.241 (1.097–1.404) 0.001* 










2) Message factors  Chi-Square Generalised Estimating Equations 







p-value Odds Ratio (95% CI) p-value 
Grade of pharmacist 
      <0.001*   <0.001* 
6 2746 31.9% (n=876)   1   
7 5145 38.1% (n=1962)   1.203 (1.061–1.365) 0.004* 
8 2100 35.1% (n=737)   1.379 (1.182–1.607) <0.001* 
Message assigned to a high-risk 
medicine 
      0.019*   0.012* 
No 7411 36.4% (n=2701)   1   
Yes 2580 33.9% (n=874)   0.848 (0.745–0.964) 0.012* 
Message relates to a high-risk 
error 
      <0.001*   # 
No 9406 35.3% (n=3316)   # # 
Yes 585 44.2% (n=259)   # # 
Message relates to medicines 
reconciliation 
      <0.001*   <0.001* 
No 5498 30.3% (n=1664)   1   
Yes 4493 42.5% (n=1911)   1.278 (1.144–1.428) <0.001* 
Communication theme 
      <0.001*   0.014* 
Dose/Frequency 8628 36.4% (n=3140)   1   
Drug Form/Route 1056 33.9% (n=358)   1.099 (0.941–1.285) 0.233 
Drug 
Use/Administration 
254 25.2% (n-64)   0.680 (0.475–0.973) 0.035* 




3) Prescription factors  Chi-Square GEE 







p-value Odds Ratio (95% CI) p-value 
Speciality 
      <0.001*   <0.001 
Medical Admissions 2555 44.9% (n=1146)   1   
Critical Care and Burns 568 38.0% (n=216)   0.921 (0.718–1.180) 0.515 
General Medicine 2207 37.3% (n=820)   1.038 (0.884–1.218) 0.651 
General Surgery 561 32.8% (n=184)   0.750 (0.602–0.934) 0.010 
Medical Specialities 2783 29.1% (n=809)   0.706 (0.610–0.816) <0.001* 
Surgical Specialities 831 25.9% (n=215)   0.585 (0.483–0.709) <0.001* 
TNO 486 38.1% (n=185)   1.192 (0.945–1.504) 0.139 
BNF category 
      <0.001*   <0.001 
Cardiovascular 2368 37.5% (n=888)   1   
Central nervous system 2499 36.2% (n=905)   1.162 (1.024–1.320) 0.020* 
Endocrine 765 41.8% (n=320)   1.132 (0.944–1.356) 0.180 
Eye, Ear, nose and 
oropharynx 
241 34.4% (n=83)   0.872 (0.646–1.176) 0.369 
Gastrointestinal 1197 26.1% (n=312)   0.771 (0.648–0.917) 0.003* 
Infection 1151 37.8% (n=435)   1.246 (1.048–1.482) 0.013* 
Malignant disease and 
immunosuppression 
81 34.6% (n=28)   0.918 (0.555–1.519) 0.740 
Musculoskeletal and 
joint disease 
223 38.6% (n=86)   1.204 (0.888–1.632) 0.232 




130 36.9% (n=48)   0.892 (0.603–1.320) 0.568 
Other 9 0.0% (n=0)   # # 
Respiratory 540 36.7% (n=198)   0.906 (0.734–1.119) 0.358 
Skin 77 19.5% (n=15)   0.546 (0.297–1.005) 0.052 
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Mode of prescription 
      <0.001*   <0.001* 
Regular 8030 41.5% (n=3330)   1   
As required 1315 18.6% (n=245)   0.374 (0.317–0.442) <0.001* 
Once-only 70 0.0% (n=0)  # # 
TTO 576 0.0% (n=0)  # # 
Prescription status 
      <0.001*     
Continued 8736 40.8% (n=3566)   #   
Deleted 1255 0.7% (n=9)   # # 
Message factor ‘Message relates to a high-risk error’ were excluded from the GEE owing to multicollinearity. 
Message factor ‘Messages associated with prescription’ and prescription factor Mode ‘TTO’ and ‘Once-only’ were excluded owing to ‘zero’ numbers that were correctly 
actioned.  Message factor Communication theme ‘Contraindication’, ‘Drug Interaction’, ‘Drug Selection’, ‘Omission’, ‘Other’ and ‘Supporting Information were removed 
from the analysis owing to zero numbers.  
Chi Square analysis based on numbers of review messages prior to exclusions.Prescription factor BNF Category ‘Other’ was deleted owing to low numbers. 
Categorical data reported as %(n), with p-value from Chi-Square test 
Significant at p<0.05 
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Appendix 12 – Chi-Square and generalised estimating equation results for time to action as requested ≤ 24 hours of review messages 
Considering: 1) Temporal; 2) Message and; 3) Prescription factors.  The results from the GEE have been reported alongside the Chi Square to allow for comparisons. Chi 
analysis shown is before any exclusions as a result of zero numbers and multicollinearity. 
1) Temporal factors    Chi-Square Generalised Estimating Equations 
    Time to Action as requested     
≤ 24 hours 
Time to action as requested            









actioned ≤ 24 
hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Day of the week review 
message assigned 
      KW0.053   <0.001*   <0.001* 
Monday 826 20.2 (2.2–48.2)   59.0% (n=487)   1   
Tuesday 797 22.1 (2.4–47.3)   56.5% (450)   0.831 (0.676–1.022) 0.079 
Wednesday 633 22.3 (2.4–48.0)   58.5% (n=370)   0.948 (0.757–1.187) 0.640 
Thursday 672 21.4 (2.3–45.4)   60.4% (n=406)   0.970 (0.779–1.208) 0.785 
Friday 611 22.8 (1.9–94.1)   51.1% (n=312)   0.663 (0.530–0.828) <0.001* 
Sat/Sun 36 37.3 (10.1–54.1)   30.6% (n=11)   0.276 (0.130–0.585) 0.001* 
Hour of day review message 
assigned 
      MW<0.001*   0.373   0.714 
00:00-12:59 2322 21.6 (2.2–49.2)   57.5% (n=1335)   1   
13:00-23:59 1253 22.1 (3.1–69.1)   55.9% (n=701)   0.973 (0.840–1.127) 
0.714 
Time taken to assign review 
message 
      KW<0.001*   <0.001*   0.001* 
< 12 hours 846 21.6 (3.1–44.2)   61.0% (n=516)   1   
12-23:59 hours 1171 19.0 (1.9–45.6)   60.7% (n=711)   1.036 (0.856–1.254) 
0.719 
1-6 days 1336 22.7 (2.2–69.8)   53.7% (n=717)   0.836 (0.686–1.019) 0.076 








2) Message factors    Chi-Square Test Generalised Estimated Equations 
    
Time to action as requested     
≤ 24 hours 
Time to action as requested            
≤ 24 hours 
  
Total no. of 
messages 




actioned ≤ 24 
hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Grade of pharmacist 
      KW<0.001*   <0.001*   0.002* 
6 876 
25.2 (3.8–78.1) 
  47.5% (n=416)   1   
7 1962 
20.4 (2.2–47.5) 





  58.2% (n=429)   1.293 (1.013–1.651) 0.039 
Message assigned to a high-risk 
medicine 
      MW0.028*   0.112   0.707 
No 2701 
22.1 (2.4–57.1) 
  56.2% (n=1518)   1   
Yes 874 20.4 (1.9–48.2) 
 
59.3% (n=518)   1.040 (0.846–1.279) 0.707 
Message relates to medicines 
reconciliation 
      MW0.349   0.125   0.859 
No 1664 24.7 (3.4-75.5)   55.6% (n=925)   1   
Yes 1911 23.1 (3.2-68.3)   58.1% (n=1111)   1.016 (0.852–1.212)  0.859 
Communication theme 
      KW0.224   0.277   0.581 
Dose/Frequency 3140 21.6 (2.4–51.6)   57.4% (n=1802)   1   
Drug Form/Route 358 22.8 (1.4–72.0)   55.0% (n=197)   0.992 (0.775–1.268) 0.992 
Drug 
Use/Administration 
64 24.2 (3.5–52.7)   50.0% (n=32)   0.946 (0.551–1.623) 0.839 








3) Prescription factors    Chi-Square Test Generalised Estimated Equations 
    Time to action as requested     
≤ 24 hours 
Time to action as requested            
≤ 24 hours 
  
Total no. of 
messages 




actioned ≤ 24 
hours %(n) 
p-value Odds Ratio (95% CI) p-value 
Speciality 
      KW<0.001*   <0.001*   0.093 
Medical Admissions 1146 19.9 (2.2–36.0)   63.8% (n=731)   1   




  56.0% (n=121)   0.831 (0.585–1.180) 0.301 
General Medicine 820 23.8 (2.2–70.8)   51.6% (n=423)   0.832 (0.658–1.052) 0.124 
General Surgery 184 22.1 (1.9–73.4)   52.2% (n=96)   0.767 (0.551–1.068) 0.116 
Medical Specialities 809 20.4 (2.2–48.0)   58.6% (n=474)   0.857 (0.684–1.073) 0.179 
Surgical Specialities 215 24.0 (4.1–90.2)   50.7% (n=109)   0.714 (0.519–0.981) 0.038 
TNO 185 28.3 (7.2–110.9)   44.3% (n=82)   0.598 (0.422–0.848) 0.004 
BNF category 
      KW<0.001*   <0.001*   0.001* 





  57.2% (n=518)   1.205 (0.987–1.471) 0.067 
Endocrine 320 21.7 (2.6–48.1)   59.1% (n=189)   1.158 (0.879–1.527) 0.297 




  45.8% (n=38)   0.806 (0.499–1.302) 0.378 
Gastrointestinal 312 23.2 (2.6–75.7)   52.2% (n=163)   0.941 (0.709–1.249) 0.674 











  57.0% (n=49)   1.142 (0.713–1.830) 0.580 









  52.1% (n=25)   0.921 (0.504–1.682) 0.788 
Respiratory 198 24.0 (2.4–69.6)   52.0% (n=103)   0.893 (0.645–1.238) 0.498 
Skin 15 19.2 (2.2–54.0)   60.0% (n=9)   1.493 (0.495–4.501) 0.477 
Mode of prescription 
      MW0.090   0.019   0.468 
Regular 3330 21.6 (2.2–51.6)   57.5% (n=1914)   1   
As required 245 24.2 (2.2–90.2)   49.8% (n=122)   0.896 (0.666–1.206) 0.468 
Prescription status 
      MW0.001*   #   # 
Continued 14350 #      #  # 
Deleted 1675 #      # # 
Message factor ‘Message relates to a high-risk error’ were excluded from the GEE owing to multicollinearity. 
Message factor ‘Messages associated with prescription’ and prescription factor Mode ‘TTO’ and ‘Once-only’ were excluded owing to ‘zero’ numbers that were correctly 
actioned.  Message factor Communication theme ‘Drug Interaction’ and ‘Other’ were excluded from the analysis owing to zero numbers. 
Message factor Communication theme ‘Contraindication’, ‘Drug Selection’, ‘Omission’ and ‘Supporting Information were removed from the analysis owing to low numbers.  
Prescription factor BNF Category ‘Other’ was deleted owing to low numbers. 
Categorical data reported as %(n), with p-value from Chi-Square test 
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